##################################################################################
# Document Properties
##################################################################################
SET DOCUMENT Authors = "xxx"
SET DOCUMENT ContactInfo = "Dhruv Chetanbhai Rathod"
SET DOCUMENT Copyright = "Copyright © 2023 Fraunhofer Institute SCAI, All rights reserved."
SET DOCUMENT Description = "HemeKG"

SET DOCUMENT Licenses = "MIT License"
SET DOCUMENT Name = "manual-curation"
SET DOCUMENT Version = "1.0.0"

###################################################################################
# Definitions Section

DEFINE NAMESPACE CHEBI AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/chebi/chebi-20230925.belns"
DEFINE NAMESPACE DO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/disease-ontology/disease-ontology-20200407.belns"
DEFINE NAMESPACE MESHD AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-diseases/mesh-diseases-20190128.belns"
DEFINE NAMESPACE HGNC AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/hgnc/hgnc-20230925.belns"
DEFINE NAMESPACE GO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go/go-20180109.belns"
DEFINE NAMESPACE GOBP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/go-biological-process/go-biological-process-20190128.belns"
DEFINE NAMESPACE MESHPP AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh-processes/mesh-processes-20190128.belns"
DEFINE NAMESPACE MESH AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mesh/mesh-names-20181007.belns"
DEFINE NAMESPACE MGI AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/mgi-mouse-genes/mgi-20230925.belns"
DEFINE NAMESPACE RGD AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/rgd-rat-genes/rgd-20230925.belns"
DEFINE NAMESPACE INTERPRO AS URL "https://arty.scai.fraunhofer.de/artifactory/bel/namespace/interpro/interpro-20170731.belns"
DEFINE NAMESPACE MIRBASE AS URL "https://raw.githubusercontent.com/pharmacome/terminology/c328ad964c08967a0417a887510b97b965a62fa5/external/mirbase-names.belns"
DEFINE NAMESPACE CONSO AS URL "https://raw.githubusercontent.com/pharmacome/conso/master/export/conso.belns"
DEFINE NAMESPACE FPLX AS URL "https://raw.githubusercontent.com/sorgerlab/famplex/e8ae9926ff95266032cb74f77973c84939bffbeb/export/famplex.belns"
DEFINE NAMESPACE PFAM AS URL "https://raw.githubusercontent.com/pharmacome/terminology/8ccfed235e418e4c8aa576f9a5ef0f838e794c7f/external/pfam-names.belns"
DEFINE NAMESPACE HGNCGENEFAMILY AS URL "https://raw.githubusercontent.com/pharmacome/terminology/73688d6dc24e309fca59a1340dc9ee971e9f3baa/external/hgnc.genefamily-names.belns"
DEFINE NAMESPACE PUBCHEM AS PATTERN "^\d+$"
DEFINE NAMESPACE CL AS PATTERN "^\d+$"

DEFINE ANNOTATION Score AS PATTERN "0.\d+"
DEFINE ANNOTATION DataSource AS LIST {"manual-curation"}

# Namespaces defined with regular expressions
# -------------------------------------------

DEFINE NAMESPACE PKG        AS PATTERN ".*"

##################################################################################

# Statements Section


SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "In AIP, there is a decreased function of tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase (IDO) that forms the first and rate-limiting enzymatic step in kynurenine generation."
path(MESHD:"AIP") decreases p(HGNC:"TDO2")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "In AIP, there is a decreased function of tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase (IDO) that forms the first and rate-limiting enzymatic step in kynurenine generation."
path(MESHD:"AIP") decreases p(HGNC:"IDO1")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Three porphyrias; acute intermittent porphyria (AIP), hereditary coproporphyria (HCP) and variegate porphyria (VP) are commonly labelled acute porphyrias (AP) since they can all present with episodic acute neurovisceral attacks."
path(MESHD:"AIP") isA path(MESHD:"porphyria")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Table: Classifications and principal clinical features"
path(MESHD:"AIP") isA path(MESHD:"porphyria")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "A 17-year-old woman with acute intermittent porphyria presented with seizures, coma, and visual disturbance."
path(MESHD:"AIP") association path(MESHD:"seizures")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "A 17-year-old woman with acute intermittent porphyria presented with seizures, coma, and visual disturbance."
path(MESHD:"AIP") association path(MESHD:"coma")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "A 17-year-old woman with acute intermittent porphyria presented with seizures, coma, and visual disturbance."
path(MESHD:"AIP") association path(MESHD:"visual disturbances")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Second, the concurrent occurrence of AIP with PRES is exceptionally rare."
path(MESHD:"AIP") association path(MESHD:"PRES")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"AIP") association path(MESHD:"PRES")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The patient also presented with PRES, an uncommon clinical syndrome characterized by reversible changes in the posterior white matter of the brain, and often associated with hypertension, immunosuppressive therapy, or other causes"
path(MESHD:"AIP") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Finally, AIP is a rare differential diagnosis of acute motor axonal neu ropathy and should be suspected when associated with abdominal pain in young women."
path(MESHD:"AIP") association path(MESHD:"GBS")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Finally, AIP is a rare differential diagnosis of acute motor axonal neu ropathy and should be suspected when associated with abdominal pain in young women."
path(MESHD:"AIP") association path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria is not a single disease but a group of nine disorders: acute intermittent porphyria (AIP), hereditary coproporphyria (HCP), variegate porphyria (VP), deltaaminolevelunic acid dehyratase deficiency porphyria (ADP), porphyria cutanea tarda (PCT), hepatoerythropoetic porphyria (HEP), congenital erythropoetic porphyria (CEP), erythropoetic protoporphyria (EPP), and X-linked protoporphyria (XLP)."
path(MESHD:"AIP") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Acute intermittent porphyria (AIP) has been associated with schizophrenia in some studies, but prior research is limited by the absence of comparison populations"
path(MESHD:"AIP") association path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Latent AIP mutations may be responsible for the finding that first-degree relatives of individuals with AIP, without manifest AIP themselves, also were at increased risk of being diagnosed with schizophrenia or bipolar disorder."
path(MESHD:"AIP") association path(MESHD:"bipolar disorder")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "AIP is an unusual autosomal dominant disorder resulting in neurovisceral attacks, occurring mostly in women."
path(MESHD:"AIP") association path(MESHD:"Acute Disease")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Psychosis may also occur."
path(MESHD:"AIP") association path(MESHD:"Psychotic Disorders")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Acute intermittent porphyria (AIP) is a rare inherited metabolic disorder."
path(MESHD:"AIP") association bp(GO:"metabolism")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "AIP is a rare hereditary metabolic disorder, one of the porphyrin metabolic disorders."
path(MESHD:"AIP") association bp(GO:"metabolism")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1.Urinary, plasmatic and faecal porphyrins and heme precursors in a patient with epilepsy and co-existing acute intermittent porphyria under treatment with different antiepileptic drugs."
path(MESHD:"AIP") association path(MESHD:"epilepsy")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"AIP") association path(MESHD:"eclampsia")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"AIP") association path(MESHD:"lupus nephritis")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"AIP") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"AIP") association path(MESHD:"Takayasu arteritis")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Conclusions: Methotrexate and actinomycin D did not induce acute porphyric attacks in this patient with acute intermittent porphyria; however, severe adverse effects were noted with methotrexate."
path(MESHD:"AIP") association a(CHEBI:"Methotrexate")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "(2) showed in vitro the porphyrinogenic quality of lamotrigine (LTG), tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria."
path(MESHD:"AIP") association a(CHEBI:"tiagabine")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "demonstrated the porphyrogenic quality of LTG, tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria, whereas vigabatrin (VGB) did not increase the level of ÃŽÂ´-aminolevulinic acid synthase."
path(MESHD:"AIP") association a(CHEBI:"tiagabine")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "(2) showed in vitro the porphyrinogenic quality of lamotrigine (LTG), tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria."
path(MESHD:"AIP") association a(CHEBI:"felbamate")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "demonstrated the porphyrogenic quality of LTG, tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria, whereas vigabatrin (VGB) did not increase the level of ÃŽÂ´-aminolevulinic acid synthase."
path(MESHD:"AIP") association a(CHEBI:"felbamate")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "(2) showed in vitro the porphyrinogenic quality of lamotrigine (LTG), tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria."
path(MESHD:"AIP") association a(CHEBI:"lamotrigine")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "# Eslicarbazepine for focal epilepsy and acute intermittent porphyria* Tamara Herrera-Fortin, Raluca Pana, Ewa Wesolowska, Josiane BourrÃƒÂ©-Tessier, Dang K. Nguyen University of Montreal Hospital Center, Montreal, Quebec, Canada Received January 6, 2020; Accepted March 12, 2020 #### Abstract porphyrias are rare genetic disorders which cause a deficiency in the enzymes involved in the biosynthesis of heme."
path(MESHD:"AIP") association a(CHEBI:"Eslicarbazepine")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Combining the patientÃ¢â‚¬â„¢s clinical symptoms (epileptic seizures, intermittent abdominal pain, and muscle atrophy), imaging fndings (reversible abnormal signals on cranial MRI), and the detection of a heterozygous c.445C>T mutation in the HMBS gene, our hospital de fnitively diagnosed AIP complicated by PRES."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"PRES")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "In this case, the patient presented initially with epilepsy, accompanied byPRES.It is relatively rare for AIP patients to present epilepsy as the frst symptom."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"PRES")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The patient also presented with PRES, an uncommon clinical syndrome characterized by reversible changes in the posterior white matter of the brain, and often associated with hypertension, immunosuppressive therapy, or other causes"
path(MESHD:"AIP") positiveCorrelation path(MESHD:"PRES")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Acute Intermittent porphyria With Epilepsy as the Initial Symptom and Posterior Reversible Encephalopathy Syndrome: A Case Report"
path(MESHD:"AIP") positiveCorrelation path(MESHD:"PRES")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The diagnosis and treatment of a young patient with AIP who showed epilepsy and posterior reversible encephalopathy syndrome (PRES) as the frst symptoms, who was admitted to our department, are reported."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"PRES")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Given the several atypical features for GBS, the diagnosis of acute intermittent porphyria (AIP) was finally suspected with significant delay."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"GBS")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "First, it presents an atypical initial manifestation of AIP: epilepsy, which is rarely reported as the frst symptom in AIP patients, who more commonly present with abdominal pain or neuropsychiatric symptoms"
path(MESHD:"AIP") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Combining the patientÃ¢â‚¬â„¢s clinical symptoms (epileptic seizures, intermittent abdominal pain, and muscle atrophy), imaging fndings (reversible abnormal signals on cranial MRI), and the detection of a heterozygous c.445C>T mutation in the HMBS gene, our hospital de fnitively diagnosed AIP complicated by PRES."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Acute intermittent porphyria (AIP) is a rare hereditary metabolic disorder, manifesting in a series of neuropsychiatric symptoms andabdominalpain."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "In 1939, WaldenstrÃƒÂ¶m ^2 noted that schizophrenia was common in families with AIP, but no statistical support was provided."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Combining the patientÃ¢â‚¬â„¢s clinical symptoms (epileptic seizures, intermittent abdominal pain, and muscle atrophy), imaging fndings (reversible abnormal signals on cranial MRI), and the detection of a heterozygous c.445C>T mutation in the HMBS gene, our hospital de fnitively diagnosed AIP complicated by PRES."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"seizure")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "A 30-year-old woman with AIP had recurrent acute abdominal pain, nausea and vomiting, constipation, persistent chest, back, and waist pain, red urine, positivity for porphobilinogen (PBG) in urine and a pathogenic mutation of the HMBS gene."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"constipation")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "In addition, there seemed to be an overrepresentation of women among those who had both AIP and bipolar disorder, but the small number of observations did not allow formal testing of this potentially important finding."
path(MESHD:"AIP") positiveCorrelation pop(MESHD:"Women")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "We confirmed AIP by the change in urine color when exposed to light and by high urinary porphobilinogen titration."
path(MESHD:"AIP") positiveCorrelation a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, elevated serum, urinary and faecal porphyrins as well as urinary porphobilinogen and D-aminolevulinic acid (table 1) suggested a diagnosis of acute intermittent porphyria (AIP), later supported by the identification of a mutation in the hydroxymethylbilane synthase (HMBS) gene (p. R167W c.499C Ã¢â€ â€™ T)."
path(MESHD:"AIP") positiveCorrelation a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Acute intermittent porphyria (AIP) is a rare hereditary metabolic disorder, manifesting in a series of neuropsychiatric symptoms andabdominalpain."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"mental illness")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "First, it presents an atypical initial manifestation of AIP: epilepsy, which is rarely reported as the frst symptom in AIP patients, who more commonly present with abdominal pain or neuropsychiatric symptoms"
path(MESHD:"AIP") positiveCorrelation path(MESHD:"mental illness")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "First, it presents an atypical initial manifestation of AIP: epilepsy, which is rarely reported as the frst symptom in AIP patients, who more commonly present with abdominal pain or neuropsychiatric symptoms"
path(MESHD:"AIP") positiveCorrelation path(MESHD:"epilepsy")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "In this case, the patient presented initially with epilepsy, accompanied byPRES.It is relatively rare for AIP patients to present epilepsy as the frst symptom."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"epilepsy")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The presence of epilepsy in patients with AIP may indicate a broader neurological impact, requiring further detailed neurological evaluation and monitoring."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"epilepsy")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Acute Intermittent porphyria With Epilepsy as the Initial Symptom and Posterior Reversible Encephalopathy Syndrome: A Case Report"
path(MESHD:"AIP") positiveCorrelation path(MESHD:"epilepsy")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The diagnosis and treatment of a young patient with AIP who showed epilepsy and posterior reversible encephalopathy syndrome (PRES) as the frst symptoms, who was admitted to our department, are reported."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"epilepsy")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Two and a half years after she was diagnosed with AIP, she was diagnosed with PSS based on dryness of the eyes and mouth, the elevation of immunoglobulins (IgG and Ig A ) and positive results on an anti-SS-A antibody test, an anti-SS-B antibody test, Schirmer's test and a labial gland biopsy."
path(MESHD:"AIP") positiveCorrelation a(GO:"IgG")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Combining the patientÃ¢â‚¬â„¢s clinical symptoms (epileptic seizures, intermittent abdominal pain, and muscle atrophy), imaging fndings (reversible abnormal signals on cranial MRI), and the detection of a heterozygous c.445C>T mutation in the HMBS gene, our hospital de fnitively diagnosed AIP complicated by PRES."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"Muscular Atrophy")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, elevated serum, urinary and faecal porphyrins as well as urinary porphobilinogen and D-aminolevulinic acid (table 1) suggested a diagnosis of acute intermittent porphyria (AIP), later supported by the identification of a mutation in the hydroxymethylbilane synthase (HMBS) gene (p. R167W c.499C Ã¢â€ â€™ T)."
path(MESHD:"AIP") positiveCorrelation a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Atypical imaging of the lesions extension: A 17-year-old woman with acute intermittent porphyria presented with seizures, coma, and visual disturbance."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"visual disturbance")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyria was initiated by oxybutynin, precipitated by Bactrim, and became full-blown after metronidazole administration."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Case presentation: In this report, we present a case of an invasive mole with lung metastasis in a 49-year-old Japanese woman who had previously been diagnosed with acute intermittent porphyria at 27 years of age but had no recent history of acute intermittent porphyria attacks."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"invasive mole")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "She was subsequently diagnosed with a acute intermittent porphyria hydatidiform mole via dilatation and curettage (D C)."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"hydatidiform mole")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Possible GI signs include ileal infarction in acute intermittent porphyria and villous atrophy in variegate porphyria (49,50)."
path(MESHD:"AIP") positiveCorrelation path(MESHD:"infarction")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "nan"
path(MESHD:"AIP") positiveCorrelation path(DO:"Primary Liver Cancer")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyria was considered only after the patient mani fested neuropsychiatric abnormalities with GBS on the differ ential list. Acute porphyria can mimic GBS clinically and is an important differential diagnosis of GBS"
path(MESHD:"AIP") increases path(MESHD:"GBS")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Symptoms of AIP typically manifest during acute attacks and may include severe abdominal cramps, a com mon initial symptom often leading to misdiagnosis as acute abdominal conditions, as observed in this case where the patient had intermittent abdominal pain without timely medical consultation."
path(MESHD:"AIP") increases path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Epilepsy is a neurological disorder, with symptoms that difer from those of AIP, such as abdominal pain and neuropsychiatric symp toms."
path(MESHD:"AIP") increases path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Individuals with AIP had a fourfold increased risk of schizophrenia or bipolar disorder."
path(MESHD:"AIP") increases path(MESHD:"bipolar disorder")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "individuals with AIP had double the risk of schizophrenia or bipolar disorder, suggesting that these associations may be as a result of common genetic influences."
path(MESHD:"AIP") increases path(MESHD:"bipolar disorder")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Symptoms of AIP typically manifest during acute attacks and may include severe abdominal cramps, a com mon initial symptom often leading to misdiagnosis as acute abdominal conditions, as observed in this case where the patient had intermittent abdominal pain without timely medical consultation."
path(MESHD:"AIP") increases path(MESHD:"Acute Disease")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Neurological symptoms are also prominent, such as acute peripheral polyneuropathy (evident in the patientÃ¢â‚¬â„¢s electromyographic fndings of neurogenic damage), seizures (consistent with the patientÃ¢â‚¬â„¢s presentation of unconsciousness and limb twitching), and muscle weakness or atrophy (noted in the supraspinatus, infraspinatus, and deltoid muscles)."
path(MESHD:"AIP") increases path(MESHD:"seizure")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "A 30-year-old woman with AIP had recurrent acute abdominal pain, nausea and vomiting, constipation, persistent chest, back, and waist pain, red urine, positivity for porphobilinogen (PBG) in urine and a pathogenic mutation of the HMBS gene."
path(MESHD:"AIP") increases a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The biochemical activity of acute intermittent porphyria was assessed using recorded maximal urinary porphobilinogen (U-PBG)."
path(MESHD:"AIP") increases a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "Initial diagnostic evaluations yielded no significant abnormalities; however, subsequent analysis revealed elevated urinary porphobilinogen, corroborating a diagnosis of acute intermittent porphyria (AIP)."
path(MESHD:"AIP") increases a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and ÃŽÂ´-aminolevulinic acid [ÃŽÂ´-ALA]) in the body [1]."
path(MESHD:"AIP") increases a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Epilepsy is a neurological disorder, with symptoms that difer from those of AIP, such as abdominal pain and neuropsychiatric symp toms."
path(MESHD:"AIP") increases path(MESHD:"mental illness")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Neurological symptoms are also prominent, such as acute peripheral polyneuropathy (evident in the patientÃ¢â‚¬â„¢s electromyographic fndings of neurogenic damage), seizures (consistent with the patientÃ¢â‚¬â„¢s presentation of unconsciousness and limb twitching), and muscle weakness or atrophy (noted in the supraspinatus, infraspinatus, and deltoid muscles)."
path(MESHD:"AIP") increases path(MESHD:"Muscular Atrophy")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1. Levels of Heme intermediates upon diagnosis and response to Hemin treatment."
path(MESHD:"AIP") increases a(MESHD:"Porphobilinogen")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Urine porphobilinogen levels collected in 3 different days were markedly elevated by 10-fold to 20-fold, urine total porphyrins level was moderately elevated by 7-fold, and levels of del ta-aminolevulinic acid (ALA), heptacarboxylporphyrin, penta carboxyporphyrin, and coproporphyrin were mildly elevated"
path(MESHD:"AIP") increases a(MESHD:"Porphobilinogen")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Urine porphobilinogen levels collected in 3 different days were markedly elevated by 10-fold to 20-fold, urine total porphyrins level was moderately elevated by 7-fold, and levels of del ta-aminolevulinic acid (ALA), heptacarboxylporphyrin, penta carboxyporphyrin, and coproporphyrin were mildly elevated"
path(MESHD:"AIP") increases a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Urine porphobilinogen levels collected in 3 different days were markedly elevated by 10-fold to 20-fold, urine total porphyrins level was moderately elevated by 7-fold, and levels of del ta-aminolevulinic acid (ALA), heptacarboxylporphyrin, penta carboxyporphyrin, and coproporphyrin were mildly elevated"
path(MESHD:"AIP") increases a(CHEBI:"Heptacarboxylporphyrin I")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Urine porphobilinogen levels collected in 3 different days were markedly elevated by 10-fold to 20-fold, urine total porphyrins level was moderately elevated by 7-fold, and levels of del ta-aminolevulinic acid (ALA), heptacarboxylporphyrin, penta carboxyporphyrin, and coproporphyrin were mildly elevated"
path(MESHD:"AIP") increases a(CHEBI:"Pentacarboxylporphyrin I")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Urine porphobilinogen levels collected in 3 different days were markedly elevated by 10-fold to 20-fold, urine total porphyrins level was moderately elevated by 7-fold, and levels of del ta-aminolevulinic acid (ALA), heptacarboxylporphyrin, penta carboxyporphyrin, and coproporphyrin were mildly elevated"
path(MESHD:"AIP") increases a(CHEBI:"Coproporphyrins")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Neurological symptoms are also prominent, such as acute peripheral polyneuropathy (evident in the patientÃ¢â‚¬â„¢s electromyographic fndings of neurogenic damage), seizures (consistent with the patientÃ¢â‚¬â„¢s presentation of unconsciousness and limb twitching), and muscle weakness or atrophy (noted in the supraspinatus, infraspinatus, and deltoid muscles)."
path(MESHD:"AIP") increases path(MESHD:"Peripheral neuropathy")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and ÃŽÂ´-aminolevulinic acid [ÃŽÂ´-ALA]) in the body [1]."
path(MESHD:"AIP") increases a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "In using chick-embryo hepatocyte culture, Reynolds and Miska (2) developed an animal model for acute intermittent porphyria and analyzed the influence of certain AEDs on hepatic enzyme induction of ÃŽÂ´-aminolevulinic acid synthase."
path(MESHD:"AIP") increases a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Neurological symptoms are also prominent, such as acute peripheral polyneuropathy (evident in the patientÃ¢â‚¬â„¢s electromyographic fndings of neurogenic damage), seizures (consistent with the patientÃ¢â‚¬â„¢s presentation of unconsciousness and limb twitching), and muscle weakness or atrophy (noted in the supraspinatus, infraspinatus, and deltoid muscles)."
path(MESHD:"AIP") increases path(MESHD:"muscle weakness")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Neurological symptoms are also prominent, such as acute peripheral polyneuropathy (evident in the patientÃ¢â‚¬â„¢s electromyographic fndings of neurogenic damage), seizures (consistent with the patientÃ¢â‚¬â„¢s presentation of unconsciousness and limb twitching), and muscle weakness or atrophy (noted in the supraspinatus, infraspinatus, and deltoid muscles)."
path(MESHD:"AIP") increases path(MESHD:"neurological symptoms")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Neurological symptoms are also prominent, such as acute peripheral polyneuropathy (evident in the patientÃ¢â‚¬â„¢s electromyographic fndings of neurogenic damage), seizures (consistent with the patientÃ¢â‚¬â„¢s presentation of unconsciousness and limb twitching), and muscle weakness or atrophy (noted in the supraspinatus, infraspinatus, and deltoid muscles)."
path(MESHD:"AIP") increases path(MESHD:"Muscular Denervation")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Thus, PRES should be suspected when patients with SLE have acute headache and seizures, especially in those patients who have high blood pressure and are on immunosuppressive treatments."
path(MESHD:"seizures") association path(MESHD:"PRES")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
path(MESHD:"seizures") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Seizures may be due to hyponatremia or represent a neurological manifestation of porphyria."
path(MESHD:"seizures") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = ", 1995 | Study in rat model Bolus dose safe | The relationship of seizures to porphyria is complex."
path(MESHD:"seizures") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "B1-B4 are cranial Flair-MRI of a 20-year-old-woman with renal artery stenosis who presented headache and seizures."
path(MESHD:"seizures") association path(MESHD:"renal artery stenosis")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Two patients were misdiagnosed with lupus encephalopathy and were given large doses of steroids and immunosuppressant medications; these patients had residual visual disturbances and seizures, respectively."
path(MESHD:"seizures") association path(MESHD:"lupus")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Pulmonary infections were associated each time with an increasing titration of porphobilinogen; the first episode was also associated with seizures and hyponatremia."
path(MESHD:"seizures") association path(MESHD:"Pulmonary infections")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Seizures may be due to hyponatremia or represent a neurological manifestation of porphyria."
path(MESHD:"seizures") association path(MESHD:"hyponatremia")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
path(MESHD:"seizures") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Atypical imaging findings involving basal ganglia and cerebellum: A 17-year-old woman with Takayasu arteritis developed headache and seizures."
path(MESHD:"seizures") positiveCorrelation path(MESHD:"headache")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "B1-B4 are cranial Flair-MRI of a 20-year-old-woman with renal artery stenosis who presented headache and seizures."
path(MESHD:"seizures") positiveCorrelation path(MESHD:"headache")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
path(MESHD:"seizures") positiveCorrelation path(MESHD:"tachycardia")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
path(MESHD:"seizures") increases path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
path(MESHD:"seizures") increases path(MESHD:"muscle weakness")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "In the following two years, the patient's epilepsy deteriorated with focal unaware seizures occurring every two to three months and eight episodes of convulsive status epilepticus despite optimizing dosages and replacing lacosamide with pregabalin."
path(MESHD:"seizures") increases path(MESHD:"status epilepticus")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "While regarding quetiapine, the main restriction for its use lies in the gastrointestinal effects that could lead to a decrease in carbohydrate intake."
path(MESHD:"coma") increases path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Two patients were misdiagnosed with lupus encephalopathy and were given large doses of steroids and immunosuppressant medications; these patients had residual visual disturbances and seizures, respectively."
path(MESHD:"visual disturbances") association path(MESHD:"lupus")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Two patients were misdiagnosed with lupus encephalopathy and were given large doses of steroids and immunosuppressant medications; these patients had residual visual disturbances and seizures, respectively."
path(MESHD:"visual disturbances") association a(CHEBI:"steroids")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Two patients were misdiagnosed with lupus encephalopathy and were given large doses of steroids and immunosuppressant medications; these patients had residual visual disturbances and seizures, respectively."
path(MESHD:"visual disturbances") association a(SCTID:"immunosuppressant")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Early recognition of PRES is vital for the prompt management of hypertension, the correction of renal dysfunction and the withdrawal of the offending agents."
path(MESHD:"PRES") decreases path(MESHD:"hypertension")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Therefore, the diagnosis of AIP should be considered when epilepsy is associated with PRES."
path(MESHD:"PRES") positiveCorrelation path(MESHD:"AIP")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Therefore, the diagnosis of AIP should be considered when epilepsy is associated with PRES."
path(MESHD:"PRES") positiveCorrelation path(MESHD:"epilepsy")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The pathogenesis of PRES is still unclear, and there are several proposed hypotheses for its pathogenesis, including high perfusion pressure breakthrough and vascular endo thelial injury. It is generally considered a result of a com bination of factors, such as increased activity of the reninÃ¢â‚¬â€œangiotensin system, increased blood pressure, waterÃ¢â‚¬â€œsodium retention, metabolite accumulation, and damage to the bloodÃ¢â‚¬â€œbrain barrier."
path(MESHD:"PRES") positiveCorrelation path(MESHD:"Arterial Pressure")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The pathogenesis of PRES is still unclear, and there are several proposed hypotheses for its pathogenesis, including high perfusion pressure breakthrough and vascular endo thelial injury. It is generally considered a result of a com bination of factors, such as increased activity of the reninÃ¢â‚¬â€œangiotensin system, increased blood pressure, waterÃ¢â‚¬â€œsodium retention, metabolite accumulation, and damage to the bloodÃ¢â‚¬â€œbrain barrier."
path(MESHD:"PRES") positiveCorrelation path(MESHD:"Endothelium, Vascular")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Therefore, PRES should be suspected whenever patients develope headache or seizure after being given cyclosporine A. Prompt withdrawal of the offending drug is very important in such cases."
path(MESHD:"PRES") increases path(MESHD:"seizure")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Therefore, PRES should be suspected whenever patients develope headache or seizure after being given cyclosporine A. Prompt withdrawal of the offending drug is very important in such cases."
path(MESHD:"PRES") increases path(MESHD:"headache")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "The typical neuroimaging presentation of PRES is vasogenic edema predominantly involving the posterior white matter of the cerebral hemispheres, especially the bilateral parietooccipital lobes; the calcarine and paramedian occipital-lobe are usually spared."
path(MESHD:"PRES") increases path(MESHD:"vasogenic edema")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Posterior reversible encephalopathy syndrome (PRES) is also an uncommon clinical syndrome characterized by localized cerebral edema in the posterior part of the brain, accompanied by abnormal signal changes in white matter areas."
path(MESHD:"PRES") increases path(MESHD:"Cerebral Edema")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Apart from the known risk factors, such as hypertension, immunosuppressants, and renal failure of various etiologies may be the precipitants of PRES."
path(MESHD:"PRES") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The patient also presented with PRES, an uncommon clinical syndrome characterized by reversible changes in the posterior white matter of the brain, and often associated with hypertension, immunosuppressive therapy, or other causes"
path(MESHD:"PRES") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Apart from the known risk factors, such as hypertension, immunosuppressants, and renal failure of various etiologies may be the precipitants of PRES."
path(MESHD:"PRES") association a(SCTID:"immunosuppressant")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"PRES") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"PRES") association path(MESHD:"SLE")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Apart from the known risk factors, such as hypertension, immunosuppressants, and renal failure of various etiologies may be the precipitants of PRES."
path(MESHD:"PRES") association path(MESHD:"renal failure")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
path(MESHD:"hypertension") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "This case report presents the case of a 20-year-old female patient who sought emergency medical attention for severe abdominal pain, nausea and vomiting, tachycardia, hypertension, and discolored urine."
path(MESHD:"hypertension") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "A 20-year-old female presented to the Emergency Department with a clinical tableau characterized by severe abdominal pain, persistent vomiting, tachycardia, hypertension, and notable dark-colored urine."
path(MESHD:"hypertension") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "The co-morbidities in those patients with high blood pressure included eclampsia, primary renal disease and lupus."
path(MESHD:"hypertension") positiveCorrelation path(MESHD:"lupus")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "A 20-year-old female presented to the Emergency Department with a clinical tableau characterized by severe abdominal pain, persistent vomiting, tachycardia, hypertension, and notable dark-colored urine."
path(MESHD:"hypertension") positiveCorrelation path(MESHD:"tachycardia")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "This case report presents the case of a 20-year-old female patient who sought emergency medical attention for severe abdominal pain, nausea and vomiting, tachycardia, hypertension, and discolored urine."
path(MESHD:"hypertension") positiveCorrelation path(MESHD:"tachycardia")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "The co-morbidities in those patients with high blood pressure included eclampsia, primary renal disease and lupus."
path(MESHD:"hypertension") positiveCorrelation path(MESHD:"eclampsia")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "A high proportion of patients had comorbidities, including peripheral neuropathy, hypertension, liver and kidney disease, and psychiatric disorders (Fig. 1)."
path(MESHD:"hypertension") positiveCorrelation path(MESHD:"peripheral neuropathy")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "A 20-year-old female presented to the Emergency Department with a clinical tableau characterized by severe abdominal pain, persistent vomiting, tachycardia, hypertension, and notable dark-colored urine."
path(MESHD:"hypertension") positiveCorrelation path(MESHD:"vomiting")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with AHP had a higher risk of kidney cancer (0.8 % vs. 0.2 %, p<0.001), hypertension, and chronic kidney disease but no increase in risk for cardiovascular disease, except for cerebrovascular disease in patients with elevated U-PBG, (aHR =1.40 [95% CI:1.06-1.85])."
path(MESHD:"hypertension") positiveCorrelation path(DO:"kidney cancer")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
path(MESHD:"hypertension") increases path(MESHD:"PRES")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The pathogenesis of PRES is still unclear, and there are several proposed hypotheses for its pathogenesis, including high perfusion pressure breakthrough and vascular endo thelial injury. It is generally considered a result of a com bination of factors, such as increased activity of the reninÃ¢â‚¬â€œangiotensin system, increased blood pressure, waterÃ¢â‚¬â€œsodium retention, metabolite accumulation, and damage to the bloodÃ¢â‚¬â€œbrain barrier."
path(MESHD:"hypertension") increases path(MESHD:"PRES")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "## Other Risk Factors for Development of Type II Diabetes Mellitus and Screening Interval There are several other risk factors increasing the risk of having/ developing type II DM; these include obesity, inactivity, high blood pressure, a family history of DM, and age."
path(MESHD:"hypertension") increases path(MESHD:"Type II Diabetes")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
path(MESHD:"hypertension") increases path(MESHD:"autonomic dysfunction")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
path(MESHD:"hypertension") association path(MESHD:"constipation")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
path(MESHD:"hypertension") association path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
path(MESHD:"hypertension") association path(DO:"kidney cancer")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, many successfully treated persons will survive to experience considerable morbidity related to Ã¢â‚¬Ëœresidual' conditions such as ischaemic heart disease, hypertension, osteoarthritis and nonhepatic cancers, which in the past would have remained secondary concerns in the context of impending liver failure."
path(MESHD:"hypertension") association path(MESHD:"ischaemic heart disease")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Cardiovascular disorders include hypertension, arrhythmia, and respiratory arrest."
path(MESHD:"hypertension") association path(MESHD:"cardiovascular diseases")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "The diagnosis is simple and cost-effective, so measurement of urinary porphobilinogen should be routinely obtained in patients with axonal GBS."
path(MESHD:"GBS") association a(MESHD:"Porphobilinogen")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "As a differential diagnosis of Guillain BarrÃƒÂ© syndrome, acute porphyria was then considered and ultimately proved to be the diagnosis."
path(MESHD:"GBS") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Another study showed a near fourfold increase in the risk of being diagnosed with schizophrenia (RR = 3.6) and bipolar disorder (RR = 3.7) in patients diagnosed with AIP."
path(MESHD:"abdominal pain") association path(MESHD:"Borderline personality disorder")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "First-degree relatives of these individuals have almost twice the risk of presenting schizophrenia (RR = 1.6) and bipolar disorder (R = 1.8) [10Ã¢â‚¬Â¢Ã¢â‚¬Â¢]."
path(MESHD:"abdominal pain") association path(MESHD:"Borderline personality disorder")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "More evidence is needed to establish the porphyria-precipitating effect of oxybutynin and metronidazole."
path(MESHD:"abdominal pain") positiveCorrelation path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "However, all these drugs are available as oral preparations only and the treatment of status epilepticus in these patients therefore warrants the use of a rapidly acting drug which can be given parenterally and is safe in porphyria."
path(MESHD:"porphyria") decreases path(MESHD:"status epilepticus")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The difference between porphyria patients and the general population reached statistical significance for nervous system disorders, gastrointestinal disorders, renal disorders, mental disorders and pain (gastrointestinal diseases 22.2 % vs. 29.9 % p=.013, cardiovascular diseases 36.8 % vs. 41.7 % p=.150, renal diseases 6.4 % vs. 10.6 % p=.032, diseases of the nervous system 11.6 % vs. 20.5 % p=.0006, mental diseases 18.0% vs. 30.4% p = <.0001, pain 4.2% vs. 15.6% p = .0003)."
path(MESHD:"porphyria") decreases path(DO:"nervous system disorders")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria may be categorized clinically as acute hepatic, blistering cutaneous, or nonblistering cutaneous depending on clinical features."
path(MESHD:"porphyria") isA path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria may be categorized clinically as acute hepatic, blistering cutaneous, or nonblistering cutaneous depending on clinical features."
path(MESHD:"porphyria") isA path(MESHD:"AHP")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
path(MESHD:"porphyria") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "F female, M male, A I P acute intermittent porphyria, H C P hereditary coproporphyria, A D H D attention deficit hyperactivity disorder, B I D bis in die, T I D ter in die ^a Diagnosis not confirmed ^b Although not a core symptom in porphyria, it was the reason that triggered the porphyria workup ^c Doses given daily unless stated otherwise."
path(MESHD:"porphyria") association path(MESHD:"mental illness")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "In one long-term study on a cohort of selected patients with symptomatic AIP, >50 % developed porphyria associated kidney disease."
path(MESHD:"porphyria") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Based on the recorded causes of death, AHP patients had a higher risk of death related to renal disease ( n=12[1.0 %] vs. ref, n=37[0.3 %], p<0.001 ), PLC ( n=54[4.3 %] vs. ref, n=20[0.2 %], p<0.001 ) and porphyria ( n=10[0.8 %] vs. ref, n=0 )."
path(MESHD:"porphyria") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
path(MESHD:"porphyria") association path(MESHD:"chronic kidney disease")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Seizures may be due to hyponatremia or represent a neurological manifestation of porphyria."
path(MESHD:"porphyria") association path(MESHD:"hyponatremia")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "We also review symptoms and pathologies of lead intoxication that affect enzymes that mediate heme synthesis and share features with porphyrias."
path(MESHD:"porphyria") association a(CHEBI:"heme")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The porphyrias are a group of rare metabolic diseases related to altered functions in the eight enzymatic steps in the heme synthesis pathway."
path(MESHD:"porphyria") association a(CHEBI:"heme")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Genetic or acquired defects of one of the eight enzymes involved in the biosynthesis of heme can result in neurovisceral symptoms, cutaneous symptoms, or a combination of the two."
path(MESHD:"porphyria") association path(MESHD:"skin disease")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "The porphyrias are highly relevant to hepatologists since patients can present with symptoms and complications that require liver transplantation (LT), and some porphyrias are associated with a high risk for primary liver cancer (PLC)."
path(MESHD:"porphyria") association path(DO:"primary liver cancer")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
path(MESHD:"porphyria") association path(DO:"primary liver cancer")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Genetic or acquired defects of one of the eight enzymes involved in the biosynthesis of heme can result in neurovisceral symptoms, cutaneous symptoms, or a combination of the two."
path(MESHD:"porphyria") association path(MESHD:"Neuralgia")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "# Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad?"
path(MESHD:"porphyria") association path(MESHD:"Hyperhomocysteinemia")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
path(MESHD:"porphyria") association a(CHEBI:"ADP")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "HighÃ¢â‚¬ÂPLC risk and the need for LT assessment are among several reasons why hepatological expertise often is essential in the management of porphyria patients."
path(MESHD:"porphyria") association p(HGNC:"PLCD1")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The heme biosynthetic pathway showing intermediates, enzymes and types of porphyria associated with each enzyme."
path(MESHD:"porphyria") association p(HGNC:"PPOX")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Diagnosis should be suspected when there is prolonged and recurrent episodes of unexplained abdominal pain-particularly when it is associated with neurological complications such as peripheral motor neuropathy, convulsions, coma or bulbar paralysis, hyponatremia or prompted by fasting, diets, or exposure to certain medications [5]."
path(MESHD:"porphyria") association path(MESHD:"Psychiatric symptoms")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Diagnosis should be suspected when there is prolonged and recurrent episodes of unexplained abdominal pain-particularly when it is associated with neurological complications such as peripheral motor neuropathy, convulsions, coma or bulbar paralysis, hyponatremia or prompted by fasting, diets, or exposure to certain medications [5]."
path(MESHD:"porphyria") association path(MESHD:"somatoform disorders")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "| Table I. Use of antiepileptic drugs in porphyria | | | | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | | Study | Study type | Result | | Gabapentin | | | | Krauss et al."
path(MESHD:"porphyria") association a(CHEBI:"antiepileptic drugs")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "| Table I. Use of antiepileptic drugs in porphyria | | | | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | | Study | Study type | Result | | Gabapentin | | | | Krauss et al."
path(MESHD:"porphyria") association a(CHEBI:"Gabapentin")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Our current knowledge about AHP-related nonhepatic cancer risk, cardiovascular, and psychiatric comorbidity is limited, and it is unknown whether AHP-type or biochemical porphyria activity are associated with differences in risk."
path(MESHD:"porphyria") association path(DO:"cancer risk")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The difference in cardiovascular disease between porphyria patients and the general population was not significant ( 41.73 % vs. 36.79 % p=.150 ).All diseases except renal diseases were more frequent in the reference group with fibromyalgia compared to the porphyria patients."
path(MESHD:"porphyria") association path(MESHD:"cardiovascular diseases")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The difference between porphyria patients and the general population reached statistical significance for nervous system disorders, gastrointestinal disorders, renal disorders, mental disorders and pain (gastrointestinal diseases 22.2 % vs. 29.9 % p=.013, cardiovascular diseases 36.8 % vs. 41.7 % p=.150, renal diseases 6.4 % vs. 10.6 % p=.032, diseases of the nervous system 11.6 % vs. 20.5 % p=.0006, mental diseases 18.0% vs. 30.4% p = <.0001, pain 4.2% vs. 15.6% p = .0003)."
path(MESHD:"porphyria") association path(MESHD:"cardiovascular diseasess")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Lead intoxication causes a 10 -fold increase in urine levels of ALA and normal or only slight increases in urine levels of PBG, as in ALADP porphyria."
path(MESHD:"porphyria") association path(MESHD:"Lead intoxication")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "As in other acute porphyrias, the mechanism of neurological damage is not well understood."
path(MESHD:"porphyria") association path(MESHD:"acute")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Moreover, considering both the well-known role of kidney impairment in increasing plasma Hcy and the possible association between acute porphyrias and progressive impairment of kidney function (Table 1) (especially in patients presenting high ALA/PBG urinary excretion), in order to minimize this possible confounding factor, we controlled all our results for creatine clearance [1-2,8,10]."
path(MESHD:"porphyria") association path(MESHD:"acute")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, MedicAlert (www.medicalert.org) provides bracelets and wallet cards that contain information on acute porphyrias."
path(MESHD:"porphyria") association path(MESHD:"acute")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
path(MESHD:"porphyria") association path(MESHD:"acute")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "The metabolic (and clinical) activity of the acute porphyrias and the efficacy of therapy can be monitored by assessing metabolite excretion."
path(MESHD:"porphyria") association path(MESHD:"acute")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Chlorpromazine | Clonazepam, 1 mg BID, Nortriptyline 10 mg gradually increased to 50 mg ."
path(MESHD:"porphyria") association path(MESHD:"Acute")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "ADP must also be differentiated from other causes of ALAD deficiency such as lead poisoning and hereditary tyrosinemia type 1, which can cause increases in ALA, coproporphyrin III and erythrocyte protoporphyrin and symptoms very much like those in acute porphyrias."
path(MESHD:"porphyria") association path(MESHD:"Lead poisoning")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The porphyrias are a group of at least eight metabolic disorders caused by alterations in enzymes involved in heme biosynthesis (Figure 1)."
path(MESHD:"porphyria") association a(CHEBI:"heme biosynthesis")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Two young adults, ages 21 and 23 years, with severe HEP developed generalized seizures and had neuroimaging evidence of cerebral cortical atrophy and calcifications in the frontal lobes, presumably related to hypoxic injury as in other porphyrias (Berenguer et al. 1997)."
path(MESHD:"porphyria") association path(MESHD:"hypoxic injury")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Moreover, considering both the well-known role of kidney impairment in increasing plasma Hcy and the possible association between acute porphyrias and progressive impairment of kidney function (Table 1) (especially in patients presenting high ALA/PBG urinary excretion), in order to minimize this possible confounding factor, we controlled all our results for creatine clearance [1-2,8,10]."
path(MESHD:"porphyria") association path(MESHD:"kidney impairment")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "We also review symptoms and pathologies of lead intoxication that affect enzymes that mediate heme synthesis and share features with porphyrias."
path(MESHD:"porphyria") association path(MESHD:"lead intoxication")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "He was diagnosed as having porphyria during an episode of status epilepticus 1 year previously based on a positive urinary test for porphobilinogen and had been receiving gabapentin and levetiracetam ever since."
path(MESHD:"porphyria") positiveCorrelation path(MESHD:"status epilepticus")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is the most prevalent porphyria disease worldwide, with a prevalence in Denmark of approximately 1 / 10000,^2 yet little is known about its prognosis."
path(MESHD:"porphyria") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "The term PCT was first suggested by WaldenstrÃƒÂ¶m ^10 in 1937 to distinguish this form of porphyria from the rare photomutilating congenital erythropoetic porphyria (Gunther's Disease)."
path(MESHD:"porphyria") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "26743054.0"}
SET DataSource = "manual-curation"
SET Support = "Ein Beispiel fÃƒÂ¼r die symptomatische, exogene Form einer PCT ist die durch Hexachlorbenzol ausgelÃƒÂ¶ste porphyria turcica."
path(MESHD:"porphyria") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Its maximal activity in hepatocytes is limited, such that, when ALA syn-thase-1 is induced, it becomes secondarily rate-limiting for porphyrin and heme synthesis, with marked accumulations of PBG and ALA, the biochemical hallmarks of active acute hepatic porphyrias."
path(MESHD:"porphyria") positiveCorrelation a(CHEBI:"heme")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Some porphyrias are caused by processes in the liver,3 some can damage the liver, some can lead to primary liver cancer (PLC)"
path(MESHD:"porphyria") positiveCorrelation path(DO:"primary liver cancer")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The terms porphyrin and porphyria are derived from the Greek word porphyrus, meaning purple."
path(MESHD:"porphyria") positiveCorrelation a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Some women have cyclic menstrual attacks, progesterone increases heme catabolism, and synthetic estrogens and progesterones induce porphyria."
path(MESHD:"porphyria") positiveCorrelation bp(GOBP:"menstrual")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "The annual incidence of PLC was 0.52 % when restricted to those with selfreported manifest porphyria disease only, and 0.86 % when further restricted to individuals with manifest AHP disease and aged 50 years or older."
path(MESHD:"porphyria") positiveCorrelation p(HGNC:"PLCD1")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Think of porphyria when a patient presents with unexplained abdominal and neuropsychiatric symptoms and/or photosensitivity."
path(MESHD:"porphyria") positiveCorrelation path(MESHD:"neuropsychiatric symptoms")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Most AEDs such as carbamazepine (CBZ), phenytoin (PHT), valproate (VPA), and lamotrigine (LTG) may precipitate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis."
path(MESHD:"porphyria") positiveCorrelation a(CHEBI:"phenytoin")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Some porphyrias are caused by processes in the liver,3 some can damage the liver, some can lead to primary liver cancer (PLC)"
path(MESHD:"porphyria") positiveCorrelation path(MESHD:"liver disease")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Figure 1).4, 5, 6 Furthermore, a plasma fluorescence scan can discriminate the characteristic emission maxima of the metabolites and support the biochemical diagnosis (Table 1).6 Beside the hepatic and erythropoietic porphyrias, secondary elevation in porphyrins have been found in patients with other diseasesÃ¢â‚¬â€especially in patients with chronic liver diseases (Supplementary Table 1).7, 8, 9, 10, 11, 12, 13 We review the pathogenesis, symptoms, and treatment of the most frequent porphyrias (PCT, AIP, and EPP) (Table 2).5, 6, 14 We present typical cases, diagnoses, and treatments and discuss therapeutic strategies in development."
path(MESHD:"porphyria") positiveCorrelation bp(MESHPP:"fluorescence")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Microabscesses formed under the stratum corneum, with neutrophilic and eosinophilic invasion, and neutrophilic exocytosis was observed in the epidermis (hematoxylin and eosin staining, Ãƒâ€”20 and Ãƒâ€”40 magnification) Table 3 porphyria classification | Type of porphyria | Enzyme inheritance | Inheritance | Clinical manifestation | | Urine concentration | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | | | | Skin | Neuropsychiatric | | | Plumboporphyria | Porphobilinogen synthase | AR, 9q34 | - | + | ALA COPRO-gen III | | Acute intermittent porphyria | Hydroxymethylbilane synthase | AD, 11q23 | - | + Abdominal pain, neuropathy, mental changes, and tachycardia | PBG ÃÆ’-ALA | | Congenital erythropoietic | Uroporphyrinogen III synthase | AR, 10q26 | + | - Skin lesion and hepatopathy in early childhood | UPG I COPRO-gen I | | porphyria cutanea tarda | Uroporphyrinogen decarboxylase | AD, 1q34 | ++ | - Dark urine, occurring after middle age | UPG | | Hereditary coproporphyria | Coproporphyrinogen oxidase | AD, 9 | + | + Abd"
path(MESHD:"porphyria") positiveCorrelation bp(GOBP:"exocytosis")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The porphyrias are a group of disorders of heme biosynthesis, each characterized by an enzymatic defect in the heme biosynthetic pathway."
path(MESHD:"porphyria") positiveCorrelation bp(GO:"heme biosynthetic process")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyrias are characterized by attacks of neurovisceral manifestations such as seizures, neuropathy, and psychosis (Solinas and Vajda, 2004; Kauppinen, 2005)."
path(MESHD:"porphyria") increases path(MESHD:"seizures")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Urine from porphyria patients may be dark or reddish in color due to the presence of excess porphyrins and related substances, and may darken further after exposure to light."
path(MESHD:"porphyria") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "In PCT, a number of different liver diseases may precipitate into the liver disease, whereas, in EPP, it is the porphyria itself which leads to liver disease, due to progressive deposition and accumulation of insoluble protoporphyrinIX in hepatocytes and bile canaliculi."
path(MESHD:"porphyria") increases path(MESHD:"liver disease")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "It should be emphasized that our case report presents a patient with partial and secondarily generalized seizures within the scope of a cryptogenic focal epilepsy since childhood, and that no porphyria-induced generalized seizures as seen in a porphyric crisis were reported."
path(MESHD:"porphyria") increases path(MESHD:"generalized seizures")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "Recurrent attacks of porphyria may lead to progressive or irreversible neuropathy and prolonged debilitation [2, 11]."
path(MESHD:"porphyria") increases path(MESHD:"neuropathy")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyrias are characterized by attacks of neurovisceral manifestations such as seizures, neuropathy, and psychosis (Solinas and Vajda, 2004; Kauppinen, 2005)."
path(MESHD:"porphyria") increases path(MESHD:"neuropathy")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Patients can develop cirrhosis due to accu- mulation of porphyria in the hepatocytes and subsequent parenchymal damage."
path(MESHD:"porphyria") increases path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Our analysis corroborates some of the Ã¢â‚¬Å“red flagsÃ¢â‚¬Â identified in the EXPLORE Study (prospective, multinational, natural history study characterizing disease activity).9 As gastrointestinal disorders, pain, and neurological disorders are more common in porphyria patients than in the general population, it can be assumed that the combination of abdominal or back pain with at least one additional symptom, mainly of a neurological nature, is also applicable to this cohort and is expected to be encountered predominantly by the specified medical specialties."
path(MESHD:"porphyria") increases path(MESHD:"gastrointestinal disorders")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Our analysis corroborates some of the Ã¢â‚¬Å“red flagsÃ¢â‚¬Â identified in the EXPLORE Study (prospective, multinational, natural history study characterizing disease activity).9 As gastrointestinal disorders, pain, and neurological disorders are more common in porphyria patients than in the general population, it can be assumed that the combination of abdominal or back pain with at least one additional symptom, mainly of a neurological nature, is also applicable to this cohort and is expected to be encountered predominantly by the specified medical specialties."
path(MESHD:"porphyria") increases path(MESHD:"neurological disorders")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The major clinical manifestations of the porphyrias are either neurologic, usually in the form of acute attacks, or cutaneous, resulting from phototoxicity."
path(MESHD:"porphyria") increases path(MP:"phototoxicity")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "erythropoietic protoporphyrias (EPP and XLEPP) can develop a severe cholestatic liver disease that is often fatal without a liver transplantation. In AP, some patients have severe recurrent attacks that do not respond to treatment and LT is a curative treatment option. Hence, the treatment aims for LT in porphyrias can be quite different."
path(MESHD:"porphyria") increases path(MESHD:"cholestatic liver disease")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "To our knowledge, this is the first study to explore the association between AIP and bipolar disorder and the largest to date to test the association between AIP and schizophrenia."
path(MESHD:"schizophrenia") association path(MESHD:"bipolar disorder")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Bipolar disorder was also included, due to its genetic overlap with schizophrenia."
path(MESHD:"schizophrenia") association path(MESHD:"bipolar disorder")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "^3 Interestingly, the PBGD MspI 2.2 kb allele was subsequently associated with schizophrenia, ^4 but later studies failed to replicate this finding."
path(MESHD:"schizophrenia") association p(HGNC:"HMBS")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Current thinking is that decreased GABAergic neurons' activity in conjunction with increased glutamate release [25], increased oxidative stress [26Ã¢â‚¬Â¢], and increased metabolites of kynurenine pathway [27] leads to disease pathology."
path(MESHD:"schizophrenia") association bp(GO:"tryptophan metabolic pathway")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Intriguingly, the kynurenine pathway has been implicated in both schizophrenia ^13 and bipolar disorder."
path(MESHD:"schizophrenia") association bp(GO:"tryptophan metabolic pathway")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Complicating matters further, some literature suggests individuals with porphyria are more likely to have anxious and obsessive personalities [11, 15].Additionally, somatoform disorders, in particular factitious disorder; a condition that if not identified, exposes the patient to unnecessary risks such as inadequate procedures and treatments, including potentially addictive drugs [12, 16]."
path(MESHD:"schizophrenia") association path(MESHD:"AP")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "individuals with AIP had double the risk of schizophrenia or bipolar disorder, suggesting that these associations may be as a result of common genetic influences."
path(MESHD:"schizophrenia") positiveCorrelation path(MESHD:"AIP")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "# Acute intermittent porphyria: comorbidity and shared familial risks with schizophrenia and bipolar disorder in Sweden"
path(MESHD:"schizophrenia") positiveCorrelation path(MESHD:"AIP")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "In sum, we found strong associations between AIP and schizophrenia and bipolar disorder that merit further attention in research and clinical practice."
path(MESHD:"bipolar disorder") association path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "^12 Because our study is based on a considerably larger cohort of individuals with AIP as compared with prior studies, and because we were able to assess a matched unexposed cohort, it lends strong support for the idea that AIP is linked to schizophrenia and bipolar disorder."
path(MESHD:"bipolar disorder") association path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "AIP can be seen as a natural model of psychotic and affective illness, as the signs and symptoms in many respects are similar to schizophrenia and bipolar disorder."
path(MESHD:"bipolar disorder") association path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Intriguingly, the kynurenine pathway has been implicated in both schizophrenia ^13 and bipolar disorder."
path(MESHD:"bipolar disorder") association path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Recent Findings Recent literature begins to clarify associations between AP, schizophrenia, bipolar disorder, and other psychopathology."
path(MESHD:"bipolar disorder") association path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Intriguingly, the kynurenine pathway has been implicated in both schizophrenia ^13 and bipolar disorder."
path(MESHD:"bipolar disorder") association bp(GO:"tryptophan metabolic pathway")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 shows the most common psychiatric disorders implicated in acute porphyria."
path(MESHD:"bipolar disorder") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Individuals with manifest AIP (exposure) and individuals with diagnoses of schizophrenia and bipolar disorder (outcomes) were identified through their first diagnoses of the respective disorder in the Swedish Patient Register."
path(MESHD:"bipolar disorder") positiveCorrelation path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "To assess risks of schizophrenia and bipolar disorder in individuals with manifest AIP (and their relatives) compared with individuals without manifest AIP (and their relatives), we estimated risk ratios (RRs) and 95 % confidence intervals using conditional logistic regressions."
path(MESHD:"bipolar disorder") positiveCorrelation path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Because shared familial risks, including genetic and environmental factors, are indicated when relatives of individuals with AIP have schizophrenia or bipolar disorder but not manifest AIP, ^11 we specified the analyses according to these conditions."
path(MESHD:"bipolar disorder") positiveCorrelation path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Compared with individuals without manifest AIP, individuals with AIP had fourfold increased risks of being diagnosed with schizophrenia ( RR=3.6,95 %CI 2.0-6.4 ) or bipolar disorder ( RR=3.7,95 %CI 2.1-6.7 )."
path(MESHD:"bipolar disorder") positiveCorrelation path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "First-degree relatives of individuals with AIP had double the risk of schizophrenia ( RR=1.6,95 % CI 1.0-2.7 ) and bipolar disorder ( RR=1.8,95 %CI 1.0-3.2, online Table DS1)."
path(MESHD:"bipolar disorder") positiveCorrelation path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "We observed that individuals with manifest AIP had a fourfold excess risk of being diagnosed with schizophrenia or bipolar disorder."
path(MESHD:"bipolar disorder") positiveCorrelation path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, first-degree relatives of individuals with AIP had double the risk of both schizophrenia and bipolar disorder."
path(MESHD:"bipolar disorder") positiveCorrelation path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Here, we linked Swedish registers to examine the risk of schizophrenia and bipolar disorder in 717 individuals diagnosed with AIP and their first-degree relatives, compared with matched individuals without AIP and their first-degree relatives."
path(MESHD:"bipolar disorder") positiveCorrelation path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Individuals with AIP had a fourfold increased risk of schizophrenia or bipolar disorder."
path(MESHD:"bipolar disorder") positiveCorrelation path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "individuals with AIP had double the risk of schizophrenia or bipolar disorder, suggesting that these associations may be as a result of common genetic influences."
path(MESHD:"bipolar disorder") positiveCorrelation path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"bipolar disorder") positiveCorrelation path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "# Acute intermittent porphyria: comorbidity and shared familial risks with schizophrenia and bipolar disorder in Sweden"
path(MESHD:"bipolar disorder") positiveCorrelation path(MESHD:"AIP")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Therefore, PRES should be suspected whenever patients develope headache or seizure after being given cyclosporine A. Prompt withdrawal of the offending drug is very important in such cases."
path(MESHD:"seizure") association a(CHEBI:"cyclosporine")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Despite having undergone several AED treatments [PHT, carbamazepine (CBZ), valproate (VPA), lamotrigine (LTG), primidone (PRM), and GBP] over the years, no seizure-free interval had been observed."
path(MESHD:"seizure") association a(CHEBI:"carbamazepine")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "After hematin administration and intense rehabilitation, the patient slowly recovered from the full-blown acute porphyria attack."
path(MESHD:"constipation") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Gastrointestinal diseases include abdominal pain, appendicitis, nausea and vomiting, constipation, diarrhoea and ileus."
path(MESHD:"constipation") association path(MESHD:"gastrointestinal disorders")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Six years ago, in the fifth week of pregnancy, the woman developed acute and severe diffuse abdominal pain, accompanied by nausea, vomiting, constipation, persistent chest, back, and lower back pain, and red urine."
path(MESHD:"constipation") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "## Case Report A 24-year-old woman was admitted with generalized abdominal pain, constipation, and recurrent vomiting for 6 days."
path(MESHD:"constipation") positiveCorrelation path(MESHD:"vomiting")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "We concluded that the attacks of acute porphyria occurred over a 2-month span, characterized by abdominal pain, constipation, autonomic neuropathy, peripheral neuropathy, psychosis, delirium, and metabolic disturbances."
path(MESHD:"constipation") positiveCorrelation path(MESHD:"Arnold Chiari malformation")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "A 30-year-old woman with AIP had recurrent acute abdominal pain, nausea and vomiting, constipation, persistent chest, back, and waist pain, red urine, positivity for porphobilinogen (PBG) in urine and a pathogenic mutation of the HMBS gene."
path(MESHD:"constipation") positiveCorrelation path(MESHD:"acute abdominal pain")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "This is often accompanied by constipation, nausea, vomiting, and symptoms of ileus and paresthesia."
path(MESHD:"constipation") positiveCorrelation path(MESHD:"ileus")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "This is often accompanied by constipation, nausea, vomiting, and symptoms of ileus and paresthesia."
path(MESHD:"constipation") positiveCorrelation path(MESHD:"paresthesia")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "The diagnosis of porphyria was confirmed by a positive urine porphobilinogen on three consecutive samples."
a(CHEBI:"porphobilinogen") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Pulmonary infections were associated each time with an increasing titration of porphobilinogen; the first episode was also associated with seizures and hyponatremia."
a(CHEBI:"porphobilinogen") increases path(MESHD:"seizures")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The occurrence of PRES in AIP patients may be due to the abnormal accumulation of porphyrin metabolites in the body caused by AIP"
a(CHEBI:"porphobilinogen") increases path(MESHD:"PRES")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyrias (APs) are inherited disorders caused by deficiencies in one of the enzymes involved in haem biosynthesis, leading to overproduction of potentially neurotoxic porphyrin precursors (delta-aminolaevulinic acid [ALA] and porphobilinogen [PBG]) in the liver when the rate-limiting enzyme, ALA synthase 1 (ALAS1), is activated."
a(CHEBI:"porphobilinogen") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Pulmonary infections were associated each time with an increasing titration of porphobilinogen; the first episode was also associated with seizures and hyponatremia."
a(CHEBI:"porphobilinogen") increases path(MESHD:"Pulmonary infections")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "causing cardiovascular spasm, contraction, and other abnormal manifestations, triggering vasogenic edema and leading to the onset of PRES"
a(CHEBI:"porphobilinogen") increases path(MESHD:"Cerebral Edema")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "AHP is characterized by the accumulation of porphyrins and/or the precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in the biosynthesis of haem."
a(CHEBI:"porphobilinogen") increases a(CHEBI:"heme")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "Resultant overproduction of the neurotoxic intermediates ÃŽÂ´-aminolevulinic acid (ALA) and porphobilinogen (PBG) leads to disabling acute neurovisceral attacks and progressive neuropathy."
a(CHEBI:"porphobilinogen") increases path(MESHD:"neuropathy")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "causing cardiovascular spasm, contraction, and other abnormal manifestations, triggering vasogenic edema and leading to the onset of PRES"
a(CHEBI:"porphobilinogen") increases path(MESHD:"Coronary Artery Spasm")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "In this case, the patient presented initially with epilepsy, accompanied byPRES.It is relatively rare for AIP patients to present epilepsy as the frst symptom."
path(MESHD:"epilepsy") association path(MESHD:"PRES")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The occurrence of epilepsy with PRES in AIP patients is relatively rare, suggesting that the neu rological efects of AIP may be more complex."
path(MESHD:"epilepsy") association path(MESHD:"PRES")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Consequently, there is only a limited range of alternative seizure treatments for patients with porphyria and coexisting epilepsy."
path(MESHD:"epilepsy") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Two population studies from Canada reported a higher prevalence of stroke, diabetes, heart disease, high blood pressure, asthma, chronic bronchitis, stomach/intestinal ulcers, arthritis, thyroid conditions, migraine, Alzheimer's disease and cancer in persons with a history of epilepsy."
path(MESHD:"epilepsy") association path(MESHD:"high blood pressure")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Two population studies from Canada reported a higher prevalence of stroke, diabetes, heart disease, high blood pressure, asthma, chronic bronchitis, stomach/intestinal ulcers, arthritis, thyroid conditions, migraine, Alzheimer's disease and cancer in persons with a history of epilepsy."
path(MESHD:"epilepsy") association path(MESHD:"heart disease")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "The second session addressed different aspects of brain development implicated in epileptogenesis, Renzo Guerrini presented data on genetic disorders of cortical development associated with epilepsy."
path(MESHD:"epilepsy") association bp(GOBP:"brain development")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "The second session addressed different aspects of brain development implicated in epileptogenesis, Renzo Guerrini presented data on genetic disorders of cortical development associated with epilepsy."
path(MESHD:"epilepsy") association path(MESHD:"genetic disorders")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "^70 Preliminary data from recent and small clinical series indicate that PGB and ZNS may represent valid alternatives as add-ons in brain tumour-related epilepsy, although larger studies are needed."
path(MESHD:"epilepsy") association path(MESHD:"brain tumour")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Two population studies from Canada reported a higher prevalence of stroke, diabetes, heart disease, high blood pressure, asthma, chronic bronchitis, stomach/intestinal ulcers, arthritis, thyroid conditions, migraine, Alzheimer's disease and cancer in persons with a history of epilepsy."
path(MESHD:"epilepsy") association path(MESHD:"asthma")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Two population studies from Canada reported a higher prevalence of stroke, diabetes, heart disease, high blood pressure, asthma, chronic bronchitis, stomach/intestinal ulcers, arthritis, thyroid conditions, migraine, Alzheimer's disease and cancer in persons with a history of epilepsy."
path(MESHD:"epilepsy") association path(MESHD:"migraine")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Hematin therapy was eventually discontinued as the patient was convinced it worsened her epilepsy."
path(MESHD:"epilepsy") association a(CHEBI:"Hematin")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Nervous system disorders cover e.g. epilepsy, polyneuropathy, convulsions, paranesthesia, and motor weakness."
path(MESHD:"epilepsy") association path(DO:"Nervous system disorders")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "A mutation in the HMBS gene was detected in the patient and her cousin, but the patient had more severe AIP and more severe symptoms (such as epilepsy and a limp), which may be related to the co-morbidity of PSS."
path(MESHD:"epilepsy") positiveCorrelation path(MESHD:"AIP")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "A mutation in the HMBS gene was detected in the patient and her cousin, but the patient had more severe AIP, more frequent seizures, and more severe symptoms (such as epilepsy and a limp), which may be related to the co-morbidity of PSS."
path(MESHD:"epilepsy") positiveCorrelation path(MESHD:"seizures")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "On the other hand, there were typical clinical manifestations of PSS such as dry eyes and a dry mouth, the elevation of immunoglobulins (IgG and IgA) and the results of Schirmer's test, an anti-SS-A antibody test, an anti-SS-B antibody test, and a labial gland biopsy were all positive."
a(GO:"IgG") positiveCorrelation path(MESHD:"dry eyes")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "On the other hand, there were typical clinical manifestations of PSS such as dry eyes and a dry mouth, the elevation of immunoglobulins (IgG and IgA) and the results of Schirmer's test, an anti-SS-A antibody test, an anti-SS-B antibody test, and a labial gland biopsy were all positive."
a(GO:"IgG") positiveCorrelation path(MESHD:"dry mouth")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Peripheral neuropathy causing pain and weakness can progress to quadraparesis and respiratory embarrassment."
path(MESHD:"Peripheral neuropathy") increases path(MESHD:"quadraparesis")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "demonstrated the porphyrogenic quality of LTG, tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria, whereas vigabatrin (VGB) did not increase the level of ÃŽÂ´-aminolevulinic acid synthase."
a(CHEBI:"5-aminolevulinic acid") association a(CHEBI:"tiagabine")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "ALA acts as an agonist of GABA autoreceptors [31], de creasing release of GABA. ALA accumulation inhibits astro cyte glutamate uptake and stimulates glutamate release, caus ingneural toxicity[32]. ALA accumulations also lead to the formation of reactive oxygen species (ROS) which increases oxidative damage to lipids and proteins [26Ã¢â‚¬Â¢]. The neuronal damage byALAoxidation has a special affinity for GABA-A receptors, which leads to an even more substantial hypo GABAergic state [33]. A rat study concluded that, with expo sure to ALA, the concentration of GABAergic synaptic sites decreased by 50%"
a(CHEBI:"5-aminolevulinic acid") decreases bp(GO:"glutamate reuptake")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "ALA acts as an agonist of GABA autoreceptors [31], de creasing release of GABA. ALA accumulation inhibits astro cyte glutamate uptake and stimulates glutamate release, caus ingneural toxicity[32]. ALA accumulations also lead to the formation of reactive oxygen species (ROS) which increases oxidative damage to lipids and proteins [26Ã¢â‚¬Â¢]. The neuronal damage byALAoxidation has a special affinity for GABA-A receptors, which leads to an even more substantial hypo GABAergic state [33]. A rat study concluded that, with expo sure to ALA, the concentration of GABAergic synaptic sites decreased by 50%"
a(CHEBI:"5-aminolevulinic acid") decreases bp(GO:"synaptic transmission, GABAergic")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The occurrence of PRES in AIP patients may be due to the abnormal accumulation of porphyrin metabolites in the body caused by AIP"
a(CHEBI:"5-aminolevulinic acid") increases path(MESHD:"PRES")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "causing cardiovascular spasm, contraction, and other abnormal manifestations, triggering vasogenic edema and leading to the onset of PRES"
a(CHEBI:"5-aminolevulinic acid") increases path(MESHD:"Cerebral Edema")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "Resultant overproduction of the neurotoxic intermediates ÃŽÂ´-aminolevulinic acid (ALA) and porphobilinogen (PBG) leads to disabling acute neurovisceral attacks and progressive neuropathy."
a(CHEBI:"5-aminolevulinic acid") increases path(MESHD:"neuropathy")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "ALA acts as an agonist of GABA autoreceptors [31], de creasing release of GABA. ALA accumulation inhibits astro cyte glutamate uptake and stimulates glutamate release, caus ingneural toxicity[32]. ALA accumulations also lead to the formation of reactive oxygen species (ROS) which increases oxidative damage to lipids and proteins [26Ã¢â‚¬Â¢]. The neuronal damage byALAoxidation has a special affinity for GABA-A receptors, which leads to an even more substantial hypo GABAergic state [33]. A rat study concluded that, with expo sure to ALA, the concentration of GABAergic synaptic sites decreased by 50%"
a(CHEBI:"5-aminolevulinic acid") increases bp(GO:"response to oxidative stress")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "ALA acts as an agonist of GABA autoreceptors [31], de creasing release of GABA. ALA accumulation inhibits astro cyte glutamate uptake and stimulates glutamate release, caus ingneural toxicity[32]. ALA accumulations also lead to the formation of reactive oxygen species (ROS) which increases oxidative damage to lipids and proteins [26Ã¢â‚¬Â¢]. The neuronal damage byALAoxidation has a special affinity for GABA-A receptors, which leads to an even more substantial hypo GABAergic state [33]. A rat study concluded that, with expo sure to ALA, the concentration of GABAergic synaptic sites decreased by 50%"
a(CHEBI:"5-aminolevulinic acid") increases a(CHEBI:"reactive oxygen species")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "causing cardiovascular spasm, contraction, and other abnormal manifestations, triggering vasogenic edema and leading to the onset of PRES"
a(CHEBI:"5-aminolevulinic acid") increases path(MESHD:"Coronary Artery Spasm")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "ALA acts as an agonist of GABA autoreceptors [31], de creasing release of GABA. ALA accumulation inhibits astro cyte glutamate uptake and stimulates glutamate release, caus ingneural toxicity[32]. ALA accumulations also lead to the formation of reactive oxygen species (ROS) which increases oxidative damage to lipids and proteins [26Ã¢â‚¬Â¢]. The neuronal damage byALAoxidation has a special affinity for GABA-A receptors, which leads to an even more substantial hypo GABAergic state [33]. A rat study concluded that, with expo sure to ALA, the concentration of GABAergic synaptic sites decreased by 50%"
a(CHEBI:"5-aminolevulinic acid") increases bp(GO:"Positive Glutamate Release")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "ALA acts as an agonist of GABA autoreceptors [31], de creasing release of GABA. ALA accumulation inhibits astro cyte glutamate uptake and stimulates glutamate release, caus ingneural toxicity[32]. ALA accumulations also lead to the formation of reactive oxygen species (ROS) which increases oxidative damage to lipids and proteins [26Ã¢â‚¬Â¢]. The neuronal damage byALAoxidation has a special affinity for GABA-A receptors, which leads to an even more substantial hypo GABAergic state [33]. A rat study concluded that, with expo sure to ALA, the concentration of GABAergic synaptic sites decreased by 50%"
a(CHEBI:"5-aminolevulinic acid") increases path(MESHD:"Neurotoxicity Syndromes")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Heme synthesis requires condensation of glycine and succinyl-CoA into 5-aminolevulinic acid (5-ALA) and the subsequent enzymatic conversion of 5-ALA into heme."
a(CHEBI:"5-aminolevulinic acid") increases a(CHEBI:"Heme")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
path(MESHD:"muscle weakness") increases path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
path(MESHD:"muscle weakness") increases path(MESHD:"vomiting")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Neuropathy, mostly muscle weakness, develops when contraindicated drugs are used."
path(MESHD:"muscle weakness") increases path(MESHD:"Neuropathy")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
path(MESHD:"muscle weakness") increases path(MESHD:"hallucinations")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
path(MESHD:"muscle weakness") increases path(MESHD:"urinary retention")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Patients treated with givosiran may have normal excretion of porphyrin precursors, as levels usually normalise before chronic neurological symptoms subside.27 All comorbidities should be excluded in any patient with AP who has chronic symptoms."
path(MESHD:"neurological symptoms") association a(DB:"Givosiran")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"renal artery stenosis") association path(MESHD:"PRES")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"renal artery stenosis") association path(MESHD:"eclampsia")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"renal artery stenosis") association path(MESHD:"lupus nephritis")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"renal artery stenosis") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "The co-morbidities in those patients with high blood pressure included eclampsia, primary renal disease and lupus."
path(MESHD:"lupus") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "The co-morbidities in those patients with high blood pressure included eclampsia, primary renal disease and lupus."
path(MESHD:"lupus") positiveCorrelation path(MESHD:"eclampsia")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Thus, PRES should be suspected when patients with SLE have acute headache and seizures, especially in those patients who have high blood pressure and are on immunosuppressive treatments."
path(MESHD:"headache") association path(MESHD:"PRES")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "B1-B4 are cranial Flair-MRI of a 20-year-old-woman with renal artery stenosis who presented headache and seizures."
path(MESHD:"headache") association path(MESHD:"renal artery stenosis")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical presentations included seizures ( 91.7 % ), headache ( 83.3 % ), visual disturbance ( 62.5 % ), encephalophathy ( 29.2 % ), and paralysis ( 8.3 % )."
path(MESHD:"headache") positiveCorrelation path(MESHD:"seizures")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "## Clinical Presentations and Prognosis Seizures and headache were the most common symptoms and occurred in 22 ( 91.7 % ) and 20 ( 83.3 % ) patients, respectively."
path(MESHD:"headache") positiveCorrelation path(MESHD:"seizures")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "This case report presents the case of a 20-year-old female patient who sought emergency medical attention for severe abdominal pain, nausea and vomiting, tachycardia, hypertension, and discolored urine."
path(MESHD:"tachycardia") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "A 20-year-old female presented to the Emergency Department with a clinical tableau characterized by severe abdominal pain, persistent vomiting, tachycardia, hypertension, and notable dark-colored urine."
path(MESHD:"tachycardia") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "A 20-year-old female presented to the Emergency Department with a clinical tableau characterized by severe abdominal pain, persistent vomiting, tachycardia, hypertension, and notable dark-colored urine."
path(MESHD:"tachycardia") positiveCorrelation path(MESHD:"vomiting")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "In the following two years, the patient's epilepsy deteriorated with focal unaware seizures occurring every two to three months and eight episodes of convulsive status epilepticus despite optimizing dosages and replacing lacosamide with pregabalin."
path(MESHD:"status epilepticus") decreases path(MESHD:"epilepsy")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "One patients was misdiagnosed during the initial stage because of atypical imaging findings, and 2 patients were diagnosed with lupus encephalopathy and given steroid and immunosupressant treatments."
a(SCTID:"immunosuppressant") decreases path(MESHD:"lupus")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Before the onset of neurological symptoms, 10 patients used steroids or immunosuppressants."
a(SCTID:"immunosuppressant") isA a(CHEBI:"steroids")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"eclampsia") association path(MESHD:"PRES")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"eclampsia") association path(MESHD:"lupus nephritis")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"eclampsia") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Co-morbid conditions include connective tissue diseases, renal disease, eclampsia, thrombotic thrombocytopenic, and acute intermittent porphyria."
path(MESHD:"eclampsia") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Co-morbid conditions include connective tissue diseases, renal disease, eclampsia, thrombotic thrombocytopenic, and acute intermittent porphyria."
path(MESHD:"eclampsia") association path(MESHD:"connective tissue diseases")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "A1-A4 are cranial MRIs of a 23-year-old woman with eclampsia who presented with headache."
path(MESHD:"eclampsia") positiveCorrelation path(MESHD:"headache")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
path(MESHD:"eclampsia") increases path(MESHD:"PRES")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
path(MESHD:"eclampsia") increases path(MESHD:"hypertension")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
path(MESHD:"eclampsia") increases path(MESHD:"acute renal failure")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"lupus nephritis") association path(MESHD:"PRES")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "A high proportion of patients had comorbidities, including peripheral neuropathy, hypertension, liver and kidney disease, and psychiatric disorders (Fig. 1)."
path(MESHD:"kidney disease") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
path(MESHD:"kidney disease") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "The association of CKD with AIP has been suggested since the 1990s. The clinical entity can be classified as porphyria- associated kidney disease (PAKD), as CKD is more likely to occur in symptomatic patients with PBG and ALA excess."
path(MESHD:"kidney disease") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"kidney disease") association path(MESHD:"lupus nephritis")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Co-morbid conditions include connective tissue diseases, renal disease, eclampsia, thrombotic thrombocytopenic, and acute intermittent porphyria."
path(MESHD:"kidney disease") association path(MESHD:"connective tissue diseases")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"kidney disease") association path(MESHD:"SLE")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
path(MESHD:"kidney disease") association path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Lymphoma, renal disease, neuropathy, and SjÃƒÂ¶gren syndrome manifest incomplete overlap with the cryoglobulinemic syndrome."
path(MESHD:"kidney disease") association path(MESHD:"lymphoma")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "The association of CKD with AIP has been suggested since the 1990s. The clinical entity can be classified as porphyriaÃ¢â‚¬Âassociated kidney disease (PAKD),23 as CKD is more likely to occur in symptomatic patients with PBG and ALA excess."
path(MESHD:"kidney disease") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | SjÃƒÂ¶gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
path(MESHD:"kidney disease") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^39 HCP and VP can also cause skin photosensitivity that in AIP only occurs when severe renal disease leads to further accumulation of plasma porphyrins."
path(MESHD:"kidney disease") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Renal diseases are defined as renal insufficiency, renal colic and interstitial nephritis."
path(MESHD:"kidney disease") increases path(MESHD:"interstitial nephritis")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Co-morbid conditions include connective tissue diseases, renal disease, eclampsia, thrombotic thrombocytopenic, and acute intermittent porphyria."
path(MESHD:"connective tissue diseases") association path(MESHD:"thrombocytopenic")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
path(MESHD:"acute renal failure") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy. ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
path(MESHD:"acute renal failure") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Ten patients ( 41.7 % ) used steroids or immunosuppressants, three ( 12.5 % ) had acute renal failure before the symptoms."
path(MESHD:"acute renal failure") association a(SCTID:"immunosuppressant")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Thus, PRES should be suspected when patients with SLE have acute headache and seizures, especially in those patients who have high blood pressure and are on immunosuppressive treatments."
path(MESHD:"SLE") association path(MESHD:"PRES")

SET Citation = {"PubMed", "26743054.0"}
SET DataSource = "manual-curation"
SET Support = "Die Therapie der ersten Wahl ist Chloroquin, das aber im Gegensatz zur Behandlung bei Malaria oder systemischem Lupus erythematodes (SLE) nur 2-mal/Woche in einer Dosis von 125 mg gegeben wird."
path(MESHD:"SLE") association path(MESHD:"Malaria")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Epilepsy, AIP, and SLE can also coexist independently, which was most likely the case with our patient who had a long-standing history of focal epilepsy."
path(MESHD:"SLE") association path(MESHD:"Epilepsy")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Additional manifestations of HH include hyperpigmentation, cardiomyopathy, diabetes mellitus, hypogonadism, hypothyroidism, and arthropathy due to pseudogout."
path(MESHD:"diabetes mellitus") association path(MESHD:"cardiomyopathy")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
path(MESHD:"diabetes mellitus") decreases p(HGNC:"ALAD")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "# Chapter 1 Diagnosis of Dermatologic Cutaneous Diseases Review ## Diagnosing diabetes mellitus in patients with porphyria cutanea tarda Anne L. Christiansen ^1, MD (D), Anette Bygum ^2, DMSc, Ole Hother-Nielsen ^3, DMSc, and Lars M. Rasmussen ^1, DMSc ^1 Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense C, Denmark, ^2 Department of Dermatology and Allergy Centre, Odense University Hospital, Odense C, Denmark, and ^3 Department of Endocrinology, Odense University Hospital, Odense C, Denmark ## Correspondence Anne Lindegaard Christiansen, MD Department of Clinical Biochemistry and Pharmacology Odense University Hospital Kloevervaenget 47, Indgang 40 5000 Odense C Denmark E-mail: anne.lindegaard@rsyd.dk [^0] ## Abstract The prevalence of diabetes mellitus is increased in patients with porphyria cutanea tarda."
path(MESHD:"diabetes mellitus") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "Besides increased risk of developing hepatocellular carcinoma, these patients also have an augmented risk of developing diabetes mellitus (DM)."
path(MESHD:"diabetes mellitus") positiveCorrelation path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"Takayasu arteritis") association path(MESHD:"PRES")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"Takayasu arteritis") association path(MESHD:"eclampsia")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"Takayasu arteritis") association path(MESHD:"lupus nephritis")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"Takayasu arteritis") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"purpura") association path(MESHD:"PRES")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"purpura") association path(MESHD:"renal artery stenosis")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"purpura") association path(MESHD:"eclampsia")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"purpura") association path(MESHD:"lupus nephritis")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"purpura") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Our study showed that PRES was associated with a variety of disorders, including SLE with lupus nephritis, primary kidney disease, eclampsia, renal artery stenosis, Takayasu arteritis, allergic purpura, and acute intermittent porphyria."
path(MESHD:"purpura") association path(MESHD:"Takayasu arteritis")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Methotrexate is commonly used to alleviate the symptoms of arthritis (11) and skin lesions (12) in patients with PSS."
a(CHEBI:"Methotrexate") decreases path(MESHD:"arthritis")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Methotrexate is commonly used to alleviate the symptoms of arthritis (11) and skin lesions (12) in patients with PSS."
a(CHEBI:"Methotrexate") decreases path(MESHD:"skin lesions")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "A porphyrinogenic capacity has also been shown in in vitro studies on LTG and TGB."
a(CHEBI:"tiagabine") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "demonstrated the porphyrogenic quality of LTG, tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria, whereas vigabatrin (VGB) did not increase the level of ÃŽÂ´-aminolevulinic acid synthase."
a(CHEBI:"felbamate") increases a(CHEBI:"ÃŽÂ´-aminolevulinic acid")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "A porphyrinogenic capacity has also been shown in in vitro studies on LTG and TGB."
a(CHEBI:"lamotrigine") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical presentations included seizures ( 91.7 % ), headache ( 83.3 % ), visual disturbance ( 62.5 % ), encephalophathy ( 29.2 % ), and paralysis ( 8.3 % )."
path(MESHD:"visual disturbance") positiveCorrelation path(MESHD:"seizures")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical presentations included seizures ( 91.7 % ), headache ( 83.3 % ), visual disturbance ( 62.5 % ), encephalophathy ( 29.2 % ), and paralysis ( 8.3 % )."
path(MESHD:"visual disturbance") positiveCorrelation path(MESHD:"headache")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "ALAS1 overexpression may result in intra-hepatic PLP deficiency."
path(MESHD:"Acute porphyria") decreases a(CHEBI:"Pyridoxal-phosphate")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Moreover, patients in the decompensated groups show also higher mean levels of Hcy/Cys ratio, suggesting a greater de rangement of Hcy trans-sulfuration pathway in these groups, which may result from PLP absolute/relative deficiency."
path(MESHD:"Acute porphyria") decreases a(CHEBI:"Pyridoxal-phosphate")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Severe abdominal pain is the most common symptom and other symptoms may include: nausea, vomiting, constipation, muscle weakness, urinary retention, palpitation (due to a rapid heart rate and often accompanied by hypertension), confusion, hallucinations, and seizures pain in the back, arms and legs."
path(MESHD:"Acute porphyria") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Psychotic Disorders")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Many studies show an association between acute por phyria and severe mental illness ["
path(MESHD:"Acute porphyria") association path(MESHD:"mental illness")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "It has become increasingly evident that AP is associated with a sig nificant risk of PLC."
path(MESHD:"Acute porphyria") association path(DO:"Primary Liver Cancer")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "An association between PLC and AP was first reported in 1984 by Lithner and Wetterberg who identified 11 patients with PLC in a cohort of 206 patients with AIP in the north of Sweden between 1960 and 1981.4"
path(MESHD:"Acute porphyria") association path(DO:"Primary Liver Cancer")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Recent Findings Recent literature begins to clarify associations between AP, schizophrenia, bipolar disorder, and other psychopathology."
path(MESHD:"Acute porphyria") association path(MESHD:"psychiatric symptoms")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Psychiatric symptoms associated with porphyria can be difficult to identify."
path(MESHD:"Acute porphyria") association path(MESHD:"psychiatric disorders")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "The majority of PLC in patients with AP are hepatocellular carcinoma (HCC), but cholangiocarcinoma and mixed HCC- cholangiocarcinoma tumours have also been reported"
path(MESHD:"Acute porphyria") association path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"catatonia")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Mania")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Depressive symptoms")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Suicide ideation")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Anxiety")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Phobias")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Obsessive-compulsive")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Somatoform disorder")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Insomnia")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Restlessness")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Impulsive Behavior")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Delirium")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Cognitive Dysfunction")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Agitation")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Histrionic Personality Disorder")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Mental disorders")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(HP:"Chronic fatigue")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1 Most common psychiatric manifestations implicated in acute porphyria"
path(MESHD:"Acute porphyria") association path(MESHD:"Mental Disorders")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Conclusions: This study's findings, collected before the introduction of givosiran, as the first approved preventive therapy for acute porphyria in Europe, highlight the need for healthcare strategies and policies tailored to the complex needs of acute porphyria patients."
path(MESHD:"Acute porphyria") association a(DB:"Givosiran")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Neuropathy is common in acute porphyria attacks."
path(MESHD:"Acute porphyria") association path(MESHD:"Psychiatric diseases")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyrias (AP) are characterized by heme deficiency and induction of hepatic 5-aminole vulinate synthase (ALAS1)."
path(MESHD:"Acute porphyria") association p(PKG:"heme deficiency")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "The majority of PLC in patients with AP are hepatocellular carcinoma (HCC), but cholangiocarcinoma and mixed HCC- cholangiocarcinoma tumours have also been reported"
path(MESHD:"Acute porphyria") association path(MESH:"Cholangiocarcinoma")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "The majority of PLC in patients with AP are hepatocellular carcinoma (HCC), but cholangiocarcinoma and mixed HCC- cholangiocarcinoma tumours have also been reported"
path(MESHD:"Acute porphyria") association path(PKG:"mixed HCC-cholangiocarcinoma")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Gastrointestinal diseases include abdominal pain, appendicitis, nausea and vomiting, constipation, diarrhoea and ileus."
path(MESHD:"Acute porphyria") association path(MESHD:"gastrointestinal disorders")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "After hematin administration and intense rehabilitation, the patient slowly recovered from the full-blown acute porphyria attack."
path(MESHD:"Acute porphyria") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "The second day after undergoing a Cesarean section, the woman had severe abdominal pain, accompanied by headaches, dizziness, blurred vision, and seizures."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"seizures")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "More evidence is needed to establish the porphyria-precipitating effect of oxybutynin and metronidazole."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyria was diagnosed, with acute intermittent porphyria as the working diagnosis."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"constipation")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "One telltale clinical pearl is that psychiatric symptoms favor acute porphyria over GBS [2]."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"constipation")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Autonomic dysfunction of the gastrointestinal system, including constipation and abdominal pain, is frequently present in acute porphyria [9]."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"constipation")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The attacks can manifest as nonspecific gastrointestinal, neurologic, cardiovascular, cutaneous, psychological, or behavioural symptoms."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"neurological symptoms")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "nan"
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"peripheral neuropathy")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "## Case Report A 24-year-old woman was admitted with generalized abdominal pain, constipation, and recurrent vomiting for 6 days."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"vomiting")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The attacks can manifest as nonspecific gastrointestinal, neurologic, cardiovascular, cutaneous, psychological, or behavioural symptoms."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"cardiovascular diseases")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyria needs to be ruled-out in patients with recurrent constipation and other abdominal symptoms, particularly after initiation of new medications."
path(MESHD:"Acute porphyria") positiveCorrelation a(CHEBI:"heme")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "In fact, this is the first reported case of acute porphyria in a patient with Arnold Chiari malformation, which are 2 separate genetic disorders."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"Arnold Chiari malformation")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "We report an unusual case of acute porphyria in a patient with Arnold Chiari syndrome."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"Arnold Chiari malformation")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Patient: Female, 33 Final Diagnosis: Acute porphyria Symptoms: Abdominal pain Ã‚Â·"
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"autonomic neuropathy")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "We concluded that the attacks of acute porphyria occurred over a 2-month span, characterized by abdominal pain, constipation, autonomic neuropathy, peripheral neuropathy, psychosis, delirium, and metabolic disturbances."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"delirium")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Case Report: A women with Arnold Chiari malformation type II who was treated with oxybutynin and antibiotics, including Bactrim for neurogenic bladder and recurrent urinary tract infection, presented with non-specific abdominal pain, constipation, and diarrhea."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"psychiatric symptoms")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The attacks can manifest as nonspecific gastrointestinal, neurologic, cardiovascular, cutaneous, psychological, or behavioural symptoms."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"psychiatric disorders")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The attacks can manifest as nonspecific gastrointestinal, neurologic, cardiovascular, cutaneous, psychological, or behavioural symptoms."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"gastrointestinal disorders")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Neuropathy is common in acute porphyria attacks."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"Neuropathy")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The attacks can manifest as nonspecific gastrointestinal, neurologic, cardiovascular, cutaneous, psychological, or behavioural symptoms."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"skin disease")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The attacks can manifest as nonspecific gastrointestinal, neurologic, cardiovascular, cutaneous, psychological, or behavioural symptoms."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"behavioural symptoms")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with AP are at risk of developing PLC"
path(MESHD:"Acute porphyria") positiveCorrelation path(DO:"primary liver cancer")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Carriers of these enzymatic defects are at a risk of presenting acute and severe neuro-visceral attacks (acute porphyric attacks, APAs) that are associated with induction of liver 5-aminole vulinate synthase (ALAS1), responsible for overproduction and tissue accumulation of neurotoxic non-porphyrin intermediates [porphobili nogen (PBG) and ÃŽÂ´-aminolevulinic acid (ALA)]"
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"Neuralgia")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"nausea")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"muscular pain")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"muscular weakness")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"fatigue")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "The most common manifestation is abdominal pain (often accompanied by constipation and signs of ileus), mimicking a surgical emergency."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"ileus")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Six years ago, in the fifth week of pregnancy, the woman developed acute and severe diffuse abdominal pain, accompanied by nausea, vomiting, constipation, persistent chest, back, and lower back pain, and red urine."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"lower back pain")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "The second day after undergoing a Cesarean section, the woman had severe abdominal pain, accompanied by headaches, dizziness, blurred vision, and seizures."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"headaches")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "The second day after undergoing a Cesarean section, the woman had severe abdominal pain, accompanied by headaches, dizziness, blurred vision, and seizures."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"dizziness")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with AP, mainly acute intermittent porphyria, have a significantly increased risk for PLC that warrants surveillance and adequate follow-up of high-risk groups."
path(MESHD:"Acute porphyria") positiveCorrelation path(MESHD:"AIP")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
path(MESHD:"Acute porphyria") increases path(MESHD:"hypertension")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Long- term complications of acute porphyria include chronic hypertension with renal impairment,10 liver damage and liver carci noma."
path(MESHD:"Acute porphyria") increases path(MESHD:"hypertension")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "We then seriously considered acute porphyria given her recurrent abdominal symptoms, medication history, and man ifestations of acute porphyria overlapping with GBS"
path(MESHD:"Acute porphyria") increases path(MESHD:"GBS")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "We then seriously considered acute porphyria given her recurrent abdominal symptoms, medication history, and man ifestations of acute porphyria overlapping with GBS"
path(MESHD:"Acute porphyria") increases path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
path(MESHD:"Acute porphyria") increases path(MESHD:"constipation")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Symptomatic AP patients had significantly higher urinary ALA and PBG levels, plasma Hcy, HHcy prevalence and Hcy/Cys ratio when compared to asymptomatic carriers of AP."
path(MESHD:"Acute porphyria") increases a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Carriers of these enzymatic defects are at a risk of presenting acute and severe neuro-visceral attacks (acute porphyric attacks, APAs) that are associated with induction of liver 5-aminole vulinate synthase (ALAS1), responsible for overproduction and tissue accumulation of neurotoxic non-porphyrin intermediates [porphobili nogen (PBG) and ÃŽÂ´-aminolevulinic acid (ALA)]"
path(MESHD:"Acute porphyria") increases a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Carriers of these enzymatic defects are at a risk of presenting acute and severe neuro-visceral attacks (acute porphyric attacks, APAs) that are associated with induction of liver 5-aminole vulinate synthase (ALAS1), responsible for overproduction and tissue accumulation of neurotoxic non-porphyrin intermediates [porphobili nogen (PBG) and ÃŽÂ´-aminolevulinic acid (ALA)]"
path(MESHD:"Acute porphyria") increases a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Symptomatic AP patients had significantly higher urinary ALA and PBG levels, plasma Hcy, HHcy prevalence and Hcy/Cys ratio when compared to asymptomatic carriers of AP."
path(MESHD:"Acute porphyria") increases a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
path(MESHD:"Acute porphyria") increases path(MESHD:"vomiting")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Clinicians should therefore be aware of the long-term complications of AP, which typically include chronic neuropathy and encephalopathy, high blood pressure and porphyria-associated kidney disease."
path(MESHD:"Acute porphyria") increases path(MESHD:"encephalopathy")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "In acute porphyria (AP), neurotoxic porphyrin precursors are produced in the liver and LT is a curative treatment option in patients with recurrent severe neuropathic attacks."
path(MESHD:"Acute porphyria") increases path(MESHD:"Neuralgia")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Long- term complications of acute porphyria include chronic hypertension with renal impairment,10 liver damage and liver carci noma."
path(MESHD:"Acute porphyria") increases path(MESHD:"liver damage")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
path(MESHD:"Acute porphyria") increases path(MESHD:"nausea")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
path(MESHD:"Acute porphyria") increases path(MESHD:"Anxiety disorders")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Long- term complications of acute porphyria include chronic hypertension with renal impairment,10 liver damage and liver carci noma."
path(MESHD:"Acute porphyria") increases path(MESHD:"renal impairment")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
path(MESHD:"Acute porphyria") increases path(MESHD:"Depression")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
path(MESHD:"Acute porphyria") increases path(MESHD:"acute abdominal pain")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
path(MESHD:"Acute porphyria") increases path(SCTID:"asthenia")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
path(MESHD:"Acute porphyria") increases path(SCTID:"palpitation")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The most common symptoms include colicky abdominal pain, nausea, vomiting, weakness, constipation, depression and anxiety, palpitation, hypertension and sun sensitivity."
path(MESHD:"Acute porphyria") increases path(MESH:"Photosensitivity Disorders")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Symptomatic AP patients had significantly higher urinary ALA and PBG levels, plasma Hcy, HHcy prevalence and Hcy/Cys ratio when compared to asymptomatic carriers of AP."
path(MESHD:"Acute porphyria") increases path(MESHD:"Hyperhomocysteinemia")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Symptomatic AP patients had significantly higher urinary ALA and PBG levels, plasma Hcy, HHcy prevalence and Hcy/Cys ratio when compared to asymptomatic carriers of AP."
path(MESHD:"Acute porphyria") increases a(CHEBI:"homocysteine")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Mean plasma homocysteine was significantly higher in patients with biochemical signs of decompensated disease"
path(MESHD:"Acute porphyria") increases a(CHEBI:"homocysteine")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyrias (AP) are characterized by heme deficiency and induction of hepatic 5-aminole vulinate synthase (ALAS1)."
path(MESHD:"Acute porphyria") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Carriers of these enzymatic defects are at a risk of presenting acute and severe neuro-visceral attacks (acute porphyric attacks, APAs) that are associated with induction of liver 5-aminole vulinate synthase (ALAS1), responsible for overproduction and tissue accumulation of neurotoxic non-porphyrin intermediates [porphobili nogen (PBG) and ÃŽÂ´-aminolevulinic acid (ALA)]"
path(MESHD:"Acute porphyria") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "In retrospect, it was apparent that a vicious cycle of fasting, worsening vomiting, and abdominal pain, likely induced by a mild eating disorder, caused excessive induction of hepatic ALAS1.With adherence to expert advice to avoid trigger factors for AIP, especially fasting, she remained stable and free of further acute attacks during a 3-year follow-up period."
path(MESHD:"Acute porphyria") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "In acute porphyria (AP), neurotoxic porphyrin precursors are produced in the liver and LT is a curative treatment option in patients with recurrent severe neuropathic attacks."
path(MESHD:"Acute porphyria") increases a(PKG:"porphyrin precursors")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Clinicians should therefore be aware of the long-term complications of AP, which typically include chronic neuropathy and encephalopathy, high blood pressure and porphyria-associated kidney disease."
path(MESHD:"Acute porphyria") increases path(MESHD:"neuropathy")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Clinicians should therefore be aware of the long-term complications of AP, which typically include chronic neuropathy and encephalopathy, high blood pressure and porphyria-associated kidney disease."
path(MESHD:"Acute porphyria") increases path(MESHD:"high blood pressure")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "The doctors at Saitama Medical Center told me that methotrexate (MTX) was most commonly used to treat my disease (invasive mole with lung metastasis) but had not been implicated as either porphyrinogenic or nonporphyrinogenic, and therefore, they carefully treated me with MTX."
path(MESHD:"invasive mole") association a(CHEBI:"methotrexate")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with AP, mainly acute intermittent porphyria, have a significantly increased risk for PLC that warrants surveillance and adequate follow-up of high-risk groups."
path(DO:"Primary Liver Cancer") association path(MESHD:"AIP")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Liver cirrhosis, which is found in over 80 % of patients with PLC in the general population [13], is typically not observed in AHP patients with PLC [6, 8, 12].Although leading theories regarding the pathogenesis linking AHP and PLC suggest that AHP could increase the risk of cancers in general [14-16], currently there is not, to our knowledge, any published evidence that persons with AHP are at an increased risk of any other cancers."
path(DO:"Primary Liver Cancer") increases path(MESHD:"liver cirrhosis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | SjÃƒÂ¶gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
path(MESHD:"lymphoma") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "The initial diagnosis and differential diagnosis of porphyrias continue to rely on biochemical, quantitative determinations of the porphyrin precursors and porphyrins in urine, stool, plasma and heparinized blood."
a(CHEBI:"porphyrins") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1.Urinary, plasmatic and faecal porphyrins and heme precursors in a patient with epilepsy and co-existing acute intermittent porphyria under treatment with different antiepileptic drugs."
a(CHEBI:"porphyrins") association path(MESHD:"epilepsy")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1.Urinary, plasmatic and faecal porphyrins and heme precursors in a patient with epilepsy and co-existing acute intermittent porphyria under treatment with different antiepileptic drugs."
a(CHEBI:"porphyrins") association path(MESHD:"AIP")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Clinical features of CEPÃ¢â‚¬â€The phenotype can vary depending on the severity of the inherited UROS mutations and levels of porphyrins in plasma and erythrocytes."
a(CHEBI:"porphyrins") association p(HGNC:"UROS")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Light that corresponds to the Soret band that maximally photoactivates porphyrins passes through window glass; therefore porphyric patients are not fully protected from skin photosensitivity by remaining indoors or in automobiles."
a(CHEBI:"porphyrins") association bp(MESHPP:"Light")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Because of their ability to absorb electromagnetic radiation from sunlight and their similarity to chlorophyll, which captures energy for photosynthesis, porphyrins are important pigments of life."
a(CHEBI:"porphyrins") association a(CHEBI:"chlorophyll")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Physical stress, menstruation, pregnancy, alcohol, pork bacon, and selected foods that contain porphyrins were found to increase urinary porphyrin concentrations."
a(CHEBI:"porphyrins") association bp(GO:"menstruation")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Renal failure with loss of urinary excretion requires porphyrin analysis in serum or plasma."
a(CHEBI:"porphyrins") association path(MESHD:"renal failure")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Phlebotomy is first-line treatment and mitigates the presence of iron overload, and hydroxychloroquine serves to inhibit porphyrin formation and promote urinary excretion of the porphyrins."
a(CHEBI:"porphyrins") decreases path(MESHD:"iron overload")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Figure 1).4, 5, 6 Furthermore, a plasma fluorescence scan can discriminate the characteristic emission maxima of the metabolites and support the biochemical diagnosis (Table 1).6 Beside the hepatic and erythropoietic porphyrias, secondary elevation in porphyrins have been found in patients with other diseasesÃ¢â‚¬â€especially in patients with chronic liver diseases (Supplementary Table 1).7, 8, 9, 10, 11, 12, 13 We review the pathogenesis, symptoms, and treatment of the most frequent porphyrias (PCT, AIP, and EPP) (Table 2).5, 6, 14 We present typical cases, diagnoses, and treatments and discuss therapeutic strategies in development."
a(CHEBI:"porphyrins") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Figure 1).4, 5, 6 Furthermore, a plasma fluorescence scan can discriminate the characteristic emission maxima of the metabolites and support the biochemical diagnosis (Table 1).6 Beside the hepatic and erythropoietic porphyrias, secondary elevation in porphyrins have been found in patients with other diseasesÃ¢â‚¬â€especially in patients with chronic liver diseases (Supplementary Table 1).7, 8, 9, 10, 11, 12, 13 We review the pathogenesis, symptoms, and treatment of the most frequent porphyrias (PCT, AIP, and EPP) (Table 2).5, 6, 14 We present typical cases, diagnoses, and treatments and discuss therapeutic strategies in development."
a(CHEBI:"porphyrins") positiveCorrelation bp(MESHPP:"fluorescence")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Most porphyriarelated drugs are thought to induce cytochrome P450 activity and thus increase the demand for hepatic heme biosynthesis, leading to increased porphyrin formation."
a(CHEBI:"porphyrins") positiveCorrelation a(CHEBI:"heme biosynthesis")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyrias (APs) are inherited disorders caused by deficiencies in one of the enzymes involved in haem biosynthesis, leading to overproduction of potentially neurotoxic porphyrin precursors (delta-aminolaevulinic acid [ALA] and porphobilinogen [PBG]) in the liver when the rate-limiting enzyme, ALA synthase 1 (ALAS1), is activated."
a(CHEBI:"porphyrins") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "However, PCT is also a less common cause of ESRD due to the accumulation of porphyrin, which damages the kidneys upon excretion. This accumulation of porphyrin is further exacerbated once the kidneys fail, leading to an increase in skin mani festations such as blistering of skin when exposed to sunlight and infections."
a(CHEBI:"porphyrins") increases path(MESHD:"renal failure")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "They lead to the accumulation of porphyrins that cause skin photosensitivity and occasionally severe liver damage."
a(CHEBI:"porphyrins") increases path(MESHD:"liver damage")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "However, PCT is also a less common cause of ESRD due to the accumulation of porphyrin, which damages the kidneys upon excretion. This accumulation of porphyrin is further exacerbated once the kidneys fail, leading to an increase in skin mani festations such as blistering of skin when exposed to sunlight and infections."
a(CHEBI:"porphyrins") increases path(MESHD:"ESRD")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Acute hepatic porphyrias (acute intermittent porphyria, variegate porphyria, hereditary coproporphyria, and aminolevulinic acid dehydratase deficient porphyria) manifest in attacks and are characterized by overproduction of porphyrin precursors, producing often serious abdominal, psychiatric, neurologic, or cardiovascular symptoms."
a(CHEBI:"porphyrins") increases path(MESHD:"Acute")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "In most cutaneous porphyrias, porphyrin-induced photosensitivity causes chronic skin fragility and formation of vesicles or bullae on light-exposed skin."
a(CHEBI:"porphyrins") increases path(MESHD:"bullae")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "When used, they should be used in lower than typical doses due to the rapid removal of accumulated porphyrin from the hepatocytes potentially causing necrosis and acute hepatitis."
a(CHEBI:"porphyrins") increases path(MESHD:"necrosis")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Although some of these conditions, such as membranous glomerulonephritis or vasculitis, may instead have been coded as renal failure/chronic kidney disease (23 ICD-9 codes for the diagnosis of viral hepatitis have been tested and validated in the Veterans Administration healthcare system, and have demonstrated high specificity and positive predictive value in the identification of HCV-infected persons [13]."
path(MESHD:"renal failure") association path(MESHD:"chronic kidney disease")

SET Citation = {"PubMed", "26743054.0"}
SET DataSource = "manual-curation"
SET Support = "J Clin Invest 56:661-667 11.Lee PK, Abrahams I, Bickers DR (1999) porphyria cutanea tarda occurring in a patient with renal failure, systemic lupus erythematosus and chronic hepatitis C infection treated with hemodialysis."
path(MESHD:"renal failure") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "In a prolonged attack, acute peripheral neuropathy (PNP) and signs of central nervous system (CNS) involvement may occur. The prevalence of acute intermittent porphyria (AIP) has been estimated at 1:2000 based on likely pathogenic variations identified in the HMBS (hydroxymethylbilane synthase) gene in Caucasians, but the estimated risk of clinical symptoms in them is low, ~1%."
path(MESHD:"peripheral neuropathy") association path(MESHD:"AIP")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
path(MESHD:"peripheral neuropathy") increases path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
path(MESHD:"peripheral neuropathy") increases path(MESHD:"muscle weakness")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
path(MESHD:"peripheral neuropathy") increases path(MESHD:"insomnia")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^57 Sufficient caloric support (carbohydrates, protein) is essential for treatment of AHP-especially when attacks are induced or amplified by low caloric intake, nausea, and vomiting, which are usually present in these patients."
path(MESHD:"vomiting") increases path(MESHD:"nausea")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "In retrospect, it was apparent that a vicious cycle of fasting, worsening vomiting, and abdominal pain, likely induced by a mild eating disorder, caused excessive induction of hepatic ALAS1.With adherence to expert advice to avoid trigger factors for AIP, especially fasting, she remained stable and free of further acute attacks during a 3-year follow-up period."
path(MESHD:"vomiting") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "To date, there is no robust pathophysiological element to support a role for porphyrin precursors in renal cancer."
path(DO:"kidney cancer") association a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
path(DO:"kidney cancer") association path(MESHD:"AHP")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy. ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
path(MESHD:"autonomic dysfunction") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy. ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
path(MESHD:"autonomic dysfunction") increases path(MESHD:"atrophy")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
path(MESHD:"chronic kidney disease") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
path(MESHD:"chronic kidney disease") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
path(MESHD:"chronic kidney disease") association path(DO:"kidney cancer")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
path(MESHD:"chronic kidney disease") association path(MESHD:"acute")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, different ICD-code distinctions between the ICD-9 (1987-1998) and ICD-10 (1997-2015) eras makes capture and labeling of some conditions such as atrial fibrillation and advanced stage chronic kidney disease (CKD) different between time periods."
path(MESHD:"chronic kidney disease") association path(MESHD:"atrial fibrillation")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with AHP had a higher risk of kidney cancer (0.8 % vs. 0.2 %, p<0.001), hypertension, and chronic kidney disease but no increase in risk for cardiovascular disease, except for cerebrovascular disease in patients with elevated U-PBG, (aHR =1.40 [95% CI:1.06-1.85])."
path(MESHD:"chronic kidney disease") positiveCorrelation path(DO:"kidney cancer")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Although some of these conditions, such as membranous glomerulonephritis or vasculitis, may instead have been coded as renal failure/chronic kidney disease (23 ICD-9 codes for the diagnosis of viral hepatitis have been tested and validated in the Veterans Administration healthcare system, and have demonstrated high specificity and positive predictive value in the identification of HCV-infected persons [13]."
path(MESHD:"chronic kidney disease") positiveCorrelation path(MESHD:"membranous glomerulonephritis")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "In various conditions associated with PCT, such as chronic HCV and alcohol use, hepcidin levels are low compared with controls."
path(MESHD:"PCT") decreases p(HGNC:"HAMP")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda (PCT) arises due to the inhibition of uroporphyrinogen decarboxylase (UROD) in the presence of hepatic iron and oxidative stress."
path(MESHD:"PCT") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT results from the inhibition of hepatic UROD, a cytoplasmic housekeeping enzyme that converts uroporphyrinogen to coproporphyrinogen."
path(MESHD:"PCT") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda is the result of absent or defective uropor phyrinogen III decarboxylase (UROD), the enzyme responsible for the conversion of uroporphyrinogen III into coproporphyrinogen III."
path(MESHD:"PCT") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is caused by reduced ( <50 % ) activity of uroporphyrinogen decarboxylase (Uro-D)."
path(MESHD:"PCT") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "PCT, the most common of the human porphyrias, is caused by deficiency in activity of hepatic uroporphyrinogen decarboxylase, the enzyme responsible for the stepwise decarboxylation of uropor phyrinogen to coproporphyrinogen."
path(MESHD:"PCT") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "## DISCUSSION porphyria cutanea tarda is the most common form of porphyria and is caused by a deficiency of uroporphyrinogen decarboxylase in the liver (1)."
path(MESHD:"PCT") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda (PCT) is a metabolic disease where the fifth enzyme in the heme synthesis, uroporphyrinogen decarboxylase (UROD), has reduced activity."
path(MESHD:"PCT") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "The pathogenesis of porphyria cutanea tarda involves deficiency and inhibition of uroporphyrinogen decarboxylase."
path(MESHD:"PCT") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT results from the inhibition of hepatic UROD, a cytoplasmic housekeeping enzyme that converts uroporphyrinogen to coproporphyrinogen."
path(MESHD:"PCT") decreases a(CHEBI:"Coproporphyrinogen III")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda is the result of absent or defective uropor phyrinogen III decarboxylase (UROD), the enzyme responsible for the conversion of uroporphyrinogen III into coproporphyrinogen III."
path(MESHD:"PCT") decreases a(CHEBI:"Coproporphyrinogen III")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Conclusions: These results indicate that ESRD patients with PCT are actually at decreased risk of some infections compared with ESRD patients without comorbid disease."
path(MESHD:"PCT") decreases path(MESHD:"infections")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Results: PCT was associated with a significantly decreased risk for 3 out of the 5 outcomes: bacterial infections (adjusted odds ratio: 0.50 ; 95 % confidence interval: 0.43-0.58 ), cellulitis ( 0.61 ; 0.53-0.71 ), and bacteremia (0.44 ; 0.38-0.52)."
path(MESHD:"PCT") decreases path(MESHD:"bacteremia")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Urine porphobilinogen is normal in PCT, and ALA is normal or only mildly increased."
path(MESHD:"PCT") causesNoChange a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
path(MESHD:"PCT") causesNoChange a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
path(MESHD:"PCT") causesNoChange a(CHEBI:"aminolevulinic acid")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Table 2"
path(MESHD:"PCT") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Table 2"
path(MESHD:"PCT") association path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "Patients have an increased risk of developing hepatocellular carcinoma14 and diabetes mellitus."
path(MESHD:"PCT") association path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "The pitfalls in the different tests along with the interfering comorbidities and treatments concerning patients with porphyria cutanea tarda complicate diagnosing these patients with diabetes mellitus."
path(MESHD:"PCT") association path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "15031049.0"}
SET DataSource = "manual-curation"
SET Support = "Irrespective of whether the increased risk of hepatocellular carcinoma in patients with PCT simply results from sporadictype PCT being a marker for common causes of liver cirrhosis, or whether the explanation for the association is more complex, ^2 one of the reasons why the recognition of PCT is important is that it is a marker for potentially treatable risk factors for hepatocellular carcinoma."
path(MESHD:"PCT") association path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "Patients have an increased risk of developing hepatocellular carcinoma14 and diabetes mellitus."
path(MESHD:"PCT") association path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "The association of liver disease, particularly alcoholic liver disease, and PCT was recognized by Brunsting et al."
path(MESHD:"PCT") association path(MESHD:"liver disease")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Also, most have reported relatively static estimates of cumulative prevalence and have not included some of the serious, but less commonly encountered, extrahepatic manifestations of HCV infection (e.g., mixed cryoglobulinaemia, membranous glomerulonephritis, porphyria cutanea tarda)."
path(MESHD:"PCT") association path(MESHD:"HCV infection")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Table 2"
path(MESHD:"PCT") association path(MESHD:"glomerulonephritis")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "The association of liver disease, particularly alcoholic liver disease, and PCT was recognized by Brunsting et al."
path(MESHD:"PCT") association path(MESHD:"alcoholic liver disease")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "SSTIs are char acterized by erythema, edema, warmth, and pain or tenderness, and the severity of the infection is highly dependent on comorbidities, critical illness, advanced age, immunocompromised status, hepatic or renal disease, and vascular insufficiency"
path(MESHD:"PCT") association path(MESHD:"erythema")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "SSTIs are char acterized by erythema, edema, warmth, and pain or tenderness, and the severity of the infection is highly dependent on comorbidities, critical illness, advanced age, immunocompromised status, hepatic or renal disease, and vascular insufficiency"
path(MESHD:"PCT") association path(MESHD:"Pain")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Kynurenic acid, a product of tryptophan metabolism, is believed to contribute to the neuroregulation of glutamate and dopamine."
path(MESHD:"PCT") association path(MESHD:"Glucose Intolerance")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Kynurenic acid, a product of tryptophan metabolism, is believed to contribute to the neuroregulation of glutamate and dopamine."
path(MESHD:"PCT") association path(MESHD:"Hyperinsulinemia")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda."
path(MESHD:"PCT") association path(MESHD:"Hemochromatosis")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Iron overload can impact disease progression and treatment options for patients with comorbid conditions, such as porphyria cutanea tarda, hepatitis C virus, and coronary artery disease."
path(MESHD:"PCT") association path(MESHD:"iron overload")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Most patients with PCT have evidence of siderosis on liver biopsy, and the disease resolves with iron deple tion."
path(MESHD:"PCT") association path(MESHD:"siderosis")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "In contrast, there is little experience concerning antiepileptic drug (AED) treatment in patients with porphyria cutanea tarda (PCT)."
path(MESHD:"PCT") association a(CHEBI:"antiepileptic drug")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Chronic hepatitis C is another risk factor for porphyria cutanea tarda."
path(MESHD:"PCT") association path(MESHD:"chronic hepatitis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "The results were interpreted to indicate that the effect of ethanol to produce a porphyria cutanea tarda phenotype is mediated by effects of alcohol on iron metabolism, specifically an effect to increase iron within hepatocytes."
path(MESHD:"PCT") association a(CHEBI:"ethanol")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Commonly seen SSTIs include ab scesses, cellulitis, folliculitis, and methicillin-resistant Staphylococcus aureus."
path(MESHD:"PCT") association path(MESHD:"cellulitis")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Commonly seen SSTIs include ab scesses, cellulitis, folliculitis, and methicillin-resistant Staphylococcus aureus."
path(MESHD:"PCT") association path(MESHD:"abscess")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Commonly seen SSTIs include ab scesses, cellulitis, folliculitis, and methicillin-resistant Staphylococcus aureus."
path(MESHD:"PCT") association path(MESHD:"folliculitis")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "SSTIs are char acterized by erythema, edema, warmth, and pain or tenderness, and the severity of the infection is highly dependent on comorbidities, critical illness, advanced age, immunocompromised status, hepatic or renal disease, and vascular insufficiency"
path(MESHD:"PCT") association path(MESHD:"edema")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is characterized by skin fragility and blistering on sun-exposed areas, most commonly the dorsal surfaces of the hands, as well as dark urine and hypertrichosis"
path(MESHD:"PCT") association path(HP:"Dark urine")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "PCT can be further complicated by skin and soft tissue infections (SSTIs)."
path(MESHD:"PCT") association path(MESH:"soft tissue infections")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Commonly seen SSTIs include ab scesses, cellulitis, folliculitis, and methicillin-resistant Staphylococcus aureus."
path(MESHD:"PCT") association path(MESHD:"Methicillin Resistant Staphylococcus aureus")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Table 2"
path(MESHD:"PCT") association path(MESHD:"Cystic Kidney")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "This study, comprising 108 patients with PCT, was intended to define the role of hemochromatosis gene (HFE) mutations in the expression of PCT and to determine the contribution of acquired factors including alcohol, hepatitis C virus (HCV), and estrogen."
path(MESHD:"PCT") association path(MESHD:"hemochromatosis")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Moreover, pa tients with PCT also have an increased prevalence of impaired glucose tolerance and diabetes mellitus."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with PCT are at increased risk for liver cancer and may benefit from surveillance, especially if they have advanced fibrosis or cirrhosis."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Consequently, these characteristics are common among patients with PCT and may explain why they have an increased risk of liver cancer and, possibly, other cancers"
path(MESHD:"PCT") positiveCorrelation path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with PCT are at increased risk for liver cancer and may benefit from surveillance, especially if they have advanced fibrosis or cirrhosis."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"HIV infection")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"Hemochromatosis")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "There is also a strong association between PCT and chronic HCV infection."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"HCV infection")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Other common cutaneous manifesta tions seen include hypertrichosis, hyperpigmentation, and a thickened appearance of the skin."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"hypertrichosis")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Other common cutaneous manifesta tions seen include hypertrichosis, hyperpigmentation, and a thickened appearance of the skin."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"hyperpigmentation")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "We defined the biochemical diagnosis of PCT as either urine urocarboxylporphyrin/creatinin greater than 6Ã‚Âµmol/mol creatinine, plasma fluorescence emission peak at 615 to 620 nm, or fecal heptacarboxylporphyrin greater than 2 nmol/g (dry weight)"
path(MESHD:"PCT") positiveCorrelation path(MESHD:"hepatitis C")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"acute myocardial infarction")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"Stroke")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"Neoplasms")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Cox regression was used to estimate hazard ratios (HRs) for patients with PCT versus control individuals, and we adjusted for differences in alcohol-related disease, hepatitis C, hemochromatosis, HIV, diabetes, AMI, stroke, cancer, COPD, and cirrhosis."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"Chronic obstructive pulmonary disease")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with PCT are at increased risk for liver cancer and may benefit from surveillance, especially if they have advanced fibrosis or cirrhosis."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"fibrosis")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is a known complication of ESKD, possibly due to iron over load resulting from a number of factors such as erythropoietin deficiency and the administration of exogenous iron."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"End Stage kidney disease")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency."
path(MESHD:"PCT") positiveCorrelation path(MESHD:"hepatitis")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Urine porphobilinogen is normal in PCT, and ALA is normal or only mildly increased."
path(MESHD:"PCT") increases a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Individuals with end-stage renal disease (ESRD), a potential complication of PCT, also exhibit an increased risk of infection."
path(MESHD:"PCT") increases path(MESHD:"kidney disease")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "However, PCT is also a less common cause of ESRD due to the accumulation of porphyrin, which damages the kidneys upon excretion. This accumulation of porphyrin is further exacerbated once the kidneys fail, leading to an increase in skin mani festations such as blistering of skin when exposed to sunlight and infections."
path(MESHD:"PCT") increases path(MESHD:"renal failure")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Reduced enzyme activity results in accumulation of porphyrins, heme intermediates, primarily in the liver and skin."
path(MESHD:"PCT") increases a(CHEBI:"heme")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Conclusions: Patients with PCT have increased mortality, primarily explained by an increased mortality from gastrointestinal diseases and from cancers of the gut, liver/gallbladder, and lungs."
path(MESHD:"PCT") increases path(MESHD:"gastrointestinal disorders")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "We found that patients with porphyria cutanea tarda have increased all-cause mortality and risk of death due to gastrointestinal diseases and cancer of the gut, liver/gallbladder, and lungs. Clinicians treating these patients must pay special attention to lifestyle and lidestyle related comorbidities"
path(MESHD:"PCT") increases path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Manifestations of PCT include blistering of sun-exposed skin and liver disease due to the accumulation of porphyrins."
path(MESHD:"PCT") increases path(MESHD:"liver disease")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "The association between PCT and impaired glucose metabolism is not fully understood but possibly implicates iron overload; a previous study showed that patients with PCT with persistently high ferritin levels were more likely to develop impaired glucose metabolism and diabetes."
path(MESHD:"PCT") increases path(MESHD:"iron overload")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The association between iron and PCT is well established. Siderosis is detected in up to 90% of patients who undergo liver biopsy, and a reduction in total body iron content by therapeutic phlebotomies leads to disease remission"
path(MESHD:"PCT") increases path(MESHD:"siderosis")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT manifests as skin fragil ity, blistering cutaneous lesions on sun-exposed areas, dark urine, and elevated plasma and urine porphyrins."
path(MESHD:"PCT") increases path(HP:"Dark urine")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
path(MESHD:"PCT") increases path(HP:"Dark urine")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is characterized by skin fragility and blistering on sun-exposed areas, most commonly the dorsal surfaces of the hands, as well as dark urine and hypertrichosis"
path(MESHD:"PCT") increases path(MESHD:"hypertrichosis")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
path(MESHD:"PCT") increases path(MESHD:"hypertrichosis")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The pathogenesis of PCT is thought to involve iron-generated free oxygen radicals that oxidize uroporphyrinogen, leading to the formation of a uroporphomethene inhibitor of UROD."
path(MESHD:"PCT") increases a(CHEBI:"reactive oxygen species")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "The association between PCT and impaired glucose metabolism is not fully understood but possibly implicates iron overload; a previous study showed that patients with PCT with persistently high ferritin levels were more likely to develop impaired glucose metabolism and diabetes."
path(MESHD:"PCT") increases a(MESHD:"Ferritins")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Reduced enzyme activity results in accumulation of porphyrins, heme intermediates, primarily in the liver and skin."
path(MESHD:"PCT") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Manifestations of PCT include blistering of sun-exposed skin and liver disease due to the accumulation of porphyrins."
path(MESHD:"PCT") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT manifests as skin fragil ity, blistering cutaneous lesions on sun-exposed areas, dark urine, and elevated plasma and urine porphyrins."
path(MESHD:"PCT") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "In all types of PCT, por phyrin accumulation and clinical symptoms of PCT do not occur unless UROD enzymatic activity falls below approxima tely 20% in the liver."
path(MESHD:"PCT") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "When hepatic UROD activity is reduced to less than 20% of normal activity, uroporphyrinogen and the porphyrinogens that are intermediates in its 4-step decarboxylation accumulate in the liver and are auto-oxidized to their corresponding porphyrins. After considerable accumulation in the liver, these porphyrins appear in plasma and bile and are excreted in the urine and stool."
path(MESHD:"PCT") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "We found that patients with porphyria cutanea tarda have increased all-cause mortality and risk of death due to gastrointestinal diseases and cancer of the gut, liver/gallbladder, and lungs. Clinicians treating these patients must pay special attention to lifestyle and lidestyle related comorbidities"
path(MESHD:"PCT") increases path(MESHD:"gastrointestinal disorders")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "We found that patients with porphyria cutanea tarda have increased all-cause mortality and risk of death due to gastrointestinal diseases and cancer of the gut, liver/gallbladder, and lungs. Clinicians treating these patients must pay special attention to lifestyle and lidestyle related comorbidities"
path(MESHD:"PCT") increases path(MESHD:"Neoplasms, Stomach")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "We found that patients with porphyria cutanea tarda have increased all-cause mortality and risk of death due to gastrointestinal diseases and cancer of the gut, liver/gallbladder, and lungs. Clinicians treating these patients must pay special attention to lifestyle and lidestyle related comorbidities"
path(MESHD:"PCT") increases path(MESHD:"Gallbladder Neoplasms")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "We found that patients with porphyria cutanea tarda have increased all-cause mortality and risk of death due to gastrointestinal diseases and cancer of the gut, liver/gallbladder, and lungs. Clinicians treating these patients must pay special attention to lifestyle and lidestyle related comorbidities"
path(MESHD:"PCT") increases path(MESHD:"Lung Neoplasms")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Manifestations of PCT include blistering of sun-exposed skin and liver disease due to the accumulation of porphyrins."
path(MESHD:"PCT") increases path(MESHD:"blisters")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is characterized by skin fragility and blistering on sun-exposed areas, most commonly the dorsal surfaces of the hands, as well as dark urine and hypertrichosis"
path(MESHD:"PCT") increases path(MESHD:"blisters")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
path(MESHD:"PCT") increases path(MESHD:"blisters")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT manifests as skin fragil ity, blistering cutaneous lesions on sun-exposed areas, dark urine, and elevated plasma and urine porphyrins."
path(MESHD:"PCT") increases path(MESHD:"blisters")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "The predominant clinical manifestations of PCT are skin fragility and blistering skin lesions."
path(MESHD:"PCT") increases path(MESHD:"blisters")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "The predominant clinical manifestations of PCT are skin fragility and blistering skin lesions."
path(MESHD:"PCT") increases path(MESHD:"Skin Diseases")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT manifests as skin fragil ity, blistering cutaneous lesions on sun-exposed areas, dark urine, and elevated plasma and urine porphyrins."
path(MESHD:"PCT") increases path(MESHD:"Skin Diseases")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is characterized by skin fragility and blistering on sun-exposed areas, most commonly the dorsal surfaces of the hands, as well as dark urine and hypertrichosis"
path(MESHD:"PCT") increases path(MESHD:"Skin Diseases")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
path(MESHD:"PCT") increases path(MESHD:"Skin Diseases")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Due to the increased photosensitivity and skin fragility, PCT patients are more susceptible to infections."
path(MESHD:"PCT") increases path(MESHD:"infections")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Manifestations of PCT include blistering of sun-exposed skin and liver disease due to the accumulation of porphyrins."
path(MESHD:"PCT") increases path(MESHD:"Skin Photosensitivity")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is characterized by skin fragility and blistering on sun-exposed areas, most commonly the dorsal surfaces of the hands, as well as dark urine and hypertrichosis"
path(MESHD:"PCT") increases path(MESHD:"Skin Photosensitivity")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
path(MESHD:"PCT") increases path(MESHD:"Skin Photosensitivity")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is diagnosed biochemically by high levels of porphyrins in the plasma and urine, with a predominance of uroporphyrinogen and hepta- and hexa- and pentacarboxyl porphyrins."
path(MESHD:"PCT") increases a(CHEBI:"Uroporphyrinogen III")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is diagnosed biochemically by high levels of porphyrins in the plasma and urine, with a predominance of uroporphyrinogen and hepta- and hexa- and pentacarboxyl porphyrins."
path(MESHD:"PCT") increases a(CHEBI:"heptacarboxylporphyrin III")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
path(MESHD:"PCT") increases a(CHEBI:"heptacarboxylporphyrin III")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is diagnosed biochemically by high levels of porphyrins in the plasma and urine, with a predominance of uroporphyrinogen and hepta- and hexa- and pentacarboxyl porphyrins."
path(MESHD:"PCT") increases a(SNOMED:"Hexacarboxylporphyrin")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
path(MESHD:"PCT") increases a(CHEBI:"Uroporphyrin III")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "However, PCT is also a less common cause of ESRD due to the accumulation of porphyrin, which damages the kidneys upon excretion. This accumulation of porphyrin is further exacerbated once the kidneys fail, leading to an increase in skin mani festations such as blistering of skin when exposed to sunlight and infections."
path(MESHD:"PCT") increases path(MESHD:"ESRD")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical manifestations of PCT are dermatological only and include increased skin fragility, bruising, vesicles, and bullae that may become hemorrhagic in the sun-exposed areas."
path(MESHD:"PCT") increases path(MESHD:"bullae")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical manifestations of PCT are dermatological only and include increased skin fragility, bruising, vesicles, and bullae that may become hemorrhagic in the sun-exposed areas."
path(MESHD:"PCT") increases path(MESHD:"bruising")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical manifestations of PCT are dermatological only and include increased skin fragility, bruising, vesicles, and bullae that may become hemorrhagic in the sun-exposed areas."
path(MESHD:"PCT") increases path(MESHD:"hemorrhagic")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
a(MESHP:"Blood Transfusion") increases path(MESHD:"PRES")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
a(MESHP:"Blood Transfusion") increases path(MESHD:"hypertension")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
a(MESHP:"Blood Transfusion") increases path(MESHD:"eclampsia")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
a(MESHP:"Blood Transfusion") increases path(MESHD:"acute renal failure")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) can reduce plasma levels of cyclosporine, tacrolimus, sirolimus and corticosteroids and so it may be necessary to increase the dose of these drugs."
a(CHEBI:"corticosteroids") decreases a(CHEBI:"cyclosporine")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) can reduce plasma levels of cyclosporine, tacrolimus, sirolimus and corticosteroids and so it may be necessary to increase the dose of these drugs."
a(CHEBI:"corticosteroids") decreases a(CHEBI:"tacrolimus")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) can reduce plasma levels of cyclosporine, tacrolimus, sirolimus and corticosteroids and so it may be necessary to increase the dose of these drugs."
a(CHEBI:"corticosteroids") decreases a(CHEBI:"sirolimus")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
a(CHEBI:"corticosteroids") increases path(MESHD:"hypertension")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Previous reports showed that the precipitants of PRES include hypertension, acute renal failure, eclampsia, blood transfusion, radio-contrast, and certain drug classes, including immunosuppressive agents, corticosteroids, and certain cytotoxic medications."
a(CHEBI:"corticosteroids") increases path(MESHD:"acute renal failure")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) can reduce plasma levels of cyclosporine, tacrolimus, sirolimus and corticosteroids and so it may be necessary to increase the dose of these drugs."
a(CHEBI:"tacrolimus") decreases a(CHEBI:"cyclosporine")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "9"
a(CHEBI:"sirolimus") decreases a(CHEBI:"cyclosporine")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) can reduce plasma levels of cyclosporine, tacrolimus, sirolimus and corticosteroids and so it may be necessary to increase the dose of these drugs."
a(CHEBI:"sirolimus") decreases a(CHEBI:"tacrolimus")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Co-morbid conditions include connective tissue diseases, renal disease, eclampsia, thrombotic thrombocytopenic, and acute intermittent porphyria."
path(MESHD:"thrombocytopenic") association path(MESHD:"thrombotic")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "One patients was misdiagnosed during the initial stage because of atypical imaging findings, and 2 patients were diagnosed with lupus encephalopathy and given steroid and immunosupressant treatments."
path(MESHD:"encephalopathy") association path(MESHD:"lupus")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Moreover, two cases in our study were diagnosed with lupus encephalopathy and were given steroid and immunosuppressant treatments that could increase blood pressure and aggravate endothelial injury."
path(MESHD:"encephalopathy") association path(MESHD:"lupus")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Two patients were misdiagnosed with lupus encephalopathy and were given large doses of steroids and immunosuppressant medications; these patients had residual visual disturbances and seizures, respectively."
path(MESHD:"encephalopathy") association path(MESHD:"lupus")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "One patients was misdiagnosed during the initial stage because of atypical imaging findings, and 2 patients were diagnosed with lupus encephalopathy and given steroid and immunosupressant treatments."
a(CHEBI:"steroid") decreases path(MESHD:"lupus")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Moreover, two cases in our study were diagnosed with lupus encephalopathy and were given steroid and immunosuppressant treatments that could increase blood pressure and aggravate endothelial injury."
a(CHEBI:"steroid") decreases path(MESHD:"lupus")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "In chronic antiepileptic treatment, carbamazepine (CBZ), oxcarbazepine (OXC) and PHT should be used with caution in patients with heart disease, and they should be avoided in the event of atrioventricular conduction dysfunction."
a(CHEBI:"carbamazepine") decreases path(MESHD:"heart disease")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Most AEDs such as carbamazepine (CBZ), phenytoin (PHT), valproate (VPA), and lamotrigine (LTG) may precipitate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis."
a(CHEBI:"carbamazepine") increases a(CHEBI:"heme")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Most AEDs such as carbamazepine (CBZ), phenytoin (PHT), valproate (VPA), and lamotrigine (LTG) may precipitate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis."
a(CHEBI:"carbamazepine") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
a(CHEBI:"carbamazepine") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Although some of these conditions, such as membranous glomerulonephritis or vasculitis, may instead have been coded as renal failure/chronic kidney disease (23 ICD-9 codes for the diagnosis of viral hepatitis have been tested and validated in the Veterans Administration healthcare system, and have demonstrated high specificity and positive predictive value in the identification of HCV-infected persons [13]."
path(MESHD:"vasculitis") association path(MESHD:"chronic kidney disease")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "In general, the patient with SLE often had underlying endothelial injury caused by vasculitis and/or its associated complications such as vessel spasm and angiopathy."
path(MESHD:"vasculitis") increases path(MESHD:"spasm")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Pulmonary infections were associated each time with an increasing titration of porphobilinogen; the first episode was also associated with seizures and hyponatremia."
path(MESHD:"hyponatremia") association path(MESHD:"seizures")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Pulmonary infections were associated each time with an increasing titration of porphobilinogen; the first episode was also associated with seizures and hyponatremia."
path(MESHD:"hyponatremia") association a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Pulmonary infections were associated each time with an increasing titration of porphobilinogen; the first episode was also associated with seizures and hyponatremia."
path(MESHD:"hyponatremia") association path(MESHD:"Pulmonary infections")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Blood chemistry revealed hyponatremia and persistent acute renal failure despite rehydration."
path(MESHD:"hyponatremia") positiveCorrelation path(MESHD:"acute renal failure")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Attacks may be complicated by neurologic findings (mental changes, convulsions, and peripheral neuropathy that may progress to respiratory paralysis), and hyponatremia."
path(MESHD:"hyponatremia") positiveCorrelation path(MESHD:"peripheral neuropathy")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "An inappropriately high secretion of antidiuretic hormone (Schwartz-Bartter syndrome) leads to a potentially lifethreatening severe hyponatremia, another diagnostic feature of acute porphyrias."
path(MESHD:"hyponatremia") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Laboratory analysis revealed a striking hyponatremia ( 117 mEq / L; normal >133 mEq / L ) with increased urine level of sodium ( 154 mEq / L )."
path(MESHD:"hyponatremia") positiveCorrelation a(CHEBI:"sodium")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "In this case, a comprehensive diagnostic evaluation was undertaken, which included analyzing biochemical assays, including those from her previous medical records to affirm the presence of SIADH characterized by hyponatremia."
path(MESHD:"hyponatremia") positiveCorrelation path(MESHD:"SIADH")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Diagnosis should be suspected when there is prolonged and recurrent episodes of unexplained abdominal pain-particularly when it is associated with neurological complications such as peripheral motor neuropathy, convulsions, coma or bulbar paralysis, hyponatremia or prompted by fasting, diets, or exposure to certain medications [5]."
path(MESHD:"hyponatremia") increases path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical presentations included seizures ( 91.7 % ), headache ( 83.3 % ), visual disturbance ( 62.5 % ), encephalophathy ( 29.2 % ), and paralysis ( 8.3 % )."
path(MESHD:"paralysis") positiveCorrelation path(MESHD:"seizures")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical presentations included seizures ( 91.7 % ), headache ( 83.3 % ), visual disturbance ( 62.5 % ), encephalophathy ( 29.2 % ), and paralysis ( 8.3 % )."
path(MESHD:"paralysis") positiveCorrelation path(MESHD:"headache")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical presentations included seizures ( 91.7 % ), headache ( 83.3 % ), visual disturbance ( 62.5 % ), encephalophathy ( 29.2 % ), and paralysis ( 8.3 % )."
path(MESHD:"paralysis") positiveCorrelation path(MESHD:"visual disturbance")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "Visual disturbance occurred in 15 patients ( 62.5 % ), mental status change was found in 7 patients ( 29.2 % ), and paralysis was present in 2 patients ( 8.3 % )."
path(MESHD:"paralysis") positiveCorrelation path(MESHD:"visual disturbance")

SET Citation = {"PubMed", "20572911.0"}
SET DataSource = "manual-curation"
SET Support = "A 57-year-old man with focal segmental glomerulosclerosis presented with headache, hemiplesia, and visual disturbances."
path(MESHD:"focal segmental glomerulosclerosis") positiveCorrelation path(MESHD:"headache")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "AIP was controlled by administering high doses of human hemin, avoiding all contraindicated medications, controlling infections, and optimizing nutrition via a jeju nostomy."
a(CHEBI:"heme") decreases path(MESHD:"AIP")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The treatment strategy for our patient, including intravenous hemin administration, discontinuation of so dium valproate (a known AIP exacerbant), and initiation of a high-carbohydrate diet, is consistent with the recom mendations in the Chinese Expert Consensus on Diagnosis and Treatment of AIP."
a(CHEBI:"heme") decreases path(MESHD:"AIP")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Specifcally, early use of hemin is emphasized in the consensus to inhibit ALAS activity, rapidly reduce porphyrin precursor accumulation (PBG and ÃŽÂ´-ALA), and alleviate symptoms"
a(CHEBI:"heme") decreases path(MESHD:"AIP")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Specifcally, early use of hemin is emphasized in the consensus to inhibit ALAS activity, rapidly reduce porphyrin precursor accumulation (PBG and ÃŽÂ´-ALA), and alleviate symptoms"
a(CHEBI:"heme") decreases a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Meanwhile, urine porphobilinogen level de creased to 0 after the 10-day Hemin treatment, and the lev els of other heme intermediates decreased as well"
a(CHEBI:"heme") decreases a(MESHD:"Porphobilinogen")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Meanwhile, urine porphobilinogen level de creased to 0 after the 10-day Hemin treatment, and the lev els of other heme intermediates decreased as well"
a(CHEBI:"heme") decreases a(CHEBI:"Heptacarboxylporphyrin I")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Meanwhile, urine porphobilinogen level de creased to 0 after the 10-day Hemin treatment, and the lev els of other heme intermediates decreased as well"
a(CHEBI:"heme") decreases a(CHEBI:"Pentacarboxylporphyrin I")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Meanwhile, urine porphobilinogen level de creased to 0 after the 10-day Hemin treatment, and the lev els of other heme intermediates decreased as well"
a(CHEBI:"heme") decreases a(CHEBI:"Coproporphyrins")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Meanwhile, urine porphobilinogen level de creased to 0 after the 10-day Hemin treatment, and the lev els of other heme intermediates decreased as well"
a(CHEBI:"heme") decreases a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Specifcally, early use of hemin is emphasized in the consensus to inhibit ALAS activity, rapidly reduce porphyrin precursor accumulation (PBG and ÃŽÂ´-ALA), and alleviate symptoms"
a(CHEBI:"heme") decreases a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "After hematin administration and intense rehabilitation, the patient slowly recovered from the full-blown acute porphyr ia attack."
a(CHEBI:"heme") decreases path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Patients presenting with hyponatremia should receive heme therapy because hyponatremia can worsen with glucose infusions."
a(CHEBI:"heme") decreases path(MESHD:"hyponatremia")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "Hemin is thought to work by decreasing levels of ALAS1, thereby reducing the production of toxic heme precursors [22Ã¢â‚¬â€œ24]."
a(CHEBI:"heme") decreases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Intravenous heme (Normosang; Orphan Europe, Puteaux, France, in Europe and some other regions, and Panhematin; Recordati Rare Diseases, Lebanon, NJ, in the United States, Mexico, and elsewhere) acts as a transcription factor that reduces expression of the ratelimiting hepatic enzyme ALAS1."
a(CHEBI:"heme") decreases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Intravenous hemin administration (4mg/kg once daily for 7 consecutive days) to inhibit ÃŽÂ´-ALA synthase (ALAS) activity and reduce porphyrin precursor accumulation; discontinuation of sodium valproate (which may exacerbate AIP) and replacement with levetiracetam (500mgtwicedaily) for seizure control; and maintenance of acid-base balance, correction of electrolyte disturbances, and a high-carbohydrate diet (daily intake Ã¢â€°Â¥ 300g) to stabilize metabolism."
a(CHEBI:"heme") decreases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Specifcally, early use of hemin is emphasized in the consensus to inhibit ALAS activity, rapidly reduce porphyrin precursor accumulation (PBG and ÃŽÂ´-ALA), and alleviate symptoms"
a(CHEBI:"heme") decreases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "nicillin, cephalosporins, imipenem, gentamicin, amikacin, vancomycin | | Physiotherapeutic measures from the very beginning | | of attacks resolved with supportive care, whereas the other two-thirds required heme therapy."
a(CHEBI:"heme") decreases a(CHEBI:"imipenem")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Intravenous hemin administration (4mg/kg once daily for 7 consecutive days) to inhibit ÃŽÂ´-ALA synthase (ALAS) activity and reduce porphyrin precursor accumulation; discontinuation of sodium valproate (which may exacerbate AIP) and replacement with levetiracetam (500mgtwicedaily) for seizure control; and maintenance of acid-base balance, correction of electrolyte disturbances, and a high-carbohydrate diet (daily intake Ã¢â€°Â¥ 300g) to stabilize metabolism."
a(CHEBI:"heme") decreases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Specifcally, early use of hemin is emphasized in the consensus to inhibit ALAS activity, rapidly reduce porphyrin precursor accumulation (PBG and ÃŽÂ´-ALA), and alleviate symptoms"
a(CHEBI:"heme") decreases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Consistently, the metabolic task 'heme synthesis' was blocked in the porphyria models (Fig. 3)."
a(CHEBI:"heme") negativeCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "In porphyria patients, Hcy accumulation is likely to result from reduced hepatic CBS and CBL activity secondary to low heme availability and to possible intra-hepatic depletion of PLP due to the ALAS1 induction [10,25-27]."
a(CHEBI:"heme") negativeCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "The porphyrias are a group of inherited disorders causing a deficiency in the heme synthesis pathway and consequently an accumulation of heme precursors (Solinas and Vajda, 2004; Kauppinen, 2005)."
a(CHEBI:"heme") negativeCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "The porphyrias are a group of eight recognized diseases, mostly inherited, in which there are defects in normal porphyrin and heme synthesis."
a(CHEBI:"heme") negativeCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "In AP, a reduced hepatic trans-sulfuration activity, resulting from either a low heme availability (in case of CBS) and/or depletion of PLP due to ALAS1 induction, may be responsible for Hcy accumulation [10,25-27]."
a(CHEBI:"heme") negativeCorrelation a(CHEBI:"PLP")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "The liver synthesizes 20 % of heme, which regulates its own production via interaction with 5-aminolevulinate synthase 1 (ALAS1)."
a(CHEBI:"heme") regulates p(HGNC:"ALAS1")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Most anticonvulsants can aggravate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-3)."
a(CHEBI:"heme") positiveCorrelation path(MESHD:"AIP")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "Many anticonvulsants can cause exacerbation of clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-5)."
a(CHEBI:"heme") positiveCorrelation path(MESHD:"AIP")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1.Urinary, plasmatic and faecal porphyrins and heme precursors in a patient with epilepsy and co-existing acute intermittent porphyria under treatment with different antiepileptic drugs."
a(CHEBI:"heme") positiveCorrelation path(MESHD:"AIP")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Each porphyria results from overproduction of heme precursors secondary to partial deficiency or, in XLP, increased activity of one of the enzymes of heme biosynthesis."
a(CHEBI:"heme") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Most anticonvulsants can aggravate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-3)."
a(CHEBI:"heme") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "Many anticonvulsants can cause exacerbation of clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-5)."
a(CHEBI:"heme") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "HSCT corrects the defective heme pathway and should be considered early in patients with severe erythropoietic porphyrias to minimize end-organ damage."
a(CHEBI:"heme") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1.Urinary, plasmatic and faecal porphyrins and heme precursors in a patient with epilepsy and co-existing acute intermittent porphyria under treatment with different antiepileptic drugs."
a(CHEBI:"heme") positiveCorrelation path(MESHD:"epilepsy")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Table 1.Urinary, plasmatic and faecal porphyrins and heme precursors in a patient with epilepsy and co-existing acute intermittent porphyria under treatment with different antiepileptic drugs."
a(CHEBI:"heme") positiveCorrelation a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "nan"}
SET DataSource = "manual-curation"
SET Support = "nan"
a(CHEBI:"heme") positiveCorrelation bp(GOBP:"metabolism")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Etiology and pathogenesis of ADPÃ¢â‚¬â€ALAD (ALA dehydratase; PBG synthase [EC 4.2.1.24]) catalyzes the formation of the monopyrrole PBG from two molecules of ALA, a precursor committed to synthesis of porphyrins, heme, and other tetrapyrroles."
a(CHEBI:"heme") positiveCorrelation a(CHEBI:"ADP")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Classification, inheritance and prevalence of the porphyrias Heme precursors in the various types of porphyria initially accumulate in either the liver or bone marrow, which are the tissues most active in heme biosynthesis."
a(CHEBI:"heme") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Heme synthesis | Prosthetic part of hemoglobin."
a(CHEBI:"heme") positiveCorrelation a(CHEBI:"hemoglobin")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "In addition, these patients may present psychiatric conditions secondary to the disease, such as adjustment disorder and substance use disorders."
a(CHEBI:"heme") positiveCorrelation bp(GOBP:"catalysis")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Heme is essential for life and is often referred to as 'pigment of life' (48)."
a(CHEBI:"heme") positiveCorrelation a(CHEBI:"pigment")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "We empirically used high doses over several months as repeated tapering attempts were associated with rebounds of urinary porphobilinogen."
a(CHEBI:"heme") increases a(MESHD:"Porphobilinogen")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Triggers such as drugs, fasting, or hormonal changes induce the first and rate limiting enzyme of the heme synthesis pathway, aminolevulinic acid synthase 1 (ALAS1), in the liver and cause downstream accumulation of 5-aminolevulinic acid (ALA) and porphobilinogen (PBG), cytotoxic porphyrin precursors associated with acute porphyria attacks."
a(CHEBI:"heme") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "ALA is further metabolized to other heme precursors, and as a result coproporphyrin III is excreted in urine in large amounts and protoporphyrin IX is increased in erythrocytes."
a(CHEBI:"heme") increases a(CHEBI:"coproporphyrin")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "Patients known to have a hepatic porphyria should not receive drugs such as carbamazepine (CBZ), VPA, PHT, CZP, DZP, and phenobarbital (PB), which are known to cause exacerbation of clinical symptoms by inducing hepatic heme synthesis ( 1-3,6,7 )."
a(CHEBI:"heme") increases path(MESHD:"hepatic porphyria")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^66 A 4.4-fold increase of reported AIP patients with recurrent attacks since the introduction of heme therapy (from 4 of 230 in 1985 to 40 of 536 in 2008) may be due to several reasons, including induction of heme oxygenase 1 , but also improved survival by heme therapy."
a(CHEBI:"heme") increases p(HGNC:"HMOX1")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "CBS and CGS activities require vitamin B6 (as PLP) and CBS also depends on heme as a cofactor [9,10,24]."
a(CHEBI:"heme") increases a(CHEBI:"PLP")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "We concluded that the attacks of acute porphyria occurred over a 2-month span, characterized by abdominal pain, constipation, autonomic neuropathy, peripheral neuropathy, psychosis, delirium, and metabolic disturbances."
path(MESHD:"Arnold Chiari malformation") positiveCorrelation path(MESHD:"diarrhea")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Autonomic dysfunction of the gastrointestinal system, including constipation and abdominal pain, is frequently present in acute porphyria [9]."
path(MESHD:"Arnold Chiari malformation") increases path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Gastrointestinal motility testing and electrogastrography (EGG) may provide a better understanding of the pathogenesis of chronic nausea and elucidate the potential role of chronic autonomic neuropathy."
path(MESHD:"autonomic neuropathy") association path(MESHD:"Chronic pain")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Clinical manifestations of AIP are broad and include neurovisceral crises, neuropathy and a range of psychiatric symptoms."
path(MESHD:"psychiatric symptoms") association path(MESHD:"AIP")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "A high proportion of patients had comorbidities, including peripheral neuropathy, hypertension, liver and kidney disease, and psychiatric disorders (Fig. 1)."
path(MESHD:"psychiatric disorders") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "A high proportion of patients had comorbidities, including peripheral neuropathy, hypertension, liver and kidney disease, and psychiatric disorders (Fig. 1)."
path(MESHD:"psychiatric disorders") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Neuropathy is common in acute porphyria attacks."
path(MESHD:"Neuropathy") association path(MESHD:"Psychiatric diseases")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | SjÃƒÂ¶gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
path(MESHD:"Neuropathy") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "15031049.0"}
SET DataSource = "manual-curation"
SET Support = "In any patient who presents with photoexposed unilocular blisters and skin fragility, the diagnosis should be considered."
path(MESHD:"skin disease") association path(MESHD:"PCT")

SET Citation = {"PubMed", "35193623.0"}
SET DataSource = "manual-curation"
SET Support = "Diagnostic reasons for disability pension that were increased compared to matched controls were PCT or skin disease in 11 of 199 cases (PCT: n=7, incident rate ratios [IRR] = 49.2, Cl=38.8,62.4; diseases of the skin and subcutaneous tissue, n=4, IRR=4.2, Cl=1.6,11.0 )."
path(MESHD:"skin disease") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Due to the increased photosensitivity and skin fragility, PCT patients are more susceptible to infections."
path(MESHD:"skin disease") increases path(MESHD:"infections")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Mortality risk during follow-up was higher among patients with AHP ( 21 % vs. 18 %, p=0.001 ), and associated with primary liver cancer, female sex, and biochemical activity."
path(DO:"primary liver cancer") association path(MESHD:"AHP")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "elevated peak PBG lev els were strongly associated with PLC risk while none of the gene carriers with only normal PBG (n = 345) developed PLC"
path(DO:"primary liver cancer") increases a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "This was confirmed in a caseÃ¢â‚¬â€œcontrol study that also identified increasing ALA and PBG levels after age 65 as an indicator of increased risk of PLC."
path(DO:"primary liver cancer") increases a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "ALAS1 activity is dependent on vitamin B6 (Pyridoxal-phosphate, PLP) as cofactor [6,7]."
a(CHEBI:"Pyridoxal-phosphate") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "This hypothesis that porphyrins are toxic is supported by a study from 1992 that showed that patients with PCT who developed hepatocellular carcinoma had a longer untreated symptomatic period."
path(MESHD:"hepatocellular carcinoma") association a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron as risk factor for hepatocellular carcinoma."
path(MESHD:"hepatocellular carcinoma") association a(CHEBI:"iron")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "Another minor risk factor is aflatoxin B1 consumption, which is responsible for most cases of hepatocellular carcinoma in Africa, where the consumption of contaminated foods is common."
path(MESHD:"hepatocellular carcinoma") association a(CHEBI:"aflatoxin B1")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The incidence of hepato-cellular carcinoma (HCC) in acute hepatic porphyria and the prevalence of patients with recurrent acute attacks of porphyria were also investigated (Innala and Andersson, 2011)."
path(MESHD:"hepatocellular carcinoma") association path(MESHD:"acute hepatic porphyria")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
path(MESHD:"hepatocellular carcinoma") association a(CHEBI:"Estrogens")

SET Citation = {"PubMed", "15031049.0"}
SET DataSource = "manual-curation"
SET Support = "Ã¢â‚¬â€I found Josep Llovet and colleaguesÃ¢â‚¬â„¢ Seminar on hepatocellular carcinoma (Dec 6, p 1907)1 helpful. Regarding risk factors, it is perhaps worth adding mention of porphyria cutanea tarda (PCT)."
path(MESHD:"hepatocellular carcinoma") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "Hepatocellular carcinoma is currently one of the most frequently occurring tumors worldwide and it has a highly negative prognosis."
path(MESHD:"hepatocellular carcinoma") isA path(MESHD:"tumor")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Heme groupcontaining proteins have essential and diverse functions in the body including oxygen transport, electron transfer, and catalysis and heme synthesis occurs in all nucleated cells [2]."
path(MESHD:"Depressive symptoms") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Depressive symptoms") association path(MESHD:"Catatonia")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Depressive symptoms") association path(MESHD:"Depressive disorders")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Suicide ideation") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Suicide ideation") association path(MESHD:"Depressive symptoms")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Suicide ideation") association path(MESHD:"Catatonia")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Suicide ideation") association path(MESHD:"Depressive disorders")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Phobias") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Somatoform disorder") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Insomnia") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Restlessness") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Delirium") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Agitation") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "We evaluated the AHP disease burden in patients aged Ã¢â€°Â¥ 12 years in a post hoc analysis of the Phase 3, randomized, double-blind, placebo-controlled ENVISION trial of givosiran (NCT03338816), an RNA interference (RNAi) therapeutic that targets the enzyme ALAS1 to decrease ALA and PBG production."
a(DB:"Givosiran") decreases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Givosiran therapy (siRNA for hepatic ALAS1) dramatically reduced plasma ALA levels within a few weeks. The drug has subsequently prevented attacks and reduced the severity of pain in AP patients."
a(DB:"Givosiran") decreases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Givosiran is a small interfering RNA that neutralizes excess ALAS1 mRNA in hepatocytes."
a(DB:"Givosiran") decreases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Since givosiran prevents the accumulation of ALA and PBG and in theory, it could reduce the risk of PAKD if porphyrin precursor levels were normal in severely affected patients."
a(DB:"Givosiran") decreases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "These results showed that the RNAi therapeutic givosiran is effective in patients with recurrent AHP regardless of prior hemin use, and that it reduces analgesic use and pain both during and between porphyria attacks."
a(DB:"Givosiran") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "In ENVISION, the number of porphyria attacks and attack severity were both reduced in patients receiving givosiran compared with those receiving placebo, regardless of prior hemin use."
a(DB:"Givosiran") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, the current study highlights the severe disease burden associated with AHP, even in patients with a relatively low rate of attacks, and supports the effectiveness of givosiran for the management of certain acute and chronic porphyria symptoms."
a(DB:"Givosiran") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^69 An interim analysis from a phase 3 trial (Envision) in 94 randomized patients with AHP and at least 2 attacks within 6 months before enrollment has been made public in April 2019, showing a significant reduction in the annualized rate of porphyria attacks, days of administered heme, and urinary ALA levels with Givosiran."
a(DB:"Givosiran") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^68 The phase 1 trial with once monthly Givosiran demonstrated high efficacy in reducing acute attacks in 6 patients with AIP."
a(DB:"Givosiran") decreases path(MESHD:"acute")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "We analyzed baseline AHP severity via chronic symptoms between attacks, comorbidities, concomitant medications, hemin-associated complications, and quality of life (QOL) and evaluated givosiran ( 2.5 mg / kg monthly) in patients with and without prior hemin prophylaxis on number and severity of attacks and pain scores during and between attacks."
a(DB:"Givosiran") decreases path(MESHD:"AHP")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "Conclusions: Patients with AHP, regardless of annualized attack rates, have considerable disease burden that may partly be alleviated with givosiran."
a(DB:"Givosiran") decreases path(MESHD:"AHP")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "These results showed that the RNAi therapeutic givosiran is effective in patients with recurrent AHP regardless of prior hemin use, and that it reduces analgesic use and pain both during and between porphyria attacks."
a(DB:"Givosiran") decreases a(CHEBI:"analgesic")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "Givosiran reduced the number and severity of attacks, days with worst pain scores above baseline, and opioid use versus placebo."
a(DB:"Givosiran") decreases a(CHEBI:"opioid")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Givosiran, an RNA interference therapy, is approved for the treatment of frequent recurrent attacks of AIP. Givosiran reduces the frequency of attacks, and the need for hemeÃ¢â‚¬Âinfusion therapy, and improves the quality of life in many patients with severe forms of AP. LongÃ¢â‚¬Âterm outcomes and realÃ¢â‚¬Âlife studies of this relatively new treatment are promising but still limited. The introduction of givosiran will probably reduce the need for LT in AIP, but LT remains an important curative option when all other treatments fail."
a(DB:"Givosiran") decreases bp(GOBP:"RNA interference")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Givosiran therapy (siRNA for hepatic ALAS1) dramatically reduced plasma ALA levels within a few weeks. The drug has subsequently prevented attacks and reduced the severity of pain in AP patients."
a(DB:"Givosiran") decreases path(MESHD:"severity of pain")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Of note, givosiran can cause transient deterioration in renal function, usually within the first 3 months of use, possibly related to local haem depletion. Long- term renal failure has also been reported in a few patients with pre- existing PAKD on givosiran. In addition, other GalNAc- conjugated siRNAs have caused mild nephropathy and hepatopathy in animal models. This is likely due to RNAi- mediated off- target effects rather than chemical modifications or perturbation of RNAi pathways, suggesting an inflammatory or immune response to these drugs. Longer and systematic nephrological follow- up is needed to assess which AP patients are at risk of developing CKD."
a(DB:"Givosiran") increases path(MESHD:"renal failure")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "Autosomal recessive defects in ferrochetalase (FECH) cause erythropoietic protoporphyria (EPP), where accumulation and photoactivity of protoporphyrin mediate both skin and liver damage."
path(MESHD:"liver damage") association a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "Autosomal recessive defects in ferrochetalase (FECH) cause erythropoietic protoporphyria (EPP), where accumulation and photoactivity of protoporphyrin mediate both skin and liver damage."
path(MESHD:"liver damage") association path(MESHD:"EPP")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "The liver damage is characterized by cholestasis due to protoporphyrin precipitation within hepatocytes and the intrahepatic biliary tree."
path(MESHD:"liver damage") increases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "The liver damage is characterized by cholestasis due to protoporphyrin precipitation within hepatocytes and the intrahepatic biliary tree."
path(MESHD:"liver damage") increases path(MESHD:"cholestasis")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Symptomatic treatment for fatigue and nausea There is currently no validated treatment for fatigue."
path(MESHD:"nausea") association path(MESHD:"fatigue")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Chronic pain, often moderately severe and mainly neuropathic in origin, is common in patients with severe recurrent attacks and is associated with fatigue and nausea, often resulting in poor quality of life."
path(MESHD:"nausea") association path(MESHD:"fatigue")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Chronic pain, often moderately severe and mainly neuropathic in origin, is common in patients with severe recurrent attacks and is associated with fatigue and nausea, often resulting in poor quality of life."
path(MESHD:"nausea") association path(MESHD:"Chronic pain")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Anxiety disorders") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Kidney disease In patients with renal impairment, AEDs which are mainly eliminated by the kidneys will have a longer half life and tend to accumulate in the blood because of the reduced glomerular filtration rate and tubular secretion."
path(MESHD:"renal impairment") increases path(MESHD:"kidney disease")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "| | Antiepileptic treatment | | Psychiatric treatment | | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | | Recommended | To be avoided | Recommended | To be avoided | | Depression | CBZ, GBP, LTG, OXC, PGB, VPA | PB, PHT, PRM, TGB, TPM | Citalopram Escitalopram Sertraline Trazodone Venlafaxine | Amoxapine Maprotiline Bupropion | | Anxiety | BZD, GBP, PGB, VPA | LEV | BZD SSRIs | - | | Psychosis | LTG, OXC, VPA | ESM, LEV, TPM | Olanzapine Quetiapine Risperidone | Chlorpromazine Clozapine | Conversely, rifampicin reduces the plasma concentration of CBZ, LTG, PB, PHT and VPA."
path(MESHD:"Depression") association a(CHEBI:"Antiepileptic")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "A 30-year-old woman with AIP had recurrent acute abdominal pain, nausea and vomiting, constipation, persistent chest, back, and waist pain, red urine, positivity for porphobilinogen (PBG) in urine and a pathogenic mutation of the HMBS gene."
path(MESHD:"acute abdominal pain") positiveCorrelation path(MESHD:"AIP")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Due to the increased photosensitivity and skin fragility, PCT patients are more susceptible to infections."
path(MESH:"Photosensitivity Disorders") increases path(MESHD:"infections")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Moreover, patients in the decompensated groups show also higher mean levels of Hcy/Cys ratio, suggesting a greater de rangement of Hcy trans-sulfuration pathway in these groups, which may result from PLP absolute/relative deficiency."
path(MESHD:"Hyperhomocysteinemia") positiveCorrelation path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Hyperhomocysteinemia (HHcy) is associated with endothelial damage, neurotoxicity and increased risk for vascular diseases."
path(MESHD:"Hyperhomocysteinemia") increases p(PKG:"endothelial damage")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "hyperhomocysteinemia (HHcy), has been related to neuro logical and endothelial damage and increased risk for vascular diseases (atherosclerosis and arterial and venous thrombosis)"
path(MESHD:"Hyperhomocysteinemia") increases p(PKG:"endothelial damage")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Hyperhomocysteinemia (HHcy) is associated with endothelial damage, neurotoxicity and increased risk for vascular diseases."
path(MESHD:"Hyperhomocysteinemia") increases path(MESH:"Neurotoxicity Syndromes")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "hyperhomocysteinemia (HHcy), has been related to neuro logical and endothelial damage and increased risk for vascular diseases (atherosclerosis and arterial and venous thrombosis)"
path(MESHD:"Hyperhomocysteinemia") increases path(MESH:"Neurotoxicity Syndromes")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Hyperhomocysteinemia (HHcy) is associated with endothelial damage, neurotoxicity and increased risk for vascular diseases."
path(MESHD:"Hyperhomocysteinemia") increases path(MESHD:"vascular disease")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "hyperhomocysteinemia (HHcy), has been related to neuro logical and endothelial damage and increased risk for vascular diseases (atherosclerosis and arterial and venous thrombosis)"
path(MESHD:"Hyperhomocysteinemia") increases path(MESHD:"vascular disease")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Table 2 summarizes homocysteine-related vitamin status and C677T polymorphism status for MTHFR gene in the studied groups."
a(CHEBI:"homocysteine") association p(HGNC:"MTHFR")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "During follow-up none of the study patients were taking vitamin supplements or drugs known to interfere with homocysteine metabolism."
a(CHEBI:"homocysteine") association a(CHEBI:"Vitamin supplements")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^2 Xenobiotics also directly induce ALAS1."
p(HGNC:"ALAS1") association a(CHEBI:"Xenobiotics")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | porphyria ('ALASm')/ sideroblastic anemia | 5-aminolevulinate synthase ( A L A S 2, Gene ID: 212, E.C. 2.3.1.37)."
p(HGNC:"ALAS1") association path(MESHD:"sideroblastic anemia")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "HHcy may represent an indirect marker of ALAS1 induction and its prevalence may be suggestive of a role of HHcy in the pathogenesis and/or comorbidities of AP."
p(HGNC:"ALAS1") association path(MESHD:"HHcy")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "ALAS1 activity is dependent on vitamin B6 (Pyridoxal-phosphate, PLP) as cofactor [6,7]."
p(HGNC:"ALAS1") association a(CHEBI:"Vitamin B6")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | porphyria ('ALASm')/ sideroblastic anemia | 5-aminolevulinate synthase ( A L A S 2, Gene ID: 212, E.C. 2.3.1.37)."
p(HGNC:"ALAS1") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Although ALA loading combined with iron enhanced the reduction of UROD activity in mice, factors that induce hepatic ALAS1 are seldom implicated in human PCT."
p(HGNC:"ALAS1") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Interestingly, both heme biosynthesis and sulphur amino acid metabolism require vitamin B6, (Pyridoxal-phosphate, PLP) an important cofactor of ALAS1 and of cystathionine ÃŽÂ² synthase (CBS) and cystathionine ÃŽÂ³-lyase (CGL) enzymes that catabolize homocysteine (Hcy)."
p(HGNC:"ALAS1") positiveCorrelation a(CHEBI:"Vitamin B6")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Induction of ALAS1 in AHPs leads to an exaggerated accumulation of the neuropharmacologic active porphyrin precursors."
p(HGNC:"ALAS1") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "This might account for the ability of intravenous glucose and other nutritional carbohydrates or gluconeogenic amino acids to attenuate signals of a fasting state, resulting in increased expression of ALAS1."
p(HGNC:"ALAS1") increases a(CHEBI:"amino acids")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
path(MESHD:"muscular pain") positiveCorrelation path(MESHD:"nausea")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
path(MESHD:"muscular weakness") positiveCorrelation path(MESHD:"nausea")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "The pathogenesis of fatigue is probably multifactorial. It could include direct or indirect consequences to brain regions involved in cognition by ALA, sequels of autonomic dysfunction, lowÃ¢â‚¬Âgrade inflammation in the liver and brain, and chronic stress caused by the disease."
path(MESHD:"fatigue") association path(MESHD:"autonomic dysfunction")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Chronic pain, often moderately severe and mainly neuropathic in origin, is common in patients with severe recurrent attacks and is associated with fatigue and nausea, often resulting in poor quality of life."
path(MESHD:"fatigue") association path(MESHD:"Chronic pain")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "The pathogenesis of fatigue is probably multifactorial. It could include direct or indirect consequences to brain regions involved in cognition by ALA, sequels of autonomic dysfunction, lowÃ¢â‚¬Âgrade inflammation in the liver and brain, and chronic stress caused by the disease."
path(MESHD:"fatigue") association path(MESHD:"inflammation")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "The pathogenesis of fatigue is probably multifactorial. It could include direct or indirect consequences to brain regions involved in cognition by ALA, sequels of autonomic dysfunction, lowÃ¢â‚¬Âgrade inflammation in the liver and brain, and chronic stress caused by the disease."
path(MESHD:"fatigue") association bp(GOBP:"cognition")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
path(MESHD:"fatigue") positiveCorrelation path(MESHD:"nausea")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Patients reporting acute attacks experienced abdominal pain as their main symptom ( 92 % ).Other frequently reported symptoms were nausea, obstipation, muscular pain, muscular weakness, palpitations, red/brown coloured urine, fatigue and psychiatric symptoms such as feelings of anxiety, depression, confusion and irritability."
path(MESHD:"fatigue") positiveCorrelation path(MESHD:"muscular pain")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "ADP must also be differentiated from other causes of ALAD deficiency such as lead poisoning and hereditary tyrosinemia type 1, which can cause increases in ALA, coproporphyrin III and erythrocyte protoporphyrin and symptoms very much like those in acute porphyrias."
a(CHEBI:"coproporphyrin") association a(CHEBI:"ADP")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "For example, in 32 members of an Australian family, 14 (including 10 adults) were determined to have HCP on the basis of a high fecal coproporphyrin III/I ratio and/or low lymphocyte CPOX enzyme activity, but only one had clinical symptoms of porphyria (Blake et al. 1992)."
a(CHEBI:"coproporphyrin") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "ADP is assumed to be a hepatic porphyria, although liver transplantation was not beneficial in a child with severe disease."
path(MESHD:"hepatic porphyria") association a(CHEBI:"ADP")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "As epileptic seizures usually occur in the acute forms of hepatic porphyria, it is not surprising that there is more experience in the management and AED treatment for these cases than for those of PCT."
path(MESHD:"hepatic porphyria") increases path(MESHD:"epileptic seizures")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^32 The overexpression of heme oxygenase-1 under conditions of inflammation, fasting, or physical or oxidative stress increases heme degradation and thereby removes feedback inhibition of ALAS1, promoting disease."
p(HGNC:"HMOX1") decreases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "ALAS1 activity is dependent on vitamin B6 (Pyridoxal-phosphate, PLP) as cofactor [6,7]."
a(CHEBI:"PLP") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "The authors suggested that ALAS1 has a higher affinity for PLP when compared to other PLP-dependent enzymes."
a(CHEBI:"PLP") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Moreover, PLP is in important co-factor for Glutamate decarboxylase (GAD) activity, the sole enzyme able to synthesize ÃŽÂ³-aminobutyric acid (GABA), a major inhibitory neurotransmitter, whose reduced effect or availability has also been observed during AP exacerbations [60-61]."
a(CHEBI:"PLP") increases a(CHEBI:"4-aminobutyric acid")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "In porphyria patients, Hcy accumulation is likely to result from reduced hepatic CBS and CBL activity secondary to low heme availability and to possible intra-hepatic depletion of PLP due to the ALAS1 induction [10,25-27]."
a(CHEBI:"PLP") negativeCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "26743054.0"}
SET DataSource = "manual-curation"
SET Support = "Merk H, Bolsen K, Lissner R, Goerz G (1986) Hexachlorobenzene alteration of benzo[a]pyrene metabolism in porphyric and non-porphyric rats."
bp(GOBP:"metabolism") association a(CHEBI:"Hexachlorobenzene")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Thyroid disease Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) influence thyroid hormone metabolism, causing a decrease in total and free thyroxin levels."
bp(GOBP:"metabolism") association path(MESHD:"Thyroid disease")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Thyroid disease Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) influence thyroid hormone metabolism, causing a decrease in total and free thyroxin levels."
bp(GOBP:"metabolism") association a(CHEBI:"thyroid hormone")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "| | Antihypertensives | Enzyme-inducing AEDs increase the metabolism of beta-blockers and dihydropyridine calcium antagonists | | | PHT reduces the active metabolite of losartan by up to 63 %."
bp(GOBP:"metabolism") association a(CHEBI:"Antihypertensives")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Other antidepressants such as citalopram, escitalopram, sertraline, trazodone and venlafaxine do not have a significant effect on AED metabolism."
bp(GOBP:"metabolism") association a(CHEBI:"trazodone")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Other antidepressants such as citalopram, escitalopram, sertraline, trazodone and venlafaxine do not have a significant effect on AED metabolism."
bp(GOBP:"metabolism") association a(CHEBI:"venlafaxine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "To evaluate potential effects of intestinal nutrient absorption on whole body metabolism, we analyzed secretion patterns obtained from the two diets."
bp(GOBP:"metabolism") association bp(GOBP:"nutrient absorption")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Succinyl-CoA is formed in mitochondria, chiefly by action of the tricarboxylic acid cycle, and it has other pathways for utilization and metabolism."
bp(GOBP:"metabolism") association bp(GOBP:"tricarboxylic acid cycle")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Xenobiotics inhibit the activities of multidrug resistance-associated proteins and/or OATPs and affect the metabolism and disposition of CPs."
bp(GOBP:"metabolism") association a(CHEBI:"Xenobiotics")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The model's failure to correctly predict some known elevated reported biomarkers, e.g. citrulline and glycogen (Supplementary Material, Table S7), highlights that enterocyte metabolism is not the only cause for biomarkers but that other tissues, such as liver and muscle, also contribute significantly to plasma biomarkers."
bp(GOBP:"metabolism") increases a(CHEBI:"citrulline")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Histidine to form-imino-glutamic acid conversion | One-carbon metabolism."
bp(GOBP:"metabolism") increases a(CHEBI:"histidine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Histidine to form-imino-glutamic acid conversion | One-carbon metabolism."
bp(GOBP:"metabolism") increases a(CHEBI:"glutamic acid")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Succinyl-CoA is formed in mitochondria, chiefly by action of the tricarboxylic acid cycle, and it has other pathways for utilization and metabolism."
bp(GOBP:"metabolism") increases a(CHEBI:"Succinyl-CoA")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
a(CHEBI:"ADP") association path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
a(CHEBI:"ADP") association path(MESHD:"Lead poisoning")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
a(CHEBI:"ADP") association path(MESHD:"tyrosinemia")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
a(CHEBI:"ADP") association path(MESHD:"alcoholism")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
a(CHEBI:"ADP") association path(MESHD:"chronic renal insufficiency")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "It has been estimated that approximately forty percent of children with hereditary tyrosinemia type 1 develop the signs and symptoms of ADP (Rank et al. 1987)."
a(CHEBI:"ADP") association path(MESHD:"hereditary tyrosinemia type 1")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Enzyme activities in AIP, HCP and VP are reduced to about 50 % of normal, indicating near or complete haplodeficiency, and are much lower in ADP, in which both alleles are affected (Nordmann et al, 1997; Badminton and Elder, 2005)."
a(CHEBI:"ADP") decreases path(MESHD:"AIP")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
a(CHEBI:"ADP") decreases p(HGNC:"ALAD")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^79,80 Hexachlorobenzene, a fungicide that was used in agriculture until 1984, inhibits UROD and causes PCT in humans and animals."
a(CHEBI:"Hexachlorobenzene") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^79,80 Hexachlorobenzene, a fungicide that was used in agriculture until 1984, inhibits UROD and causes PCT in humans and animals."
a(CHEBI:"Hexachlorobenzene") isA a(CHEBI:"fungicide")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Thyroid disease Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) influence thyroid hormone metabolism, causing a decrease in total and free thyroxin levels."
path(MESHD:"Thyroid disease") decreases a(CHEBI:"thyroxin")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Thyroid disease Enzyme-inducing AEDs (CBZ, PB, PHT, PRM) influence thyroid hormone metabolism, causing a decrease in total and free thyroxin levels."
a(CHEBI:"thyroid hormone") association path(MESHD:"Thyroid disease")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Succinyl-CoA is formed in mitochondria, chiefly by action of the tricarboxylic acid cycle, and it has other pathways for utilization and metabolism."
bp(GOBP:"tricarboxylic acid cycle") increases a(CHEBI:"Succinyl-CoA")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Under an average American diet, the model for type I citrullinemia (OMIM: 215700 ), which is defective in ASS1 (GeneID: 445, E.C.6.3.4.5), led to an increased flux through the citrulline basolateral secretion reaction, a single fumarate producing reaction ('ADSL1'), and a decreased flux through the fumarase ('FUM')."
a(CHEBI:"citrulline") increases path(MESHD:"citrullinemia")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to citrulline conversion | For arginine synthesis."
a(CHEBI:"citrulline") increases a(CHEBI:"glutamine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Histidine to form-imino-glutamic acid conversion | One-carbon metabolism."
a(CHEBI:"histidine") increases a(CHEBI:"glutamic acid")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Histidine to form-imino-glutamic acid conversion | One-carbon metabolism."
a(CHEBI:"histidine") increases a(CHEBI:"imino")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Histidine to form-imino-glutamic acid conversion | One-carbon metabolism."
a(CHEBI:"glutamic acid") increases a(CHEBI:"imino")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "We concluded that the attacks of acute porphyria occurred over a 2-month span, characterized by abdominal pain, constipation, autonomic neuropathy, peripheral neuropathy, psychosis, delirium, and metabolic disturbances."
a(CHEBI:"oxybutynin") decreases path(MESHD:"Arnold Chiari malformation")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Case Report: A women with Arnold Chiari malformation type II who was treated with oxybutynin and antibiotics, including Bactrim for neurogenic bladder and recurrent urinary tract infection, presented with non-specific abdominal pain, constipation, and diarrhea."
a(CHEBI:"oxybutynin") decreases path(MESHD:"neurogenic bladder")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Case Report: A women with Arnold Chiari malformation type II who was treated with oxybutynin and antibiotics, including Bactrim for neurogenic bladder and recurrent urinary tract infection, presented with non-specific abdominal pain, constipation, and diarrhea."
a(CHEBI:"oxybutynin") decreases path(MESHD:"urinary tract infection")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyria was initiated by oxybutynin, precipitated by Bactrim, and became full-blown after metronidazole administration."
a(CHEBI:"oxybutynin") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "nan"}
SET DataSource = "manual-curation"
SET Support = "nan"
a(CHEBI:"oxybutynin") increases path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "nan"}
SET DataSource = "manual-curation"
SET Support = "nan"
a(CHEBI:"Bactrim") increases path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "The underlying mechanism is that metabolism of certain medications demands more hepatic cytochrome P450 enzymes, which derive from heme [1]."
a(CHEBI:"Bactrim") increases a(CHEBI:"oxybutynin")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Liver cirrhosis, which is the most common risk factor (>80%) for PLC in general, is less common in patients with AP- associated PLC. Other contributing liver diseases leading to inflammation and fibrosis, such as viral hepatitis, hepatic steatosis or alcoholic liver diseases, are uncommon in AP patients."
p(HGNC:"PLCD1") increases path(MESHD:"liver cirrhosis")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "The significant risk of PLC in AP has prompted recommendations for liver cancer surveillance by ultrasound imaging every 6Ã¢â‚¬â€œ12 months from the age of 50 in patients with a history of symptomatic AP disease.4 Due to the previous lack of evidence, patients with biochemical activity who never had symptoms are not included in these recommendations."
p(HGNC:"PLCD1") increases path(DO:"liver cancer")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Olanzapine 10 mg changed to aripiprazole due to cramping."
path(MESHD:"neuropsychiatric symptoms") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
a(CHEBI:"phenytoin") decreases path(MESHD:"epileptic seizure")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
a(CHEBI:"phenytoin") decreases path(MESHD:"cardiovascular diseases")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Most AEDs such as carbamazepine (CBZ), phenytoin (PHT), valproate (VPA), and lamotrigine (LTG) may precipitate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis."
a(CHEBI:"phenytoin") increases a(CHEBI:"heme")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
a(CHEBI:"phenytoin") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
a(CHEBI:"phenytoin") increases path(MESHD:"arrhythmias")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
a(CHEBI:"phenytoin") increases path(MESHD:"hypotension")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Several antiepileptic drugs (AEDs), through their hepatic metabolism and consequent induction of heme synthesis, may precipitate acute attacks in patients with clinically latent hepatic porphyria (Solinas and Vajda, 2004; Thunell et al."
a(CHEBI:"antiepileptic drugs") increases a(CHEBI:"heme")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "| Table I. Use of antiepileptic drugs in porphyria | | | | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | | Study | Study type | Result | | Gabapentin | | | | Krauss et al."
a(CHEBI:"Gabapentin") association a(CHEBI:"antiepileptic drugs")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Our main aim was not to establish a precise estimate of the incidence or prevalence of hypertension in patients with AHP, but rather to assess if the high rates of HT and CKD influence the risk of secondary cardiovascular diseases in relation to AHP type and U-PBG status."
path(MESHD:"cardiovascular diseasess") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Looking more closely at the health challenges faced by acute porphyria patients, it was found that these patients were more likely to suffer from nervous system disorders, pain, and mental disorders in the first year before the index compared to the general population."
path(DO:"nervous system disorders") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "Another variable conditioning the natural history of HCC is the severity of the underlying liver disease."
path(MESHD:"liver disease") association path(MESHD:"HCC")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Conclusions and recommendations Evidence for a role for hepatic iron as a co-morbid factor in liver disease, particularly in chronic hepatitis C and steatohepatitis (alcoholic or nonalcoholic), continues to mount."
path(MESHD:"liver disease") association path(MESHD:"chronic hepatitis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "The prevalence of liver disease in patients with lichen planus is reported to be as high as 35 % .^10 Several small studies have suggested that HCV may be related."
path(MESHD:"liver disease") association path(MESHD:"lichen planus")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
path(MESHD:"liver disease") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "As with HCV infection, it has been reported that, at least in western countries, carriers of HBsAg rarely develop HCC, but the incidence with increasing severity of liver disease reaches 0.5- 0.8 % per year in patients with underlying chronic hepatitis and 1.5-6.6 % in patients with liver cirrhosis."
path(MESHD:"liver disease") increases path(MESHD:"HCV infection")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "As with HCV infection, it has been reported that, at least in western countries, carriers of HBsAg rarely develop HCC, but the incidence with increasing severity of liver disease reaches 0.5- 0.8 % per year in patients with underlying chronic hepatitis and 1.5-6.6 % in patients with liver cirrhosis."
path(MESHD:"liver disease") increases path(MESHD:"HCC")

SET Citation = {"PubMed", "35193623.0"}
SET DataSource = "manual-curation"
SET Support = "In a previous study, we found an increased risk of premature death in persons with sporadic PCT, although not familial PCT, due mostly to liver disease and alcohol and substance abuse [17]."
path(MESHD:"liver disease") increases path(MESHD:"premature death")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "On average, patients with XLP have more severe disease, with higher protoporphyrin levels and perhaps a greater risk of liver disease than do those with EPP."
path(MESHD:"liver disease") increases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Clinical manifestations of AIP are broad and include neurovisceral crises, neuropathy and a range of psychiatric symptoms."
path(MESHD:"neuropathy") association path(MESHD:"AIP")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Lymphoma, renal disease, neuropathy, and SjÃƒÂ¶gren syndrome manifest incomplete overlap with the cryoglobulinemic syndrome."
path(MESHD:"neuropathy") association path(MESHD:"lymphoma")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Lymphoma, renal disease, neuropathy, and SjÃƒÂ¶gren syndrome manifest incomplete overlap with the cryoglobulinemic syndrome."
path(MESHD:"neuropathy") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, neuropathy, lymphoma, and SjÃƒÂ¶gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
path(MESHD:"neuropathy") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "As a result, the main triggers for chronic encephalopathy and neuropathy in AP may be the constant excess of ALA and lowÃ¢â‚¬Âgrade inflammation of hepatic origin."
path(MESHD:"neuropathy") increases path(MESHD:"encephalopathy")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Worsening neuropathy led to respiratory failure requiring mechanical ventilation and she was transferred to our ICU.Clinical findings on admission included proximal weakness with hypoesthesia, facial diplegia, and abolished tendon reflexes, except for the Achilles reflexes; additional central nervous system signs were present including visual blurring, hallucinations, and seizures."
path(MESHD:"neuropathy") increases path(MESHD:"respiratory failure")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "The natural history of hepatocellular carcinoma is heterogeneous and is influenced by nodule dimension, the mono- or plurifocality of lesions at diagnosis, the growth rate of the tumor, and the stage of the underlying cirrhosis."
path(MESHD:"cirrhosis") association path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with HH and significant alcohol consumption have a higher incidence of cirrhosis and other complications."
path(MESHD:"cirrhosis") association bp(MESHPP:"alcohol consumption")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "In six cohort studies, 26% (range 0%Ã¢â‚¬â€œ40%) of the 53 patients with AP- associated PLC had cirrhosis. Of the seven French patients with PLC, two had not only cirrho- sis but also chronic viral hepatitis, which is strongly associated with the development of fibrosis. In the histological samples of the 13 Swedish patients with AP and PLC, mild to moderate fibrosis was common and one- third had cirrhosis."
path(MESHD:"cirrhosis") association path(MESHD:"chronic viral hepatitis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Long-term infection is necessary for the development of most extrahepatic manifestations; many are present primarily in patients with cirrhosis."
path(MESHD:"cirrhosis") association path(MESHD:"Long-term")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Only 30% of alcoholics develop cirrhosis."
path(MESHD:"cirrhosis") association path(MESHD:"alcoholics")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with HH and significant alcohol consumption have a higher incidence of cirrhosis and other complications."
path(MESHD:"cirrhosis") association path(MESHD:"HH")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Decreased hepatic insulin clearance leading to hyperinsulinemia and development of insulin resistance, as well as reduced hepatic uptake of glucose, are all known to occur in cirrhosis and to predispose the cirrhotic patient to the development of non-insulin-dependent DM."
path(MESHD:"cirrhosis") decreases a(CHEBI:"insulin")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "The association of PCT with HCV is strongest in those patients that have cirrhosis (60-90 %)^76,78 In all countries, PCT is an uncommon complication of HCV infection."
path(MESHD:"cirrhosis") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = ", 2002), in 119 consecutive patients with chronic hepatitis C, the H F E mutations commonly associated with hereditary hemochromatosis were significantly more common in these patients in comparison with findings for control subjects ( 48 % vs. 37.9 %, P=.04 ), and advanced degrees of hepatic fibrosis or cirrhosis developed at younger ages in patients who had the C282Y mutation of H F E, especially in C 282 Y^+1 s homozygotes."
path(MESHD:"cirrhosis") positiveCorrelation path(MESHD:"chronic hepatitis")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The presence of the C282Y mutation was strongly associated with the presence of more advanced degrees of fibrosis or cirrhosis."
path(MESHD:"cirrhosis") positiveCorrelation path(MESHD:"fibrosis")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The HFE mutations were significantly more common in these patients in comparison with findings for control subjects ( 48 % versus 37.9 %, p=0.04 ), and advanced degrees of hepatic fibrosis or cirrhosis developed at younger ages in patients who had the C282Y mutation of HFE, especially in C282Y homozygotes."
path(MESHD:"cirrhosis") positiveCorrelation p(HGNC:"HFE")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Decreased hepatic insulin clearance leading to hyperinsulinemia and development of insulin resistance, as well as reduced hepatic uptake of glucose, are all known to occur in cirrhosis and to predispose the cirrhotic patient to the development of non-insulin-dependent DM."
path(MESHD:"cirrhosis") increases path(MESHD:"insulin resistance")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyria was initiated by oxybutynin, precipitated by Bactrim, and became full-blown after metronidazole administration."
a(CHEBI:"metronidazole") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "In addition, these patients may present psychiatric conditions secondary to the disease, such as adjustment disorder and substance use disorders."
path(MESHD:"porphyria") association a(CHEBI:"heme biosynthesis")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Case Report: A women with Arnold Chiari malformation type II who was treated with oxybutynin and antibiotics, including Bactrim for neurogenic bladder and recurrent urinary tract infection, presented with non-specific abdominal pain, constipation, and diarrhea."
a(CHEBI:"hematin") decreases path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Intermittent constipation and vague abdominal pain were considered to be adverse effects of oxybutynin and iron replacement in the first 3 hospital encounters; the patient's neuropsychiatric manifestations were initially thought to be known adverse reactions to metronidazole [5]."
a(CHEBI:"medications") increases path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, neuropathy, lymphoma, and SjÃƒÂ¶gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
path(MESHD:"HCV infection") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Among hospitalized persons with HCV infection the prevalence of mental disorders, tobacco use/COPD, alcohol abuse, substance abuse and chronic kidney disease was particularly high (65 Although the tolerability of newer HCV regimens appears to have much improved, recent trials using direct acting antivirals have typically excluded participants with impaired renal function, recent alcohol or substance abuse, malignancy, autoimmune disorders and significant heart disease, for example [23,24]."
path(MESHD:"HCV infection") association path(MESHD:"chronic kidney disease")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Tobacco use, alcohol dependence, hepatitis C, and HIV were associated with an increased risk of PCT."
path(MESHD:"HCV infection") association path(MESHD:"PCT")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, neuropathy, lymphoma, and SjÃƒÂ¶gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
path(MESHD:"HCV infection") association path(MESHD:"neuropathy")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Ferritin plasma concentrations and serological markers of HCV infection were evaluated."
path(MESHD:"HCV infection") association p(HGNC:"FTH1")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Note that this is an opposite relationship compared with the general population, where complaint of dry eyes (5 %) is more common than finding histological evidence (<0.5 %) .^62 Of patients with SjÃƒÂ¶gren syndrome, however, only 5 to 10 % has evidence of HCV infection."
path(MESHD:"HCV infection") association path(MESHD:"Sjoegren syndrome")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, neuropathy, lymphoma, and SjÃƒÂ¶gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
path(MESHD:"HCV infection") association path(MESHD:"Sjoegren syndrome")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, neuropathy, lymphoma, and SjÃƒÂ¶gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
path(MESHD:"HCV infection") association path(MESHD:"mixed cryoglobulinemia")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, neuropathy, lymphoma, and SjÃƒÂ¶gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
path(MESHD:"HCV infection") association path(MESHD:"lymphoma")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "In various conditions associated with PCT, such as chronic HCV and alcohol use, hepcidin levels are low compared with controls."
path(MESHD:"HCV infection") decreases p(HGNC:"HAMP")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "This viral infection can lead to a reduction in hepcidin levels and generate hepatocyte oxidative damage"
path(MESHD:"HCV infection") decreases p(HGNC:"HAMP")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Other conditions, considered Ã¢â‚¬Ëœhigh priorityÃ¢â‚¬â„¢ for HCV treatment include HBV or HIV coinfection, nonalcoholic fatty liver disease (associated with metabolic syndrome), diabetes mellitus and porphyria cutanea tarda."
path(MESHD:"HCV infection") positiveCorrelation path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Other conditions, considered Ã¢â‚¬Ëœhigh priorityÃ¢â‚¬â„¢ for HCV treatment include HBV or HIV coinfection, nonalcoholic fatty liver disease (associated with metabolic syndrome), diabetes mellitus and porphyria cutanea tarda."
path(MESHD:"HCV infection") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "We also examined the prevalence of extrahepatic conditions whose presence would be an indication for HCV treatment, including cryoglobulinaemia, vasculitis, proteinuria, nephrotic syndrome, membranoproliferative glomerulonephritis and porphyria cutanea tarda."
path(MESHD:"HCV infection") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with PCT should be screened for HFE mutations and for HCV."
path(MESHD:"HCV infection") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "We also examined the prevalence of extrahepatic conditions whose presence would be an indication for HCV treatment, including cryoglobulinaemia, vasculitis, proteinuria, nephrotic syndrome, membranoproliferative glomerulonephritis and porphyria cutanea tarda."
path(MESHD:"HCV infection") positiveCorrelation path(MESHD:"vasculitis")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Conclusions: This case report, for the first time, documents acute porphyria attack as a result of a sequential combination of 3 common medications."
path(MESHD:"HCV infection") positiveCorrelation path(MESHD:"HBV")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "This is the first case report of the concomitant presence of both acute porphyria and Arnold Chiari malformation, 2 genetic disorders with unclear association."
path(MESHD:"HCV infection") positiveCorrelation path(MESHD:"HIV infection")

SET Citation = {"PubMed", "25697467.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyria is a debilitating disorder caused by accumulation of intermediates of heme as a result of enzyme deficiency in heme synthesis [1]."
path(MESHD:"HCV infection") positiveCorrelation path(MESHD:"nonalcoholic fatty liver disease")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "We also examined the prevalence of extrahepatic conditions whose presence would be an indication for HCV treatment, including cryoglobulinaemia, vasculitis, proteinuria, nephrotic syndrome, membranoproliferative glomerulonephritis and porphyria cutanea tarda."
path(MESHD:"HCV infection") positiveCorrelation path(MESHD:"Cryoglobulinaemia")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "We also examined the prevalence of extrahepatic conditions whose presence would be an indication for HCV treatment, including cryoglobulinaemia, vasculitis, proteinuria, nephrotic syndrome, membranoproliferative glomerulonephritis and porphyria cutanea tarda."
path(MESHD:"HCV infection") positiveCorrelation path(MESHD:"Proteinuria")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "We also examined the prevalence of extrahepatic conditions whose presence would be an indication for HCV treatment, including cryoglobulinaemia, vasculitis, proteinuria, nephrotic syndrome, membranoproliferative glomerulonephritis and porphyria cutanea tarda."
path(MESHD:"HCV infection") positiveCorrelation path(MESHD:"Nephrotic syndrome")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "We also examined the prevalence of extrahepatic conditions whose presence would be an indication for HCV treatment, including cryoglobulinaemia, vasculitis, proteinuria, nephrotic syndrome, membranoproliferative glomerulonephritis and porphyria cutanea tarda."
path(MESHD:"HCV infection") positiveCorrelation path(MESHD:"glomerulonephritis")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Factors contributing to the development of PCT include alcohol use, hepatitis C virus infection, human immunodeficiency virus, estrogen use, UROD pathogenic variants, and hereditary hemochromatosis."
path(MESHD:"HCV infection") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Contributing environmental factors include alcohol use and hepatitis C virus (HCV) infection."
path(MESHD:"HCV infection") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The most common environmental or acquired factors are alcohol use, HCV, estrogen use, human immunodeficiency virus (HIV), and smoking."
path(MESHD:"HCV infection") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
path(MESHD:"HCV infection") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "^1,2 Unlike other forms of porphyria, PCT usually is an acquired disease precipitated by extrinsic risk factors that commonly include excessive alcohol consumption, smoking, and chronic hepatitis C virus (HCV) infection."
path(MESHD:"HCV infection") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "# INTRODUCTION Approximately 2.7 million noninstitutionalized persons in the United States have chronic hepatitis C virus (HCV) infection [1] and, accordingly, are at risk for development of advanced liver disease and hepatocellular carcinoma [2]."
path(MESHD:"HCV infection") increases path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "^1,2 Unlike other forms of porphyria, PCT usually is an acquired disease precipitated by extrinsic risk factors that commonly include excessive alcohol consumption, smoking, and chronic hepatitis C virus (HCV) infection."
path(MESHD:"HCV infection") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "This viral infection can lead to a reduction in hepcidin levels and generate hepatocyte oxidative damage"
path(MESHD:"HCV infection") increases bp(GO:"response to oxidative stress")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "# INTRODUCTION Approximately 2.7 million noninstitutionalized persons in the United States have chronic hepatitis C virus (HCV) infection [1] and, accordingly, are at risk for development of advanced liver disease and hepatocellular carcinoma [2]."
path(MESHD:"HCV infection") increases path(MESHD:"advanced liver disease")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Also, most have reported relatively static estimates of cumulative prevalence and have not included some of the serious, but less commonly encountered, extrahepatic manifestations of HCV infection (e.g., mixed cryoglobulinaemia, membranous glomerulonephritis, porphyria cutanea tarda)."
path(MESHD:"HCV infection") increases path(MESHD:"cryoglobulinaemia")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "In addition, HCV infection is associated with an array of nonhepatic conditions, directly or indirectly related to effects of the virus itself, which contribute to overall hepatitis C-related morbidity [3-9]."
path(MESHD:"HCV infection") increases path(MESHD:"hepatitis")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "At that time, he had an acute HCV infection and jaundice that required a prolonged hospitalization."
path(MESHD:"HCV infection") increases path(MESHD:"acute")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Elevated urinary uroporphyrin levels are detected in only 0.5 to 22 % of patients with chronic HCV infection."
path(MESHD:"HCV infection") increases a(CHEBI:"uroporphyrin")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Many are older patients with longstanding HCV infection and symptomatic cryoglobulinemia."
path(MESHD:"HCV infection") increases path(MESHD:"cryoglobulinemia")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "In the early 1990s, multiple investigators simultaneously reported that 50 to 90 % of patients with essential MC had HCV infection."
path(MESHD:"HCV infection") increases path(MESHD:"MC")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "Epidemiologic studies associate HBV, as well as HCV, with the development of HCC."
path(MESHD:"HBV") increases path(MESHD:"HCC")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Tobacco use, alcohol dependence, hepatitis C, and HIV were associated with an increased risk of PCT."
path(MESHD:"HIV infection") association path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Factors contributing to the development of PCT include alcohol use, hepatitis C virus infection, human immunodeficiency virus, estrogen use, UROD pathogenic variants, and hereditary hemochromatosis."
path(MESHD:"HIV infection") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The most common environmental or acquired factors are alcohol use, HCV, estrogen use, human immunodeficiency virus (HIV), and smoking."
path(MESHD:"HIV infection") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
path(MESHD:"HIV infection") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "However, it is currently unresolved whether mild-to-moderate hepatic iron deposition or heterozygosity for the C282Y mutation plays a role in human alcoholic liver disease or in nonalcoholic fatty liver disease or nonalcoholic steatohepatitis."
path(MESHD:"nonalcoholic fatty liver disease") association path(MESHD:"alcoholic liver disease")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Of MC-associated MPGN, 81 % is HCV RNA+ versus 25 % of noncryoglobulinemic glomerulonephritis."
path(MESHD:"glomerulonephritis") association path(MESHD:"MPGN")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Mycophenolate mofetil can inhibit the proliferation of activated B cells and reduce serum immunoglobulin levels (5), and especially in patients with PSS associated with hyperglobulinemia and glomerulonephritis (6)."
path(MESHD:"glomerulonephritis") association a(CHEBI:"Mycophenolate mofetil")

SET Citation = {"PubMed", "26743054.0"}
SET DataSource = "manual-curation"
SET Support = "Aber auch bei PCT-Patienten ohne Mutationen in HFE findet sich erhÃƒÂ¶hte Eisenspeicherung bei verminderter Bildung von Hepcidin [20]."
p(HGNC:"HAMP") association p(HGNC:"HFE")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "To our knowledge, there are no published data on erythroferrone (ERFE), the main bone marrow-derived regulator of hepcidin, in EPP."
p(HGNC:"HAMP") association p(HGNC:"ERFE")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "An important milestone in understanding iron homeostasis was the discovery and characterization of hepcidin, ^115 a 25 -amino acid peptide synthesized mainly in the liver, which acts as a negative regulator of ferroportin, the key iron transporter across the basolateral membrane of duodenal enterocytes, hepatocytes, and macrophages."
p(HGNC:"HAMP") decreases p(HGNC:"SLC40A1")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Hepcidin causes degradation of the iron export transporter ferroportin in gut enterocytes and macrophages, and low levels of hepcidin result in increased iron absorption in the gut and increased iron export out of cells such as macrophages and hepatocytes."
p(HGNC:"HAMP") decreases p(HGNC:"SLC40A1")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "We also demonstrated that hepcidin levels were positively associated with ferritin and haemoglobin levels, suggesting normal physiologic iron regulation in patients with EPP."
p(HGNC:"HAMP") positiveCorrelation p(HGNC:"FTH1")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "The annual incidence of developing HCC, like that for the HCV, is conditioned by the presence and severity of the underlying liver disease."
path(MESHD:"HCC") association path(MESHD:"liver disease")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "The annual risk of developing HCC in HCV-infected patients depends on the presence and severity of the underlying liver disease."
path(MESHD:"HCC") association path(MESHD:"liver disease")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Fourteen new cases of HCC (11 from Sweden) were reported in patients with acute porphyria."
path(MESHD:"HCC") positiveCorrelation path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "HCC carcinogenesis in AP"
path(MESHD:"HCC") increases path(MESHD:"carcinogenesis")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "The association of liver disease, particularly alcoholic liver disease, and PCT was recognized by Brunsting et al."
path(MESHD:"alcoholic liver disease") association path(MESHD:"liver disease")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Severe alcoholic liver disease is associated with the haemochromatosis gene mutant."
path(MESHD:"alcoholic liver disease") association path(MESHD:"hemochromatosis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron, HFE gene mutations, and alcoholic liver disease Patients with alcoholic liver disease commonly have elevations of serum iron indices (serum ferritin and percent iron saturation) (Bonkovsky & Obando, 1999; Milman et al."
path(MESHD:"alcoholic liver disease") positiveCorrelation a(CHEBI:"iron")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "There are several reasons why hepatic iron overload may occur in patients with alcoholic liver disease, including increased ingestion of iron (as in classical African dietary iron overload), increased intestinal iron absorption [perhaps due to up-regulation of divalent cation (or metal) transporter 1 or to an increase in the maintenance of iron in the reduced [^0]: * Corresponding author."
path(MESHD:"alcoholic liver disease") increases path(MESHD:"iron overload")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Etiology and pathogenesis of ADPÃ¢â‚¬â€ALAD (ALA dehydratase; PBG synthase [EC 4.2.1.24]) catalyzes the formation of the monopyrrole PBG from two molecules of ALA, a precursor committed to synthesis of porphyrins, heme, and other tetrapyrroles."
p(HGNC:"ALAD") association a(CHEBI:"ADP")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "ADP must also be differentiated from other causes of ALAD deficiency such as lead poisoning and hereditary tyrosinemia type 1, which can cause increases in ALA, coproporphyrin III and erythrocyte protoporphyrin and symptoms very much like those in acute porphyrias."
p(HGNC:"ALAD") decreases a(CHEBI:"coproporphyrin")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "ALAD is present in vast abundance in mammalian cells; for example in liver its activity is 80 to 100 -fold greater than that of ALAS, the first and ratelimiting enzyme for hepatic heme biosynthesis (Kappas et al. 1995)."
p(HGNC:"ALAD") positiveCorrelation a(CHEBI:"heme biosynthesis")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Patients who are heterozygous for a mutation that reduces ALAD activity by 50 % develop acute porphyria symptoms once they have an even slight increase in lead exposure."
p(HGNC:"ALAD") increases path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The ALAD enzyme activity is reduced in diabetes mellitus (Fernandez-Cuartero et al."
p(HGNC:"ALAD") negativeCorrelation path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency."
p(HGNC:"UROD") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Hepatic uroporphyrinogen decarboxylase activity in porphyria cutanea tarda patients: the influence of virus C infection."
p(HGNC:"UROD") association path(MESHD:"PCT")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of hemochromatosis alleles."
p(HGNC:"UROD") association path(MESHD:"Familial PCT")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The disease becomes active when acquired factors, such as iron, alcohol, Hepatitis C Virus (HCV), HIV, estrogens (used, for example, in oral contraceptives and prostate cancer treatment) and possibly smoking, combine to cause a deficiency of UROD in the liver."
p(HGNC:"UROD") association a(CHEBI:"estrogens")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The disease becomes active when acquired factors, such as iron, alcohol, Hepatitis C Virus (HCV), HIV, estrogens (used, for example, in oral contraceptives and prostate cancer treatment) and possibly smoking, combine to cause a deficiency of UROD in the liver."
p(HGNC:"UROD") association a(CHEBI:"oral contraceptives")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron, HFE gene mutations, and porphyria cutanea tarda porphyria cutanea tarda, the most common of the human porphyrias, is caused by a deficiency in activity of hepatic uroporphyrinogen decarboxylase, the enzyme responsible for the stepwise decarboxylation of uroporphyrinogen to coproporphyrinogen, during the process of heme synthesis."
p(HGNC:"UROD") decreases a(CHEBI:"iron")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "In the presence of iron, CyP450 enzymes catalyze the conversion of uroporphyrinogen into uroporphomethene, an inhibitor of UROD, as shown in mice."
p(HGNC:"UROD") decreases a(CHEBI:"CYP450")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "The fifth enzyme of the heme synthetic pathway is UROD, which carries out the stepwise conversion of the beta acetate moieties of uro'gen 1 or uro'gen 3 to hepta-, hexa-, penta-, and finally to tetra-carboxyl porphyrinogens, the latter better known as CP'ogens 1 and 3."
p(HGNC:"UROD") increases a(CHEBI:"porphyrinogens")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Since the UROD enzyme activity is markedly reduced in HEP, it is sufficient to lead to accumulation of highly carboxylated porphyrinogens and porphyrins in liver and possibly other tissues."
p(HGNC:"UROD") increases a(CHEBI:"porphyrinogens")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "The actual intermediate in the biosynthetic pathway to heme is coproporphyrinogen 3 (CP'ogen3) (Figure 1), formed by serial decarboxylations from uroporphyrinogen3 (uro'gen3) by the enzyme uroporphyrinogen decarboxylase (UROD), as shown in Figure 2."
p(HGNC:"UROD") increases a(CHEBI:"coproporphyrinogen")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Both PCT and HEP (described in the next section) are due to deficient activity of hepatic uroporphyrinogen decarboxylase, the fifth enzyme in the heme biosynthetic pathway."
p(HGNC:"UROD") negativeCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "## porphyria Cutanea Tarda ## Pathophysiology Low activity ( <20 % ) of hepatic uroporphyrinogen decarboxylase (UROD) underlies all cases of PCT (acquired type 1 or familial type 2)."
p(HGNC:"UROD") negativeCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "A few days later, the hepatic enzymes increased [GGT, 4.99 SI; ALT, 3.31 SI; aspartate aminotransferase (AST), 1.74 SI) ], and the patient complained of pruritus and erythema."
path(MESHD:"erythema") positiveCorrelation path(MESHD:"pruritus")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Only CBZ could cause a seizure reduction, but this treatment had to be discontinued as an elevation of the transaminases as well as pruritus and erythema were noted."
path(MESHD:"erythema") positiveCorrelation path(MESHD:"pruritus")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Pain stress contributes to neuroendocrine reactions that activate ALAS1 and exacerbate symptoms."
path(MESHD:"Pain") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Amongst them well recognized are: alcohol abuse, oestrogen replacement therapy, iron overload, haemodialysis, viral infections (hepatitis C, hepatitis B, HIV virus), exposure to polychlorinated hydrocarbons and inherited mutations in the HFE gene concerning classic haemochromatosis."
path(MESHD:"Hemochromatosis") association a(CHEBI:"oestrogen")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda Zaneta J. Bulaj, John D. Phillips, Richard S. Ajioka, Michael R. Franklin, Linda M. Griffen, Donald J. Guinee, Corwin Q. Edwards, and James P. Kushner Inherited and acquired factors have been implicated in the pathogenesis of porphyria cutanea tarda (PCT), a disorder characterized by a photosensitive dermatosis and hepatic siderosis."
path(MESHD:"Hemochromatosis") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Factors contributing to the development of PCT include alcohol use, hepatitis C virus infection, human immunodeficiency virus, estrogen use, UROD pathogenic variants, and hereditary hemochromatosis."
path(MESHD:"Hemochromatosis") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Heterozygosity of the haemochromatosis mutation, C282Y, does not influence susceptibility to alcoholic cirrhosis."
path(MESHD:"Hemochromatosis") causesNoChange path(MESHD:"alcoholic cirrhosis")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "A possible explanation of our finding is that in our patient population, coexistence of various concomitant precipitat ing factors such as iron overload, oestrogen replacement therapy and HCV infection, seems to facilitate cumulatively the manifesta tion of PCT."
path(MESHD:"iron overload") association path(MESHD:"PCT")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda is associated with hepatic iron overload and responds to iron-reduction therapy."
path(MESHD:"iron overload") association path(MESHD:"PCT")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "It is yet unclear whether the pathology of liver disease in patients with HCV is influenced by iron overload or limited to the direct cell damage from replication of the virus and subsequent inflammation."
path(MESHD:"iron overload") association path(MESHD:"liver disease")

SET Citation = {"PubMed", "35193623.0"}
SET DataSource = "manual-curation"
SET Support = "This may be explained in part by PCT itself or treatment for PCT, such as digestive issues as a known side-effect of chloroquine, used for treatment of PCT or related to for example hepatitis C, iron overload or other co-morbidities."
path(MESHD:"iron overload") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "35193623.0"}
SET DataSource = "manual-curation"
SET Support = "This may be explained in part by PCT itself or treatment for PCT, such as digestive issues as a known side-effect of chloroquine, used for treatment of PCT or related to for example hepatitis C, iron overload or other co-morbidities."
path(MESHD:"iron overload") association a(CHEBI:"chloroquine")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "These data indicate that the most dramatic effect of HFE mutations on the hepatic iron overload seen in PCT occurs when the Cys282Tyr/Cys282Tyr genotype is present."
path(MESHD:"iron overload") association p(HGNC:"HFE")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Other HFE mutations associated with iron overload have recently been described, but these occur infrequently."
path(MESHD:"iron overload") association p(HGNC:"HFE")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Nonalcoholic steatohepatitis has been associated with evidence of iron overload (Bacon et al."
path(MESHD:"iron overload") association path(MESHD:"Nonalcoholic steatohepatitis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Up-regulation of transferrin receptor expression in hepatocytes by habitual alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease."
path(MESHD:"iron overload") association p(HGNC:"TFRC")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Up-regulation of transferrin receptor expression in hepatocytes by habitual alcohol drinking is implicated in hepatic iron overload in alcoholic liver disease."
path(MESHD:"iron overload") association bp(MESHPP:"alcohol drinking")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Iron is often implicated in the pathogenesis of sporadic-type PCT because overload facilitates the formation of oxygen-free radicals, which in turn can facilitate the formation of a UROD inhibitor"
path(MESHD:"iron overload") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "In addition to increased duodenal absorption, other mechanisms have been postulated as causes of portosystemic shuntrelated iron overload, including relative hepatic hypoxia, and associated pancreatic insufficiency with decreased bicarbonate secretion (Grace & Powell, 1974)."
path(MESHD:"iron overload") decreases a(CHEBI:"bicarbonate")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "The association between PCT and impaired glucose metabolism is not fully understood but possibly implicates iron overload; a previous study showed that patients with PCT with persistently high ferritin levels were more likely to develop impaired glucose metabolism and diabetes."
path(MESHD:"iron overload") positiveCorrelation path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Iron is often implicated in the pathogenesis of sporadic-type PCT because overload facilitates the formation of oxygen-free radicals, which in turn can facilitate the formation of a UROD inhibitor"
path(MESHD:"iron overload") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The generation of uroporphomethene is dependent on the amount of iron in the liver in murine models, and in mice with heterozygous UROD knock out, iron overload is sufficient to cause a PCT phenotype"
path(MESHD:"iron overload") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is a known complication of ESKD, possibly due to iron over load resulting from a number of factors such as erythropoietin deficiency and the administration of exogenous iron."
path(MESHD:"iron overload") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Thus, heavy iron overload per se can cause serious damage, including cirrhosis and hepatocellular carcinoma in the liver."
path(MESHD:"iron overload") increases path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Heavy iron overload causes serious damage, including cirrhosis and hepatocellular carcinoma in the liver."
path(MESHD:"iron overload") increases path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "In addition to a mutation in the gene coding for UROD, several factors are known to reduce enzyme activity and thus facilitate porphyrin accumulation: high alcohol intake, smoking, iron overload, hepatitis C, human immundeficiency virus (HIV), and estrogen use in women."
path(MESHD:"iron overload") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "A role for modest iron overload in increasing severity of alcohol-induced liver disease has been well established from results of experimental studies."
path(MESHD:"iron overload") increases path(MESHD:"liver disease")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Results of studies in a rat model of alcoholic liver disease have demonstrated clearly the synergistic effect of diet-induced iron overload and alcohol in the production of increased oxidative stress in the liver and the development of hepatic fibrosis or cirrhosis (Tsukamoto et al."
path(MESHD:"iron overload") increases path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Thus, heavy iron overload per se can cause serious damage, including cirrhosis and hepatocellular carcinoma in the liver."
path(MESHD:"iron overload") increases path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Heavy iron overload causes serious damage, including cirrhosis and hepatocellular carcinoma in the liver."
path(MESHD:"iron overload") increases path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The major recognized risk factors for disease development are chronic hepatitis C(CHC), heavy alcohol use, iron overload (which is generally only mild or moderate), and estrogen use."
path(MESHD:"iron overload") increases path(MESHD:"chronic hepatitis")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Iron is often implicated in the pathogenesis of sporadic-type PCT because overload facilitates the formation of oxygen-free radicals, which in turn can facilitate the formation of a UROD inhibitor"
path(MESHD:"iron overload") increases a(CHEBI:"reactive oxygen species")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Interestingly, patients suffering TM manifest several of PCT's predisposing factors as a result of their underlying disease such as iron overload, blood-borne infections (e.g. viral hepatitis) or oestrogen replacement therapy because of amenorrhoea."
path(MESHD:"iron overload") increases path(MESH:"beta-Thalassemia")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Also, iron overload may increase oxidative stress (ROS) which can induce ALA synthase and increase the production of ALA, which in turn, may increase uroporphyrinogen production."
path(MESHD:"iron overload") increases bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Results of studies in a rat model of alcoholic liver disease have demonstrated clearly the synergistic effect of diet-induced iron overload and alcohol in the production of increased oxidative stress in the liver and the development of hepatic fibrosis or cirrhosis (Tsukamoto et al."
path(MESHD:"iron overload") increases bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Results of studies in a rat model of alcoholic liver disease have demonstrated clearly the synergistic effect of diet-induced iron overload and alcohol in the production of increased oxidative stress in the liver and the development of hepatic fibrosis or cirrhosis (Tsukamoto et al."
path(MESHD:"iron overload") increases path(MESHD:"hepatic fibrosis")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Both HCV infection and alcohol excess have been associated with hepatic siderosis."
path(MESHD:"siderosis") association path(MESHD:"HCV infection")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "first suggested that hemochromatosis gene mutations were responsible for the hepatic siderosis in many patients with PCT."
path(MESHD:"siderosis") association path(MESHD:"hemochromatosis")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
path(MESHD:"siderosis") association a(CHEBI:"Estrogens")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "^4,6 In this respect we believe that bearing in mind the comorbidities of the patients with epilepsy at the time of chosing an antiepileptic drug (AED) should improve overall health and quality of life in those with epilepsy."
a(CHEBI:"antiepileptic drug") decreases path(MESHD:"epilepsy")

SET Citation = {"PubMed", "26743054.0"}
SET DataSource = "manual-curation"
SET Support = "J Clin Invest 56:661-667 11.Lee PK, Abrahams I, Bickers DR (1999) porphyria cutanea tarda occurring in a patient with renal failure, systemic lupus erythematosus and chronic hepatitis C infection treated with hemodialysis."
path(MESHD:"chronic hepatitis") association path(MESHD:"renal failure")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "The Japanese study reported that it takes 13 years from a presumed infection, which was produced by a blood transfusion infected with HCV , to the development of chronic hepatitis."
path(MESHD:"chronic hepatitis") association a(MESHP:"Blood Transfusion")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection."
path(MESHD:"chronic hepatitis") association path(MESHD:"hereditary hemochromatosis")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "As with HCV infection, it has been reported that, at least in western countries, carriers of HBsAg rarely develop HCC, but the incidence with increasing severity of liver disease reaches 0.5- 0.8 % per year in patients with underlying chronic hepatitis and 1.5-6.6 % in patients with liver cirrhosis."
path(MESHD:"chronic hepatitis") increases path(MESHD:"liver disease")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "(2002), namely, that, in patients who are homozygous for the C282Y mutation and who have chronic hepatitis C , it is extraordinarily likely that cirrhosis will develop, and at a young age."
path(MESHD:"chronic hepatitis") increases path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "As with HCV infection, it has been reported that, at least in western countries, carriers of HBsAg rarely develop HCC, but the incidence with increasing severity of liver disease reaches 0.5- 0.8 % per year in patients with underlying chronic hepatitis and 1.5-6.6 % in patients with liver cirrhosis."
path(MESHD:"chronic hepatitis") increases path(MESHD:"HCV infection")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "As with HCV infection, it has been reported that, at least in western countries, carriers of HBsAg rarely develop HCC, but the incidence with increasing severity of liver disease reaches 0.5- 0.8 % per year in patients with underlying chronic hepatitis and 1.5-6.6 % in patients with liver cirrhosis."
path(MESHD:"chronic hepatitis") increases path(MESHD:"HCC")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Most patients with chronic hepatitis C , including those with elevated serum ferritin level, elevated serum iron saturation, or both, have not been found to have elevations in hepatic iron concentrations."
path(MESHD:"chronic hepatitis") increases p(HGNC:"FTH1")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "(1999) observed an unexpectedly high frequency ( 2.7 % ) of C282Y homozygosity among patients with chronic hepatitis C and biochemical evidence of increased iron in patients with HFE mutations in comparison with findings for those without."
path(MESHD:"chronic hepatitis") increases p(HGNC:"HFE")

SET Citation = {"PubMed", "26743054.0"}
SET DataSource = "manual-curation"
SET Support = "J Clin Invest 56:661-667 11.Lee PK, Abrahams I, Bickers DR (1999) porphyria cutanea tarda occurring in a patient with renal failure, systemic lupus erythematosus and chronic hepatitis C infection treated with hemodialysis."
path(MESHD:"chronic hepatitis") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "These favorable effects of iron reduction alone confirmed and extended results of earlier reports, which had shown significant improvements in serum levels of alanine aminotransferase in patients with chronic hepatitis C who previously had not experienced complete or sustained virological responses to interferon and who then were treated by iron-reduction therapy by means of therapeutic phlebotomy (Hayashi et al."
path(MESHD:"chronic hepatitis") increases p(HGNC:"GPT")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Only 1 of 70 (1%) patients with noncirrhotic chronic hepatitis had glucose intolerance, compared with 34 of 165 (21%) patients with cirrhosis."
path(MESHD:"chronic hepatitis") increases path(MESHD:"glucose intolerance")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection."
path(MESHD:"chronic hepatitis") increases path(MESHD:"hepatic fibrosis")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Other recent evidence indicates that the prevalence of HFE gene mutations is increased in chronic viral hepatitis and that patients with chronic hepatitis C harboring especially the C282Y mutation are more likely to suffer from advanced hepatic fibrosis or cirrhosis and to do so at younger ages."
path(MESHD:"chronic hepatitis") increases p(HGNC:"HFE",var("p.?"))

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The latter change may well occur due to downregulation by ethanol (actually, its proximate oxidation product, acetaldehyde) of hepatic production of hepcidin, ^11 which, in turn, appears to be the key regulator of expression of ferroportin on the basolateral membrane of duodenal enterocytes."
a(CHEBI:"ethanol") decreases p(HGNC:"HAMP")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The latter change may well occur due to downregulation by ethanol (actually, its proximate oxidation product, acetaldehyde) of hepatic production of hepcidin, ^11 which, in turn, appears to be the key regulator of expression of ferroportin on the basolateral membrane of duodenal enterocytes."
a(CHEBI:"ethanol") decreases a(CHEBI:"acetaldehyde")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Results of a recent study in mice lacking expression of the HFE gene showed that ethanol treatment increased hepatic nonheme iron and hepatic 5-aminolevulinate synthase activity in the H F E^-/-, but not in wild-type, mice (Sinclair et al."
a(CHEBI:"ethanol") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Corresponding to this was higher hepatic hydroxyproline content in animals given ethanol and iron compared with the other three groups (not shown in this figure)."
a(CHEBI:"ethanol") increases a(CHEBI:"hydroxyproline")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Results of a recent study in mice lacking expression of the H F E gene showed that ethanol treatment increased hepatic nonheme iron and hepatic 5 -aminolevulinate synthase activity in the H F E-/- mice, but not in wild-type mice."
a(CHEBI:"ethanol") increases a(CHEBI:"aminolevulinate")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The hepatic production of malondialdehyde (MDA) and 4-hydroxynonenal (4HNE), aldehydic products of lipid peroxidation that directly stimulate collagen synthesis, was elevated twofold in rats fed with high fat, ethanol, and iron, compared with rats fed with fat and ethanol.(Fig. 1A, B) Also, the group fed with ethanol, iron, and fat showed significant fibrogenic activity (Fig. 2)."
a(CHEBI:"ethanol") increases a(CHEBI:"malondialdehyde")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "For cellulitis, patients of increasing age, female sex, on hemodialysis, with catheter and graft compared to AVF access, and with diagnoses of tobacco use, alcohol dependence, hepatitis C, or HIV were at increased risk."
path(MESHD:"cellulitis") positiveCorrelation path(MESHD:"hepatitis")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Female sex, catheter compared to AVF access, tobacco use, hepatitis C, and HIV were associated with an increased risk of abscess."
path(MESHD:"abscess") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Increasing age, black and other race compared to white race, Hispanic ethnicity, hemodialysis modality, and alcohol dependence were associated with a decreased risk of abscess."
path(MESHD:"abscess") association path(DO:"alcohol dependence")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Commonly seen SSTIs include abscesses, cellulitis, folliculitis, and methicillin-resistant Staphylococcus aureus."
path(MESHD:"folliculitis") positiveCorrelation path(MESHD:"cellulitis")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Patients have symptoms of burning, itching, pain, erythema, and edema on sun-exposed skin areas, sometimes but not always resembling sunburn."
path(MESHD:"edema") positiveCorrelation path(MESHD:"erythema")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Patients have symptoms of burning, itching, pain, erythema, and edema on sun-exposed skin areas, sometimes but not always resembling sunburn."
path(MESHD:"edema") positiveCorrelation path(MESHD:"itching")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Other skin manifestations include hyperpigmentation, hypertrichosis, alopecia due to scaring and purplish heliotrope suffusion of periorbital areas."
path(MESHD:"hypertrichosis") positiveCorrelation path(MESHD:"hyperpigmentation")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Porphyrins are phototoxic, resulting in cutaneous symptoms such as blisters, sores, hyperpigmentation, and hypertrichosis on sun-exposed areas."
path(MESHD:"hypertrichosis") positiveCorrelation path(MESHD:"hyperpigmentation")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Facial hyperpigmentation and hypertrichosis may occur."
path(MESHD:"hypertrichosis") positiveCorrelation path(MESHD:"hyperpigmentation")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "Porphyrins are phototoxic, resulting in cutaneous symptoms such as blisters, sores, hyperpigmentation, and hypertrichosis on sun-exposed areas."
path(MESHD:"hypertrichosis") positiveCorrelation path(MESHD:"blisters")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Figure 1 Patient with hypertrichosis of zygomatics, hyperpigmentation, scars and bullae of the face and hands."
path(MESHD:"hyperpigmentation") positiveCorrelation path(MESHD:"hypertrichosis")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Other common cutaneous manifestations seen include hypertrichosis, hyperpigmentation, and a thickened appearance of the skin."
path(MESHD:"hyperpigmentation") positiveCorrelation path(MESHD:"hypertrichosis")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "^13-16 A study of 1,930 Finnish men reported that the men with ferritin level Ã¢â€°Â¥ 200 ng / dL had a risk 2.2 times higher of acute myocardial infarction when compared to men with lower serum ferritin level."
path(MESHD:"acute myocardial infarction") positiveCorrelation p(HGNC:"FTH1")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Risk factors of fibrosis in alcohol-induced liver disease."
path(MESHD:"fibrosis") association path(MESHD:"liver disease")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity."
path(MESHD:"fibrosis") association p(HGNC:"HFE")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis."
path(MESHD:"fibrosis") association path(MESHD:"nonalcoholic steatohepatitis")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Determining the degree of fibrosis by some means is needed due to the increased risk of hepatocellular carcinoma (HCC) in HH patients with advanced fibrosis and cirrhosis."
path(MESHD:"fibrosis") positiveCorrelation path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "In most of these patients, cirrhosis is already present ^20 but in a few only some degree of fibrosis is seen."
path(MESHD:"fibrosis") positiveCorrelation path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 27, 1695-1699."
path(MESHD:"fibrosis") positiveCorrelation path(MESHD:"hereditary hemochromatosis")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "We were able to grade 84 of the 89 liver biopsies for active inflammation and staging of fibrosis."
path(MESHD:"fibrosis") positiveCorrelation path(MESHD:"inflammation")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "In six cohort studies, 26% (range 0%Ã¢â‚¬â€œ40%) of the 53 patients with AP- associated PLC had cirrhosis. Of the seven French patients with PLC, two had not only cirrho- sis but also chronic viral hepatitis, which is strongly associated with the development of fibrosis. In the histological samples of the 13 Swedish patients with AP and PLC, mild to moderate fibrosis was common and one- third had cirrhosis."
path(MESHD:"fibrosis") increases path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "However, patients with end-stage kidney disease (ESKD) have high levels of hepcidin and are also at risk of developing PCT"
path(MESHD:"End Stage kidney disease") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
path(MESHD:"End Stage kidney disease") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "However, patients with end-stage kidney disease (ESKD) have high levels of hepcidin and are also at risk of developing PCT"
path(MESHD:"End Stage kidney disease") increases p(HGNC:"HAMP")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Excess porphyrins in the skin interact with light of approximately 400 nm -wavelength and are activated and generate reactive oxygen species that cause skin damage and increased fragility (Grossman and Poh-Fitzpatrick, 1980; Lim, 1989)."
a(CHEBI:"reactive oxygen species") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The harmful effects are related to increased oxidative stress and production of reactive oxygen species causing oxidative damage to lipids, proteins, and nucleic acids."
a(CHEBI:"reactive oxygen species") increases bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Yet, as described elsewhere in this issue, excessive iron is toxic to all types of cells because it increases oxidative stress and reactive oxygen species, which in turn cause the oxidation of lipids, proteins, and nucleic acids."
a(CHEBI:"reactive oxygen species") increases bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "The toxicity of iron is believed to involve increased oxidative stress, with iron-catalyzed production of reactive oxygen species causing oxidative damage to lipids, proteins, and nucleic acids."
a(CHEBI:"reactive oxygen species") increases bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "A \'twohit\' theory has been suggested, which involves accumulation of fat in the liver, especially in the form of free fatty acids (\'first hit\'), coupled with a \'second hit\' that produces increased oxidative stress and reactive oxygen species."
a(CHEBI:"reactive oxygen species") increases path(MESHD:"fatty liver")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The pathogenesis of PCT is thought to involve iron-generated free oxygen radicals that oxidize uroporphyrinogen, leading to the formation of a uroporphomethene inhibitor of UROD."
a(CHEBI:"reactive oxygen species") increases a(PKG:"Uroporphomethene")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "his study also found that persistently elevated serum ferritin over time was an independent risk factor for DM"
a(MESHD:"Ferritins") increases path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "The association between PCT and impaired glucose metabolism is not fully understood but possibly implicates iron overload; a previous study showed that patients with PCT with persistently high ferritin levels were more likely to develop impaired glucose metabolism and diabetes."
a(MESHD:"Ferritins") increases path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Porphyrins may be directly neurotoxic and trigger neurologic complications such as seizures."
a(CHEBI:"porphyrins") increases path(MESHD:"seizures")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The occurrence of PRES in AIP patients may be due to the abnormal accumulation of porphyrin metabolites in the body caused by AIP"
a(CHEBI:"porphyrins") increases path(MESHD:"PRES")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "causing cardiovascular spasm, contraction, and other abnormal manifestations, triggering vasogenic edema and leading to the onset of PRES"
a(CHEBI:"porphyrins") increases path(MESHD:"Cerebral Edema")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "These por phyrins are activated by light exposure (especially at wavelengths near 400 nm) and generate reactive oxygen species that damage sun-exposed skin."
a(CHEBI:"porphyrins") increases a(CHEBI:"reactive oxygen species")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "These por phyrins are activated by light exposure (especially at wavelengths near 400 nm) and generate reactive oxygen species that damage sun-exposed skin."
a(CHEBI:"porphyrins") increases path(MESHD:"Skin Diseases")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "causing cardiovascular spasm, contraction, and other abnormal manifestations, triggering vasogenic edema and leading to the onset of PRES"
a(CHEBI:"porphyrins") increases path(MESHD:"Coronary Artery Spasm")

SET Citation = {"PubMed", "15031049.0"}
SET DataSource = "manual-curation"
SET Support = "In any patient who presents with photoexposed unilocular blisters and skin fragility, the diagnosis should be considered."
path(MESHD:"blisters") association path(MESHD:"PCT")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Increasing age, female sex, Hispanic ethnicity, and alcohol dependence were associated with a decreased risk of blisters."
path(MESHD:"blisters") association path(DO:"alcohol dependence")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Mycophenolate mofetil can inhibit the proliferation of activated B cells and reduce serum immunoglobulin levels (5), and especially in patients with PSS associated with hyperglobulinemia and glomerulonephritis (6)."
a(CHEBI:"Mycophenolate mofetil") decreases bp(GOBP:"proliferation")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "The proportion of hospitalizations with an in-hospital death decreased significantly from 3.7 From 2004 to 2011, significant increases were found in the prevalence of obesity, hypertension, diabetes, disorders of lipid metabolism, metabolic syndrome, tobacco use/COPD, mental disorders, renal failure/chronic kidney disease, nonhepatic cancers, connective tissue disease, osteoarthritis and ischaemic heart disease among hospitalized persons with HCV infection (P < 0.0001) (Table 2)."
path(MESHD:"obesity") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "The comorbidities assessed in this study were obesity, hypertension, diabetes, disorders of lipid metabolism, metabolic syndrome (a composite variable using the presence of at least two of the following: obesity, hypertension, diabetes or disorder of lipid metabolism), tobacco use/chronic obstructive pulmonary disease (COPD), mental disorders (which encompassed affective, thought and anxiety disorders), alcohol abuse, substance abuse except alcohol, renal failure/chronic kidney disease (including dialysis), ischaemic heart disease, nonhepatic cancers (which included head and neck, lung, prostate, oesophageal, breast and non-Hodgkin's lymphoma), osteoarthritis, connective tissue disease, hepatitis B virus (HBV) infection and HIV infection."
path(MESHD:"obesity") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "## Other Risk Factors for Development of Type II Diabetes Mellitus and Screening Interval There are several other risk factors increasing the risk of having/ developing type II DM; these include obesity, inactivity, high blood pressure, a family history of DM, and age."
path(MESHD:"obesity") increases path(MESHD:"Type II Diabetes")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "The proportion of hospitalizations with an in-hospital death decreased significantly from 3.7 From 2004 to 2011, significant increases were found in the prevalence of obesity, hypertension, diabetes, disorders of lipid metabolism, metabolic syndrome, tobacco use/COPD, mental disorders, renal failure/chronic kidney disease, nonhepatic cancers, connective tissue disease, osteoarthritis and ischaemic heart disease among hospitalized persons with HCV infection (P < 0.0001) (Table 2)."
path(MESHD:"connective tissue disease") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "The two women with the substantially elevated urinary porphyrin levels had a combination of predisposing factors: they were receiving oestrogen replacement therapy because of amenorrhoea, had markedly elevated plasma ferritin concentration, while one of them was HCV positive."
p(HGNC:"FTH1") association a(CHEBI:"oestrogen")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "The two women with the substantially elevated urinary porphyrin levels had a combination of predisposing factors: they were receiving oestrogen replacement therapy because of amenorrhoea, had markedly elevated plasma ferritin concentration, while one of them was HCV positive."
p(HGNC:"FTH1") positiveCorrelation a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "They found a significant correlation between hepcidin mRNA expression and HIC and serum ferritin but not with the hepatic activity index, fibrosis stage, or viral load."
p(HGNC:"FTH1") positiveCorrelation p(HGNC:"HAMP")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "They noted that chronic carriers for hepatitis B had elevated serum iron or ferritin compared with individuals who achieved !"
p(HGNC:"FTH1") positiveCorrelation path(MESHD:"hepatitis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron, HFE gene mutations, and alcoholic liver disease Patients with alcoholic liver disease commonly have elevations of serum iron indices (serum ferritin and percent iron saturation) (Bonkovsky & Obando, 1999; Milman et al."
p(HGNC:"FTH1") positiveCorrelation a(CHEBI:"iron")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Homozygotes for the Cys282Tyr mutation with grade 3 alcohol consumption had higher ferritin values and liver iron content than alcohol abusers who were not homozygotes."
p(HGNC:"FTH1") positiveCorrelation bp(MESHPP:"alcohol consumption")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, neuropathy, lymphoma, and SjÃƒÂ¶gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
path(MESHD:"Sjoegren syndrome") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
path(MESHD:"Sjoegren syndrome") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Lymphoma, renal disease, neuropathy, and SjÃƒÂ¶gren syndrome manifest incomplete overlap with the cryoglobulinemic syndrome."
path(MESHD:"Sjoegren syndrome") association path(MESHD:"lymphoma")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Lymphoma, renal disease, neuropathy, and SjÃƒÂ¶gren syndrome manifest incomplete overlap with the cryoglobulinemic syndrome."
path(MESHD:"Sjoegren syndrome") association path(MESHD:"neuropathy")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
path(MESHD:"Sjoegren syndrome") association path(MESHD:"lymphoma")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "With the exceptions of cryoglobulinemia, lymphoma, and Sjogren syndrome, no pathogenic mechanism has been proposed for most of these associations."
path(MESHD:"Sjoegren syndrome") association path(MESHD:"lymphoma")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, neuropathy, lymphoma, and SjÃƒÂ¶gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
path(MESHD:"Sjoegren syndrome") association path(MESHD:"lymphoma")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "With the exceptions of cryoglobulinemia, lymphoma, and Sjogren syndrome, no pathogenic mechanism has been proposed for most of these associations."
path(MESHD:"Sjoegren syndrome") association path(MESHD:"cryoglobulinemia")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Lymphoma, renal disease, neuropathy, and SjÃƒÂ¶gren syndrome manifest incomplete overlap with the cryoglobulinemic syndrome."
path(MESHD:"Sjoegren syndrome") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | SjÃƒÂ¶gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
path(MESHD:"Sjoegren syndrome") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Although only 10 % of HCV-infected persons will have symptomatic xerophthalmia or xerostomia, Ã¢â€°Â¤ 77 % will have evidence of SjÃƒÂ¶gren syndrome if it is sought with diagnostic tests (Table 6)."
path(MESHD:"Sjoegren syndrome") positiveCorrelation path(MESHD:"xerophthalmia")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Note that this is an opposite relationship compared with the general population, where complaint of dry eyes (5 %) is more common than finding histological evidence (<0.5 %) .^62 Of patients with SjÃƒÂ¶gren syndrome, however, only 5 to 10 % has evidence of HCV infection."
path(MESHD:"Sjoegren syndrome") positiveCorrelation path(MESHD:"dry eyes")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Primary SjÃƒÂ¶gren's syndrome (PSS) is a chronic inflammatory autoimmune disease that mainly affects exocrine glands such as the lacrimal and salivary glands (2) and that has a definite familial aggregation."
path(MESHD:"Sjoegren syndrome") isA path(MESHD:"autoimmune disease")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, neuropathy, lymphoma, and SjÃƒÂ¶gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
path(MESHD:"mixed cryoglobulinemia") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, neuropathy, lymphoma, and SjÃƒÂ¶gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
path(MESHD:"mixed cryoglobulinemia") association path(MESHD:"lymphoma")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | SjÃƒÂ¶gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
path(MESHD:"mixed cryoglobulinemia") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
path(MESHD:"lymphoma") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, neuropathy, lymphoma, and SjÃƒÂ¶gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
path(MESHD:"lymphoma") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, neuropathy, lymphoma, and SjÃƒÂ¶gren syndrome with or without mixed cryoglobulinemia are all strongly associated with HCV infection."
path(MESHD:"lymphoma") association path(MESHD:"neuropathy")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "With the exceptions of cryoglobulinemia, lymphoma, and Sjogren syndrome, no pathogenic mechanism has been proposed for most of these associations."
path(MESHD:"lymphoma") association path(MESHD:"cryoglobulinemia")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "It is essential that future reports of disease associations with hepatitis C contain control groups that are well matched for age, sex, and severity of liver disease, because these are the most common confounding variables."
path(MESHD:"hepatitis") association path(MESHD:"liver disease")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Amongst them well recognized are: alcohol abuse, oestrogen replacement therapy, iron overload, haemodialysis, viral infections (hepatitis C, hepatitis B, HIV virus), exposure to polychlorinated hydrocarbons and inherited mutations in the HFE gene concerning classic haemochromatosis."
path(MESHD:"hepatitis") association path(MESHD:"iron overload")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Amongst them well recognized are: alcohol abuse, oestrogen replacement therapy, iron overload, haemodialysis, viral infections (hepatitis C, hepatitis B, HIV virus), exposure to polychlorinated hydrocarbons and inherited mutations in the HFE gene concerning classic haemochromatosis."
path(MESHD:"hepatitis") association path(DO:"alcohol abuse")

SET Citation = {"PubMed", "35193623.0"}
SET DataSource = "manual-curation"
SET Support = "This may be explained in part by PCT itself or treatment for PCT, such as digestive issues as a known side-effect of chloroquine, used for treatment of PCT or related to for example hepatitis C, iron overload or other co-morbidities."
path(MESHD:"hepatitis") association a(CHEBI:"chloroquine")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Several studies have reported an association between hepatitis C and diabetes mellitus (DM).Problems in interpreting these studies include the frequent failure to account for other variables that predispose to diabetes and the lack of matched control groups."
path(MESHD:"hepatitis") association path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Amongst them well recognized are: alcohol abuse, oestrogen replacement therapy, iron overload, haemodialysis, viral infections (hepatitis C, hepatitis B, HIV virus), exposure to polychlorinated hydrocarbons and inherited mutations in the HFE gene concerning classic haemochromatosis."
path(MESHD:"hepatitis") association a(CHEBI:"oestrogen")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Tobacco use, alcohol dependence, hepatitis C, and HIV were associated with an increased risk of PCT."
path(MESHD:"hepatitis") association path(DO:"alcohol dependence")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "HFE mutations, alcohol and hepatitis C are known to decrease hepcidin levels and thereby increase iron absorption from the intestine."
path(MESHD:"hepatitis") decreases p(HGNC:"HAMP")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "For cellulitis, patients of increasing age, female sex, on hemodialysis, with catheter and graft compared to AVF access, and with diagnoses of tobacco use, alcohol dependence, hepatitis C, or HIV were at increased risk."
path(MESHD:"hepatitis") positiveCorrelation path(DO:"alcohol dependence")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Controlling for demographic and clinical covariates the final models (Table 3 and Fig. 2) indicated that: - For bacterial infections, increasing age, female sex, hemodialysis modality, tobacco use, alcohol dependence, and hepatitis C and HIV diagnoses were associated with an increased risk of the infection."
path(MESHD:"hepatitis") positiveCorrelation path(DO:"alcohol dependence")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "In addition to a mutation in the gene coding for UROD, several factors are known to reduce enzyme activity and thus facilitate porphyrin accumulation: high alcohol intake, smoking, iron overload, hepatitis C, human immundeficiency virus (HIV), and estrogen use in women."
path(MESHD:"hepatitis") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "The main risk factors of HCC are the hepatitis B (HBV) and the hepatitis C (HCV) viruses, which together account for three quarters of all cases worldwide."
path(MESHD:"hepatitis") increases path(MESHD:"HCC")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency."
path(MESHD:"hepatitis") increases p(HGNC:"HFE")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "For example, thyroid disease has been frequently reported in persons with hepatitis C. Many of these reports, however, are of persons undergoing interferon treatment for their hepatitis, and ÃŽÂ± interferon has been known to unmask thyroid disease in patients with other illnesses."
path(MESHD:"hepatitis") increases path(MESHD:"thyroid disease")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "For systemic bacteremia, ESRD patients of increasing age, female sex, on hemodialysis, with catheter and graft compared to AVF access, and diagnosed with tobacco use, alcohol dependence, hepatitis C, or HIV were at increased risk for bacteremia."
path(MESHD:"hepatitis") increases path(MESHD:"bacteremia")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
path(MESHD:"acute") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The acute hepatic porphyrias (AHP) are associated with long-term complications such as primary liver cancer, hypertension, and chronic kidney disease."
path(MESHD:"acute") association path(DO:"primary liver cancer")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "# Hyperhomocysteinemia in patients with acute porphyrias: A potentially dangerous metabolic crossroad?"
path(MESHD:"acute") association path(MESHD:"Hyperhomocysteinemia")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "About 20% of those with an acute attack report photosensitivity although bullae and skin fragility are much less common than in VP Although disease-causing CPOX mutations occur equally in males and females, acute attacks are much more frequent in women, mainly between ages 16 and 45 years (the years of active ovulation)."
path(MESHD:"acute") association p(HGNC:"CPOX")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "However, the key drugs used in systemic therapy, such as methylprednisolone and cyclophosphamide, can induce the acute onset of AIP."
path(MESHD:"acute") association a(CHEBI:"methylprednisolone")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "Resultant overproduction of the neurotoxic intermediates ÃŽÂ´-aminolevulinic acid (ALA) and porphobilinogen (PBG) leads to disabling acute neurovisceral attacks and progressive neuropathy."
path(MESHD:"acute") increases a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron also induces heme oxygenase, causing depletion of a regulatory heme pool and thus derepression of ALA synthase, which further increases the production of uroporphyrinogen and uroporphyrin."
a(CHEBI:"uroporphyrin") decreases p(HGNC:"HMOX1")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron also induces heme oxygenase, causing depletion of a regulatory heme pool and thus derepression of ALA synthase, which further increases the production of uroporphyrinogen and uroporphyrin."
a(CHEBI:"uroporphyrin") decreases a(CHEBI:"iron")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "The diagnosis of PCT was based on typical clinical features and was confirmed by increased urine excretion of uroporphyrin (quantified spectrophotometrically) and skin biopsy."
a(CHEBI:"uroporphyrin") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "In a study using 130 cases of CEP, dermal deposits of uroporphyrin frequently induced dramatic phototoxic oxygen-dependent skin damage with extensive ulcerations and mutilations."
a(CHEBI:"uroporphyrin") increases path(MESHD:"skin damage")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Drug eruption is a common adverse effect of various types of nonchemotherapeutic drugs, and it was highly unlikely that there was any relationship between cutaneous symptoms and porphyria in our patient because no changes in her urinary coproporphyrin or uroporphyrin levels were observed throughout her episode."
a(CHEBI:"uroporphyrin") causesNoChange path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
a(CHEBI:"uroporphyrin") causesNoChange path(MESHD:"Drug eruption")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
path(MESHD:"cryoglobulinemia") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
path(MESHD:"cryoglobulinemia") association path(MESHD:"lymphoma")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
path(MESHD:"cryoglobulinemia") association path(MESHD:"peripheral neuropathies")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "The risk of other cardiovascular conditions commonly associated with HT such as heart failure, atrial fibrillation, ischemic heart disease, and peripheral artery disease did not differ between the AHP groups and comparators."
path(MESHD:"cryoglobulinemia") association path(MESHD:"Sjogren syndrome")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Also, most have reported relatively static estimates of cumulative prevalence and have not included some of the serious, but less commonly encountered, extrahepatic manifestations of HCV infection (e.g., mixed cryoglobulinaemia, membranous glomerulonephritis, porphyria cutanea tarda)."
path(MESHD:"atrial fibrillation") association path(MESHD:"heart failure")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Among hospitalized persons with HCV infection the prevalence of mental disorders, tobacco use/COPD, alcohol abuse, substance abuse and chronic kidney disease was particularly high (65 Although the tolerability of newer HCV regimens appears to have much improved, recent trials using direct acting antivirals have typically excluded participants with impaired renal function, recent alcohol or substance abuse, malignancy, autoimmune disorders and significant heart disease, for example [23,24]."
path(MESHD:"membranous glomerulonephritis") association path(MESHD:"HCV infection")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Among hospitalized persons with HCV infection the prevalence of mental disorders, tobacco use/COPD, alcohol abuse, substance abuse and chronic kidney disease was particularly high (65 Although the tolerability of newer HCV regimens appears to have much improved, recent trials using direct acting antivirals have typically excluded participants with impaired renal function, recent alcohol or substance abuse, malignancy, autoimmune disorders and significant heart disease, for example [23,24]."
path(DO:"alcohol abuse") association path(MESHD:"chronic kidney disease")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "In a previous study, we found an increased risk of premature death in persons with sporadic PCT, although not familial PCT, due mostly to liver disease and alcohol and substance abuse [17]."
path(DO:"substance abuse") association path(MESHD:"chronic kidney disease")

SET Citation = {"PubMed", "35193623.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, many successfully treated persons will survive to experience considerable morbidity related to Ã¢â‚¬Ëœresidual' conditions such as ischaemic heart disease, hypertension, osteoarthritis and nonhepatic cancers, which in the past would have remained secondary concerns in the context of impending liver failure."
path(DO:"substance abuse") increases path(MESHD:"premature death")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, many successfully treated persons will survive to experience considerable morbidity related to Ã¢â‚¬Ëœresidual' conditions such as ischaemic heart disease, hypertension, osteoarthritis and nonhepatic cancers, which in the past would have remained secondary concerns in the context of impending liver failure."
path(MESHD:"osteoarthritis") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, many successfully treated persons will survive to experience considerable morbidity related to Ã¢â‚¬Ëœresidual' conditions such as ischaemic heart disease, hypertension, osteoarthritis and nonhepatic cancers, which in the past would have remained secondary concerns in the context of impending liver failure."
path(MESHD:"osteoarthritis") association path(MESHD:"ischaemic heart disease")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, many successfully treated persons will survive to experience considerable morbidity related to Ã¢â‚¬Ëœresidual' conditions such as ischaemic heart disease, hypertension, osteoarthritis and nonhepatic cancers, which in the past would have remained secondary concerns in the context of impending liver failure."
path(MESHD:"liver failure") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, many successfully treated persons will survive to experience considerable morbidity related to Ã¢â‚¬Ëœresidual' conditions such as ischaemic heart disease, hypertension, osteoarthritis and nonhepatic cancers, which in the past would have remained secondary concerns in the context of impending liver failure."
path(MESHD:"liver failure") association path(MESHD:"ischaemic heart disease")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "^120,121 Erythrocyte concentrates that suppress erythropoiesis and plasma exchange that removes excess metal-free protoporphyrin have been used to treat liver failure or prevent further decompensation."
path(MESHD:"liver failure") association path(MESHD:"osteoarthritis")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "More often, a rapidly progressive cholestatic liver failure characterizes the symptomatic debut."
path(MESHD:"liver failure") decreases bp(MESHPP:"erythropoiesis")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Alcohol also inhibits other enzymes in the heme pathway, and chronic alcoholism suppresses erythropoiesis and increases dietary iron absorption."
path(MESHD:"liver failure") increases path(MESHD:"cholestatic")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Hypocortisolism, factors related to erythropoiesis and celiac disease, should be excluded."
bp(MESHPP:"erythropoiesis") association a(CHEBI:"heme")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Although some of these conditions, such as membranous glomerulonephritis or vasculitis, may instead have been coded as renal failure/chronic kidney disease (23 ICD-9 codes for the diagnosis of viral hepatitis have been tested and validated in the Veterans Administration healthcare system, and have demonstrated high specificity and positive predictive value in the identification of HCV-infected persons [13]."
bp(MESHPP:"erythropoiesis") association path(MESHD:"Hypocortisolism")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Relative risk assessments are also affected by the PLC incidences in the reference populations, which vary with the prevalence of viral hepatitis and other liver diseases."
path(MESHD:"viral hepatitis") association path(MESHD:"chronic kidney disease")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Iron, HFE gene mutations, and viral hepatitis An association between iron and viral hepatitis was first highlighted by Blumberg et al."
path(MESHD:"viral hepatitis") association p(HGNC:"PLCD1")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Liver cirrhosis, which is the most common risk factor (>80%) for PLC in general, is less common in patients with AP- associated PLC. Other contributing liver diseases leading to inflammation and fibrosis, such as viral hepatitis, hepatic steatosis or alcoholic liver diseases, are uncommon in AP patients."
path(MESHD:"viral hepatitis") association a(CHEBI:"iron")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Interestingly, patients suffering TM manifest several of PCT's predisposing factors as a result of their underlying disease such as iron overload, blood-borne infections (e.g. viral hepatitis) or oestrogen replacement therapy because of amenorrhoea."
path(MESHD:"viral hepatitis") increases path(MESHD:"liver cirrhosis")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Iron loading has also been described after portosystemic shunts and in endstage liver disease."
path(MESHD:"viral hepatitis") increases path(MESH:"beta-Thalassemia")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron in liver diseases other than hemochromatosis."
a(CHEBI:"iron") association path(MESHD:"liver disease")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda (PCT) arises due to the inhibition of uroporphyrinogen decarboxylase (UROD) in the presence of hepatic iron and oxidative stress."
a(CHEBI:"iron") association path(MESHD:"hemochromatosis")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Iron accumulation is more likely to occur in subjects with the common HFE mutations associated with hereditary hemochromatosis."
a(CHEBI:"iron") positiveCorrelation path(MESHD:"liver disease")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron is the most important cofactor and hemochromatosis gene mutations (HFE) (mostly heterozygous) are found in up to two-thirds of the patients."
a(CHEBI:"iron") positiveCorrelation p(HGNC:"HFE")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Iron accumulation is more likely to occur in subjects with the common HFE mutations associated with hereditary hemochromatosis."
a(CHEBI:"iron") positiveCorrelation path(MESHD:"hemochromatosis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Multiple studies have examined the complex interplay between iron regulation and haematopoiesis in EPP"
a(CHEBI:"iron") positiveCorrelation path(MESHD:"hereditary hemochromatosis")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "^77 Iron does not directly inhibit UROD."
a(CHEBI:"iron") positiveCorrelation bp(MESH:"Hematopoiesis")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
a(CHEBI:"iron") causesNoChange p(HGNC:"UROD")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Recognize the central role of iron in PCT pathogenesis"
a(CHEBI:"iron") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The association between iron and PCT is well established. Siderosis is detected in up to 90% of patients who undergo liver biopsy, and a reduction in total body iron content by therapeutic phlebotomies leads to disease remission"
a(CHEBI:"iron") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is often the result of multiple environmental and inherited factors: UROD pathogenic variants reduce baseline levels of this enzyme, and other factors influence iron and oxidative stress in hepatocytes."
a(CHEBI:"iron") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
a(CHEBI:"iron") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Iron is central to the pathophysiology of PCT, leading to the formation of a UROD inhibitor, present in the liver, that prevents the decarboxylation of uroporphyrinogen to coproporphyrinogen during heme biosynthesis."
a(CHEBI:"iron") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Notably, due to the potential for iron to increase protoporphyrin levels and light sensitivity in EPP, current guidelines recommend against routine iron supplementation unless there is signifi cant anaemia or iron deficiency"
a(CHEBI:"iron") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Most patients with PCT have evidence of siderosis on liver biopsy, and the disease resolves with iron deple tion."
a(CHEBI:"iron") increases path(MESH:"Photosensitivity Disorders")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "^1,2 Iron can increase reactive oxygen species (ROS), which, in turn, increases the rate of oxidation of uroporphyrinogens."
a(CHEBI:"iron") increases path(MESHD:"siderosis")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "The generation of uroporphomethene is dependent on the amount of iron in the liver in murine models, and in mice with heterozygous UROD knock out, iron overload is sufficient to cause a PCT phenotype"
a(CHEBI:"iron") increases a(CHEBI:"reactive oxygen species")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The generation of uroporphomethene is dependent on the amount of iron in the liver in murine models, and in mice with heterozygous UROD knock out, iron overload is sufficient to cause a PCT phenotype"
a(CHEBI:"iron") increases a(CHEBI:"reactive oxygen species")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Iron is central to the pathophysiology of PCT, leading to the formation of a UROD inhibitor, present in the liver, that prevents the decarboxylation of uroporphyrinogen to coproporphyrinogen during heme biosynthesis."
a(CHEBI:"iron") increases a(PKG:"Uroporphomethene")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Notably, due to the potential for iron to increase protoporphyrin levels and light sensitivity in EPP, current guidelines recommend against routine iron supplementation unless there is signifi cant anaemia or iron deficiency"
a(CHEBI:"iron") increases a(PKG:"Uroporphomethene")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
a(CHEBI:"iron") increases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
a(CHEBI:"iron") increases a(CHEBI:"cytochrome")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "On completionof thisarticle, the reader will (1) recognize iron as a risk factor for certain nonhemochromatotic disorders a"
a(CHEBI:"iron") increases bp(MESHPP:"oxidation")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "In hepatocytes, alcohol and iron are believed to act synergistically to generate free radicals, which contribute to the forma tion of the uroporphomethene that inhibits hepatic UROD, as well as cause cellular damage."
a(CHEBI:"iron") increases p(PKG:"nonhemochromatotic disorders")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Indeed, there is an association between the trait of beta-thalassae mia and PCT."
a(CHEBI:"iron") increases a(CHEBI:"free radical")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "According to our results, patients with TM demonstrate an increased prevalence of PCT, in relation to the general population."
path(MESH:"beta-Thalassemia") association path(MESHD:"PCT")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Herein, we evaluate a potential causal relation between PCT and TM, focusing on PCT's predisposing factors."
path(MESH:"beta-Thalassemia") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Beta thalassaemia major (TM) is a clinical entity with a wide spectrum of clinical manifestations as a result of life-long transfusion-dependent anaemia."
path(MESH:"beta-Thalassemia") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "The prevalence of cryoglobulinaemia, vasculitis, nephrotic syndrome or membranoproliferative glomerulonephritis and porphyria cutanea tarda among hospitalizations with HCV infection was consistently low during the study period (i.e., <0.5 % )."
path(MESH:"beta-Thalassemia") increases path(MESHD:"anaemia")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "However, it was recently observed that areas that have a high incidence of HCC and high aflatoxin intake correspond to areas in which HBV infection is endemic and that patients at higher risk of developing HCC are those who are exposed to both HBV and AFB1 risk factors."
path(MESHD:"membranoproliferative glomerulonephritis") association path(MESHD:"cryoglobulinaemia")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "Other risk factors include aflatoxin B1 intake, alcohol consumption, and some hereditary diseases, among which are hereditary hemochromatosis, hereditary tyrosinemia, and ÃŽÂ±_1 anti-trypsin deficiency."
a(CHEBI:"aflatoxin B1") increases path(MESHD:"HCC")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "Low-dose hydroxychloroquine (100 mg orally twice weekly) is an alternative option for patients with PCT who do not have access to or cannot tolerate therapeutic phlebotomy, and who do not have marked iron overload. Chloroquine can be used as well, but hydroxychloroquine is preferred because of its superior safety pro file. These 4-aminoquinolines are taken up in hepatocyte lysosomes, which then release large amounts of accumu lated porphyrins."
a(CHEBI:"aflatoxin B1") increases path(MESHD:"tyrosinemia")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Hydroxychloroquine (and chloroquine) in the amounts used for other diseases cause hepatotoxicity in PCT, and this adverse effect is largely avoided with the low-dose regimen."
a(CHEBI:"chloroquine") decreases path(MESHD:"PCT")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Once patients and control subjects are matched for cirrhosis and other variables known to predispose persons to DM, the association between HCV and DM is weak but still present nevertheless."
a(CHEBI:"chloroquine") increases path(MESHD:"hepatotoxicity")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Decreased hepatic insulin clearance leading to hyperinsulinemia and development of insulin resistance, as well as reduced hepatic uptake of glucose, are all known to occur in cirrhosis and to predispose the cirrhotic patient to the development of non-insulin-dependent DM."
path(MESHD:"diabetes mellitus") association path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "^1 PCT patients are primarily diagnosed and treated by dermatologists, who may not be aware of the association with and the pitfalls in testing for DM in these patients."
path(MESHD:"diabetes mellitus") decreases a(CHEBI:"insulin")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "Clinicians need to know the pros and cons for each test to be able to properly diagnose PCT patients with possible DM.This article provides an update on the knowledge of DM in PCT patients and the relevant available tests and recommendations for a diagnostic procedure."
path(MESHD:"diabetes mellitus") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "In the largest US retrospective study of 1117 patients with chronic viral hepatitis, the prevalence of type 2 DM was 21 % in patients with HCV versus 12 % in patients with hepatitis B virus (HBV)."
path(MESHD:"diabetes mellitus") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "## Methods to Detect the Level of Glycemia for the Diagnosis and Monitoring of Diabetes Mellitus The definition of diabetes is based on the presence of hyperglycemia."
path(MESHD:"diabetes mellitus") positiveCorrelation path(MESHD:"chronic viral hepatitis")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "## Diabetes Mellitus - Definition and Clinical Course DM is a serious metabolic disease defined by hyperglycemia and complicated by micro- and macrovascular abnormalities."
path(MESHD:"diabetes mellitus") positiveCorrelation path(MESHD:"hyperglycemia")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "In the largest US retrospective study of 1117 patients with chronic viral hepatitis, the prevalence of type 2 DM was 21 % in patients with HCV versus 12 % in patients with hepatitis B virus (HBV)."
path(MESHD:"diabetes mellitus") positiveCorrelation path(MESHD:"hyperglycemia")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "A possible explanation of our finding is that in our patient population, coexistence of various concomitant precipitat ing factors such as iron overload, oestrogen replacement therapy and HCV infection, seems to facilitate cumulatively the manifesta tion of PCT."
path(MESHD:"diabetes mellitus") increases path(MESHD:"type 2")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Interestingly, patients suffering TM manifest several of PCT's predisposing factors as a result of their underlying disease such as iron overload, blood-borne infections (e.g. viral hepatitis) or oestrogen replacement therapy because of amenorrhoea."
a(CHEBI:"oestrogen") association path(MESHD:"PCT")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "For systemic bacteremia, ESRD patients of increasing age, female sex, on hemodialysis, with catheter and graft compared to AVF access, and diagnosed with tobacco use, alcohol dependence, hepatitis C, or HIV were at increased risk for bacteremia."
a(CHEBI:"oestrogen") decreases path(MESHD:"PCT")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "HFE mutations, alcohol and hepatitis C are known to decrease hepcidin levels and thereby increase iron absorption from the intestine."
path(DO:"alcohol dependence") increases path(MESHD:"bacteremia")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "High prevalence of the His63Asp HFE mutation in Italian patients with porphyria cutanea tarda."
p(HGNC:"HFE") decreases p(HGNC:"HAMP")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Pathogenic variants in the HFE gene found in hereditary hemochromatosis are more common than expected in PCT, even in the absence of marked iron over load."
p(HGNC:"HFE") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with PCT should be screened for HFE mutations and for HCV."
p(HGNC:"HFE") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Others have found that 24 of 113 patients with alcoholic liver disease ( 21 % ) carried the C282Y mutation of HFE, compared with 7 of 92(7.6 %) in the control group ( P=.007 )."
p(HGNC:"HFE") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Correlation of the iron phenotype with the HFE genotype The hepatic iron concentration, transferrin saturation, and the serum ferritin concentration were highest in PCT patients who were homozygous for the Cys282Tyr mutation (Table 3)."
p(HGNC:"HFE") positiveCorrelation path(MESHD:"alcoholic liver disease")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "We found that 69.4 % of NASH patients carried one of the two mutations of HFE (versus 40.5 % of controls)."
p(HGNC:"HFE") positiveCorrelation p(HGNC:"FTH1")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Most patients with clinically evident hemochromatosis are homozygous for the ancestral Cys282Tyr mutation at the HFE locus, ^27 and it has been estimated that approximately half of the Cys282Tyr homozygotes develop clinically significant iron overload."
p(HGNC:"HFE") positiveCorrelation path(MESHD:"NASH")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "In contrast, no effect of heterozygosity for HFE mutations (C282Y or H63D) on severity of alcoholic liver disease was observed among 257 patients from the north of England (Grove et al."
p(HGNC:"HFE") increases path(MESHD:"hemochromatosis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease."
p(HGNC:"HFE") causesNoChange path(MESHD:"alcoholic liver disease")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Other investigators from Australia ^31 did not report an increased susceptibility to alcoholic cirrhosis in patients with the C282Y HFE mutation, compared with findings for control subjects."
p(HGNC:"HFE") causesNoChange path(MESHD:"alcoholic liver disease")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "nan"
p(HGNC:"HFE") causesNoChange path(MESHD:"alcoholic cirrhosis")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "In addition, HCV infection is associated with an array of nonhepatic conditions, directly or indirectly related to effects of the virus itself, which contribute to overall hepatitis C-related morbidity [3-9]."
path(MESHD:"morbidity") association path(MESHD:"HCV infection")

SET Citation = {"PubMed", "25894392.0"}
SET DataSource = "manual-curation"
SET Support = "Familial porphyria cutanea tarda: characterization of seven novel uroporphyrinogen decarboxylase mutations and frequency of hemochromatosis alleles."
path(MESHD:"morbidity") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Mutations at the HFE locus, HCV infection, excess alcohol intake, and exposure to estrogens all proved to be risk factors for the development of PCT."
path(MESHD:"Familial PCT") positiveCorrelation path(MESHD:"hemochromatosis")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "relative roles of hemochromatosis gene (HFE) mutations, HCV, alcohol, and estrogens as risk factors for disease expression."
a(CHEBI:"estrogens") association p(HGNC:"HFE")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Approximately 18 % of American women between the ages of 18 and 44 use oral contraceptives, ^55 and 15 % of postmenopausal American women use medicinal estrogens as hormone replacement therapy."
a(CHEBI:"estrogens") association path(MESHD:"hemochromatosis")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
a(CHEBI:"estrogens") isA a(CHEBI:"oral contraceptives")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "With liver injury or increased oxidative stress in general, more porphyrinogens are nonenzymatically oxidized to the corresponding porphyrins."
a(CHEBI:"porphyrinogens") association a(CHEBI:"CYP450")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "With liver injury or increased oxidative stress in general, more porphyrinogens are nonenzymatically oxidized to the corresponding porphyrins."
a(CHEBI:"porphyrinogens") association bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Decreased UROD leads to increased production of 8- to 5-carboxymethyl substituted porphyrinogens (De Matteis, 1998)."
a(CHEBI:"porphyrinogens") association path(MESHD:"liver injury")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "However, as hepatic MTX metabolism does not involve cytochrome P450, the association between MTX and PCT cannot be explained by this mechanism."
a(CHEBI:"porphyrinogens") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with PCT usually carry polymorphic variants of CyP450 genes, leading to higher enzyme activities, whereas patients with familial PCT express a polymorphic variant of glycerol phosphate O acyltransferase that is associated with iron accumulation in HFE-associated hemochromatosis."
a(CHEBI:"CYP450") association bp(GOBP:"metabolism")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "The cytochrome P450 1A2 has been implicated in PCT pathogenesis in a murine model of PCT24; however, which CYPs might be involved in human PCT has not been conclusively established."
a(CHEBI:"CYP450") association p(HGNC:"HFE")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Little is known about the porphyrogenic potentials of newer agents such as levetiracetam, which is reported not to induce the hepatic cytochrome P-450 system."
a(CHEBI:"CYP450") association path(MESHD:"PCT")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "A liver-specific isozyme of cytochrome P450, P4501A2 (CYP1A2), is essential for chemically-induced porphyria in mice, ^65 but induction of CYP1A2 alone is not sufficient to produce a porphyric response in rats."
a(CHEBI:"CYP450") association a(CHEBI:"levetiracetam")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
a(CHEBI:"CYP450") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "ALAS1 is induced via induction of cytochrome P450 (CyP450), such as by xenobiotics, smoking, excess alcohol consumption, fasting, and female sex hormones."
a(CHEBI:"CYP450") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "At least in murine models, cytochrome P450 enzyme activity is involved in the generation of this inhibitor."
a(CHEBI:"CYP450") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
a(CHEBI:"CYP450") increases a(PKG:"Uroporphomethene")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "HFE genotyping DNA was available from 87 patients with PCT ( 64 with S-PCT and 23 with F-PCT) and from 56 clinically normal subjects married to members of well-characterized hemochromatosis pedigrees."
a(CHEBI:"CYP450") increases bp(MESHPP:"oxidation")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with PCT usually carry polymorphic variants of CyP450 genes, leading to higher enzyme activities, whereas patients with familial PCT express a polymorphic variant of glycerol phosphate O acyltransferase that is associated with iron accumulation in HFE-associated hemochromatosis."
path(MESHD:"hemochromatosis") association p(HGNC:"HFE")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with PCT usually carry polymorphic variants of CyP450 genes, leading to higher enzyme activities, whereas patients with familial PCT express a polymorphic variant of glycerol phosphate O acyltransferase that is associated with iron accumulation in HFE-associated hemochromatosis."
path(MESHD:"hemochromatosis") association p(HGNC:"HFE")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "In human beings with porphyria cutanea tarda, the presence of H F E gene mutations is the major reason for increased hepatic iron, with alcohol perhaps playing a secondary role, as has just been described for the mouse model of human hemochromatosis."
path(MESHD:"hemochromatosis") association a(CHEBI:"CYP450")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "C282Y and H63D mutation of the hemochromatosis gene in German porphyria cutanea tarda patients."
path(MESHD:"hemochromatosis") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "The disease always occurs with a normal or increased amount of hepatic iron, and iron deficiency is protective, and the prevalence of HFE (hemochromatosis) mutations is increased."
path(MESHD:"hemochromatosis") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Alcohol consumption, a history of smoking, prior HIV or hepatitis C infection, hemochromatosis, estrogen exposure, or the combination of two or more of these factors increases the susceptibility to symptomatic PCT."
path(MESHD:"hemochromatosis") positiveCorrelation p(HGNC:"HFE")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "In addition to the well-known hepatotoxicity of heavy iron overload, as occurs in hemochromatosis, whether primary (hereditary) or secondary, evidence continues to mount that lesser degrees of hepatic iron loading may worsen liver [^0]injury or hepatic fibrosis in nonhemochromatotic liver diseases."
path(MESHD:"hemochromatosis") increases path(MESHD:"hepatitis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Regarding the type of AP, most assessments of PLC risk are based on cohorts with a predominance of patients with AIP. Sporadic cases of PLC in patients with VP and HCP have been published,11,15,74Ã¢â‚¬â€œ77 but large VP or HCP cohort studies exploring PLC risk are lacking and specific risk estimates for these forms of AP are scarce."
path(MESHD:"hemochromatosis") increases path(MESHD:"hepatotoxicity")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "| Two cases of co-existence of variegate porphyria and celiac disease have been reported."
path(MESHD:"VP") association path(DO:"Primary Liver Cancer")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "VP is an autosomal dominant genetic disorder due to partially deficient activity of the mitochondrial enzyme protoporphyrinogen oxidase (PPOX) (Brenner and Bloomer, 1980; Singal and Anderson, 2013).Enzyme activity is approximately 50 percent of normal in all tissues and mitochondria-containing cells that have been examined, including lymphocytes and cultured fibroblasts (Meissner, Hift and Corrigall, 2003)."
path(MESHD:"VP") association path(MESHD:"celiac disease")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "This pattern of porphyrin elevation is characteristic but not completely specific since uroporphyrin elevation occurs in other porphyrias, and a PCT-like pattern occurs in some patients with variegate porphyria (VP)."
path(MESHD:"VP") decreases p(HGNC:"PPOX")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Table: Classifications and principal clinical features"
path(MESHD:"VP") increases a(CHEBI:"Uroporphyrinogen III")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The prevalence of VP is 1 in 300 among the white population of Dutch descent in South African population, due to a founder effect (Eales, Day, and Blekkenhorst, 1980; Meissner et al. 1996; Hift et al. 1997; Meissner, Corrigall and Hift, 2012)."
path(MESHD:"VP") isA path(MESHD:"porphyria")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "In the 8th and final step of heme synthesis, the enzyme FECH inserts ferrous iron into PP to form heme."
bp(MESHPP:"founder effect") increases path(MESHD:"VP")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "The oxidative process involves CYPs and requires ferrous iron (Phillips et al."
a(CHEBI:"ferrous iron") increases a(CHEBI:"heme")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "There is persuasive evidence that iron reduction decreases insulin resistance, and it likely also decreases oxidative stress, two key pathogenic features of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis."
a(CHEBI:"ferrous iron") increases a(CHEBI:"CYPs")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda (PCT) arises due to the inhibition of uroporphyrinogen decarboxylase (UROD) in the presence of hepatic iron and oxidative stress."
bp(MESHPP:"oxidative stress") association path(MESHD:"nonalcoholic fatty liver disease")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "^32 The overexpression of heme oxygenase-1 under conditions of inflammation, fasting, or physical or oxidative stress increases heme degradation and thereby removes feedback inhibition of ALAS1, promoting disease."
bp(MESHPP:"oxidative stress") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Results of studies in a rat model of alcoholic liver disease have demonstrated clearly the synergistic effect of diet-induced iron overload and alcohol in the production of increased oxidative stress in the liver and the development of hepatic fibrosis or cirrhosis (Tsukamoto et al."
bp(MESHPP:"oxidative stress") increases p(HGNC:"HMOX1")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Increased oxidative stress by liver injury from accumulated iron increases the likelihood that uroporphyrinogen will be oxidized to uroporphyrin."
bp(MESHPP:"oxidative stress") increases path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is often the result of multiple environmental and inherited factors: UROD pathogenic variants reduce baseline levels of this enzyme, and other factors influence iron and oxidative stress in hepatocytes."
bp(MESHPP:"oxidative stress") increases a(CHEBI:"uroporphyrin")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Future studies should seek to solidify the relationship between porphyria and mental illness with the aim to have evidence-based guidelines."
bp(MESHPP:"oxidative stress") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Results of studies in a rat model of alcoholic liver disease have demonstrated clearly the synergistic effect of diet-induced iron overload and alcohol in the production of increased oxidative stress in the liver and the development of hepatic fibrosis or cirrhosis (Tsukamoto et al."
bp(MESHPP:"oxidative stress") increases a(CHEBI:"glutamate")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "A \'twohit\' theory has been suggested, which involves accumulation of fat in the liver, especially in the form of free fatty acids (\'first hit\'), coupled with a \'second hit\' that produces increased oxidative stress and reactive oxygen species."
bp(MESHPP:"oxidative stress") increases path(MESHD:"hepatic fibrosis")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "There is growing evidence that only a mild degree of iron overload is sufficient to enhance alco-hol-induced liver injury."
bp(MESHPP:"oxidative stress") increases path(MESHD:"fatty liver disease")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The relationship between protoporphyrin and platelet count remained similar when adjusting for ferritin and ALT ( ÃŽÂ²=-0.36, p<0.001, Figure 1A), surrogates for iron status and liver injury, respectively, which can also affect platelet count."
path(MESHD:"liver injury") association path(MESHD:"iron overload")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "With liver injury or increased oxidative stress in general, more porphyrinogens are nonenzymatically oxidized to the corresponding porphyrins."
path(MESHD:"liver injury") association a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Increased oxidative stress by liver injury from accumulated iron increases the likelihood that uroporphyrinogen will be oxidized to uroporphyrin."
path(MESHD:"liver injury") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "With liver injury or increased oxidative stress in general, more porphyrinogens are nonenzymatically oxidized to the corresponding porphyrins."
path(MESHD:"liver injury") increases a(CHEBI:"uroporphyrin")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "The hepatic UROD protein level remains at its genetically determined level in all types of PCT, but hepatic enzyme activity is reduced to less than about 20% of normal, suggesting the presence of an enzyme inhibitor. Phillips and colleagues identified this inhibitor as a uroporphomethene, probably derived from the partial oxidization of uroporphyrinogen"
path(MESHD:"liver injury") increases bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The hepatic UROD protein level remains at its genetically determined level in all types of PCT, but hepatic enzyme activity is reduced to less than about 20% of normal, suggesting the presence of an enzyme inhibitor. Phillips and colleagues identified this inhibitor as a uroporphomethene, probably derived from the partial oxidization of uroporphyrinogen"
a(PKG:"Uroporphomethene") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Uroporphomethene differs from uroporphyrinogen by a single oxidized bridge carbon, and although it is able to bind strongly to the active site of UROD, it is unable to serve as a sub strate."
a(PKG:"Uroporphomethene") isA a(CHEBI:"uroporphyrinogen III")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The pathogenesis of PCT is thought to involve iron-generated free oxygen radicals that oxidize uroporphyrinogen, leading to the formation of a uroporphomethene inhibitor of UROD."
a(PKG:"Uroporphomethene") isA a(CHEBI:"uroporphyrinogen III")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Proteasome inhibitors or chemical chaperones might stabilize abnormal UROS variants to increase its activity and reduce porphyrin accumulation and skin photosensitivity in patients with CEP."
a(PKG:"Uroporphomethene") negativeCorrelation p(HGNC:"UROD")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "A mild variant with low uroporphyrin I levels due to a missense mutation (A66V) encoding residual uroporphyrinogen III synthase activity."
p(HGNC:"UROS") decreases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "A defect in this pathway can lead to the accumulation of porphyrins, which absorb electromagnetic radiation from sunlight similarly to the chlorophyll in plants and algae that utilize solar energy for photosynthesis."
p(HGNC:"UROS") increases a(CHEBI:"uroporphyrin")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "A defect in this pathway can lead to the accumulation of porphyrins, which absorb electromagnetic radiation from sunlight similarly to the chlorophyll in plants and algae that utilize solar energy for photosynthesis."
a(CHEBI:"chlorophyll") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "The patient also had a moderate hepatomegaly, and liver biopsy revealed a slight steatosis, a reticuloendothelial hemosiderin accumulation, and red fluorescence under Wood's light."
bp(MESHPP:"fluorescence") positiveCorrelation path(SCTID:"Steatosis")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^110 As many as 23 % of patients with EPP develop protoporphyrin-containing gallstones that emit red fluorescence under long-wave ultraviolet light."
bp(MESHPP:"fluorescence") increases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Excess porphyrins in the skin interact with light of approximately 400 nm -wavelength and are activated and generate reactive oxygen species that cause skin damage and increased fragility (Grossman and Poh-Fitzpatrick, 1980; Lim, 1989)."
path(MESHD:"skin damage") increases a(CHEBI:"reactive oxygen species")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Sun exposure then activates these products facilitating an immune reaction and subsequent skin damage."
path(MESHD:"skin damage") increases bp(GOBP:"immune reaction")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Table: Classifications and principal clinical features"
path(MESHD:"blistering") isA path(MESHD:"porphyria")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Table: Classifications and principal clinical features"
a(CHEBI:"5-Aminolevulinic acid") isA path(MESHD:"porphyria")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Hepatoerythropoietic porphyria (HEP) HEP is a rare form of cutaneous porphyria (Romeo and Levin, 1969), with approximately 40 cases were reported up to 2010 (Cantatore-Francis et al."
path(MESHD:"Hepatoerythropoietic porphyria") positiveCorrelation path(MESHD:"cutaneous porphyria")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Erythrocyte porphyrins are normal or mildly elevated in PCT but markedly elevated in HEP and congenital erythropoietic porphyria"
path(MESHD:"Hepatoerythropoietic porphyria") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Mild cases of HEP may resemble PCT but are readily differentiated by marked eleva tion in erythrocyte zinc protoporphyrin."
path(MESHD:"Hepatoerythropoietic porphyria") increases a(CHEBI:"zinc protoporphyrin")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "In contrast, the need for erythroid heme synthesis is rather constant throughout life, although it, too, maybe stimulated under conditions of blood loss or hemolysis."
path(MESHD:"hemolysis") positiveCorrelation a(CHEBI:"heme")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Hemolytic anemia is less frequent and severe than in CEP, but anemia due at least in part to hemolysis is common, and may be accompanied by hepatosplenomegaly ((Meguro et al."
path(MESHD:"hemolysis") positiveCorrelation path(MESHD:"Hemolytic anemia")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "secondary anemia due to hemolysis"
path(MESHD:"hemolysis") positiveCorrelation path(MESHD:"anemia")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Mild to severe hemolysis is a feature of CEP and is accompanied by anisocytosis, poikilocytosis, polychromasia, basophilic stippling, reticulocytosis, increased circulating nucleated red cells, and absence of haptoglobin."
path(MESHD:"hemolysis") positiveCorrelation path(MESHD:"reticulocytosis")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Hemolytic anemia is less frequent and severe than in CEP, but anemia due at least in part to hemolysis is common, and may be accompanied by hepatosplenomegaly ((Meguro et al."
path(MESHD:"Hemolytic anemia") positiveCorrelation path(SCTID:"Hepatosplenomegaly")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Mild anemia due at least in part to hemolysis is common, and may be accompanied by hepatosplenomegaly ((Meguro et al."
path(MESHD:"anemia") positiveCorrelation path(MESHD:"hemolysis")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Mild anemia due at least in part to hemolysis is common, and may be accompanied by hepatosplenomegaly ((Meguro et al."
path(SCTID:"Hepatosplenomegaly") positiveCorrelation path(MESHD:"hemolysis")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Long-term compli cations of AHP include recurrent severe acute attacks, kidney failure, hypertension [5] and pri mary liver cancer (PLC)"
path(MESHD:"AHP") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with AHP had a higher risk of kidney cancer (0.8 % vs. 0.2 %, p<0.001), hypertension, and chronic kidney disease but no increase in risk for cardiovascular disease, except for cerebrovascular disease in patients with elevated U-PBG, (aHR =1.40 [95% CI:1.06-1.85])."
path(MESHD:"AHP") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
path(MESHD:"AHP") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Long-term compli cations of AHP include recurrent severe acute attacks, kidney failure, hypertension [5] and pri mary liver cancer (PLC)"
path(MESHD:"AHP") association path(MESHD:"Acute Disease")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Based on the recorded causes of death, AHP patients had a higher risk of death related to renal disease ( n=12[1.0 %] vs. ref, n=37[0.3 %], p<0.001 ), PLC ( n=54[4.3 %] vs. ref, n=20[0.2 %], p<0.001 ) and porphyria ( n=10[0.8 %] vs. ref, n=0 )."
path(MESHD:"AHP") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with AHP had a higher risk of kidney cancer (0.8 % vs. 0.2 %, p<0.001), hypertension, and chronic kidney disease but no increase in risk for cardiovascular disease, except for cerebrovascular disease in patients with elevated U-PBG, (aHR =1.40 [95% CI:1.06-1.85])."
path(MESHD:"AHP") association path(MESHD:"chronic kidney disease")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
path(MESHD:"AHP") association path(MESHD:"chronic kidney disease")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Our findings confirmed a substantially higher risk of PLC associated with AHP compared to the general population."
path(MESHD:"AHP") association path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "A strong association between AHP and PLC was f irst described by Swedish investigators in 1984"
path(MESHD:"AHP") association path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Long-term compli cations of AHP include recurrent severe acute attacks, kidney failure, hypertension [5] and pri mary liver cancer (PLC)"
path(MESHD:"AHP") association path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Long-term compli cations of AHP include recurrent severe acute attacks, kidney failure, hypertension [5] and pri mary liver cancer (PLC)"
path(MESHD:"AHP") association path(MESHD:"kidney failure")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "The novel findings of a moderate to substantial association between AHP and kidney and endometrial cancers should be investigated further."
path(MESHD:"AHP") association path(DO:"endometrial cancers")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "PLC risk was substantially higher for individuals with an AHP diagnosis compared to the reference population [adjusted hazard ratio (aHR) 108, 95% confidence interval (CI) 56207]."
path(MESHD:"AHP") positiveCorrelation path(DO:"Primary Liver Cancer")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Based on the recorded causes of death, AHP patients had a higher risk of death related to renal disease ( n=12[1.0 %] vs. ref, n=37[0.3 %], p<0.001 ), PLC ( n=54[4.3 %] vs. ref, n=20[0.2 %], p<0.001 ) and porphyria ( n=10[0.8 %] vs. ref, n=0 )."
path(MESHD:"AHP") positiveCorrelation path(DO:"Primary Liver Cancer")

SET Citation = {"PubMed", "36028858.0"}
SET DataSource = "manual-curation"
SET Support = "Accumulation of ALA and PBG is thought to cause injury primarily to the nervous system, as well as to other organs, such as the liver and kidneys [2-4].Of the four subtypes of AHP, the most common is acute intermittent porphyria (AIP) [1]."
path(MESHD:"AHP") increases path(MESHD:"AIP")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "AHP is characterized by the accumulation of porphyrins and/or the precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in the biosynthesis of haem."
path(MESHD:"AHP") increases a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "AHP is characterized by the accumulation of porphyrins and/or the precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in the biosynthesis of haem."
path(MESHD:"AHP") increases a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "AHP is characterized by the accumulation of porphyrins and/or the precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in the biosynthesis of haem."
path(MESHD:"AHP") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "AHP is characterized by the accumulation of porphyrins and/or the precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in the biosynthesis of haem."
path(MESHD:"AHP") increases a(CHEBI:"heme")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria may be categorized clinically as acute hepatic, blistering cutaneous, or nonblistering cutaneous depending on clinical features."
path(MESHD:"AHP") isA path(MESHD:"porphyria")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, AHP is associated with an increased risk of kidney cancer, hypertension, chronic kidney disease, and mortality but not with cardiovascular disease or other nonhepatic cancers."
path(MESHD:"AHP") causesNoChange path(MESHD:"cardiovascular diseases")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Erythropoietic protoporphyria (EPP) is an inherited disorder of haem biosynthesis that results in the accumulation of protoporphyrin IX, a photosensitive molecule that causes severe cutaneous pain and, in a minority of patients, cholestatic liver disease."
path(MESHD:"cholestatic liver disease") association path(MESHD:"EPP")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "ADP must also be differentiated from other causes of ALAD deficiency such as lead poisoning and hereditary tyrosinemia type 1, which can cause increases in ALA, coproporphyrin III and erythrocyte protoporphyrin and symptoms very much like those in acute porphyrias."
path(MESHD:"Lead poisoning") increases a(CHEBI:"coproporphyrin")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^h Lead poisoning affects 3 enzymes involved in heme biosynthesis (ALAD, CPOX, and FECH)."
a(CHEBI:"heme biosynthesis") association path(MESHD:"Lead poisoning")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
a(CHEBI:"heme biosynthesis") association path(MESHD:"Lead poisoning")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Most porphyriarelated drugs are thought to induce cytochrome P450 activity and thus increase the demand for hepatic heme biosynthesis, leading to increased porphyrin formation."
a(CHEBI:"heme biosynthesis") positiveCorrelation a(CHEBI:"CYP450")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia."
a(CHEBI:"heme biosynthesis") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyrias (APs) are inherited disorders caused by deficiencies in one of the enzymes involved in haem biosynthesis, leading to overproduction of potentially neurotoxic porphyrin precursors (delta-aminolaevulinic acid [ALA] and porphobilinogen [PBG]) in the liver when the rate-limiting enzyme, ALA synthase 1 (ALAS1), is activated."
a(CHEBI:"heme biosynthesis") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyrias (APs) are inherited disorders caused by deficiencies in one of the enzymes involved in haem biosynthesis, leading to overproduction of potentially neurotoxic porphyrin precursors (delta-aminolaevulinic acid [ALA] and porphobilinogen [PBG]) in the liver when the rate-limiting enzyme, ALA synthase 1 (ALAS1), is activated."
a(CHEBI:"heme biosynthesis") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Two young adults, ages 21 and 23 years, with severe HEP developed generalized seizures and had neuroimaging evidence of cerebral cortical atrophy and calcifications in the frontal lobes, presumably related to hypoxic injury as in other porphyrias (Berenguer et al. 1997)."
path(MESHD:"hypoxic injury") increases path(MESHD:"atrophy")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Two young adults, ages 21 and 23 years, with severe HEP developed generalized seizures and had neuroimaging evidence of cerebral cortical atrophy and calcifications in the frontal lobes, presumably related to hypoxic injury as in other porphyrias (Berenguer et al. 1997)."
path(MESHD:"hypoxic injury") increases bp(MESHPP:"calcifications")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "We also review symptoms and pathologies of lead intoxication that affect enzymes that mediate heme synthesis and share features with porphyrias."
path(MESHD:"lead intoxication") association a(CHEBI:"heme")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Heme therapy can relieve symptoms of lead intoxication and ALADP."
path(MESHD:"lead intoxication") association a(CHEBI:"Heme")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "Other risk factors include aflatoxin B1 intake, alcohol consumption, and some hereditary diseases, among which are hereditary hemochromatosis, hereditary tyrosinemia, and ÃŽÂ±_1 anti-trypsin deficiency."
path(MESHD:"tyrosinemia") association path(MESHD:"hereditary hemochromatosis")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
path(MESHD:"tyrosinemia") decreases p(HGNC:"ALAD")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Type 1 tyrosinemia is not a primary disorder of porphyrin metabolism but indirectly leads to similar biochemical changes and porphyria-like symptoms as in ALADP, caused by the accumulation of succinyl acetone, a potent inhibitor of ALAD."
path(MESHD:"tyrosinemia") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
path(MESHD:"alcoholism") decreases p(HGNC:"ALAD")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The differential diagnosis of ADP should include other hepatic porphyrias (AIP, HCP and VP) and toxic states in which ALAD enzyme activity is suppressed, which include lead poisoning, hereditary tyrosinemia, zinc deficiency, smoking, alcoholism, diabetes mellitus, and chronic renal insufficiency."
path(MESHD:"chronic renal insufficiency") decreases p(HGNC:"ALAD")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "ADP must also be differentiated from other causes of ALAD deficiency such as lead poisoning and hereditary tyrosinemia type 1, which can cause increases in ALA, coproporphyrin III and erythrocyte protoporphyrin and symptoms very much like those in acute porphyrias."
path(MESHD:"hereditary tyrosinemia type 1") increases a(CHEBI:"coproporphyrin")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Succinylacetone, a structural analogue of ALA and a potent inhibitor of ALAD (Sassa and Kappas, 1983), is increased in plasma and urine of patients with hereditary tyrosinemia type 1 (Lindblad, Lindstedt and Steen, 1977)."
path(MESHD:"hereditary tyrosinemia type 1") increases a(CHEBI:"Succinylacetone")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "Other risk factors include aflatoxin B1 intake, alcohol consumption, and some hereditary diseases, among which are hereditary hemochromatosis, hereditary tyrosinemia, and ÃŽÂ±_1 anti-trypsin deficiency."
path(MESHD:"hereditary hemochromatosis") association a(CHEBI:"aflatoxin B1")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "One reason for iron accumulation is mutations of the HFE genes associated with hereditary hemochromatosis."
path(MESHD:"hereditary hemochromatosis") association p(HGNC:"HFE")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron accumulation is more likely to occur in subjects with the common HFE mutations associated with hereditary hemochromatosis."
path(MESHD:"hereditary hemochromatosis") association p(HGNC:"HFE")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = ", 2002), in 119 consecutive patients with chronic hepatitis C, the H F E mutations commonly associated with hereditary hemochromatosis were significantly more common in these patients in comparison with findings for control subjects ( 48 % vs. 37.9 %, P=.04 ), and advanced degrees of hepatic fibrosis or cirrhosis developed at younger ages in patients who had the C282Y mutation of H F E, especially in C 282 Y^+1 s homozygotes."
path(MESHD:"hereditary hemochromatosis") positiveCorrelation path(MESHD:"chronic hepatitis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 27, 1695-1699."
path(MESHD:"hereditary hemochromatosis") positiveCorrelation path(MESHD:"chronic hepatitis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Indeed, recent study findings from Australia, summarized by Fletcher and Powell elsewhere in this volume, highlight the synergistic effects of alcohol and hereditary hemochromatosis in producing advanced degrees of hepatic fibrosis and cirrhosis."
path(MESHD:"hereditary hemochromatosis") increases path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Indeed, recent study findings from Australia, summarized by Fletcher and Powell elsewhere in this volume, highlight the synergistic effects of alcohol and hereditary hemochromatosis in producing advanced degrees of hepatic fibrosis and cirrhosis."
path(MESHD:"hereditary hemochromatosis") increases path(MESHD:"hepatic fibrosis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection."
path(MESHD:"hereditary hemochromatosis") increases path(MESHD:"hepatic fibrosis")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Additional risk factors include myeloproliferative disorders, exposure to polyhalogenated compounds, estrogen therapy, diseases of iron overload like hereditary hemochromatosis (HH), and potentially, HIV infection."
path(MESHD:"hereditary hemochromatosis") increases path(MESHD:"myeloproliferative disorders")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Succinylacetone, a structural analogue of ALA and a potent inhibitor of ALAD (Sassa and Kappas, 1983), is increased in plasma and urine of patients with hereditary tyrosinemia type 1 (Lindblad, Lindstedt and Steen, 1977)."
a(CHEBI:"Succinylacetone") decreases p(HGNC:"ALAD")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Lead metal inhibits ALAD activity by displacing zinc from the enzyme (Bergdahl et al. 1997; Granick, Sassa and Kappas, 1978).Individuals with heterozygous ALAD deficiency may be more susceptible to lead poisoning (Doss, Laubenthal and Stoppler, 1984)."
a(CHEBI:"zinc") decreases p(HGNC:"ALAD")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Specialized porphyria laboratories report levels of total erythrocyte, metal-free, and zinc-protoporphyrin."
a(CHEBI:"zinc") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "FECH also catalyzes the insertion of zinc, to form zinc protoporphyrin from any protoporphyrin that remains after completion of heme synthesis."
a(CHEBI:"zinc") increases p(HGNC:"FECH")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^113 The proportion of zinc-protoporphyrin to metal-free protoporphyrin is significantly higher in patients with XLP ( >25 % ) than in those with EPP (up to 15%).Notably, urinary porphyrins are normal in protoporphyrias."
a(CHEBI:"zinc") increases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^g In XLP, the ratio of zinc-bound protoporphyrin to metal-free protoporphyrin is >25 %."
a(CHEBI:"zinc") increases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Specialized porphyria laboratories report levels of total erythrocyte, metal-free, and zinc-protoporphyrin."
a(CHEBI:"zinc") increases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "EPP arises due to pathogenic variants in ferrochelatase (FECH), the last step in haem biosynthesis, which incorpo rates iron into protoporphyrin to form haem."
p(HGNC:"FECH") association path(MESHD:"EPP")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^h Lead poisoning affects 3 enzymes involved in heme biosynthesis (ALAD, CPOX, and FECH)."
p(HGNC:"FECH") association path(MESHD:"Lead poisoning")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
p(HGNC:"FECH") association a(CHEBI:"Lead")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
p(HGNC:"FECH") association path(MESHD:"Lead poisoning")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^105,106 FECH deficiency increases levels of metalfree erythrocyte PPIX, in contrast to secondary elevations of zinc-bound erythrocyte protoporphyrin that are caused by iron deficiency, lead intoxication, or hemolytic anemia."
p(HGNC:"FECH") decreases a(CHEBI:"zinc")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with erythropoietic protoporphyria have either a decreased activity of ferrochelatase (FECH) or a gain of function of aminolevulinic acid synthase 2 (ALAS2), leading to overproduction of protoporphyrin IX"
p(HGNC:"FECH") decreases a(CHEBI:"protoporphyrin IX")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^105,106 FECH deficiency increases levels of metalfree erythrocyte PPIX, in contrast to secondary elevations of zinc-bound erythrocyte protoporphyrin that are caused by iron deficiency, lead intoxication, or hemolytic anemia."
p(HGNC:"FECH") decreases a(CHEBI:"erythrocyte protoporphyrin")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Etiology and pathogenesis of EPP and XLPÃ¢â‚¬â€EPP is caused by mutations in the gene encoding FECH, a mitochondrial enzyme that catalyzes the insertion of ferrous iron (Fe^2+) into protoporphyrin to form heme (Todd 1994; Poh-Fitzpatrick, 1995; Cox, 1997; Elder, 1999)."
p(HGNC:"FECH") increases a(CHEBI:"heme")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "In the 8th and final step of heme synthesis, the enzyme FECH inserts ferrous iron into PP to form heme."
p(HGNC:"FECH") increases a(CHEBI:"heme")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "## Protoporphyrias ## Pathophysiology EPP is caused by a partial deficiency of FECH, which catalyzes the final step in heme synthesis (Figure 1)."
p(HGNC:"FECH") increases a(CHEBI:"heme")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "FECH also catalyzes the insertion of zinc, to form zinc protoporphyrin from any protoporphyrin that remains after completion of heme synthesis."
p(HGNC:"FECH") increases a(CHEBI:"zinc protoporphyrin")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Because impaired FECH activity reduces formation of zinc protoporphyrin, more than 85 More than 130 FECH mutations have been identified in EPP (HGMD, 2014)."
p(HGNC:"FECH") increases a(CHEBI:"zinc protoporphyrin")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Because FECH is not deficient in XLP, some of the excess protopophryin measured in erythrocytes is zinc-chelated and only 50 Ã¢Ë†Â¼ 85 % is metal-free."
p(HGNC:"FECH") increases a(CHEBI:"zinc")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "The disease is characterized by overproduction and accumulation of protoporphyrin, the highly hydrophobic and photoactive substrate of the ferrochelatase enzyme."
p(HGNC:"FECH") increases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Administration of an antisense oligonucleotide that prevents the abnormal splicing of the nascent mutant FECH mRNA in developing human erythroblasts of a patient with EPP increased the production of functional FECH and reduced the accumulation of PPIX.130 ## Case Report A 67-year-old female patient presented with pronounced photosensitivity (burning, stinging pain, swelling, and itching) on light-exposed skin areas (prominent in the face and on the back of the hands) since early childhood."
p(HGNC:"FECH") increases bp(GOBP:"splicing")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "nan"
a(CHEBI:"protoporphyrin") association p(HGNC:"EPO")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "We found that protoporphyrin was significantly associated with platelet count (ÃŽÂ² = Ã¢Ë†â€™0.36, p < 0.001, Figure 1A), mean cor puscular volume (MCV, ÃŽÂ² = Ã¢Ë†â€™0.18, p = 0.029, Figure 1B), spleen length (ÃŽÂ² = 0.34, p = 0.013, Figure 1C), erythro poietin (EPO, ÃŽÂ² = 0.63, p = 0.011, Figure S1A) and alanine aminotransferase (ALT, ÃŽÂ² = 0.22, p < 0.001, Figure 1D)."
a(CHEBI:"protoporphyrin") association bp(MESHPP:"extramedullary hematopoiesis")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Finally, spleen size, a potential marker for extramedullary haematopoiesis, has not been rigorously examined in EPP, nor has its relationship with protoporphyrin levels and thrombocytopenia."
a(CHEBI:"protoporphyrin") association a(MESH:"platelet count")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "We found that protoporphyrin was significantly associated with platelet count (ÃŽÂ² = Ã¢Ë†â€™0.36, p < 0.001, Figure 1A), mean cor puscular volume (MCV, ÃŽÂ² = Ã¢Ë†â€™0.18, p = 0.029, Figure 1B), spleen length (ÃŽÂ² = 0.34, p = 0.013, Figure 1C), erythro poietin (EPO, ÃŽÂ² = 0.63, p = 0.011, Figure S1A) and alanine aminotransferase (ALT, ÃŽÂ² = 0.22, p < 0.001, Figure 1D)."
a(CHEBI:"protoporphyrin") association a(MESH:"platelet count")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Moreover, protoporphyrin was associated with platelet count, even when controlling for spleen size."
a(CHEBI:"protoporphyrin") association a(MESH:"platelet count")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "This suggests that the relation ship between protoporphyrin and platelets could be related to a pathway that leads to an increase in spleen size, but there could also be a separate mechanism that does not involve the spleen."
a(CHEBI:"protoporphyrin") association a(MESH:"mean corpuscular volume")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "We found that protoporphyrin was significantly associated with platelet count (ÃŽÂ² = Ã¢Ë†â€™0.36, p < 0.001, Figure 1A), mean cor puscular volume (MCV, ÃŽÂ² = Ã¢Ë†â€™0.18, p = 0.029, Figure 1B), spleen length (ÃŽÂ² = 0.34, p = 0.013, Figure 1C), erythro poietin (EPO, ÃŽÂ² = 0.63, p = 0.011, Figure S1A) and alanine aminotransferase (ALT, ÃŽÂ² = 0.22, p < 0.001, Figure 1D)."
a(CHEBI:"protoporphyrin") association a(MESH:"mean corpuscular volume")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "We also found associations between protoporphyrin and MCV and between protoporphyrin and spleen length."
a(CHEBI:"protoporphyrin") association path(MESHD:"splenomegaly")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "We found that protoporphyrin was significantly associated with platelet count (ÃŽÂ² = Ã¢Ë†â€™0.36, p < 0.001, Figure 1A), mean cor puscular volume (MCV, ÃŽÂ² = Ã¢Ë†â€™0.18, p = 0.029, Figure 1B), spleen length (ÃŽÂ² = 0.34, p = 0.013, Figure 1C), erythro poietin (EPO, ÃŽÂ² = 0.63, p = 0.011, Figure S1A) and alanine aminotransferase (ALT, ÃŽÂ² = 0.22, p < 0.001, Figure 1D)."
a(CHEBI:"protoporphyrin") association path(MESHD:"splenomegaly")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "We also found associations between protoporphyrin and MCV and between protoporphyrin and spleen length."
a(CHEBI:"protoporphyrin") association path(MESHD:"splenomegaly")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "For the first time, to our knowledge, we documented mild splenic enlargement in patients with EPP and found a direct relationship between protoporphyrin levels and spleen length."
a(CHEBI:"protoporphyrin") association path(MESHD:"splenomegaly")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Therefore, we posit that the relationship between spleen size and protoporphyrin levels is an intriguing observation that deserves further investigation beyond this study."
a(CHEBI:"protoporphyrin") association p(MESH:"Alanine Aminotransferase")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "We found that protoporphyrin was significantly associated with platelet count (ÃŽÂ² = Ã¢Ë†â€™0.36, p < 0.001, Figure 1A), mean cor puscular volume (MCV, ÃŽÂ² = Ã¢Ë†â€™0.18, p = 0.029, Figure 1B), spleen length (ÃŽÂ² = 0.34, p = 0.013, Figure 1C), erythro poietin (EPO, ÃŽÂ² = 0.63, p = 0.011, Figure S1A) and alanine aminotransferase (ALT, ÃŽÂ² = 0.22, p < 0.001, Figure 1D)."
a(CHEBI:"protoporphyrin") decreases path(MESHD:"liver failure")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^120,121 Erythrocyte concentrates that suppress erythropoiesis and plasma exchange that removes excess metal-free protoporphyrin have been used to treat liver failure or prevent further decompensation."
a(CHEBI:"protoporphyrin") decreases bp(MESHPP:"erythropoiesis")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "rythrocyte concentrates that suppress erythropoiesis and plasma exchange that removes excess metal-free protoporphyrin have been used to treat liver failure or prevent further decompensation."
a(CHEBI:"protoporphyrin") decreases a(CHEBI:"zinc")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "^f In EPP, the ratio of zinc-bound protoporphyrin to metal-free protoporphyrin is significantly lower ( <15 % ) than in XLP."
a(CHEBI:"protoporphyrin") decreases p(HGNC:"FECH")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "The combination of two allelic variants reduces overall FECH activity to 35 % of normal or less, causing accumulation of protoporphyrin during hemoglobin synthesis (Gouya et al."
a(CHEBI:"protoporphyrin") negativeCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "In this study of 152 patients with EPP followed at four specialized porphyria centres in the United States and Europe, we found a significant inverse linear association between protoporphyrin levels and platelet counts."
a(CHEBI:"protoporphyrin") negativeCorrelation path(MESHD:"thrombocytopenia")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Mild thrombocytopenia has also been observed in EPP, with an inverse relationship between protoporphyrin levels and platelet count."
a(CHEBI:"protoporphyrin") increases path(MESHD:"liver damage")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "The accumulation of protoporphyrin can cause liver damage when the hepatic load exceeds the canalicular excretion capacity."
a(CHEBI:"protoporphyrin") increases path(MESH:"Photosensitivity Disorders")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Protoporphyrin accumulation leads to painful sensitivity to sunlight in all patients and hepatobiliary dis ease in some patients."
a(CHEBI:"protoporphyrin") increases p(HGNC:"FECH")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Etiology and pathogenesis of EPP and XLPÃ¢â‚¬â€EPP is caused by mutations in the gene encoding FECH, a mitochondrial enzyme that catalyzes the insertion of ferrous iron (Fe^2+) into protoporphyrin to form heme (Todd 1994; Poh-Fitzpatrick, 1995; Cox, 1997; Elder, 1999)."
a(CHEBI:"protoporphyrin") increases path(MESHD:"EPP")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Elevated levels of erythrocyte metal- free protoporphyrin IX (hereafter re ferred to as Ã¢â‚¬ËœprotoporphyrinÃ¢â‚¬â„¢) are diagnostic of EPP, with ge netic testing ruling out X- linked protoporphyria, a distinct protoporphyria caused by variants in ALAS2"
a(CHEBI:"protoporphyrin") increases path(MESHD:"severe disease")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "On average, patients with XLP have more severe disease, with higher protoporphyrin levels and perhaps a greater risk of liver disease than do those with EPP."
a(CHEBI:"protoporphyrin") increases path(MESHD:"cholestasis")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "The liver damage is characterized by cholestasis due to protoporphyrin precipitation within hepatocytes and the intrahepatic biliary tree."
a(CHEBI:"protoporphyrin") increases path(PKG:"hepatobillary disease")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Protoporphyrin accumulation leads to painful sensitivity to sunlight in all patients and hepatobiliary dis ease in some patients."
a(CHEBI:"protoporphyrin") increases path(MESH:"Gallstone Disease")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Gallstone disease thought to result mainly from protoporphyrin precipitation in the gallbladder, may occur even in childhood"
a(CHEBI:"trichloroethylene") decreases p(HGNC:"ALAD")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The ALAD enzyme activity has also been shown to be reduced when rats were exposed to trichloroethylene (Fujita et al. 1984), styrene (Fujita et al. 1986), lead (Sassa, Granick, Kappas, 1975), and iron (Bonkovsky et al. 1987)."
a(CHEBI:"styrene") decreases p(HGNC:"ALAD")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The ALAD enzyme activity has also been shown to be reduced when rats were exposed to trichloroethylene (Fujita et al. 1984), styrene (Fujita et al. 1986), lead (Sassa, Granick, Kappas, 1975), and iron (Bonkovsky et al. 1987)."
a(CHEBI:"hemoglobin") increases a(CHEBI:"zinc protoporphyrin")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The excess zinc protoporphyrin in erythrocytes is probably formed from pathway intermediates that accumulate during hemoglobin synthesis and are later metabolized to protoporphyrin, and then complexed with zinc (Phillips et al."
bp(MESHPP:"erythropoietic") isA path(MESHD:"porphyria")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "This is the basis for classification of porphyrias as either hepatic or erythropoietic."
p(HGNC:"ALAS2") association p(HGNC:"EPO")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "In contrast to the liver, iron and erythropoietin, instead of heme, regulate the ratecontrolling bone marrow enzyme ALAS2."
p(HGNC:"ALAS2") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "It is the most recently described porphyria, and results from gain of function mutations of the erythroid-specific form on ÃŽÂ´-aminolevulinic acid synthase (ALAS2), which catalyzes the first step in heme biosynthesis in marrow erythroid cells."
p(HGNC:"ALAS2") increases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Heterozygous females may have normal or elevated levels of protoporphyrin depending on the degree of inactivation of the X chromosome that carries the ALAS2 mutation (Whatley et al."
p(HGNC:"ALAS2") increases a(CHEBI:"protoporphyrin IX")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with erythropoietic protoporphyria have either a decreased activity of ferrochelatase (FECH) or a gain of function of aminolevulinic acid synthase 2 (ALAS2), leading to overproduction of protoporphyrin IX"
a(CHEBI:"protoporphyrin IX") increases path(MESHD:"liver disease")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Protoporphyrin IX reacts to visible light causing painful photosensitivity (9), and hepatic toxicity leading to liver disease in up to 20% of erythropoietic protoporphyria patients, varying from elevated liver enzymes, cholelithiasis to acute liver failure (~3%)"
a(CHEBI:"protoporphyrin IX") increases path(MESHD:"Photosensitivity")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Protoporphyrin IX reacts to visible light causing painful photosensitivity (9), and hepatic toxicity leading to liver disease in up to 20% of erythropoietic protoporphyria patients, varying from elevated liver enzymes, cholelithiasis to acute liver failure (~3%)"
a(CHEBI:"protoporphyrin IX") increases path(EFO:"hepatotoxicity")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Protoporphyrin IX reacts to visible light causing painful photosensitivity (9), and hepatic toxicity leading to liver disease in up to 20% of erythropoietic protoporphyria patients, varying from elevated liver enzymes, cholelithiasis to acute liver failure (~3%)"
a(CHEBI:"protoporphyrin IX") increases path(HP:"Abnormal liver enzyme level")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Protoporphyrin IX reacts to visible light causing painful photosensitivity (9), and hepatic toxicity leading to liver disease in up to 20% of erythropoietic protoporphyria patients, varying from elevated liver enzymes, cholelithiasis to acute liver failure (~3%)"
a(CHEBI:"protoporphyrin IX") increases path(MESHD:"Cholelithiasis")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Protoporphyrin IX reacts to visible light causing painful photosensitivity (9), and hepatic toxicity leading to liver disease in up to 20% of erythropoietic protoporphyria patients, varying from elevated liver enzymes, cholelithiasis to acute liver failure (~3%)"
a(CHEBI:"protoporphyrin IX") increases path(MESHD:"Acute Liver Failure")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Protoporphyrin IX reacts to visible light causing painful photosensitivity (9), and hepatic toxicity leading to liver disease in up to 20% of erythropoietic protoporphyria patients, varying from elevated liver enzymes, cholelithiasis to acute liver failure (~3%)"
path(MESHD:"itching") positiveCorrelation path(MESHD:"Swelling")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Swelling, burning, itching, and redness of the skin may appear during or after exposure to sunlight."
path(MESHD:"redness of the skin") positiveCorrelation path(MESHD:"itching")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Swelling, burning, itching, and redness of the skin may appear during or after exposure to sunlight."
path(MESHD:"redness of the skin") positiveCorrelation path(MESHD:"Swelling")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Swelling, burning, itching, and redness of the skin may appear during or after exposure to sunlight."
path(MESHD:"EPP") association path(MESHD:"liver damage")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Between 25% and 33% of patients with EPP display some degree of liver dam age."
path(MESHD:"EPP") association a(CHEBI:"Afamelanotide")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Afamelanotide for erythropoietic protoporphyria. Increasing skin pigmentation with afamelanotide, an ÃŽÂ±-melanocyte stimulating hormone analogue, can significantly increase sunlight tolerance"
path(MESHD:"EPP") association p(HGNC:"ALPL")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Alkaline phosphatase levels (strongly related to vitamin D deficiency) and low bone relevant physical activity are the most relevant predictors for osteoporosis in erythropoietic protoporphyria patients"
path(MESHD:"EPP") association p(HGNC:"ALPL")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "The prevalence of osteoporosis and osteopenia is greatly increased in erythropoietic protoporphyria patients. Factors that significantly correlate with low bone mineral density in this population are alkaline phosphatase (related to vitamin D deficiency) and the amount of weight bearing exercise."
path(MESHD:"EPP") association a(CHEBI:"Vitamin D")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Alkaline phosphatase levels (strongly related to vitamin D deficiency) and low bone relevant physical activity are the most relevant predictors for osteoporosis in erythropoietic protoporphyria patients"
path(MESHD:"EPP") association a(CHEBI:"Vitamin D")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "The prevalence of osteoporosis and osteopenia is greatly increased in erythropoietic protoporphyria patients. Factors that significantly correlate with low bone mineral density in this population are alkaline phosphatase (related to vitamin D deficiency) and the amount of weight bearing exercise."
path(MESHD:"EPP") positiveCorrelation path(MESHD:"cholestatic liver disease")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Among the cutaneous porphyrias, erythropoietic pro toporphyria (EPP) can lead to cholestatic liver failure where LT cures the liver disease but not the porphyria."
path(MESHD:"EPP") positiveCorrelation path(MESHD:"thrombocytopenia")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Therefore, splenic sequestration may be a more likely cause of the mild throm bocytopenia observed in EPP."
path(MESHD:"EPP") positiveCorrelation path(MESHD:"iron deficiency anemia")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Although some data suggest EPP cutaneous reactions may have some measurable inflammatory component,3,17,18 inflammation is expected to decrease haemoglobin but in crease ferritin and platelet count.19 Therefore, the laboratory values we observed seem more consistent with iron defi ciency anaemia than anaemia of inflammation."
path(MESHD:"EPP") positiveCorrelation path(MESHD:"sideroblastic anemia")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "However, erythropoietic protoporphyria patients have been reported to have small intestinal signs and have also been reported to develop eventually sideroblastic anemia (91)."
path(MESHD:"EPP") positiveCorrelation path(MESHD:"Osteoporosis")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "The prevalence of osteoporosis and osteopenia is greatly increased in erythropoietic protoporphyria patients. Factors that significantly correlate with low bone mineral density in this population are alkaline phosphatase (related to vitamin D deficiency) and the amount of weight bearing exercise."
path(MESHD:"EPP") positiveCorrelation path(MESHD:"Osteoporosis")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Alkaline phosphatase levels (strongly related to vitamin D deficiency) and low bone relevant physical activity are the most relevant predictors for osteoporosis in erythropoietic protoporphyria patients"
path(MESHD:"EPP") positiveCorrelation path(MESHD:"Osteoporosis")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "In addition to a high prevalence of vitamin D deficiency, the prevalence of osteoporosis in erythropoietic protoporphyria patients is very high"
path(MESHD:"EPP") positiveCorrelation path(MESHD:"Osteoporosis")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "The aim of this study was to evaluate bone mineral density and known osteoporosis risk factors in erythropoietic protoporphyria patients."
path(MESHD:"EPP") positiveCorrelation path(MESHD:"osteopenia")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "The prevalence of osteoporosis and osteopenia is greatly increased in erythropoietic protoporphyria patients. Factors that significantly correlate with low bone mineral density in this population are alkaline phosphatase (related to vitamin D deficiency) and the amount of weight bearing exercise."
path(MESHD:"EPP") isA path(MESHD:"porphyria")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "The non-acute porphyrias are porphyria cutanea tarda, erythropoietic protoporphyria, X-linked protoporphyria, and the rare congenital erythropoietic porphyria."
path(MESHD:"EPP") decreases a(CHEBI:"iron")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "On the contrary, Graziadei et al. observed that in 20 patients with EPP, sTfR levels were higher than those of the control patients, indicating decreased total body iron stores. In the present study, ferritin was lower in EPP patients than controls, which is both highly sensitive and specific for reduced total body iron stores."
path(MESHD:"EPP") decreases p(HGNC:"FECH")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "All patients had to have a confirmed diagnosis of erythropoietic protoporphyria, based on phototoxic symptoms with increased free protoporphyrin IX levels (> 4 times the upper limit of normal: 1.5 umol/ L in erythrocytes), and detection of known pathogenic mutations in the FECH gen, or a gain of function mutation in the ALAS2 gene."
path(MESHD:"EPP") decreases p(HGNC:"FECH")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "EPP arises due to pathogenic variants in ferrochelatase (FECH), the last step in haem biosynthesis, which incorpo rates iron into protoporphyrin to form haem."
path(MESHD:"EPP") decreases a(MESH:"platelet count")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "In a caseÃ¢â‚¬â€œcontrol analysis, platelet count, haemoglobin, MCV and ferritin levels were all lower in EPP patients than in matched controls."
path(MESHD:"EPP") decreases a(MESH:"mean corpuscular volume")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "In a caseÃ¢â‚¬â€œcontrol analysis, platelet count, haemoglobin, MCV and ferritin levels were all lower in EPP patients than in matched controls."
path(MESHD:"EPP") decreases path(MESHD:"Bone Density")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "large cohort of erythropoietic protoporphyria patients, clinically significant lower bone density was found in a high number of patients: osteopenia in 36% and osteoporosis in 23% of patients."
path(MESHD:"EPP") decreases path(MESHD:"Bone Density")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, low bone mineral density, osteopenia or even osteoporosis, is found in over half of the erythropoietic protoporphyria patients in this study."
path(MESHD:"EPP") decreases path(MESHD:"Bone Density")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "The prevalence of osteoporosis and osteopenia is greatly increased in erythropoietic protoporphyria patients. Factors that significantly correlate with low bone mineral density in this population are alkaline phosphatase (related to vitamin D deficiency) and the amount of weight bearing exercise."
path(MESHD:"EPP") decreases a(CHEBI:"hemoglobin")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "In a caseÃ¢â‚¬â€œcontrol analysis, platelet count, haemoglobin, MCV and ferritin levels were all lower in EPP patients than in matched controls."
path(MESHD:"EPP") decreases p(PFAM:"Ferritin")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "In a caseÃ¢â‚¬â€œcontrol analysis, platelet count, haemoglobin, MCV and ferritin levels were all lower in EPP patients than in matched controls."
path(MESHD:"EPP") decreases p(PFAM:"Ferritin")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "On the contrary, Graziadei et al. observed that in 20 patients with EPP, sTfR levels were higher than those of the control patients, indicating decreased total body iron stores. In the present study, ferritin was lower in EPP patients than controls, which is both highly sensitive and specific for reduced total body iron stores."
path(MESHD:"EPP") decreases p(HGNC:"ferrochelatase")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "Autosomal recessive defects in ferrochetalase (FECH) causeery thropoieticprotoporphyria(EPP),whereaccumulationandphotoactiv ity of protoporphyrin mediate both skin and liver damage."
path(MESHD:"EPP") decreases p(HGNC:"ferrochelatase")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "The patient with EPP, Patient 5, was 18yearsold,withaconfirmedFECHdeletionandalowexpressionpre disposing single-nucleotide polymorphism(SNP)."
path(MESHD:"EPP") increases path(MESHD:"Pain")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with erythropoietic protoporphyria (EPP, OMIM 177000) suffer from extreme pain after (sun) light exposure."
path(MESHD:"EPP") increases a(CHEBI:"reactive oxygen species")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "The pathophysiology is thought to involve the production of reactive oxygen species and complement after light activates protoporphyrin."
path(MESHD:"EPP") increases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Protoporphyrin accumulation leads to painful sensitivity to sunlight in all patients and hepatobiliary dis ease in some patients."
path(MESHD:"EPP") increases p(HGNC:"ALAS2")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "All patients had to have a confirmed diagnosis of erythropoietic protoporphyria, based on phototoxic symptoms with increased free protoporphyrin IX levels (> 4 times the upper limit of normal: 1.5 umol/ L in erythrocytes), and detection of known pathogenic mutations in the FECH gen, or a gain of function mutation in the ALAS2 gene."
path(MESHD:"EPP") increases a(CHEBI:"protoporphyrin IX")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Erythropoietic protoporphyria is a rare metabolic disease with painful photosensitivity due to protoporphyrin IX accumulation, resulting in lifelong light avoidance behaviour."
path(MESHD:"EPP") increases a(CHEBI:"protoporphyrin IX")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with erythropoietic protoporphyria have either a decreased activity of ferrochelatase (FECH) or a gain of function of aminolevulinic acid synthase 2 (ALAS2), leading to overproduction of protoporphyrin IX"
path(MESHD:"EPP") increases a(CHEBI:"protoporphyrin IX")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "All patients had to have a confirmed diagnosis of erythropoietic protoporphyria, based on phototoxic symptoms with increased free protoporphyrin IX levels (> 4 times the upper limit of normal: 1.5 umol/ L in erythrocytes), and detection of known pathogenic mutations in the FECH gen, or a gain of function mutation in the ALAS2 gene."
path(MESHD:"EPP") increases path(MESHD:"Osteoporosis")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "large cohort of erythropoietic protoporphyria patients, clinically significant lower bone density was found in a high number of patients: osteopenia in 36% and osteoporosis in 23% of patients."
path(MESHD:"EPP") increases path(MESHD:"Osteoporosis")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, low bone mineral density, osteopenia or even osteoporosis, is found in over half of the erythropoietic protoporphyria patients in this study."
path(MESHD:"EPP") increases path(MESHD:"osteopenia")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "large cohort of erythropoietic protoporphyria patients, clinically significant lower bone density was found in a high number of patients: osteopenia in 36% and osteoporosis in 23% of patients."
path(MESHD:"EPP") increases path(MESHD:"osteopenia")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, low bone mineral density, osteopenia or even osteoporosis, is found in over half of the erythropoietic protoporphyria patients in this study."
path(MESHD:"EPP") increases path(MESHD:"Photosensitivity")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Erythropoietic protoporphyria is a rare metabolic disease with painful photosensitivity due to protoporphyrin IX accumulation, resulting in lifelong light avoidance behaviour."
path(MESHD:"EPP") increases path(MESHD:"Photosensitivity")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with erythropoietic protoporphyria (EPP, OMIM 177000) suffer from extreme pain after (sun) light exposure."
a(CHEBI:"Lead") association p(HGNC:"ALAD")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
a(CHEBI:"Lead") association a(CHEBI:"heme biosynthesis")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
a(CHEBI:"Lead") association path(MESHD:"Lead poisoning")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
a(CHEBI:"Lead") association p(HGNC:"CPOX")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
a(CHEBI:"erythrocyte protoporphyrin") positiveCorrelation path(MESHD:"erythema")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Sun-induced erythema and blistering occurred by age 2 years in 75% of reported cases of patients. Biochemical abnormalities resemble PCT, but with substantial elevations of erythrocyte protoporphyrin (predominantly zinc protoporphyrin) level."
path(MESHD:"splenomegaly") positiveCorrelation path(MESHD:"Anemia")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "^135 Anemia and splenomegaly may develop later."
path(MESHD:"thrombocytopenia") association a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Finally, spleen size, a potential marker for extramedullary haematopoiesis, has not been rigorously examined in EPP, nor has its relationship with protoporphyrin levels and thrombocytopenia."
path(MESHD:"thrombocytopenia") association path(MESHD:"EPP")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Yet, thrombocytopenia in EPP re mains poorly characterized, and levels of the megakaryocyte- stimulating hormone thrombopoietin (TPO) have not been reported."
path(MESHD:"thrombocytopenia") association bp(MESHPP:"extramedullary hematopoiesis")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Finally, spleen size, a potential marker for extramedullary haematopoiesis, has not been rigorously examined in EPP, nor has its relationship with protoporphyrin levels and thrombocytopenia."
path(MESHD:"bullae") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Skin biopsy was performed in these two patients revealing findings compatible with dermatological porphyria: subepidermal bullae with festooning of Table 1 Clinical characteristics of enrolled patients | Patients | Age | Ferritin (ng/mL) | HCV | Hormonal replacement therapy | Urinary porphyrin ( ÃŽÂ¼g / Lt ) | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ: | | 1 | 34 | 902 | + | + | 7300 | | 2 | 29 | 540 | | + | 1185 | | 3 | 34 | 654 | | | 230 | | 4 | 33 | 4531 | | + | 203 | | 5 | 16 | 165 | | | 160 | | 6 | 38 | 3310 | + | | 142 | | 7 | 19 | 3410 | | | 76 | | 8 | 35 | 1919 | + | | 47 | | 9 | 21 | 5022 | | | 66 | | 10 | 27 | 264 | | | 95 | | 11 | 29 | 357 | | | 120 | | 12 | 41 | 293 | | + | 95 | | 13 | 32 | 2812 | + | + | 47 | | 14 | 24 | 164 | | | 57 | | 15 | 34 | 255 | | + | 95 | | 16 | 30 | 637 | | | 59 | | 17 | 48 | 592 | | | 33 | | 18 | 33 | 3041 | + | + | 52 | !"
path(MESHD:"bullae") positiveCorrelation path(MESHD:"hypertrichosis")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Figure 1 Patient with hypertrichosis of zygomatics, hyperpigmentation, scars and bullae of the face and hands."
path(MESHD:"bullae") increases a(GO:"IgG")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "al papillae into the bullae and in direct immunofluorescence deposition of IgG immunoglobulins around the blood vessels of the papillary dermis and dermoepidermal junction."
a(SCTID:"Exposure to light") increases path(MESHD:"swelling")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Continued light exposure can cause swelling, and redness, and systemic symptoms that can last for several days."
a(SCTID:"Exposure to light") increases path(MESHD:"redness")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Continued light exposure can cause swelling, and redness, and systemic symptoms that can last for several days."
path(MESHD:"iron deficiency anemia") positiveCorrelation path(MESHD:"protoporphyria")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Mild iron deficiency anemia is a common feature of protoporphyria, and is poorly explained (Goerz et al."
p(HGNC:"CPOX") association path(MESHD:"Lead poisoning")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^h Lead poisoning affects 3 enzymes involved in heme biosynthesis (ALAD, CPOX, and FECH)."
p(HGNC:"CPOX") association path(MESHD:"Lead poisoning")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "^139 ## Lead Poisoning Lead affects 3 enzymes involved in heme biosynthesis: ALAD, CPOX, and FECH (Figure 1)."
p(HGNC:"CPOX") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Certain CPOX mutations release the substrate after one decarboxylation as harderoporphyrinogen, a tricarboxylate porphyrinogen that is then oxidized to the corresponding porphyrin."
p(HGNC:"CPOX") increases bp(GOBP:"ovulation")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "About 20% of those with an acute attack report photosensitivity although bullae and skin fragility are much less common than in VP"
a(CHEBI:"porphyrinogen") increases a(CHEBI:"tricarboxylate")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Certain CPOX mutations release the substrate after one decarboxylation as harderoporphyrinogen, a tricarboxylate porphyrinogen that is then oxidized to the corresponding porphyrin."
path(MESHD:"atrophy") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy. ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
path(MESHD:"atrophy") association path(MESHD:"vascular lesions")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy. ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
path(MESHD:"atrophy") positiveCorrelation path(MESHD:"generalized seizures")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Two young adults, ages 21 and 23 years, with severe HEP developed generalized seizures and had neuroimaging evidence of cerebral cortical atrophy and calcifications in the frontal lobes, presumably related to hypoxic injury as in other porphyrias (Berenguer et al. 1997)."
path(MESHD:"vascular lesions") association path(MESHD:"atrophy")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy."
bp(MESHPP:"calcifications") positiveCorrelation path(MESHD:"osteolysis")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Skeletal changes such as osteolysis and calcifications were frequent (Fritsch et al. 1997)."
path(MESHD:"myeloproliferative disorder") association path(MESHD:"neurological impairment")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Another patient was a child with neurological impairment from birth, and the sixth was an adult and disease onset associated with a myeloproliferative disorder (Sassa, 1998; Maruno et al."
path(MESHD:"spontaneous abortions") association p(HGNC:"ALAD")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "This study suggested that most instances of compound heterozygosity in ALAD result in spontaneous abortions."
path(MESHD:"CEP") association p(HGNC:"UROS")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Clinical features of CEPÃ¢â‚¬â€The phenotype can vary depending on the severity of the inherited UROS mutations and levels of porphyrins in plasma and erythrocytes."
path(MESHD:"CEP") association path(MESHD:"Metabolic Bone Disease")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "At the age of 20 he began to experience pain in the spine and sternum. He was investigated for metabolic bone disease at the age of 22."
path(MESHD:"CEP") decreases p(HGNC:"UROS")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "Congenital erythropoietic heme biosynthesis, porphyria (CEP) is a rare disorder of resulting from reduced activity enzyme uroporphyrinogen (III) cosynthetase."
path(MESHD:"CEP") decreases p(HGNC:"UROS")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "In patients with congenital erythropoietic porphyria (CEP), auto somal recessive deficiencies in uroporphyrinogen III synthase (UROS) lead to accumulation of the UROS substrate hydroxymethylbilane, which is converted to metabolites that accumulate in bone marrow erythroid precursors and are released into plasma by diffusion or hemolysis."
path(MESHD:"CEP") decreases a(CHEBI:"Vitamin D")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Although tbe serum 250H vitamin D concentration was very low (because of light avoidance) there was no evidence that the bone disease was a consequence of this"
path(MESHD:"CEP") decreases a(CHEBI:"Vitamin D")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Privational vitamin D deficiency may also occur."
path(MESHD:"CEP") decreases path(MESHD:"Bone Density")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Spinal bone density (assessed by DPA) was reduced and at the hip bone density was at the lower limit of normal."
path(MESHD:"CEP") decreases path(MESHD:"Bone Density")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Biochemical and histological studies showed accelerated bone turnover."
path(MESHD:"CEP") decreases path(MESHD:"Life Expectancy")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical syndrome is marked by extreme photosensitivity, which results in mutilation of light exposed areas, but hemolytic anemia, hepato-spleno- megaly, erythrodontia, and a reduced life expectancy are also recognised features"
path(MESHD:"CEP") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "The term PCT was first suggested by WaldenstrÃƒÂ¶m ^10 in 1937 to distinguish this form of porphyria from the rare photomutilating congenital erythropoetic porphyria (Gunther's Disease)."
path(MESHD:"CEP") positiveCorrelation path(MESHD:"Osteoporosis")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "We conclude that CEP has a distinctive osteodystropby comprising osteolysis of light-exposed ex- tremities and a high turnover type of osteoporosis."
path(MESHD:"CEP") positiveCorrelation path(MESHD:"osteopenia")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "In this young man with CEP we have observed a form of generalised osteopenia affecting both the axial and peripheral skeleton and clinically characterised by bone pain and crush fractures of the spine."
path(MESHD:"CEP") positiveCorrelation path(MESHD:"Metabolic Bone Disease")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Bone disease has been occasionally noted, but is not well characterised."
path(MESHD:"CEP") positiveCorrelation path(HP:"Bone pain")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "On examination he had minimal bone tenderness, but no myopathy or kyphosis."
path(MESHD:"CEP") positiveCorrelation path(HP:"Bone pain")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "In this young man with CEP we have observed a form of generalised osteopenia affecting both the axial and peripheral skeleton and clinically characterised by bone pain and crush fractures of the spine."
path(MESHD:"CEP") positiveCorrelation path(HP:"Bone pain")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "We describe a man with CEP who developed bone pain and spinal crush fractures at the age of 22."
path(MESHD:"CEP") positiveCorrelation path(MESHD:"Compression Fractures")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "We describe a man with CEP who developed bone pain and spinal crush fractures at the age of 22."
path(MESHD:"CEP") positiveCorrelation path(PKG:"osteodystrophy")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "We conclude that CEP has a distinctive osteodystropby comprising osteolysis of light-exposed ex- tremities and a high turnover type of osteoporosis."
path(MESHD:"CEP") positiveCorrelation path(PKG:"osteodystrophy")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "This report describes the osteodystrophy of CEP."
path(MESHD:"CEP") positiveCorrelation path(MESHD:"Acro-Osteolysis")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "We conclude that CEP has a distinctive osteodystropby comprising osteolysis of light-exposed ex- tremities and a high turnover type of osteoporosis."
path(MESHD:"CEP") positiveCorrelation path(MESHD:"Bone Demineralization")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Although bone demineralization and fractures have been described in patients with CEP (Piomelli et al. 1986), bone disease has not been generally recognized as a complication of this disorder."
path(MESHD:"CEP") positiveCorrelation path(MESHD:"Fractures")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Although bone demineralization and fractures have been described in patients with CEP (Piomelli et al. 1986), bone disease has not been generally recognized as a complication of this disorder."
path(MESHD:"CEP") positiveCorrelation path(MESHD:"Neonatal Jaundice")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "CEP was diagnosed at the age of two months in an infant presenting with persistent neonatal jaundice and hemolysis."
path(MESHD:"CEP") positiveCorrelation path(MESHD:"Hemolysis")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "CEP was diagnosed at the age of two months in an infant presenting with persistent neonatal jaundice and hemolysis."
path(MESHD:"CEP") increases path(MESH:"Photosensitivity Disorders")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Upon absorption of light, these highly photoreactive com pounds cause oxidative damage to the cell membrane and organelles"
path(MESHD:"CEP") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Congenital erytbropoietic porphyria (CEP) is a rare disorder of heme biosynthesis that results in the production of large quantities of photoactive porphyrins."
path(MESHD:"CEP") increases path(MESHD:"Hemolytic anemia")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical syndrome is dominated by extreme photosensitivity with mutilation of light exposed extremities and bemolytic anemia."
path(MESHD:"CEP") increases path(MESHD:"Hemolytic anemia")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Skeletal radiographs revealed features typical of other severe hemolytic anemias, but in addition there was loss of the terminal phalanges of the hand as a result of photomutilation."
path(MESHD:"CEP") increases path(MESHD:"Hemolytic anemia")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical syndrome is marked by extreme photosensitivity, which results in mutilation of light exposed areas, but hemolytic anemia, hepato-spleno- megaly, erythrodontia, and a reduced life expectancy are also recognised features"
path(MESHD:"CEP") increases a(CHEBI:"hydroxymethylbilane")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "In patients with congenital erythropoietic porphyria (CEP), auto somal recessive deficiencies in uroporphyrinogen III synthase (UROS) lead to accumulation of the UROS substrate hydroxymethylbilane, which is converted to metabolites that accumulate in bone marrow erythroid precursors and are released into plasma by diffusion or hemolysis."
path(MESHD:"CEP") increases path(MESHD:"Photosensitivity")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical syndrome is dominated by extreme photosensitivity with mutilation of light exposed extremities and bemolytic anemia."
path(MESHD:"CEP") increases path(PKG:"photomutilation")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Skeletal radiographs revealed features typical of other severe hemolytic anemias, but in addition there was loss of the terminal phalanges of the hand as a result of photomutilation."
path(MESHD:"CEP") increases path(PKG:"photomutilation")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical syndrome is marked by extreme photosensitivity, which results in mutilation of light exposed areas, but hemolytic anemia, hepato-spleno- megaly, erythrodontia, and a reduced life expectancy are also recognised features"
path(MESHD:"CEP") increases path(PKG:"photomutilation")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "There was extensive photomutilation of the face and hands with scarring alopecia and shortening of the digits."
path(MESHD:"CEP") increases path(SNOMED:"Hepatosplenomegaly")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical syndrome is marked by extreme photosensitivity, which results in mutilation of light exposed areas, but hemolytic anemia, hepato-spleno- megaly, erythrodontia, and a reduced life expectancy are also recognised features"
path(MESHD:"CEP") increases path(HP:"erythrodontia")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "The clinical syndrome is marked by extreme photosensitivity, which results in mutilation of light exposed areas, but hemolytic anemia, hepato-spleno- megaly, erythrodontia, and a reduced life expectancy are also recognised features"
path(MESHD:"CEP") increases path(MESHD:"alopecia")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "There was extensive photomutilation of the face and hands with scarring alopecia and shortening of the digits."
path(MESHD:"CEP") increases bp(MESHPP:"oxidative damage")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Upon absorption of light, these highly photoreactive com pounds cause oxidative damage to the cell membrane and organelles"
bp(MESHPP:"mutations") association path(MESHD:"CEP")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Clinical features of CEPÃ¢â‚¬â€The phenotype can vary depending on the severity of the inherited UROS mutations and levels of porphyrins in plasma and erythrocytes."
a(CHEBI:"hydroxymethylbilane") increases a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Examinations revealed positivity for porphobilinogen (PBG) in urine and a mutation in the hydroxymethylbilane synthetase (HMBS) gene: c. 806 C>G (p.Thr269Arg) (Figure 1)."
a(CHEBI:"hydroxymethylbilane") increases a(CHEBI:"coproporphyrinogen")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "^133,134 This leads to accumulation of hydroxymethylbilane, spontaneously (non-enzymatically) forming uroporphyrinogen I, that is further metabolized to the non-functional end product coproporphyrinogen I. Spontaneous oxidation of the porphyrinogens generates porphyrins that accumulate in tissues."
a(CHEBI:"hydroxymethylbilane") increases p(HGNC:"UROS")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "UROS catalyzes the conversion of hydroxymethylbilane, a linear tetrapyrrole, to the cyclic tetrapyrrole uroporphyrinogen III."
path(MESHD:"hydrops") positiveCorrelation path(MESHD:"CEP")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Biochemical diagnosis of a fatal case of Gunther's disease in a newborn with hydrops foetalis."
path(MESHD:"Gunther's disease") isA path(MESHD:"CEP")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Compared to PCT, the cutaneous features of HEP typically have earlier onset, increased severity leading to disfigurement, and closer resemblance to those in CEP (Günther disease)."
p(HGNC:"EPX") association p(HGNC:"FECH")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "It is not known why in families with two disabling FECH mutations, EPP is associated with palmar keratoderma."
path(MESHD:"carcinogenesis") association a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "In general, VP and HCP are less clinically active and have lower levels of ALA, which is regarded as the most likely porphyrin precursor to be involved in carcinogenesis."
a(CHEBI:"antidiuretic hormone") increases path(MESHD:"hyponatremia")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "The latter may be due to hyponatremia, resulting from hypothalamic involvement and inappropriately high levels of antidiuretic hormone."
a(CHEBI:"antidiuretic hormone") increases path(MESHD:"hyponatremia")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "An inappropriately high secretion of antidiuretic hormone (Schwartz-Bartter syndrome) leads to a potentially lifethreatening severe hyponatremia, another diagnostic feature of acute porphyrias."
a(CHEBI:"progesterone") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The reproductive steroids progesterone, medroxyprogesterone and testosterone are particularly potent inducers of hepatic ALAS1 (Kappas, Sassa and Anderson, 1983; Thunell, Pomp and Brun, 2007)."
a(CHEBI:"progesterone") increases a(CHEBI:"estrogens")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Some women have cyclic menstrual attacks, progesterone increases heme catabolism, and synthetic estrogens and progesterones induce porphyria."
a(CHEBI:"progesterone") increases bp(MESHPP:"luteal phase")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Some women have attacks during the luteal phase of the cycle when levels of progesterone are increased."
path(MESHD:"sideroblastic anemia") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "| | porphyria ('ALASm')/ sideroblastic anemia | 5-aminolevulinate synthase ( A L A S 2, Gene ID: 212, E.C. 2.3.1.37)."
path(MESHD:"HHcy") decreases a(CHEBI:"Vitamin B6")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Causes of HHcy include the defects in its catabolism, which may be inherited (congenital enzymatic defects) or acquired (as in deficiencies of B6, folic acid, or vitamin B12 which are important enzymatic cofactors) and/or associated to conditions responsible for renal or liver failure [9,10,18-22]."
path(MESHD:"HHcy") decreases a(CHEBI:"folic acid")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Causes of HHcy include the defects in its catabolism, which may be inherited (congenital enzymatic defects) or acquired (as in deficiencies of B6, folic acid, or vitamin B12 which are important enzymatic cofactors) and/or associated to conditions responsible for renal or liver failure [9,10,18-22]."
path(MESHD:"HHcy") positiveCorrelation path(SCTID:"Deep venous thrombosis")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "After exclusion of factors showing a high collinearity, at multivariate analysis, only disease status (i.e. being in APBP/APSP groups) was shown to be an independent predictor of HHcy [OR = 25 (95 Three patients had a history of deep vein thrombosis."
path(MESHD:"HHcy") increases path(MESHD:"peripheral neuropathy")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The link between AP, HHcy and vitamin deficiency is also intriguing if considering that the clinic of peripheral neuropathy resulting from a deficiency in PLP shows striking resemblances to that observed in acute porphyrias [45-47].When considering the high prevalence of vitamin deficiencies in the general population [18,48,49], and in porphyria patients [50], it is likely that depletion of vitamin cofactors in multiple tissues promoted by a deficiency in heme biosynthesis may contribute to worsen other underlying deficiencies."
a(CHEBI:"testosterone") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The reproductive steroids progesterone, medroxyprogesterone and testosterone are particularly potent inducers of hepatic ALAS1 (Kappas, Sassa and Anderson, 1983; Thunell, Pomp and Brun, 2007)."
a(CHEBI:"testosterone") increases a(CHEBI:"medroxyprogesterone")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The reproductive steroids progesterone, medroxyprogesterone and testosterone are particularly potent inducers of hepatic ALAS1 (Kappas, Sassa and Anderson, 1983; Thunell, Pomp and Brun, 2007)."
a(CHEBI:"medroxyprogesterone") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The reproductive steroids progesterone, medroxyprogesterone and testosterone are particularly potent inducers of hepatic ALAS1 (Kappas, Sassa and Anderson, 1983; Thunell, Pomp and Brun, 2007)."
bp(MESHPP:"diets") increases p(HGNC:"PPARGC1A")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Fasting and low calorie diets can cause attacks due to ALAS induction, and this effect is mediated by PGC-1 ÃŽÂ± (Phillips and Kushner, 2005)."
a(CHEBI:"serum cholesterol") association path(MESHD:"hyperthyroidism")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Increased serum T4 and thyroxine binding globulin in the absence of hyperthyroidism, and elevated serum cholesterol and low-density lipoprotein (LDL), are sometimes seen."
path(MESHD:"NASH") association path(MESHD:"fibrosis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity."
path(MESHD:"NASH") association p(HGNC:"HFE")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity."
path(MESHD:"NASH") association p(HGNC:"HFE")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "An Australian study showed that the major HFE mutation (C282Y) associated with HH is correlated with iron abnormalities found in patients with NASH."
path(MESHD:"NASH") positiveCorrelation p(HGNC:"HFE")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Serum iron indices and hepatic iron staining were higher in our NASH patients who carried HFE mutations than in those who did not, but there was no difference in HIC or HII between the NASH patients with and without HFE mutations."
path(MESHD:"quadriplegia") increases path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "VP can cause acute attacks identical to those in AIP, with abdominal pain, vomiting, constipation, hypertension, tachycardia, and neuromuscular weakness that can progress to quadriplegia and respiratory weakness (Chemmanur and Bonkovsky, 2004)."
path(MESHD:"quadriplegia") increases path(MESHD:"tachycardia")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "VP can cause acute attacks identical to those in AIP, with abdominal pain, vomiting, constipation, hypertension, tachycardia, and neuromuscular weakness that can progress to quadriplegia and respiratory weakness (Chemmanur and Bonkovsky, 2004)."
path(MESHD:"quadriplegia") increases path(MESHD:"vomiting")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "VP can cause acute attacks identical to those in AIP, with abdominal pain, vomiting, constipation, hypertension, tachycardia, and neuromuscular weakness that can progress to quadriplegia and respiratory weakness (Chemmanur and Bonkovsky, 2004)."
path(MESHD:"quadriplegia") increases bp(MESHPP:"neuromuscular weakness")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "VP can cause acute attacks identical to those in AIP, with abdominal pain, vomiting, constipation, hypertension, tachycardia, and neuromuscular weakness that can progress to quadriplegia and respiratory weakness (Chemmanur and Bonkovsky, 2004)."
path(MESHD:"respiratory paralysis") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
path(MESHD:"respiratory paralysis") association path(MESHD:"constipation")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
path(MESHD:"quadriparesis") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The most common manifestations are abdominal pain, constipation, tachycardia, hypertension, pain in the back, chest, and extremities, anxiety, agitation, seizures, and neuromuscular weakness that may progress to quadriparesis and respiratory paralysis."
a(CHEBI:"estrogen") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Factors contributing to the development of PCT include alcohol use, hepatitis C virus infection, human immunodeficiency virus, estrogen use, UROD pathogenic variants, and hereditary hemochromatosis."
a(CHEBI:"estrogen") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The most common environmental or acquired factors are alcohol use, HCV, estrogen use, human immunodeficiency virus (HIV), and smoking."
a(CHEBI:"estrogen") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "31374307.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
a(CHEBI:"estrogen") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "In addition to a mutation in the gene coding for UROD, several factors are known to reduce enzyme activity and thus facilitate porphyrin accumulation: high alcohol intake, smoking, iron overload, hepatitis C, human immundeficiency virus (HIV), and estrogen use in women."
a(CHEBI:"estrogen") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Five of these women had prominent hepatic steatosis; 1 had estrogen-induced hepatic adenomas, but the porphyrin content of a biopsy specimen taken from the adenoma did not differ from a sample from a normal portion of the liver (data not shown)."
a(CHEBI:"estrogen") increases p(HGNC:"SERPINA7")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Other abnormalities include increased serum T4, thyroxine binding globulin (but AIP patients are usually euthyroid, only rarely frankly thyrotoxic), and elevated cholesterol and low-density lipoprotein (LDL), simulating an exaggerated estrogen effect."
a(CHEBI:"estrogen") increases path(MESHD:"hepatic steatosis")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Five of these women had prominent hepatic steatosis; 1 had estrogen-induced hepatic adenomas, but the porphyrin content of a biopsy specimen taken from the adenoma did not differ from a sample from a normal portion of the liver (data not shown)."
a(CHEBI:"estrogen") increases path(MESHD:"hepatic adenomas")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Five of these women had prominent hepatic steatosis; 1 had estrogen-induced hepatic adenomas, but the porphyrin content of a biopsy specimen taken from the adenoma did not differ from a sample from a normal portion of the liver (data not shown)."
path(MESHD:"hepatic adenomas") association a(CHEBI:"Estrogens")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
a(CHEBI:"methylprednisolone") increases path(MESHD:"AIP")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "However, the key drugs used in systemic therapy, such as methylprednisolone and cyclophosphamide, can induce the acute onset of AIP."
path(MESHD:"infectious") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "On the other hand, a PCT diagnosis, black and other race compared to white race, and Hispanic ethnicity were associated with a decreased risk of cellulitis.- PCT showed no significant association with blisters, although tobacco use and hepatitis C were associated with increased risk of Table 3 Descriptive statistics by infectious outcomes."
path(MESHD:"infectious") increases p(HGNC:"UROD")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Although disease-causing CPOX mutations occur equally in males and females, acute attacks are much more frequent in women, mainly between ages 16 and 45 years (the years of active ovulation)."
a(CHEBI:"Hydroxychloroquine") increases path(MESHD:"hepatotoxicity")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Hydroxychloroquine (and chloroquine) in the amounts used for other diseases cause hepatotoxicity in PCT, and this adverse effect is largely avoided with the low-dose regimen."
path(MESHD:"UROD deficiency") increases a(CHEBI:"porphyrinogens")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "This UROD deficiency is sufficient to lead to accumulation of highly carboxylated porphyrinogens and porphyrins in liver and possibly other tissues."
path(MESHD:"ulcerations") association a(CHEBI:"uroporphyrin")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "In a study using 130 cases of CEP, dermal deposits of uroporphyrin frequently induced dramatic phototoxic oxygen-dependent skin damage with extensive ulcerations and mutilations."
path(MESHD:"Splenomegaly") positiveCorrelation path(MESHD:"hemolytic anemia")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Splenomegaly and hemolytic anemia were typical internal symptoms."
path(MESHD:"hemolytic anemia") increases a(CHEBI:"zinc")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "^105,106 FECH deficiency increases levels of metalfree erythrocyte PPIX, in contrast to secondary elevations of zinc-bound erythrocyte protoporphyrin that are caused by iron deficiency, lead intoxication, or hemolytic anemia."
p(HGNC:"HP") positiveCorrelation path(MESHD:"hemolysis")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "Mild to severe hemolysis is a feature of CEP and is accompanied by anisocytosis, poikilocytosis, polychromasia, basophilic stippling, reticulocytosis, increased circulating nucleated red cells, and absence of haptoglobin."
a(CHEBI:"Afamelanotide") decreases path(MESH:"Photosensitivity Disorders")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Afamelanotide was approved in 2019 as a photosensitivity reducing treatment for EPP, but requires regular visits to providers trained on the implant and is not widely available; there are no similar therapies for CEP"
path(MESHD:"Osteoporosis") association a(CHEBI:"VPA")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "GBP* | OXC, TPM, VPA | CBZ, PB, PHT, PRM | | Osteoporosis | BZD, LEV, LTG, PGB, ZNS."
path(MESHD:"Osteoporosis") decreases path(MESHD:"Bone Density")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Osteoporosis increases the risk of fragility fractures"
path(MESHD:"Osteoporosis") decreases path(MESHD:"Bone Density")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, low bone mineral density, osteopenia or even osteoporosis, is found in over half of the erythropoietic protoporphyria patients in this study."
path(MESHD:"Osteoporosis") positiveCorrelation path(MESHD:"EPP")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, low bone mineral density, osteopenia or even osteoporosis, is found in over half of the erythropoietic protoporphyria patients in this study."
path(MESHD:"Osteoporosis") increases path(HP:"Bone fragility")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "large cohort of erythropoietic protoporphyria patients, clinically significant lower bone density was found in a high number of patients: osteopenia in 36% and osteoporosis in 23% of patients."
path(MESHD:"Osteoporosis") increases path(HP:"Bone fragility")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "In conclusion, low bone mineral density, osteopenia or even osteoporosis, is found in over half of the erythropoietic protoporphyria patients in this study."
a(CHEBI:"hemoglobin") positiveCorrelation p(HGNC:"HAMP")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "We also demonstrated that hepcidin levels were positively associated with ferritin and haemoglobin levels, suggesting normal physiologic iron regulation in patients with EPP."
a(CHEBI:"hemoglobin") positiveCorrelation p(HGNC:"FTH1")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "We also demonstrated that hepcidin levels were positively associated with ferritin and haemoglobin levels, suggesting normal physiologic iron regulation in patients with EPP."
path(MESHD:"Hepatoerythropoietic porphyria") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Hepatoerythropoietic porphyria: A variant of childhood-onset porphyria cutanea tarda."
bp(GOBP:"excretion") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "The metabolic (and clinical) activity of the acute porphyrias and the efficacy of therapy can be monitored by assessing metabolite excretion."
bp(GOBP:"excretion") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "The diagnosis of PCT was based on typical clinical features and was confirmed by increased urine excretion of uroporphyrin (quantified spectrophotometrically) and skin biopsy."
bp(GOBP:"excretion") increases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "26132003.0"}
SET DataSource = "manual-curation"
SET Support = "Metal-free protoporphyrin enters the plasma from the bone marrow and circulating erythrocytes and is then transported to the skin, causing photosensitivity, and to the liver for excretion into bile (Bloomer et al."
bp(MESHPP:"enterohepatic circulation") increases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "26494868.0"}
SET DataSource = "manual-curation"
SET Support = "Some protoporphyrin may subsequently be reabsorbed and undergo enterohepatic circulation (Ibrahim and Watson, 1968)."
p(HGNC:"HMBS") association path(MESHD:"AIP")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Acute intermittent porphyria (AIP) is an autosomal dominant inherited error of metabolism resulting from a partial deficiency in haem biosynthetic enzymes, caused by mutations in the PBGD gene."
p(HGNC:"HMBS") association path(MESHD:"peripheral neuropathy")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "In a prolonged attack, acute peripheral neuropathy (PNP) and signs of central nervous system (CNS) involvement may occur. The prevalence of acute intermittent porphyria (AIP) has been estimated at 1:2000 based on likely pathogenic variations identified in the HMBS (hydroxymethylbilane synthase) gene in Caucasians, but the estimated risk of clinical symptoms in them is low, ~1%."
p(HGNC:"HMBS") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Nanoparticular PBGD RNA was recently shown to target hepatocytes, restore deficient enzyme activity, and protect from induced porphyria attacks in mice."
p(HGNC:"HMBS") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "If urine analysis identifies an acute (hepatic) porphyria, it is necessary to measure the activity of PBGD in erythrocytes and perform genetic analyses, to confirm a diagnosis of AIP"
p(HGNC:"HMBS") increases a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Examinations revealed positivity for porphobilinogen (PBG) in urine and a mutation in the hydroxymethylbilane synthetase (HMBS) gene: c. 806 C>G (p.Thr269Arg) (Figure 1)."
p(HGNC:"HMBS") increases path(MESHD:"epilepsy")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "A mutation in the HMBS gene was detected in the patient and her cousin, but the patient had more severe AIP and more severe symptoms (such as epilepsy and a limp), which may be related to the co-morbidity of PSS."
p(HGNC:"HMBS") increases p(HGNC:"PLCD1")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "It has been speculated that the high incidence of APÃ¢â‚¬Âassociated PLC found in Swedish studies might be related to the presence of the dominating HMBS founder gene variant (c.593G>A), found in approximately 2 / 3 of Swedish patients with AIP."
p(HGNC:"HMBS") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Detection of a mutation in the HMBS gene causing porphyria: c. 806 C>G : p."
p(HGNC:"HMBS") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "^21,22 ## Acute Hepatic porphyrias ## Pathophysiology AIP, HCP, and VP are caused by defects in enzyme (PBGD, CPOX, and protoporphyrinogen oxidase, respectively) and are promoted by excess activity of the first enzyme in hepatic heme synthesis, ALAS1 (Figure 1)."
p(HGNC:"HMBS") increases a(CHEBI:"hydroxymethylbilane")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Examinations revealed positivity for porphobilinogen (PBG) in urine and a mutation in the hydroxymethylbilane synthetase (HMBS) gene: c. 806 C>G (p.Thr269Arg) (Figure 1)."
p(HGNC:"HMBS") increases bp(MESHPP:"missense mutation")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Whole exon sequencing revealed a heterozygous missense mutation HMBS:NM_000190:exon12:c.806C>G (p.Thr269Arg) in the woman and her cousin."
p(HGNC:"HMBS") increases a(CHEBI:"tetrapyrrole")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "nan"
bp(GO:"tryptophan metabolic pathway") association path(MESHD:"bipolar disorder")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "This makes sense as ALA accumulation in the brain is one of the most significant findings involved in psychiatric manifestations of porphyria, specifically accountable for psychomotor agitation, hallucinations, anxiety, and depressive behaviors [25] (Table 2).ALA acts as an agonist of GABA autoreceptors [31], decreasing release of GABA."
bp(GO:"tryptophan metabolic pathway") increases bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Current thinking is that decreased GABAergic neurons' activity in conjunction with increased glutamate release [25], increased oxidative stress [26Ã¢â‚¬Â¢], and increased metabolites of kynurenine pathway [27] leads to disease pathology."
bp(GO:"tryptophan metabolic pathway") increases a(CHEBI:"glutamate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Manifestation of psychiatric behaviors in a mouse model of griseofulvin-induced hepatic porphyria."
a(CHEBI:"glutamate") increases a(CHEBI:"ammonia")

SET Citation = {"PubMed", "26743054.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to ammonia conversion | Glutaminase activity to generate glutamate."
a(CHEBI:"Sunitinib") increases path(SNOMED:"Pseudoporphyria (disorder)")

SET Citation = {"PubMed", "26743054.0"}
SET DataSource = "manual-curation"
SET Support = "Sanz-Motilva V, Martorell-Calatayud A, Llombart B, Requena C, Serra-GuillÃƒÂ©n C, Nagore E, GuillÃƒÂ©n C, Traves V, Sanmartin O (2015) Sunitinib-induced pseudoporphyria."
a(CHEBI:"porphyrin metabolism") association a(CHEBI:"chloroquine")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Goerz G, Bolsen K, Merk H (1985) Influence of chloroquine on the porphyrin metabolism."
p(HGNC:"GPT") association a(CHEBI:"Ribavirin")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Ribavirin monotherapy failed as a potential cure for HCV liver disease because it only improved alanine aminotransferase (ALT) without achieving sustained viral clearance."
p(HGNC:"GPT") positiveCorrelation path(MESHD:"erythema")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "A few days later, the hepatic enzymes increased [GGT, 4.99 SI; ALT, 3.31 SI; aspartate aminotransferase (AST), 1.74 SI) ], and the patient complained of pruritus and erythema."
p(HGNC:"GPT") positiveCorrelation path(MESHD:"pruritus")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "A few days later, the hepatic enzymes increased [GGT, 4.99 SI; ALT, 3.31 SI; aspartate aminotransferase (AST), 1.74 SI) ], and the patient complained of pruritus and erythema."
p(HGNC:"GPT") causesNoChange p(HGNC:"GOT1")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "There were no significant differences in ALT, aspartate transaminase or total bilirubin between the EPP cases and controls (Figure S2A-C)."
path(MESHD:"glucose intolerance") association path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Cirrhosis, on the other hand, was strongly associated with glucose intolerance."
path(MESHD:"hepatic fibrosis") positiveCorrelation path(MESHD:"chronic hepatitis")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = ", 2002), in 119 consecutive patients with chronic hepatitis C, the H F E mutations commonly associated with hereditary hemochromatosis were significantly more common in these patients in comparison with findings for control subjects ( 48 % vs. 37.9 %, P=.04 ), and advanced degrees of hepatic fibrosis or cirrhosis developed at younger ages in patients who had the C282Y mutation of H F E, especially in C 282 Y^+1 s homozygotes."
path(MESHD:"hepatic fibrosis") positiveCorrelation p(HGNC:"HFE")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The HFE mutations were significantly more common in these patients in comparison with findings for control subjects ( 48 % versus 37.9 %, p=0.04 ), and advanced degrees of hepatic fibrosis or cirrhosis developed at younger ages in patients who had the C282Y mutation of HFE, especially in C282Y homozygotes."
path(MESHD:"hepatic fibrosis") negativeCorrelation p(HGNC:"HAMP")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "A recent study of 36 patients showed that mRNA of hepcidin correlated with albumin synthesis and HIC and inversely correlated with the degree of hepatic fibrosis."
path(MESHD:"hepatic fibrosis") negativeCorrelation p(HGNC:"ALB")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "A recent study of 36 patients showed that mRNA of hepcidin correlated with albumin synthesis and HIC and inversely correlated with the degree of hepatic fibrosis."
path(MESHD:"hepatic fibrosis") negativeCorrelation a(CHEBI:"mRNA")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "A recent study of 36 patients showed that mRNA of hepcidin correlated with albumin synthesis and HIC and inversely correlated with the degree of hepatic fibrosis."
p(HGNC:"HFE",var("p.?")) positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "type 3 PCT. HFE mutations or shared environmental factors may be present in such families"
p(HGNC:"HFE",var("p.?")) positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Inherited factors may include UROD and HFE pathogenic variants."
p(HGNC:"HFE",var("p.?")) positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
p(HGNC:"HFE",var("p.?")) positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "In human beings with PCT, the presence of HFE gene mutations is the major reason for increased hepatic iron, with alcohol perhaps playing a secondary role, as has just been described for the mouse model of human hemochromatosis."
p(HGNC:"HFE",var("p.?")) positiveCorrelation path(MESHD:"iron overload")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "In human beings with PCT, the presence of HFE gene mutations is the major reason for increased hepatic iron, with alcohol perhaps playing a secondary role, as has just been described for the mouse model of human hemochromatosis."
p(HGNC:"HFE",var("p.?")) increases path(MESHD:"Hemochromatosis")

SET Citation = {"PubMed", "26743054.0"}
SET DataSource = "manual-curation"
SET Support = "Mahon C, Purvis D, Laughton S, Bradbeer P, Teague L (2014) Imatinib mesylate-induced pseudoporphyria in two children."
a(CHEBI:"Imatinib mesylate") increases path(SNOMED:"Pseudoporphyria (disorder)")

SET Citation = {"PubMed", "26743054.0"}
SET DataSource = "manual-curation"
SET Support = "Merk H, Bolsen K, Lissner R, Goerz G (1986) Hexachlorobenzene alteration of benzo[a]pyrene metabolism in porphyric and non-porphyric rats."
a(CHEBI:"benzo[a]pyrene") association a(CHEBI:"Hexachlorobenzene")

SET Citation = {"PubMed", "26743054.0"}
SET DataSource = "manual-curation"
SET Support = "Eine vermehrte UV-Licht-unabhÃƒÂ¤ngige Kollagensynthese durch Porphyrine lieÃƒÅ¸ sich experimentell nachweisen [22]."
bp(MESHPP:"UV") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"methotrexate") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "After she received 100 mg of methotrexate, drug eruptions were observed starting on day 3 and grew progressively worse."
path(MESHD:"drug eruptions") decreases a(CHEBI:"methotrexate")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "After five uneventful cycles of actinomycin D, our patient achieved and maintained a normal serum human chorionic gonadotropin level for 3 years."
a(CHEBI:"human chorionic gonadotropin") association a(CHEBI:"actinomycin")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"actinomycin") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Conclusions: Methotrexate and actinomycin D did not induce acute porphyric attacks in this patient with acute intermittent porphyria; however, severe adverse effects were noted with methotrexate."
a(CHEBI:"actinomycin") causesNoChange a(CHEBI:"Methotrexate")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "On day 8, the erythema became brown (*upper panel*); bullous lesions were observed on her hands (*middle panel*), and mucosal erosion of her mouth continued (*lower panel*)."
path(MESHD:"bullous") positiveCorrelation path(MESHD:"erythema")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "In cases not involving potentially porphyrinogenic chemotherapeutic agents, stresses such as sepsis from neutropenia and long fasting related to gastrointestinal toxicity or pain [6] could also induce acute attacks."
path(MESHD:"neutropenia") increases path(MESHD:"sepsis")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Hematologic growth factors, including G-CSF, have been reported to be safe for porphyria patients [12], and this was true in our experience."
p(HGNC:"CSF3") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "However, as she was unable to recover from neutropenia (ANC remained at 12 / ÃŽÂ¼L on day 13), additional subcutaneous G-CSF at 150 ÃŽÂ¼ g / day was administered for 2 days beginning on day 13, and her neutropenia finally resolved on day 15 (ANC, 1598 / ÃŽÂ¼L ).During that time, her skin lesions and stomatitis also began to improve, and the prednisolone dose was reduced to 40 mg / day."
p(HGNC:"CSF3") decreases path(MESHD:"neutropenia")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Our results thus indicate that G-CSF can help to prevent acute attacks resulting from sepsis."
p(HGNC:"CSF3") decreases path(MESHD:"sepsis")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Among commonly prescribed antiemetics, the 5-hydroxytryptamine receptor antagonist ondansetron and glucocorticoid are also considered safe for patients with porphyria [4, 5]."
a(CHEBI:"ondansetron") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Central antiemetics such as ondansetron or metoclopramide may be used for severe attacks of nausea in AP."
a(CHEBI:"ondansetron") decreases path(MESHD:"nausea")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Among commonly prescribed antiemetics, the 5-hydroxytryptamine receptor antagonist ondansetron and glucocorticoid are also considered safe for patients with porphyria [4, 5]."
a(CHEBI:"glucocorticoid") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Average daily alcohol consumption was estimated in all 108 patients as follows: grade 0 (consumed no alcohol): 11 (10%) patients, including 3 children; grade 1 (drank only occasionally): 24 (22%) patients ( 5 men and 19 women); grade 2 (consumed between 20 and 70 g of alcohol daily): 23 (21%) patients ( 17 men and 6 women); and grade 3 (consumed more than 70 g of alcohol daily): 40 (46%) patients ( 42 men and 8 women)."
bp(MESHPP:"alcohol consumption") positiveCorrelation a(CHEBI:"Alcohol")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Such acute attacks are the most concerning manifestation of porphyria and are known to be induced by certain drugs, infection, alcohol consumption, smoking, fasting, and stress."
bp(MESHPP:"alcohol consumption") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "ALAS1 is induced via induction of cytochrome P450 (CyP450), such as by xenobiotics, smoking, excess alcohol consumption, fasting, and female sex hormones."
bp(MESHPP:"alcohol consumption") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Such acute attacks are the most concerning manifestation of porphyria and are known to be induced by certain drugs, infection, alcohol consumption, smoking, fasting, and stress."
bp(MESHPP:"alcohol consumption") increases path(MESHD:"acute")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "Other risk factors include aflatoxin B1 intake, alcohol consumption, and some hereditary diseases, among which are hereditary hemochromatosis, hereditary tyrosinemia, and ÃŽÂ±_1 anti-trypsin deficiency."
bp(MESHPP:"alcohol consumption") increases path(MESHD:"tyrosinemia")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Tobacco use, alcohol dependence, hepatitis C, and HIV were associated with an increased risk of PCT."
a(CHEBI:"Alcohol") association path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "In various conditions associated with PCT, such as chronic HCV and alcohol use, hepcidin levels are low compared with controls."
a(CHEBI:"Alcohol") decreases p(HGNC:"HAMP")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Alcohol consumption decreases hepcidin expression and thereby increases iron absorption, which is mostly carried out by duodenal enterocytes."
a(CHEBI:"Alcohol") decreases p(HGNC:"HAMP")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Factors contributing to the development of PCT include alcohol use, hepatitis C virus infection, human immunodeficiency virus, estrogen use, UROD pathogenic variants, and hereditary hemochromatosis."
a(CHEBI:"Alcohol") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Contributing environmental factors include alcohol use and hepatitis C virus (HCV) infection."
a(CHEBI:"Alcohol") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The most common environmental or acquired factors are alcohol use, HCV, estrogen use, human immunodeficiency virus (HIV), and smoking."
a(CHEBI:"Alcohol") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
a(CHEBI:"Alcohol") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "In hepatocytes, alcohol and iron are believed to act synergistically to generate free radicals, which contribute to the forma tion of the uroporphomethene that inhibits hepatic UROD, as well as cause cellular damage."
a(CHEBI:"Alcohol") increases a(CHEBI:"free radical")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "The folic acid antagonist MTX is most frequently used to treat gestational trophoblastic disease (GTD) [2], as well as leukemia and other cancers [^0]such as breast cancer and urothelial carcinoma."
a(CHEBI:"folic acid antagonist") decreases path(MESHD:"gestational trophoblastic disease")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "The folic acid antagonist MTX is most frequently used to treat gestational trophoblastic disease (GTD) [2], as well as leukemia and other cancers [^0]such as breast cancer and urothelial carcinoma."
a(CHEBI:"folic acid antagonist") decreases path(MESHD:"leukemia")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "The folic acid antagonist MTX is most frequently used to treat gestational trophoblastic disease (GTD) [2], as well as leukemia and other cancers [^0]such as breast cancer and urothelial carcinoma."
a(CHEBI:"folic acid antagonist") decreases path(DO:"breast cancer")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "The folic acid antagonist MTX is most frequently used to treat gestational trophoblastic disease (GTD) [2], as well as leukemia and other cancers [^0]such as breast cancer and urothelial carcinoma."
a(CHEBI:"folic acid antagonist") decreases path(MESHD:"urothelial carcinoma")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "In addition to GTD treatment, ACT-D is used to treat Wilms' tumor, Ewing sarcoma, and rhabdomyosarcoma; however, this agent has been reported to induce hepatic vein obstruction."
path(MESHD:"rhabdomyosarcoma") decreases path(MESHD:"GTD")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "She received intravenous prednisolone at 60 mg / day beginning on day 5 to treat the drug eruption."
a(CHEBI:"prednisolone") decreases path(MESHD:"drug eruption")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "| | CBZ | | PB | | PHT | | VPA | | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | | Anthracyclines | Ã¢â€ â€œ | Ã¢â€ â€œ | Ã¢â€ â€œ | Ã¢â€ â€œ | Ã¢â€ â€œ | Ã¢â€ â€œ | | | Cyclophosphamide | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | | | Cisplatin | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œÃ¢â€ â€˜ | | Corticosteroids | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | Ã¢â€ â€œÃ¢â€ â€˜ | | | Etoposides | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | | | Fluorpyrimidines | | | | | Ã¢â€ â€œ | Ã¢â€ â€˜ | | | Irinotecan topotecan | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | | | Methotrexate | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Nitrosureas | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€˜| | Taxoides | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | | | Vincristine | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | | The arrows on the left hand side of the boxes indicate the effect of interaction on the plasma levels of the cytotoxic and corticosteroid drugs and the ones on the right hand side indicate the effect on plasma levels of AEDs."
a(CHEBI:"Cyclophosphamide") association a(CHEBI:"Anthracyclines")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the cause of this pain. Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"Cyclophosphamide") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"Cyclophosphamide") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"azathioprine") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"5-fluorouracil") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"busulfan") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"procarbazine") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"hexamethylmelamine") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"Dacarbazine") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"chlorambucil") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"melphalan") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"Mitomycin") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"cyclophosphamide") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "However, the key drugs used in systemic therapy, such as methylprednisolone and cyclophosphamide, can induce the acute onset of AIP."
a(CHEBI:"cyclophosphamide") increases path(MESHD:"AIP")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"mitoxantrone") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"cytosine arabinoside") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"doxorubicin") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"6-thioguanine") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"vincristine") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "Prior to that, I had been treated in ambulatory centers and hospitals many times for abdominal pain, but the clinicians could not diagnose the Table 5 Carcinostatic medications and porphyria Porphyrinogenic (chick studies): Cyclophosphamide, azathioprine, 5-fluorouracil, busulfan, procarbazine, hexamethylmelamine Porphyrinogenic (case reports): Cyclophosphamide, busulfan, methotrexate Nonporphyrinogenic (chick studies): Dacarbazine, chlorambucil, melphalan Nonporphyrinogenic (case reports): Mitomycin C, cyclophosphamide, mitoxantrone, 5-fluorouracil, cytosine arabinoside, doxorubicin, 6-thioguanine, vincristine, procarbazine, methotrexate, actinomycin D, cisplatin cause of this pain."
a(CHEBI:"cisplatin") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "26781485.0"}
SET DataSource = "manual-curation"
SET Support = "The doctors at Saitama Medical Center told me that methotrexate (MTX) was most commonly used to treat my disease (invasive mole with lung metastasis) but had not been implicated as either porphyrinogenic or nonporphyrinogenic, and therefore, they carefully treated me with MTX."
path(DO:"lung metastasis") association a(CHEBI:"methotrexate")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "ALA is associated with oxidative stress and DNA damage, is cytotoxic in vitro, and is elevated in tyrosinemia type 1 , which has also been associated with a high risk of liver cancer."
path(DO:"liver cancer") association bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "ALA is associated with oxidative stress and DNA damage, is cytotoxic in vitro, and is elevated in tyrosinemia type 1 , which has also been associated with a high risk of liver cancer."
path(DO:"liver cancer") association bp(MESHPP:"DNA damage")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "It is yet unclear whether the pathology of liver disease in patients with HCV is influenced by iron overload or limited to the direct cell damage from replication of the virus and subsequent inflammation."
path(MESHD:"inflammation") association path(MESHD:"iron overload")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "As a result, the main triggers for chronic encephalopathy and neuropathy in AP may be the constant excess of ALA and lowÃ¢â‚¬Âgrade inflammation of hepatic origin."
path(MESHD:"inflammation") increases path(MESHD:"encephalopathy")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^32 The overexpression of heme oxygenase-1 under conditions of inflammation, fasting, or physical or oxidative stress increases heme degradation and thereby removes feedback inhibition of ALAS1, promoting disease."
path(MESHD:"inflammation") increases p(HGNC:"HMOX1")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "As a result, the main triggers for chronic encephalopathy and neuropathy in AP may be the constant excess of ALA and lowÃ¢â‚¬Âgrade inflammation of hepatic origin."
path(MESHD:"inflammation") increases path(MESHD:"neuropathy")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Four types of diagnosis-specific non-PLC malignancies with more than two cases were identified as follows: kidney (n=3), endometrial (n=3), breast (n=3) and prostate cancers (n=4).The exposed were at a sevenfold increased risk of kidney cancer compared with the reference population and a sixfold increased risk of endometrial cancer (Table 3)."
path(DO:"prostate cancers") positiveCorrelation p(HGNC:"PLCD1")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Kidney cancer is more common in patients with kidney failure, although the cause of this association is not well understood [27]."
path(MESHD:"kidney failure") association path(DO:"kidney cancer")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "Renal impairment is a known cause of morbidity in those with acute intermittent porphyria [28]."
path(MESHD:"Renal impairment") positiveCorrelation path(MESHD:"AIP")

SET Citation = {"PubMed", "28730628.0"}
SET DataSource = "manual-curation"
SET Support = "AHP is characterized by the accumulation of porphyrins and/or the precursors delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) in the biosynthesis of haem."
a(CHEBI:"heme") increases a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "AEDs and obesity Some AEDs are associated with weight gain (CBZ, CLB, GBP, PGB and VPA) and others with weight loss (TPM and ZNS).The majority have a neutral effect in this respect."
a(CHEBI:"VPA") association path(MESHD:"obesity")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "| | CBZ | | PB | | PHT | | VPA | | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | | Anthracyclines | Ã¢â€ â€œ | Ã¢â€ â€œ | Ã¢â€ â€œ | Ã¢â€ â€œ | Ã¢â€ â€œ | Ã¢â€ â€œ | | | Cyclophosphamide | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | | | Cisplatin | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œÃ¢â€ â€˜ | | Corticosteroids | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | Ã¢â€ â€œÃ¢â€ â€˜ | | | Etoposides | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | | | Fluorpyrimidines | | | | | Ã¢â€ â€œ | Ã¢â€ â€˜ | | | Irinotecan topotecan | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | | | Methotrexate | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Nitrosureas | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€˜| | Taxoides | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | | | Vincristine | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | | The arrows on the left hand side of the boxes indicate the effect of interaction on the plasma levels of the cytotoxic and corticosteroid drugs and the ones on the right hand side indicate the effect on plasma levels of AEDs."
a(CHEBI:"VPA") association a(CHEBI:"Anthracyclines")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "GBP* | BZD, CBZ, ESM, PB, PHT, PRM, TGB, ZNS | LTG, VPA | | Renal impairment | BZD, CBZ, ESM, PHT, TGB, VPA | GBP, LEV, LTG, OXC, PB, PGB, PRM, TPM, ZNS | - | | porphyria | LEV, OXC, PGB."
a(CHEBI:"VPA") association path(MESHD:"Renal impairment")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "VPA only causes a minimal reduction of cyclosporine and tacrolimus levels."
a(CHEBI:"VPA") decreases a(CHEBI:"cyclosporine")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "^32,33 The most recommended AEDs in renal impairment and haemodialysis are those that are mainly eliminated by the liver, such as BZD, CBZ, ESM, PHT, TGB and VPA."
a(CHEBI:"VPA") decreases path(MESHD:"renal impairment")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "| Antiplatelets | Salicylates increase the free fraction of VPA."
a(CHEBI:"VPA") positiveCorrelation a(CHEBI:"Antiplatelets")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Response to conventional AEDs seems to be variable, with 70 % of patients with brain tumours treated with CBZ, 51 % of those treated with PHT, and 44 % of those treated with VPA having persistent seizures."
a(CHEBI:"VPA") increases path(MESHD:"seizures")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Their study showed that CBZ, VPA, and clonazepam (CZP) increased the production of porphyrin to the same level as was found before for phenobarbital (PB) and PHT (8)."
a(CHEBI:"VPA") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
a(CHEBI:"VPA") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Some studies with small sample size found that patients on VPA treatment who gained weight showed insulin resistance that was reversible on withdrawal of VPA."
a(CHEBI:"VPA") increases path(MESHD:"insulin resistance")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Some studies suggest that VPA might stimulate the viral replication of latent HIV in vitro, but more recent results are negative and there is thus no evidence against it."
a(CHEBI:"VPA") increases bp(MESHPP:"viral replication")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "| | | VPA increases levels of nimodipine by 50 %."
a(CHEBI:"VPA") increases a(CHEBI:"nimodipine")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Likewise, VPA can cause a subclinical, reversible increase in TSH."
a(CHEBI:"VPA") increases a(CHEBI:"TSH")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Vitamin D deficiency is a risk factor for lower bone mineral density and osteoporosis"
path(MESHD:"Vitamin D Deficiency") decreases path(MESHD:"Bone Density")

SET Citation = {"PubMed", "28815553.0"}
SET DataSource = "manual-curation"
SET Support = "Afamelanotide, an agonistic analogue of ÃŽÂ±-melanocyte-stimulating hormone, received marketing authorization and been released for treatment in the EU. This drug has been shown in double blind placebo controlled trials to increase the amount of time erythropoietic protoporphyria patients can be exposed to light and to reduce the severity of phototoxic symptoms"
a(CHEMBL:"Afamelanotide") decreases path(MESHD:"Photosensitivity")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "porphyrias are a group of rare metabolic disorders most commonly attributed to a hereditary mutation that alters enzymatic activity in the heme biosynthesis pathway [1 Ã‚Â· Ã‚Â·"
path(MESHD:"Catatonia") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Depressive disorders") association path(MESHD:"Bipolar and related disorders")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "nan"
a(CHEBI:"Antipsychotics") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "nan"
a(CHEBI:"quetiapine") decreases a(CHEBI:"carbohydrate")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The treatment strategy for our patient, including intravenous hemin administration, discontinuation of so dium valproate (a known AIP exacerbant), and initiation of a high-carbohydrate diet, is consistent with the recom mendations in the Chinese Expert Consensus on Diagnosis and Treatment of AIP."
a(CHEBI:"carbohydrate") decreases path(MESHD:"AIP")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The total carbohydrate content in the diet was converted to starch and dextrin uptake, since polysaccharides are most abundant carbohydrate component present in our diet (1)."
a(CHEBI:"carbohydrate") increases a(CHEBI:"starch")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Antipsychotics, are safe for use in individuals with porphyria."
path(MESHD:"peripheral motor neuropathy") increases path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Diagnosis should be suspected when there is prolonged and recurrent episodes of unexplained abdominal pain-particularly when it is associated with neurological complications such as peripheral motor neuropathy, convulsions, coma or bulbar paralysis, hyponatremia or prompted by fasting, diets, or exposure to certain medications [5]."
path(MESHD:"bulbar paralysis") increases path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Summary Broad psychiatric symptoms have been associated to acute porphyria (AP) and correspond to a spectrum of heterogeneous manifestations such as anxiety, affective alterations, behavioral changes, personality, and psychotic symptoms."
path(MESHD:"adjustment disorder") association path(MESHD:"psychiatric conditions")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Summary Broad psychiatric symptoms have been associated to acute porphyria (AP) and correspond to a spectrum of heterogeneous manifestations such as anxiety, affective alterations, behavioral changes, personality, and psychotic symptoms."
path(DO:"substance use disorders") association path(MESHD:"adjustment disorder")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Somatic symptom disorders") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(DO:"Sleep-wake disorders") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"conduct disorders") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Neurocognitive disorders") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Personality disorders") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| Psychiatric diagnosis | Psychiatric symptoms in acute porphyria | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Schizophrenia spectrum and other psychotic disorders | Psychosis | | | Catatonia | | | Bipolar and related disorders | Hypomania and mania | | Depressive disorders | Depressive symptoms | | | Suicide ideation attempts | | | Anxiety disorders | Anxiety | | | Phobias | | | Obsessive-compulsive and related disorders | Obsessions and compulsions | | Somatic symptom disorders | Somatoform disorder symptoms | | Sleep-wake disorders | Insomnia | | | Restlessness | | | Disruptive, impulse control and conduct disorders | Aggressiveness | | | Impulsivity | | | Neurocognitive disorders | Delirium | | | Cognitive decline | | | | Agitation | | | Personality disorders | Histrionic personality trait | | Other disorders | Altered mental status | | | Chronic fatigue | | | Relationship difficulties |"
path(MESHD:"Chronic fatigue") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "| | Personality traits | Not specified | Emotional lability, Borderline personality disorder considered | Not specified | Not specified | Not specified | Not specified | Not specified | | Classical symptoms | Sharp Teeth ^b | Abdominal pain | Abdominal pain, dark urine | Not specified | Dark urine | None | Abdominal pain, nausea, vomiting."
path(MESHD:"cramping") association a(CHEBI:"Olanzapine")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Consistent with what was previously described, when reviewing what is available in the medical literature, there are no studies with sufficient methodological strength offering guidance as to how one should approach and manage of a patient with porphyria and associated neuropsychiatric symptoms."
a(CHEBI:"tryptophan metabolism") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyrias typically present with unspecific neurovisceral symptoms such as abdominal pain ( 90 % ), bloating, nausea, vomiting, and tachycardia."
path(MESHD:"attention deficit hyperactivity disorder") association path(MESHD:"AIP")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Hepatic alteration of tryptophan metabolism in an acute porphyria model its relation with gluconeogenic blockage."
path(MESHD:"attention deficit hyperactivity disorder") association path(MESHD:"hereditary coproporphyria")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Regarding the type of AP, most assessments of PLC risk are based on cohorts with a predominance of patients with AIP. Sporadic cases of PLC in patients with VP and HCP have been published,11,15,74Ã¢â‚¬â€œ77 but large VP or HCP cohort studies exploring PLC risk are lacking and specific risk estimates for these forms of AP are scarce."
path(MESHD:"hereditary coproporphyria") association path(DO:"Primary Liver Cancer")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "However, little is known concerning antiepileptic drug (AED) treatment in patients with hereditary coproporphyria."
path(MESHD:"hereditary coproporphyria") association a(CHEBI:"antiepileptic drug")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with variegate porphyria and hereditary coproporphyria can present with skin photosensitivity."
path(MESHD:"hereditary coproporphyria") association path(MESHD:"VP")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Inherited or acquired defects in CPOX may thus give rise to increased accumulation of copro'gen 3, such as occurs in hereditary coproporphyria (hereditary coproporphyria) or heavy alcohol use or exposure to heavy metals, which inhibit CPOX activity."
path(MESHD:"hereditary coproporphyria") decreases p(HGNC:"CPOX")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Three porphyrias; acute intermittent porphyria (AIP), hereditary coproporphyria (HCP) and variegate porphyria (VP) are commonly labelled acute porphyrias (AP) since they can all present with episodic acute neurovisceral attacks."
path(MESHD:"hereditary coproporphyria") isA path(MESHD:"porphyria")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "F female, M male, A I P acute intermittent porphyria, H C P hereditary coproporphyria, A D H D attention deficit hyperactivity disorder, B I D bis in die, T I D ter in die ^a Diagnosis not confirmed ^b Although not a core symptom in porphyria, it was the reason that triggered the porphyria workup ^c Doses given daily unless stated otherwise."
a(CHEBI:"griseofulvin") increases path(MESHD:"hepatic porphyria")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "In summary, in both alcoholic and nonalcoholic steatohepatitis and fatty liver disease, there is both experimental and clinical evidence that increased oxidative stress plays an important role."
path(MESHD:"fatty liver disease") increases bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "In summary, in both alcoholic and nonalcoholic steatohepatitis and fatty liver disease, there is experimental and clinical evidence that increased oxidative stress plays an important role."
path(MESHD:"fatty liver disease") increases bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The predicted reduced urea secretion flux (Fig. 4) in the porphyria models was due to a reduced urea cycle, indicating ammonia toxicity."
a(CHEBI:"ammonia") decreases bp(GOBP:"urea cycle")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Synthesis of urea | Elimination of ammonia."
a(CHEBI:"ammonia") increases bp(GOBP:"Synthesis of urea")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "Current thinking is that decreased GABAergic neurons' activity in conjunction with increased glutamate release [25], increased oxidative stress [26Ã¢â‚¬Â¢], and increased metabolites of kynurenine pathway [27] leads to disease pathology."
path(MESHD:"hallucinations") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "This results in severe abdominal pain, vomiting, constipation, palpitations, urinary retention, and neurological manifestations like confusion, hallucinations, seizures, and peripheral neuropathy, which could lead to profound muscle weakness and, in some cases, psychiatric disturbances like insomnia, anxiety, and depression."
path(MESHD:"hallucinations") increases path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "The kynurenine pathway was recently introduced as relevant in the development of schizophrenia and bipolar disorder."
a(CHEBI:"Kynurenic acid") regulates a(CHEBI:"glutamate")

SET Citation = {"PubMed", "29392446.0"}
SET DataSource = "manual-curation"
SET Support = "The kynurenine pathway was recently introduced as relevant in the development of schizophrenia and bipolar disorder."
a(CHEBI:"Kynurenic acid") regulates a(CHEBI:"dopamine")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron and chronic viral hepatitis."
path(MESHD:"chronic viral hepatitis") association a(CHEBI:"iron")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "HCV patients with cirrhosis and DM have high insulin levels, consistent with the insulin resistance seen in cirrhosis."
a(CHEBI:"insulin") positiveCorrelation path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "## porphyria Cutanea Tarda and Diabetes Mellitus Knowledge about an association between PCT and altered glucose metabolism arose in the 1950s, ^15 and since then several cohort studies have shown a relatively high prevalence, 15 24 %, of diabetes."
bp(GOBP:"glucose metabolism") association path(MESHD:"PCT")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "For example, cirrhosis has been associated with abnormal glucose metabolism for more than 20 years."
bp(GOBP:"glucose metabolism") association path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "## porphyria Cutanea Tarda and Diabetes Mellitus Knowledge about an association between PCT and altered glucose metabolism arose in the 1950s, ^15 and since then several cohort studies have shown a relatively high prevalence, 15 24 %, of diabetes."
bp(GOBP:"glucose metabolism") association path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "## Diabetes Mellitus - Definition and Clinical Course DM is a serious metabolic disease defined by hyperglycemia and complicated by micro- and macrovascular abnormalities."
path(MESHD:"metabolic disease") association path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "## Methods to Detect the Level of Glycemia for the Diagnosis and Monitoring of Diabetes Mellitus The definition of diabetes is based on the presence of hyperglycemia."
path(MESHD:"Glycemia") positiveCorrelation path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "29516487.0"}
SET DataSource = "manual-curation"
SET Support = "## Methods to Detect the Level of Glycemia for the Diagnosis and Monitoring of Diabetes Mellitus The definition of diabetes is based on the presence of hyperglycemia."
path(MESHD:"Glycemia") positiveCorrelation path(MESHD:"hyperglycemia")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | | Carbonic anhydrase activity | For availability of bicarbonate."
a(CHEBI:"bicarbonate") association p(HGNC:"CA1")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "There is no doubt that alcohol plays a major role in increasing liver damage in HH, and heterozygosity for the H F E mutations associated with HH likely play some role in increasing iron loading and liver injury."
path(MESHD:"HH") increases path(MESHD:"liver damage")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Synergistic effects of alcohol and HH in producing advanced degrees of hepatic fibrosis and cirrhosis have been well described."
path(MESHD:"HH") increases path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Synergistic effects of alcohol and HH in producing advanced degrees of hepatic fibrosis and cirrhosis have been well described."
path(MESHD:"HH") increases path(MESHD:"hepatic fibrosis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Decreased hepatic insulin clearance leading to hyperinsulinemia and development of insulin resistance, as well as reduced hepatic uptake of glucose, are all known to occur in cirrhosis and to predispose the cirrhotic patient to the development of non-insulin-dependent DM."
path(MESHD:"insulin resistance") decreases a(CHEBI:"insulin")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | SjÃƒÂ¶gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
path(MESHD:"hepatitis") association path(MESHD:"PCT")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | SjÃƒÂ¶gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
path(MESHD:"hepatitis") association path(MESHD:"Thyroid disease")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Hepatitis C and C282Y heterozygosity can decrease UROD activity and therefore decrease conversion of uroporphyrinogen to coproporphyrinogen, which in turn, can be oxidized in the presence of P450 1A2."
path(MESHD:"hepatitis") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Hepatitis C and C282Y heterozygosity can decrease UROD activity and therefore decrease conversion of uroporphyrinogen to coproporphyrinogen, which in turn, can be oxidized in the presence of P450 1A2."
path(MESHD:"hepatitis") decreases a(CHEBI:"coproporphyrinogen")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Hepatitis B , on the other hand, causes less than 5 % of MC."
path(MESHD:"hepatitis") increases path(MESHD:"MC")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Also, iron overload may increase oxidative stress (ROS) which can induce ALA synthase and increase the production of ALA, which in turn, may increase uroporphyrinogen production."
a(CHEBI:"ROS") increases bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "In a small proportion of patients, the cutaneous symptoms are associated with abdominal pain, about one-quarter display abnormal liver enzyme activities and rarely develop severe hepatobiliary injury, including jaundice and liver cirrhosis, can occur."
path(MESHD:"jaundice") association path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "At that time, he had an acute HCV infection and jaundice that required a prolonged hospitalization."
path(MESHD:"jaundice") positiveCorrelation path(MESHD:"HCV infection")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "^21 Multiple studies have shown that the heterozygosity for HFE is significantly linked to the risk of cardiovascular events, including the fact that heterozygosity for C282Y has been shown to be a risk factor for myocardial infarction in men and cerebrovascular death in women."
path(MESHD:"cardiovascular events") association p(HGNC:"HFE")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "^21 Multiple studies have shown that the heterozygosity for HFE is significantly linked to the risk of cardiovascular events, including the fact that heterozygosity for C282Y has been shown to be a risk factor for myocardial infarction in men and cerebrovascular death in women."
path(MESHD:"cerebrovascular") association p(HGNC:"HFE")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Other skin manifestations include hyperpigmentation, hypertrichosis, alopecia due to scaring and purplish heliotrope suffusion of periorbital areas."
path(DO:"alopecia") positiveCorrelation path(MESHD:"hypertrichosis")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Other skin manifestations include hyperpigmentation, hypertrichosis, alopecia due to scaring and purplish heliotrope suffusion of periorbital areas."
path(DO:"alopecia") positiveCorrelation path(MESHD:"hyperpigmentation")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Additional manifestations of HH include hyperpigmentation, cardiomyopathy, diabetes mellitus, hypogonadism, hypothyroidism, and arthropathy due to pseudogout."
path(MESHD:"hypogonadism") association path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Additional manifestations of HH include hyperpigmentation, cardiomyopathy, diabetes mellitus, hypogonadism, hypothyroidism, and arthropathy due to pseudogout."
path(MESHD:"arthropathy") association path(MESHD:"diabetes mellitus")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "It is yet unclear whether the pathology of liver disease in patients with HCV is influenced by iron overload or limited to the direct cell damage from replication of the virus and subsequent inflammation."
bp(GOBP:"replication") increases path(MESHD:"inflammation")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
a(CHEBI:"cytochrome") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron, especially in concert with cytochrome(s) P450, increases oxidation of porphyrinogens to porphyrins."
a(CHEBI:"cytochrome") increases bp(MESHPP:"oxidation")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Yet, as described elsewhere in this issue, excessive iron is toxic to all types of cells because it increases oxidative stress and reactive oxygen species, which in turn cause the oxidation of lipids, proteins, and nucleic acids."
bp(MESHPP:"oxidation") increases a(CHEBI:"reactive oxygen species")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Yet, as described elsewhere in this issue, excessive iron is toxic to all types of cells because it increases oxidative stress and reactive oxygen species, which in turn cause the oxidation of lipids, proteins, and nucleic acids."
bp(MESHPP:"oxidation") increases bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "In hepatocytes, alcohol and iron are believed to act synergistically to generate free radicals, which contribute to the forma tion of the uroporphomethene that inhibits hepatic UROD, as well as cause cellular damage."
a(CHEBI:"free radical") increases a(PKG:"Uroporphomethene")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Iron overload can impact disease progression and treatment options for patients with comorbid conditions, such as porphyria cutanea tarda, hepatitis C virus, and coronary artery disease."
path(MESHD:"coronary artery disease") association path(MESHD:"PCT")

SET Citation = {"PubMed", "32269472.0"}
SET DataSource = "manual-curation"
SET Support = "Iron overload can impact disease progression and treatment options for patients with comorbid conditions, such as porphyria cutanea tarda, hepatitis C virus, and coronary artery disease."
path(MESHD:"coronary artery disease") association path(MESHD:"iron overload")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
a(CHEBI:"Estrogens") increases path(MESHD:"hepatic steatosis")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
a(CHEBI:"Estrogens") increases path(MESHD:"intrahepatic cholestasis")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
path(MESHD:"intrahepatic cholestasis") increases path(MESHD:"hepatic steatosis")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Estrogens have been reported to cause hepatic steatosis, intrahepatic cholestasis, hepatic adenomas, hepatocellular carcinomas, and peliosis hepatitis, ^57-60 but hepatic siderosis has not been recognized."
path(MESHD:"peliosis hepatitis") association a(CHEBI:"Estrogens")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "HFE genotyping DNA was available from 87 patients with PCT ( 64 with S-PCT and 23 with F-PCT) and from 56 clinically normal subjects married to members of well-characterized hemochromatosis pedigrees."
a(CHEBI:"DNA") association p(HGNC:"HFE")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "HFE genotyping DNA was available from 87 patients with PCT ( 64 with S-PCT and 23 with F-PCT) and from 56 clinically normal subjects married to members of well-characterized hemochromatosis pedigrees."
a(CHEBI:"DNA") association path(MESHD:"hemochromatosis")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "The highest 24 -hour urine porphyrin excretion, 26921 ÃŽÂ¼ g, was found in a 65 -year-old woman who was receiving chemotherapy for metastatic lung cancer."
path(MESHD:"metastatic lung cancer") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "Interaction between iron metabolism and 2,3,7,8-tetrachlorodibenzo-p-dioxin in mice with variants of the Ahr gene: a hepatic oxidative mechanism."
a(CHEBI:"iron") association a(CHEBI:"tetrachlorodibenzo-p-dioxin")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is characterized clinically by a photosensitive dermatosis associated with skin fragility and blistering."
path(MESHD:"dermatosis") positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Most anticonvulsants can aggravate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-3)."
a(CHEBI:"anticonvulsants") increases a(CHEBI:"heme")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "Many anticonvulsants can cause exacerbation of clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-5)."
a(CHEBI:"anticonvulsants") increases a(CHEBI:"heme")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Most anticonvulsants can aggravate clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-3)."
a(CHEBI:"anticonvulsants") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "Many anticonvulsants can cause exacerbation of clinically latent porphyria by inducing hepatic metabolism and increasing hepatic heme synthesis, as is well known for acute intermittent porphyria (1-5)."
a(CHEBI:"anticonvulsants") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "Use of propofol anesthesia and adjunctive treatment with levetiracetam and gabapentin in managing status epilepticus in a patient of acute intermittent porphyria A 12-year-old boy presented to us in the emergency with a 3-day history of progressive drowsiness and intermittent generalized seizures followed by status epilepticus of 1 day duration."
a(CHEBI:"gabapentin") decreases path(MESHD:"status epilepticus")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "reported one patient with complex partial and secondarily generalized seizures and PCT with phenytoin (PHT; 300 mg / day), who was then safely treated with gabapentin (GBP), an AED with no influence on hepatic enzymes."
a(CHEBI:"gabapentin") decreases a(CHEBI:"phenytoin")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Actually, only gabapentin (GBP), an AED without any hepatic metabolism, is known as a potential therapy for partial seizures in patients having hepatic forms of porphyria."
a(CHEBI:"gabapentin") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "He was diagnosed as having porphyria during an episode of status epilepticus 1 year previously based on a positive urinary test for porphobilinogen and had been receiving gabapentin and levetiracetam ever since."
a(CHEBI:"gabapentin") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Table 6"
a(CHEBI:"gabapentin") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
path(MESHD:"arrhythmias") association path(MESHD:"epileptic seizure")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
path(MESHD:"arrhythmias") association path(MESHD:"cardiovascular diseases")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
path(MESHD:"hypotension") association path(MESHD:"epileptic seizure")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
path(MESHD:"hypotension") association path(MESHD:"cardiovascular diseases")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Cardiovascular disease In the acute management of an epileptic seizure, intravenous phenytoin (PHT) can cause arrhythmias and hypotension."
path(MESHD:"epileptic seizure") association path(MESHD:"cardiovascular diseases")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "HT was more common among patients with AHP ( n=253,20 % ), and particularly in the U-PBG-positive AIP subgroup ( n=148,30 % ) than among the comparators (n=1834,15 %; Table 5, Figure 2A,B)."
path(MESHD:"cardiovascular diseases") positiveCorrelation path(MESHD:"AHP")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Oxcarbazepine appeared to be safe when used in a patient with focal seizures and hepatic porphyria, however, that patient had porphyria cutanea tarda which is not one of the inducible porphyrias and is not drug sensitive (Elder, 1998; Gaida-Hommernick et al."
a(CHEBI:"Oxcarbazepine") decreases path(MESHD:"hepatic porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Table 6"
a(CHEBI:"Oxcarbazepine") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Oxcarbazepine (OCBZ), a new AED for treating focal epilepsies, presents a low level of hepatic induction for certain microsomal enzymes (6) and might therefore be suitable for treating patients with hepatic forms of porphyria The patient is a 28 -year-old man who has had complex partial and secondarily generalized seizures since childhood, with a seizure frequency of at least five to six per month."
a(CHEBI:"Oxcarbazepine") decreases path(MESHD:"epilepsies")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "OXC has been used successfully in an isolated case of porphyria cutanea tarda and alsoin anothercaseof intermittent acute porphyria."
a(CHEBI:"Oxcarbazepine") causesNoChange path(MESHD:"AIP")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "OXC has been used successfully in an isolated case of porphyria cutanea tarda and also in another case of intermittent acute porphyria."
a(CHEBI:"Oxcarbazepine") causesNoChange path(MESHD:"PCT")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "In chronic antiepileptic treatment, carbamazepine (CBZ), oxcarbazepine (OXC) and PHT should be used with caution in patients with heart disease, and they should be avoided in the event of atrioventricular conduction dysfunction."
path(MESHD:"heart disease") association a(CHEBI:"antiepileptic")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "The patient also had a moderate hepatomegaly, and liver biopsy revealed a slight steatosis, a reticuloendothelial hemosiderin accumulation, and red fluorescence under Wood's light."
path(SCTID:"Steatosis") positiveCorrelation path(MESHD:"hepatomegaly")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Eventually, her seizure condition became much better controlled with one to two convulsive seizures per year using a combination of CBZ, clobazam and levetiracetam (age 29 to 32 years)."
a(CHEBI:"levetiracetam") decreases path(MESHD:"seizure")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "After 4 hours, the hyponatremia worsened ( 110 mEq / L ) and generalized convulsions necessitated the administration of levetiracetam, intubation, stepwise careful compensation of hyponatremia with intravenous sodium chloride (3%), and mechanical ventilation for 2 days."
a(CHEBI:"levetiracetam") decreases path(MESHD:"hyponatremia")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Intravenous hemin administration (4mg/kg once daily for 7 consecutive days) to inhibit ÃŽÂ´-ALA synthase (ALAS) activity and reduce porphyrin precursor accumulation; discontinuation of sodium valproate (which may exacerbate AIP) and replacement with levetiracetam (500mgtwicedaily) for seizure control; and maintenance of acid-base balance, correction of electrolyte disturbances, and a high-carbohydrate diet (daily intake Ã¢â€°Â¥ 300g) to stabilize metabolism."
a(CHEBI:"levetiracetam") causesNoChange path(MESHD:"AIP")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "In addition, the replacement of sodium valproate with levetiracetam aligns with the consensusÃ¢â‚¬â„¢s warning against porphyrogenic anti epileptics, demonstrating the practical value of adhering to guideline-based treatment in improving patient outcomes."
a(CHEBI:"levetiracetam") causesNoChange path(MESHD:"AIP")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Liver histology of explanted livers from patients with AIP who had undergone liver transplantation revealed hemosiderosis associated with years of regular haematin infusions."
a(CHEBI:"Hematin") association path(MESHD:"hemosiderosis")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Haematin infusions have reduced the activity of hepatic ALAS1 and subsequently lowered plasma and urinary ALA levels for 7Ã¢â‚¬â€œ10 days. This was sufficient for a patient to recover from an acute attack."
a(CHEBI:"Hematin") decreases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "LowÃ¢â‚¬Âgrade inflammation has been found in the livers of AP patients with recurrent attacks and chronic symptoms. The authors hypothesise that recurrent haematin infusions may have led to chronic liver inflammation, but that chronic AP may also have induced it."
a(CHEBI:"Hematin") increases path(MESHD:"inflammation")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "For the im- mediate treatment of seizures, diazepam (DZP) is recommended, but its effectiveness is lost the longer the patient takes the drug."
a(CHEBI:"diazepam") decreases path(MESHD:"seizures")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Bromides have been recommended for long-term management in case of acute intermittent porphyria and seizures."
a(CHEBI:"Bromides") decreases path(MESHD:"seizures")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Bromides have been recommended for long-term management in case of acute intermittent porphyria and seizures."
a(CHEBI:"Bromides") decreases path(MESHD:"AIP")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Actually, only gabapentin (GBP), an AED without any hepatic metabolism, is known as a potential therapy for partial seizures in patients having hepatic forms of porphyria."
path(MESHD:"partial seizures") association a(CHEBI:"gabapentin")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "# Eslicarbazepine for focal epilepsy and acute intermittent porphyria* Tamara Herrera-Fortin, Raluca Pana, Ewa Wesolowska, Josiane BourrÃƒÂ©-Tessier, Dang K. Nguyen University of Montreal Hospital Center, Montreal, Quebec, Canada Received January 6, 2020; Accepted March 12, 2020 #### Abstract porphyrias are rare genetic disorders which cause a deficiency in the enzymes involved in the biosynthesis of heme."
path(MESHD:"focal epilepsy") association a(CHEBI:"Eslicarbazepine")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "We report a patient with focal epilepsy and la tent hereditary coproporphyria who had exacerbation of clini cal symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without ex acerbation of clinically latent porphyria."
path(MESHD:"focal epilepsy") association path(MESHD:"hereditary coproporphyria")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "It should be emphasized that our case report presents a patient with partial and secondarily generalized seizures within the scope of a cryptogenic focal epilepsy since childhood, and that no porphyria-induced generalized seizures as seen in a porphyric crisis were reported."
path(MESHD:"focal epilepsy") increases path(MESHD:"generalized seizures")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "Their study showed that CBZ, VPA, and clonazepam (CZP) increased the production of porphyrin to the same level as was found before for phenobarbital (PB) and PHT (8)."
a(CHEBI:"clonazepam") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "demonstrated the porphyrogenic quality of LTG, tiagabine (TGB), and felbamate (FBM) in acute intermittent porphyria, whereas vigabatrin (VGB) did not increase the level of ÃŽÂ´-aminolevulinic acid synthase."
a(CHEBI:"vigabatrin") causesNoChange a(CHEBI:"ÃŽÂ´-aminolevulinic acid")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "A few days later, the hepatic enzymes increased [GGT, 4.99 SI; ALT, 3.31 SI; aspartate aminotransferase (AST), 1.74 SI) ], and the patient complained of pruritus and erythema."
p(HGNC:"GOT1") positiveCorrelation path(MESHD:"erythema")

SET Citation = {"PubMed", "11422339.0"}
SET DataSource = "manual-curation"
SET Support = "A few days later, the hepatic enzymes increased [GGT, 4.99 SI; ALT, 3.31 SI; aspartate aminotransferase (AST), 1.74 SI) ], and the patient complained of pruritus and erythema."
p(HGNC:"GOT1") positiveCorrelation path(MESHD:"pruritus")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "The natural history of hepatocellular carcinoma is heterogeneous and is influenced by nodule dimension, the mono- or plurifocality of lesions at diagnosis, the growth rate of the tumor, and the stage of the underlying cirrhosis."
path(MESHD:"tumor") association path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Little is known about the carcinogenic mechanisms involved in the development of HCC in AP, but the features mentioned above indicate an APÃ¢â‚¬Âspecific tumour development process."
path(MESHD:"tumor") association path(MESHD:"HCC")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "In most cases hepatocellular carcinoma develops in cirrhotic livers, where the persistent proliferation of liver cells represents the key factor of progression to hepatocellular carcinoma independent of the etiology."
bp(GOBP:"proliferation") increases path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "In a small proportion of patients, the cutaneous symptoms are associated with abdominal pain, about one-quarter display abnormal liver enzyme activities and rarely develop severe hepatobiliary injury, including jaundice and liver cirrhosis, can occur."
path(MESHD:"liver cirrhosis") association path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Most patients with AP and PLC do not have other chronic liver diseases or liver cirrhosis."
path(MESHD:"liver cirrhosis") association path(DO:"Primary Liver Cancer")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "In almost all cases, neoplastic degeneration occurs in patients with liver cirrhosis, whereas only a few cases of HCV-associated HCC have been reported in the noncirrhotic liver, indicating that this virus possibly has a mutagenic effect."
path(MESHD:"liver cirrhosis") increases path(MESHD:"HCC")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "Nevertheless, it is a frequent etiologic agent of liver cirrhosis, through which it can favor the development of HCC."
path(MESHD:"liver cirrhosis") increases path(MESHD:"HCC")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Most HCCs develop in the setting of longÃ¢â‚¬Âstanding inflammation associated with an underlying chronic liver disease that leads to liver cirrhosis or advanced fibrosis."
path(MESHD:"liver cirrhosis") increases path(MESHD:"HCC")

SET Citation = {"PubMed", "12095924.0"}
SET DataSource = "manual-curation"
SET Support = "AFB1 has recently been redimensioned as an etiologic factor in HCC, because although its consumption is high in those countries, such as Africa and Asia, where the incidence of HCC is high, it seems to be only a cofactor of neoplastic degeneration."
path(MESHD:"neoplastic") association a(CHEBI:"aflatoxin B1")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | SjÃƒÂ¶gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
path(MESHD:"Infection") association path(MESHD:"PCT")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | SjÃƒÂ¶gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
path(MESHD:"Infection") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | SjÃƒÂ¶gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
path(MESHD:"Corneal ulcers") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | SjÃƒÂ¶gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
path(MESHD:"Lichen planus") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | SjÃƒÂ¶gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
path(MESHD:"Pulmonary fibrosis") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Although only 10 % of HCV-infected persons will have symptomatic xerophthalmia or xerostomia, Ã¢â€°Â¤ 77 % will have evidence of SjÃƒÂ¶gren syndrome if it is sought with diagnostic tests (Table 6)."
path(MESHD:"xerophthalmia") positiveCorrelation path(MESHD:"xerostomia")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Among the woman's family members, a cousin had similar attacks of abdominal pain, but the symptoms were mild, and there were no symptoms such as a dry mouth and dry eyes."
path(MESHD:"dry eyes") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Major Syndromes Associated with Hepatitis C Infection, Grouped According to Strength of Association | High | Intermediate | Low | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | Cryoglobulinemic syndrome (Cutaneous leukocytoclastic vasculitis, arthritis, weakness) | porphyria cutanea tarda | Thyroid disease | | Renal disease | Diabetes | Corneal ulcers | | Neuropathy | | Lichen planus | | Lymphoma | Pulmonary fibrosis | | | SjÃƒÂ¶gren syndrome | Fibromyalgia | | culitis was 100 %, whereas the sensitivity of the cryoglobulin test was only 40 % .^14 In situations in which the sensitivity of the cryoglobulin test is high, the RF test does not detect any additional cases of mixed cryoglobulinemia and, in fact, will miss some."
path(MESHD:"Fibromyalgia") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "On B cells, CD81 is associated with CD19 and CR2 and also with MCH class II (Figure 2)."
p(HGNC:"CD81") association p(HGNC:"CD19")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "On B cells, CD81 is associated with CD19 and CR2 and also with MCH class II (Figure 2)."
p(HGNC:"CD81") association p(HGNC:"CR2")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "MC-associated neuropathy is usually a moderate axonal sensory polyneuropathy."
path(MESHD:"sensory polyneuropathy") increases path(MESHD:"neuropathy")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "In a well-documented case, progression from MC to accelerated malignant lymphoma occurred at the time of a second mutation of the myc oncogene to the ÃŽÂ» light-chain locus."
p(HGNC:"MYC") increases path(MESHD:"malignant lymphoma")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "In a well-documented case, progression from MC to accelerated malignant lymphoma occurred at the time of a second mutation of the myc oncogene to the ÃŽÂ» light-chain locus."
path(MESHD:"malignant lymphoma") isA path(MESHD:"lymphoma")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Recognizing that HCV infection alone may account for autoantibodies that were previously thought to be specific for autoimmune hepatitis may prevent the erroneous diagnosis of autoimmune hepatitis in association with HCV infection."
path(MESHD:"autoimmune hepatitis") association path(MESHD:"HCV infection")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Renal disease, lymphoma, Sjogren syndrome, and peripheral neuropathies manifest incomplete overlap with cryoglobulinemia."
path(MESHD:"peripheral neuropathies") association path(MESHD:"kidney disease")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Another site reported not infrequently is the stomach, and HCV has been associated with gastric lymphoproliferation and has been proposed to be a potential cause, in addition to Helicobacter pylori, for mucosa-associated lymphoid tissue lymphomas."
path(MESHD:"lymphoma") association path(MESHD:"lymphoproliferation")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "The preponderance of data indicates that HCV-associated lymphomas arise out of B cell proliferation that is driven by the same process that drives cryoglobulinemia production."
bp(GOBP:"cell proliferation") increases path(MESHD:"cryoglobulinemia")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "The preponderance of data indicates that HCV-associated lymphomas arise out of B cell proliferation that is driven by the same process that drives cryoglobulinemia production."
bp(GOBP:"cell proliferation") increases path(MESHD:"lymphoma")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Antiviral therapy is efficacious for extrahepatic manifestations, although mostly features related to cryoglobulinemia have been studied in trials."
a(CHEBI:"Antiviral therapy") decreases path(MESHD:"cryoglobulinemia")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Decreased hepatic insulin clearance leading to hyperinsulinemia and development of insulin resistance, as well as reduced hepatic uptake of glucose, are all known to occur in cirrhosis and to predispose the cirrhotic patient to the development of non-insulin-dependent DM."
path(DO:"hyperinsulinemia") decreases a(CHEBI:"insulin")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "No data has been published regarding the effects of combined pegylated interferon and ribavirin, which is now the state-of-the-art therapy for active liver disease caused by HCV."
a(CHEBI:"ribavirin") decreases path(MESHD:"liver disease")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "The management of chronic hepatitis C has been improved with the demonstration that the combination of interferon and ribavirin is superior to interferon alone for cure of hepatitis C. Further improvements have been possible with the use of long-acting, pegylated interferons plus ribavirin, such that apparent cures are now possible in about 50 % of patients who are able to afford and to tolerate such combination therapy for 1 year (Fried et al."
a(CHEBI:"ribavirin") decreases path(MESHD:"chronic hepatitis")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The management of CHC has been improved with the demonstration that the combination of interferon and ribavirin is superior to interferon alone for cure of hepatitis C.Further improvements have been possible with the use of long-acting, pegylated interferons plus ribavirin, such that apparent cures are now possible in Ã¢Ë†Â¼ 50 to 60 % of patients who are able to afford and to tolerate such combination therapy for 1 year."
a(CHEBI:"ribavirin") decreases path(MESHD:"hepatitis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "The most frequent cutaneous manifestation of the MC syndrome is palpable purpura of the lower extremities, although upper extremities, abdomen, and/or buttocks are sometimes also involved."
path(MESHD:"palpable purpura") positiveCorrelation path(DO:"Cutaneous Vasculitis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "The most frequent cutaneous manifestation of the MC syndrome is palpable purpura of the lower extremities, although upper extremities, abdomen, and/or buttocks are sometimes also involved."
path(DO:"Cutaneous Vasculitis") association path(MESHD:"Skin Diseases")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "The symptoms of MC syndrome are caused by vascular deposition of the cryoprecipitate, which contains HCV RNA, low-density lipoprotein, IgG, and a highly restricted monoclonal IgM that has RF activity (Figure 1)."
a(CHEBI:"RNA") increases a(GO:"IgG")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "However, almost all patients who do not achieve clearance of HCV RNA will relapse shortly after treatment is stopped."
a(CHEBI:"RNA") increases path(MESHD:"relapse")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "Most common are acute symptomatic generalized seizures occurring in the context of AIP in relapse (Winkler et al."
path(MESHD:"relapse") increases path(MESHD:"generalized seizures")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "The process begins as a lymphocytic capillaritis of the glands, which progresses to a lymphocytic sialadenitis."
path(SCTID:"Capillaritis") increases path(MESHD:"sialadenitis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "The triad of purpura, arthralgias, and weakness has been used to define patients with MC syndrome since 1966, but this definition is no longer adequate because additional symptoms are now known to be related to MC (Table 3)."
path(MESHD:"arthralgias") positiveCorrelation path(MESHD:"purpura")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Arthralgias are relatively common in HCV, but arthritis not related to MC is Table 2.Reported Prevalences of Cryoglobulinemia in Persons Infected with Hepatitis C | Country | HCV (n) | Cryo+ (%) | RF+(%) | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | | Sweden ^7 | 21 | 0 | ND | | Israel ^8 | 90 | 11 | 44 % | | Germany ^9 | 132 | 28 | 42 % | | France ^10 | 58 | 36 | 70 % | | France ^11 | 321 | 56 | 38 % | | Korea ^12 | 49 | 59 | 14 % | Cryo, cryoglobulinemia."
path(MESHD:"Cryoglobulinemia") association path(MESHD:"hepatitis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Arthralgias are relatively common in HCV, but arthritis not related to MC is Table 2.Reported Prevalences of Cryoglobulinemia in Persons Infected with Hepatitis C | Country | HCV (n) | Cryo+ (%) | RF+(%) | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | :Ã¢â‚¬â€œ: | | Sweden ^7 | 21 | 0 | ND | | Israel ^8 | 90 | 11 | 44 % | | Germany ^9 | 132 | 28 | 42 % | | France ^10 | 58 | 36 | 70 % | | France ^11 | 321 | 56 | 38 % | | Korea ^12 | 49 | 59 | 14 % | Cryo, cryoglobulinemia."
path(MESHD:"Cryoglobulinemia") association path(MESHD:"Arthralgias")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Over time, pigmentation, depigmentation, hirsutism, and sclerodermoid appearance can develop."
path(MESHD:"hirsutism") positiveCorrelation a(CHEBI:"pigmentation")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Compared with patients with non-HCV-related cryoglobulinemia, HCV patients have the same frequency of cutaneous involvement, renal involvement, and peripheral neuropathy, but they less frequently manifest fever, lymphadenopathy, articular involvement, or Raynaud phenomenon."
path(SCTID:"Raynaud's phenomenon") association path(MESHD:"cryoglobulinemia")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "The current case involved a 30-year-old woman who had episodic abdominal pain for six years and a dry mouth and eyes for three and a half years."
path(MESHD:"dry mouth") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Among the woman's family members, a cousin had similar attacks of abdominal pain, but the symptoms were mild, and there were no symptoms such as a dry mouth and dry eyes."
path(MESHD:"dry mouth") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "The patient also had cutaneous purpura, renal damage, hypothyroidism, and other extra-glandular lesions with dry mouth and eyes."
path(MESHD:"dry mouth") positiveCorrelation path(MESHD:"purpura")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "On the other hand, there were typical clinical manifestations of PSS such as dry eyes and a dry mouth, the elevation of immunoglobulins (IgG and IgA) and the results of Schirmer's test, an anti-SS-A antibody test, an anti-SS-B antibody test, and a labial gland biopsy were all positive."
path(MESHD:"dry mouth") positiveCorrelation path(MESHD:"dry eyes")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "In the United States, 10 to 20 % of MPGN is associated with HCV infection."
p(MESHD:"MPGN") association path(MESHD:"HCV infection")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "They often ( 72 % ) have serum albumin <3 g / dL with mild renal insufficiency."
path(MESHD:"renal insufficiency") negativeCorrelation p(HGNC:"ALB")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "A recent study of 36 patients showed that mRNA of hepcidin correlated with albumin synthesis and HIC and inversely correlated with the degree of hepatic fibrosis."
p(HGNC:"ALB") positiveCorrelation p(HGNC:"HAMP")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "However, 88 % will have abnormal liver biopsy consistent with chronic active hepatitis, often with cirrhosis (50 %) .^35 Complement levels are also depressed in the majority."
path(MESHD:"chronic active hepatitis") increases path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "However, combined antiviral and immunosuppressive therapy may be treatment of choice in patients with severe renal disease."
a(CHEBI:"antiviral") decreases path(MESHD:"kidney disease")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "A case control study performed in Italy found that HCV infection increased the risk for NHL of the liver or salivary glands by 50 -fold, which was greater than the relative risk of hepatocellular carcinoma."
path(MESHD:"NHL") positiveCorrelation path(MESHD:"HCV infection")

SET Citation = {"PubMed", "12640289.0"}
SET DataSource = "manual-curation"
SET Support = "Almost all patients with pre-existing DM or hypertension (80-100%) develop an interferon-associated retinopathy that may be permanent."
path(MESHD:"retinopathy") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Once endocytosed, the small interfering RNA is cleaved from the conjugate to potently reduce levels of ALAS1 mRNA and protein."
a(CHEBI:"mRNA") decreases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^31 Heme is not a direct inhibitor of ALAS1 at physiologically achievable concentrations, but rather decreases stability of ALAS1 messenger RNA (mRNA) and therefore its protein expression."
a(CHEBI:"mRNA") decreases a(CHEBI:"Heme")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Administration of an antisense oligonucleotide that prevents the abnormal splicing of the nascent mutant FECH mRNA in developing human erythroblasts of a patient with EPP increased the production of functional FECH and reduced the accumulation of PPIX.130 ## Case Report A 67-year-old female patient presented with pronounced photosensitivity (burning, stinging pain, swelling, and itching) on light-exposed skin areas (prominent in the face and on the back of the hands) since early childhood."
a(CHEBI:"mRNA") increases p(HGNC:"FECH")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The latter change may well occur due to downregulation by ethanol (actually, its proximate oxidation product, acetaldehyde) of hepatic production of hepcidin, ^11 which, in turn, appears to be the key regulator of expression of ferroportin on the basolateral membrane of duodenal enterocytes."
a(CHEBI:"acetaldehyde") decreases p(HGNC:"HAMP")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "In addition to increased duodenal absorption, other mechanisms have been postulated as causes of portosystemic shuntrelated iron overload, including relative hepatic hypoxia, and associated pancreatic insufficiency with decreased bicarbonate secretion (Grace & Powell, 1974)."
path(MESHD:"pancreatic insufficiency") decreases a(CHEBI:"bicarbonate")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron, HFE gene mutations, and end-stage liver disease Serum iron indices and hepatic iron concentrations are often increased in patients with end-stage liver disease."
path(MESHD:"end-stage liver disease") positiveCorrelation a(CHEBI:"iron")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Iron storage disorders of the liver."
path(MESHD:"storage disorders") association a(CHEBI:"iron")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Spur cell anaemia acid hepatic iron stores in patients with alcoholic liver disease undergoing orthotopic liver transplantation."
path(MESHD:"anaemia") association path(MESHD:"alcoholic liver disease")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "Hemochromatosis gene modifies course of hepatis C viral infection."
path(MESHD:"viral infection") association path(MESHD:"Hemochromatosis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis."
path(MESHD:"liver fibrosis and cirrhosis") association path(MESHD:"chronic hepatitis")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis."
path(MESHD:"liver fibrosis and cirrhosis") association p(HGNC:"HFE")

SET Citation = {"PubMed", "12957298.0"}
SET DataSource = "manual-curation"
SET Support = "In summary, in both alcoholic and nonalcoholic steatohepatitis and fatty liver disease, there is both experimental and clinical evidence that increased oxidative stress plays an important role."
path(MESHD:"alcoholic liver disease") increases bp(MESHPP:"oxidative stress")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "We report a patient with focal epilepsy and la tent hereditary coproporphyria who had exacerbation of clini cal symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without ex acerbation of clinically latent porphyria."
a(CHEBI:"Valproate") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "We report a patient with focal epilepsy and la tent hereditary coproporphyria who had exacerbation of clini cal symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without ex acerbation of clinically latent porphyria."
a(CHEBI:"Primidone") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
a(CHEBI:"Primidone") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Table 6"
a(CHEBI:"Levetiracetam") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "Levetiracetam (LEV) might be suitable for treating patients with hereditary coproporphyria."
a(CHEBI:"Levetiracetam") decreases path(MESHD:"hereditary coproporphyria")

SET Citation = {"PubMed", "15101839.0"}
SET DataSource = "manual-curation"
SET Support = "We report a patient with focal epilepsy and la tent hereditary coproporphyria who had exacerbation of clini cal symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without ex acerbation of clinically latent porphyria."
a(CHEBI:"Levetiracetam") causesNoChange path(MESHD:"porphyria")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The major recognized risk factors for disease development are chronic hepatitis C(CHC), heavy alcohol use, iron overload (which is generally only mild or moderate), and estrogen use."
path(MESHD:"CHC") increases path(MESHD:"chronic hepatitis")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Mortality associated with CHC virus infection is mainly attributable to progression of hepatic fibrosis and subsequent occurrence of cirrhosis with its complications of portal hypertension and hepatocellular carcinoma."
path(MESHD:"virus infection") increases path(MESHD:"hepatocellular carcinoma")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Mortality associated with CHC virus infection is mainly attributable to progression of hepatic fibrosis and subsequent occurrence of cirrhosis with its complications of portal hypertension and hepatocellular carcinoma."
path(MESHD:"virus infection") increases path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Mortality associated with CHC virus infection is mainly attributable to progression of hepatic fibrosis and subsequent occurrence of cirrhosis with its complications of portal hypertension and hepatocellular carcinoma."
path(MESHD:"virus infection") increases path(MESHD:"hepatic fibrosis")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Mortality associated with CHC virus infection is mainly attributable to progression of hepatic fibrosis and subsequent occurrence of cirrhosis with its complications of portal hypertension and hepatocellular carcinoma."
path(MESHD:"virus infection") increases path(MESHD:"portal hypertension")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "In summary, hepcidin appears to be a key liverderived peptide important in iron homeostasis."
a(CHEBI:"peptide") association p(HGNC:"HAMP")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "An Australian study showed that the major HFE mutation (C282Y) associated with HH is correlated with iron abnormalities found in patients with NASH."
path(MESHD:"abnormalities") association p(HGNC:"HFE")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The hepatic production of malondialdehyde (MDA) and 4-hydroxynonenal (4HNE), aldehydic products of lipid peroxidation that directly stimulate collagen synthesis, was elevated twofold in rats fed with high fat, ethanol, and iron, compared with rats fed with fat and ethanol.(Fig. 1A, B) Also, the group fed with ethanol, iron, and fat showed significant fibrogenic activity (Fig. 2)."
a(CHEBI:"MDA") increases a(CHEBI:"malondialdehyde")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The hepatic production of malondialdehyde (MDA) and 4-hydroxynonenal (4HNE), aldehydic products of lipid peroxidation that directly stimulate collagen synthesis, was elevated twofold in rats fed with high fat, ethanol, and iron, compared with rats fed with fat and ethanol.(Fig. 1A, B) Also, the group fed with ethanol, iron, and fat showed significant fibrogenic activity (Fig. 2)."
a(CHEBI:"4-hydroxynonenal") increases a(CHEBI:"malondialdehyde")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The hepatic production of malondialdehyde (MDA) and 4-hydroxynonenal (4HNE), aldehydic products of lipid peroxidation that directly stimulate collagen synthesis, was elevated twofold in rats fed with high fat, ethanol, and iron, compared with rats fed with fat and ethanol.(Fig. 1A, B) Also, the group fed with ethanol, iron, and fat showed significant fibrogenic activity (Fig. 2)."
a(CHEBI:"4HNE") increases a(CHEBI:"malondialdehyde")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The hepatic production of malondialdehyde (MDA) and 4-hydroxynonenal (4HNE), aldehydic products of lipid peroxidation that directly stimulate collagen synthesis, was elevated twofold in rats fed with high fat, ethanol, and iron, compared with rats fed with fat and ethanol.(Fig. 1A, B) Also, the group fed with ethanol, iron, and fat showed significant fibrogenic activity (Fig. 2)."
bp(MESHPP:"lipid peroxidation") increases a(CHEBI:"malondialdehyde")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The hepatic production of malondialdehyde (MDA) and 4-hydroxynonenal (4HNE), aldehydic products of lipid peroxidation that directly stimulate collagen synthesis, was elevated twofold in rats fed with high fat, ethanol, and iron, compared with rats fed with fat and ethanol.(Fig. 1A, B) Also, the group fed with ethanol, iron, and fat showed significant fibrogenic activity (Fig. 2)."
path(MESHD:"fibrogenic") increases a(CHEBI:"malondialdehyde")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "Use of propofol anesthesia and adjunctive treatment with levetiracetam and gabapentin in managing status epilepticus in a patient of acute intermittent porphyria A 12-year-old boy presented to us in the emergency with a 3-day history of progressive drowsiness and intermittent generalized seizures followed by status epilepticus of 1 day duration."
a(CHEBI:"propofol") decreases path(MESHD:"status epilepticus")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "The porphyrias are a group of uncommonly inherited metabolic disorders in which there is disturbance of haem synthesis."
a(CHEBI:"heme biosynthesis") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "A recessive form of PNH due to *ARGEF2* gene mutations has also been reported in children with microcephaly, severe delay and early-onset seizures."
path(SNOMED:"PNH") increases path(MESHD:"seizures")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "Lissencephaly-pachygyria and subcortical band heterotopia (SBH) result from mutations of either the *LIS1* or *XLIS* gene."
p(HGNC:"PAFAH1B1") increases path(MESHD:"Lissencephaly")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "Lissencephaly-pachygyria and subcortical band heterotopia (SBH) result from mutations of either the *LIS1* or *XLIS* gene."
p(HGNC:"PAFAH1B1") increases path(MESHD:"pachygyria")

SET Citation = {"PubMed", "18454784.0"}
SET DataSource = "manual-curation"
SET Support = "List of drugs to be avoided in porphyria | Common drugs | Antiepileptic drugs | | :Ã¢â‚¬â€œ | :Ã¢â‚¬â€œ | | I. Sulfonamides | I. Carbamazepine | | 2."
a(CHEBI:"Sulfonamides") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "A possible explanation of our finding is that in our patient population, coexistence of various concomitant precipitat ing factors such as iron overload, oestrogen replacement therapy and HCV infection, seems to facilitate cumulatively the manifesta tion of PCT."
path(MESHD:"Hepacivirus") association path(MESHD:"PCT")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Interestingly, patients suffering TM manifest several of PCT's predisposing factors as a result of their underlying disease such as iron overload, blood-borne infections (e.g. viral hepatitis) or oestrogen replacement therapy because of amenorrhoea."
path(MESHD:"amenorrhoea") association path(MESHD:"viral hepatitis")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Interestingly, patients suffering TM manifest several of PCT's predisposing factors as a result of their underlying disease such as iron overload, blood-borne infections (e.g. viral hepatitis) or oestrogen replacement therapy because of amenorrhoea."
path(MESHD:"amenorrhoea") association a(CHEBI:"oestrogen")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "The two women with the substantially elevated urinary porphyrin levels had a combination of predisposing factors: they were receiving oestrogen replacement therapy because of amenorrhoea, had markedly elevated plasma ferritin concentration, while one of them was HCV positive."
path(MESHD:"amenorrhoea") association a(CHEBI:"oestrogen")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Prior treatment with oestrogen replacement therapy was determined and toxicological tests from hair samples were performed to exclude exposure to polychlorinated hydrocarbons."
a(CHEBI:"hydrocarbons") association a(CHEBI:"oestrogen")

SET Citation = {"PubMed", "20236192.0"}
SET DataSource = "manual-curation"
SET Support = "Twenty-four hour urine specimens revealed substantially high level of urinary porphyrins in the two patients presenting with dermatological lesions, while a mild elevation was demonstrated in three other patients, one amongst them being with pseudoscleroderma."
path(DO:"pseudoscleroderma") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
a(CHEBI:"phenobarbital") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
a(CHEBI:"topiramate") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "The induction of hepatic haemosynthesis on the part of enzyme-inducing AEDs can exacerbate the symptoms of porphyr ia. Treatment with CBZ,PB,PHT,PRM,TPM,VPAandZNSshouldbe avoided."
a(CHEBI:"zonisamide") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Table 6"
a(CHEBI:"Pregabalin") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Pregabalin (PGB) should be used with care in cases of heart failure due to left ventricular systolic dysfunction."
a(CHEBI:"Pregabalin") decreases path(MESHD:"heart failure")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Pregabalin (PGB) should be used with care in cases of heart failure due to left ventricular systolic dysfunction."
a(CHEBI:"Pregabalin") decreases path(MESHD:"left ventricular systolic dysfunction")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The risk of other cardiovascular conditions commonly associated with HT such as heart failure, atrial fibrillation, ischemic heart disease, and peripheral artery disease did not differ between the AHP groups and comparators."
path(MESHD:"heart failure") association path(MESHD:"cardiovascular conditions")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Table 6"
a(CHEBI:"benzodiazepine") increases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Intravenous magnesium sulphate and BZDs have also been used in isolated cases of status epilepticus, although in theory BZDs can worsen porphyria symptoms."
a(CHEBI:"magnesium sulphate") decreases path(MESHD:"status epilepticus")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Intravenous magnesium sulphate and BZDs have also been used in isolated cases of status epilepticus, although in theory BZDs can worsen porphyria symptoms."
a(CHEBI:"magnesium sulphate") decreases path(MESHD:"porphyria")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "GBP* | - | CBZ, OXC, PB, PRM, VPA | | Hypothyroidism | BZD, LEV, LTG, PGB, ZNS."
path(MESHD:"Hypothyroidism") association a(CHEBI:"VPA")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "GBP* | VPA | CBZ, PB, PHT, PRM | | Obesity | TPM, ZNS | CBZ, CLB | GBP, PGB, VPA | | HIV | LEV, PGB, TPM."
path(MESHD:"Obesity") association a(CHEBI:"VPA")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "GBP* | CBZ, OXC, PHT, TPM, VPA | BZD, PB, PRM | | Brain tumour | LEV, VPA."
path(MESHD:"Brain tumour") association a(CHEBI:"VPA")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Lung disease Parenteral use of barbiturates, BZD and PHT can cause respiratory depression."
path(MESHD:"respiratory depression") association path(MESHD:"Lung disease")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "^20 ## 5.Liver disease In the case of hepatic dysfunction, the hepatic metabolism of some AEDs is impaired, and there may be associated hypoalbuminaemia."
path(MESHD:"hepatic dysfunction") increases path(MESHD:"liver disease")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "| | CBZ | | LTG | | PB | | PHT | | VPA | | | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | Ã¢â‚¬â€ | | Albendazole | Ã¢â€ â€œ | = | | | Ã¢â€ â€œ | = | Ã¢â€ â€œ | = | | | | Carbapenems | | | | | | | | | | Ã¢â€ â€œ | | Ciprofloxacin | | | | | | | | Ã¢â€ â€œ | | | | Clarithromycin | | Ã¢â€ â€˜ | | | | | | | | | | Doxycycline | Ã¢â€ â€œ | | | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | | | | Erythromycin | | Ã¢â€ â€˜ | | | | | | | | | | Fluconazole | | Ã¢â€ â€˜ | | | | | | Ã¢â€ â€˜ | Ã¢â€ â€˜ | | | NRTI | = | = | = | = | = | | = | = | = | = | | NNRTI | Ã¢â€ â€œ | Ã¢â€ â€˜ | = | Ã¢â€ â€˜ | Ã¢â€ â€œ | Ã¢â€ â€˜ | Ã¢â€ â€œ | Ã¢â€ â€˜ | = | Ã¢â€ â€˜ | | PI | Ã¢â€ â€œ | Ã¢â€ â€˜ | = | Ã¢â€ â€˜ | Ã¢â€ â€œ | Ã¢â€ â€˜ | Ã¢â€ â€œ | Ã¢â€ â€˜ | = | Ã¢â€ â€˜ | | Isoniazid | | Ã¢â€ â€˜ | | | | | | Ã¢â€ â€˜ | | Ã¢â€ â€˜ | | Ketoconazole | | Ã¢â€ â€˜ | | | | | | | | | | Metronidazole | Ã¢â€ â€œ | Ã¢â€ â€˜ | | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | | | | Praziquantel | Ã¢â€ â€œ | = | | | Ã¢â€ â€œ | = | Ã¢â€ â€œ | = | | | | Rifampicin | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Ã¢â€ â€œ | | Sulphonamides | | | | | | | | Ã¢â€ â€˜ | | | The arrows on the left hand side of the boxes indicate the effect of interaction on the plasma levels of the antibiotics and the ones on the right hand side indicate the effect on plasma levels of AEDs."
a(CHEBI:"Albendazole") decreases a(CHEBI:"VPA")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Azathioprine, mycophenolate and muromonab-CD3 (OKT3) are not significantly affected by AEDs."
a(CHEBI:"mycophenolate") causesNoChange a(CHEBI:"Azathioprine")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Azathioprine can not be used together with febuxostat (9), and has potent myelosuppressive action (10)."
a(CHEBI:"Azathioprine") isA path(MEDDRA:"Myelosuppression")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "However, the use of Diazepam (oral or rectal route) or Midazolam (buccal or intranasal route) is recommended for acute treatment of prolonged and cluster seizures."
a(CHEBI:"Diazepam") decreases path(MESHD:"seizures")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "However, the use of Diazepam (oral or rectal route) or Midazolam (buccal or intranasal route) is recommended for acute treatment of prolonged and cluster seizures."
a(CHEBI:"Midazolam") decreases path(MESHD:"seizures")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "Conclusions: In this review we make recommendations based on the best scientific evidence available for treating epilepsy in patients with other comorbidities, including the treatment of epileptic seizures in acute situations as well as chronic antiepileptic treatment."
a(CHEBI:"antiepileptic") decreases path(MESHD:"epilepsy")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "The use of intravenous PHT or fosphenytoin is contraindicated in patients with severe heart disease and second or third degree atrioventricular block."
a(CHEBI:"fosphenytoin") decreases path(MESHD:"heart disease")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "The use of intravenous PHT or fosphenytoin is contraindicated in patients with severe heart disease and second or third degree atrioventricular block."
a(CHEBI:"fosphenytoin") decreases path(MESHD:"atrioventricular block")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "In our case, ESL was chosen over oxcarbazepine given that it has fewer interactions with the CYP450s system (Peltola et al."
a(CHEBI:"oxcarbazepine") decreases a(CHEBI:"CYP450")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "In chronic antiepileptic treatment, carbamazepine (CBZ), oxcarbazepine (OXC) and PHT should be used with caution in patients with heart disease, and they should be avoided in the event of atrioventricular conduction dysfunction."
a(CHEBI:"oxcarbazepine") decreases path(MESHD:"heart disease")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "| Antiplatelets | Salicylates increase the free fraction of VPA."
a(CHEBI:"Salicylates") increases a(CHEBI:"VPA")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "| | Antiarrhythmics | Enzyme-inducing AEDs increase the metabolism of antiarrhythmics and so it may be necessary to increase the doses of the latter."
a(CHEBI:"Antiarrhythmics") increases bp(GOBP:"metabolism")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "| | Antihypertensives | Enzyme-inducing AEDs increase the metabolism of beta-blockers and dihydropyridine calcium antagonists | | | PHT reduces the active metabolite of losartan by up to 63 %."
a(CHEBI:"losartan") decreases bp(GOBP:"metabolism")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "AEDs and obesity Some AEDs are associated with weight gain (CBZ, CLB, GBP, PGB and VPA) and others with weight loss (TPM and ZNS).The majority have a neutral effect in this respect."
path(MESHD:"weight loss") decreases path(MESHD:"obesity")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "In the treatment of neurocysticercosis, enzyme-inducing AEDs reduce the concentration of praziquantel and albendazole by over 50 %."
a(CHEBI:"praziquantel") decreases path(MESHD:"neurocysticercosis")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "In the treatment of neurocysticercosis, enzyme-inducing AEDs reduce the concentration of praziquantel and albendazole by over 50 %."
a(CHEBI:"albendazole") decreases path(MESHD:"neurocysticercosis")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "In the treatment of tuberculosis, isoniazid inhibits the metabolism of CBZ, PHT and VPA, and can cause toxicity."
a(CHEBI:"isoniazid") decreases bp(GOBP:"metabolism")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "In the treatment of tuberculosis, isoniazid inhibits the metabolism of CBZ, PHT and VPA, and can cause toxicity."
a(CHEBI:"isoniazid") decreases a(CHEBI:"VPA")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "The interaction between VPA and amitriptyline or nortriptyline can cause an increase of up to 60 % in the plasma levels of these drugs, causing intoxication."
a(CHEBI:"amitriptyline") increases a(CHEBI:"VPA")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "The interaction between VPA and amitriptyline or nortriptyline can cause an increase of up to 60 % in the plasma levels of these drugs, causing intoxication."
a(CHEBI:"nortriptyline") increases a(CHEBI:"VPA")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "SSRIs can cause hyponatraemia and so they must be used with caution when combined with CBZ or OXC."
path(MESHD:"hyponatraemia") association a(CHEBI:"SSRIs")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "There are, however, exceptions, and certain antidepressants such as amoxapine, maprotiline and bupropion and certain neuroleptics such as clozapine and chlorpromazine have a higher epileptogenic risk."
a(CHEBI:"amoxapine") increases path(MESHD:"epilepsy")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "There are, however, exceptions, and certain antidepressants such as amoxapine, maprotiline and bupropion and certain neuroleptics such as clozapine and chlorpromazine have a higher epileptogenic risk."
a(CHEBI:"maprotiline") increases path(MESHD:"epilepsy")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "There are, however, exceptions, and certain antidepressants such as amoxapine, maprotiline and bupropion and certain neuroleptics such as clozapine and chlorpromazine have a higher epileptogenic risk."
a(CHEBI:"bupropion") increases path(MESHD:"epilepsy")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "There are, however, exceptions, and certain antidepressants such as amoxapine, maprotiline and bupropion and certain neuroleptics such as clozapine and chlorpromazine have a higher epileptogenic risk."
a(CHEBI:"clozapine") increases path(MESHD:"epilepsy")

SET Citation = {"PubMed", "20554455.0"}
SET DataSource = "manual-curation"
SET Support = "There are, however, exceptions, and certain antidepressants such as amoxapine, maprotiline and bupropion and certain neuroleptics such as clozapine and chlorpromazine have a higher epileptogenic risk."
a(CHEBI:"chlorpromazine") increases path(MESHD:"epilepsy")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Tachycardia, hypertension, and sweating are often present."
path(MESHD:"Tachycardia") positiveCorrelation path(MESHD:"hypertension")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Tachycardia coupled with hypertension and a reddish dark urine are further diagnostic signs (Figure 2A)."
path(MESHD:"Tachycardia") positiveCorrelation path(MESHD:"hypertension")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Hyponatremia may be due to the syndrome of inappropriate antidiuretic hormone secretion, but gastrointestinal or renal sodium losses are sometimes important (until dehydration) [1]."
path(MESHD:"dehydration") decreases a(CHEBI:"sodium")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Other clinical signs include vomiting, failure to thrive, dehydration, disacchariduria including lactosuria, renal tubular acidosis and amino aciduria."
path(MESHD:"dehydration") positiveCorrelation path(MESHD:"vomiting")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Hypertension, sphincter dysfunction, and severe gastroparesis impeding enteral feeding were initially ascribed to dysautonomia."
path(MESHD:"dysautonomia") association path(MESHD:"Hypertension")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Hypertension, sphincter dysfunction, and severe gastroparesis impeding enteral feeding were initially ascribed to dysautonomia."
path(MESHD:"gastroparesis") association path(MESHD:"dysautonomia")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The literature review revealed that the major source of pyruvate, which serves as the precursor for lactate and alanine production, is glucose rather than glutamine in sIECs."
a(CHEBI:"pyruvate") increases a(CHEBI:"lactate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The literature review revealed that the major source of pyruvate, which serves as the precursor for lactate and alanine production, is glucose rather than glutamine in sIECs."
a(CHEBI:"pyruvate") increases a(CHEBI:"alanine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The latter converts alanine to pyruvate, which subsequently enters gluconeogenesis providing endogenous glucose."
a(CHEBI:"pyruvate") increases a(CHEBI:"alanine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "We identified metabolic pathways known to occur within these cells, including sIEC-specific pathways, such as citrulline and proline metabolism, the conversion of fructose to glucose and the re-synthesis of triglyceride and cholesterol-ester."
a(CHEBI:"glucose") increases a(CHEBI:"citrulline")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The literature review revealed that the major source of pyruvate, which serves as the precursor for lactate and alanine production, is glucose rather than glutamine in sIECs."
a(CHEBI:"glucose") increases a(CHEBI:"pyruvate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The latter converts alanine to pyruvate, which subsequently enters gluconeogenesis providing endogenous glucose."
a(CHEBI:"glucose") increases a(CHEBI:"pyruvate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The literature review revealed that the major source of pyruvate, which serves as the precursor for lactate and alanine production, is glucose rather than glutamine in sIECs."
a(CHEBI:"glucose") increases a(CHEBI:"lactate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The latter converts alanine to pyruvate, which subsequently enters gluconeogenesis providing endogenous glucose."
a(CHEBI:"glucose") increases a(CHEBI:"alanine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Another noteworthy observation was the failure to synthesize alanine from glutamine in the absence of glucose, which we observed for both diets (when glucose was removed under this particular simulation condition)."
a(CHEBI:"glucose") increases a(CHEBI:"alanine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The literature review revealed that the major source of pyruvate, which serves as the precursor for lactate and alanine production, is glucose rather than glutamine in sIECs."
a(CHEBI:"glucose") increases a(CHEBI:"alanine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The latter converts alanine to pyruvate, which subsequently enters gluconeogenesis providing endogenous glucose."
a(CHEBI:"glucose") increases bp(GOBP:"gluconeogenesis")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The latter converts alanine to pyruvate, which subsequently enters gluconeogenesis providing endogenous glucose."
bp(GOBP:"gluconeogenesis") increases a(CHEBI:"pyruvate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The latter converts alanine to pyruvate, which subsequently enters gluconeogenesis providing endogenous glucose."
bp(GOBP:"gluconeogenesis") increases a(CHEBI:"alanine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "When simulating the average American diet, glucose-galactose malabsorption (OMIM: 606 824) affected in silico the highest number of metabolic tasks (i.e. 22 out of 50) (Fig. 3), including reduced fluxes through gluconeogenesis from glutamine and the synthesis of gamma-aminobutyric-acid, i.e. GABA from putrescine."
bp(GOBP:"gluconeogenesis") negativeCorrelation path(MESHD:"glucose-galactose malabsorption")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| In one case, trans-mural infarction of distal ileum and the existence of sickle cell anemia caused death (49)."
path(MESHD:"sickle cell anemia") positiveCorrelation path(MESHD:"infarction")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Hypocortisolism, factors related to erythropoiesis and celiac disease, should be excluded."
path(MESHD:"celiac disease") association path(MESHD:"Hypocortisolism")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Coincidental existence of porphyrias and celiac disease also exists, villous atrophy has been seen (50)."
path(MESHD:"celiac disease") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, the type I citrullinemia model was able to utilize partially the urea cycle by synthesizing ornithine, which was then converted either to glutamate by the ornithine transaminase (E.C.2.6.1.13) or to citrulline by the ornithine carbamoyltransferase (E.C. 2.1.3.3)."
path(MESHD:"citrullinemia") increases a(CHEBI:"glutamate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, the type I citrullinemia model was able to utilize partially the urea cycle by synthesizing ornithine, which was then converted either to glutamate by the ornithine transaminase (E.C.2.6.1.13) or to citrulline by the ornithine carbamoyltransferase (E.C. 2.1.3.3)."
path(MESHD:"citrullinemia") increases a(CHEBI:"ornithine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "When comparing the results for the maximal possible flux values of the different metabolic tasks, we found an increased flux for the synthesis of important products, such as glucose, ornithine and citrulline, from glutamine in the average American diet compared with the balanced diet (Table 1)."
a(CHEBI:"glutamine") increases a(CHEBI:"citrulline")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to ammonia conversion | Glutaminase activity to generate glutamate."
a(CHEBI:"glutamine") increases a(CHEBI:"glutamate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to ammonia conversion | Glutaminase activity to generate glutamate."
a(CHEBI:"glutamine") increases a(CHEBI:"ammonia")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to lactate conversion | Utilization of glutamine, sparing glucose."
a(CHEBI:"glutamine") increases a(CHEBI:"lactate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | | Synthesis of alanine from glutamine | To be sent to the liver."
a(CHEBI:"glutamine") increases a(CHEBI:"alanine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "When comparing the results for the maximal possible flux values of the different metabolic tasks, we found an increased flux for the synthesis of important products, such as glucose, ornithine and citrulline, from glutamine in the average American diet compared with the balanced diet (Table 1)."
a(CHEBI:"glutamine") increases a(CHEBI:"glucose")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to glucose conversion | Endogenous glucose production."
a(CHEBI:"glutamine") increases a(CHEBI:"glucose")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "When comparing the results for the maximal possible flux values of the different metabolic tasks, we found an increased flux for the synthesis of important products, such as glucose, ornithine and citrulline, from glutamine in the average American diet compared with the balanced diet (Table 1)."
a(CHEBI:"glutamine") increases a(CHEBI:"ornithine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | | Glutamine to carbon dioxide conversion | Utilization of glutamine, sparing glucose."
a(CHEBI:"glutamine") increases a(CHEBI:"carbon dioxide")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Simultaneously, the glutamine oxidation flux to carbon dioxide was higher under the average American dietary regime, reflecting the higher glutamine availability in this diet."
a(CHEBI:"glutamine") increases a(CHEBI:"carbon dioxide")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to proline conversion | Delivery to the liver."
a(CHEBI:"glutamine") increases a(CHEBI:"proline")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to citrulline conversion | For arginine synthesis."
a(CHEBI:"glutamine") increases a(CHEBI:"arginine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, the type I citrullinemia model was able to utilize partially the urea cycle by synthesizing ornithine, which was then converted either to glutamate by the ornithine transaminase (E.C.2.6.1.13) or to citrulline by the ornithine carbamoyltransferase (E.C. 2.1.3.3)."
a(CHEBI:"ornithine") increases a(CHEBI:"glutamate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to ornithine conversion | For spermine synthesis."
a(CHEBI:"ornithine") increases a(CHEBI:"glutamine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, the type I citrullinemia model was able to utilize partially the urea cycle by synthesizing ornithine, which was then converted either to glutamate by the ornithine transaminase (E.C.2.6.1.13) or to citrulline by the ornithine carbamoyltransferase (E.C. 2.1.3.3)."
a(CHEBI:"ornithine") increases bp(GOBP:"urea cycle")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Under an average American diet, the model for type I citrullinemia (OMIM: 215700 ), which is defective in ASS1 (GeneID: 445, E.C.6.3.4.5), led to an increased flux through the citrulline basolateral secretion reaction, a single fumarate producing reaction ('ADSL1'), and a decreased flux through the fumarase ('FUM')."
bp(GOBP:"secretion") increases path(MESHD:"citrullinemia")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Thus, there likely can be competition for succinylCoA between heme synthesis and the formation of succinate, fumarate, malate, and other tricarboxylic acid cycle intermediates."
a(CHEBI:"fumarate") association a(CHEBI:"heme")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Under an average American diet, the model for type I citrullinemia (OMIM: 215700 ), which is defective in ASS1 (GeneID: 445, E.C.6.3.4.5), led to an increased flux through the citrulline basolateral secretion reaction, a single fumarate producing reaction ('ADSL1'), and a decreased flux through the fumarase ('FUM')."
a(CHEBI:"fumarate") increases path(MESHD:"citrullinemia")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Under an average American diet, the model for type I citrullinemia (OMIM: 215700 ), which is defective in ASS1 (GeneID: 445, E.C.6.3.4.5), led to an increased flux through the citrulline basolateral secretion reaction, a single fumarate producing reaction ('ADSL1'), and a decreased flux through the fumarase ('FUM')."
p(HGNC:"FH") increases path(MESHD:"citrullinemia")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Under an average American diet, the model for type I citrullinemia (OMIM: 215700 ), which is defective in ASS1 (GeneID: 445, E.C.6.3.4.5), led to an increased flux through the citrulline basolateral secretion reaction, a single fumarate producing reaction ('ADSL1'), and a decreased flux through the fumarase ('FUM')."
p(HGNC:"FH") increases a(CHEBI:"fumarate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "These predictions were consistent with the reported build-up of citrulline in patients (37).Moreover, the model predicted an increased flux through the luminal uptake reactions of two amino acid transporters, ASCT2 (SLC1A5, GeneID: 6510) and B(0)AT1 (SLC6A19, GeneID: 340024 ), and through the alanine transaminase (E.C.2.6.1.2."
p(HGNC:"SLC1A5") increases a(CHEBI:"citrulline")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "These predictions were consistent with the reported build-up of citrulline in patients (37).Moreover, the model predicted an increased flux through the luminal uptake reactions of two amino acid transporters, ASCT2 (SLC1A5, GeneID: 6510) and B(0)AT1 (SLC6A19, GeneID: 340024 ), and through the alanine transaminase (E.C.2.6.1.2."
p(HGNC:"SLC6A19") increases a(CHEBI:"citrulline")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, the type I citrullinemia model was able to utilize partially the urea cycle by synthesizing ornithine, which was then converted either to glutamate by the ornithine transaminase (E.C.2.6.1.13) or to citrulline by the ornithine carbamoyltransferase (E.C. 2.1.3.3)."
bp(GOBP:"urea cycle") increases a(CHEBI:"glutamate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The predicted reduced urea secretion flux (Fig. 4) in the porphyria models was due to a reduced urea cycle, indicating ammonia toxicity."
bp(GOBP:"urea cycle") negativeCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Gyrate atrophy (OMIM: 258 870) and ornithine translocase deficiency (OMIM: 238 970) are caused by mutations in ornithine aminotransferase (OAT, GeneID: 4942, E.C. 2.6.1.13) and mitochondrial ornithine transporter (SLC25A15, GeneID: 10 166), respectively."
p(HGNC:"OAT") positiveCorrelation path(MESHD:"Gyrate atrophy")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Gyrate atrophy (OMIM: 258 870) and ornithine translocase deficiency (OMIM: 238 970) are caused by mutations in ornithine aminotransferase (OAT, GeneID: 4942, E.C. 2.6.1.13) and mitochondrial ornithine transporter (SLC25A15, GeneID: 10 166), respectively."
p(HGNC:"OAT") increases path(MESHD:"Gyrate atrophy")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "While gyrate atrophy patients usually have vision loss (OMIM: 258 870), ornithine translocase deficiency is associated with neurocognitive deficits, liver dysfunctions and lethargy (56)."
path(MESHD:"ornithine translocase deficiency") decreases path(MESHD:"Gyrate atrophy")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Gyrate atrophy patients have degenerative changes in the white matter and brain atrophy (57), whereas for ornithine translocase deficiency patients usually show developmental delay, ataxia, spasticity and learning disabilities (56)."
path(DO:"brain atrophy") positiveCorrelation path(MESHD:"Gyrate atrophy")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Gyrate atrophy patients have degenerative changes in the white matter and brain atrophy (57), whereas for ornithine translocase deficiency patients usually show developmental delay, ataxia, spasticity and learning disabilities (56)."
path(MESHD:"ataxia") positiveCorrelation path(DO:"brain atrophy")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Gyrate atrophy patients have degenerative changes in the white matter and brain atrophy (57), whereas for ornithine translocase deficiency patients usually show developmental delay, ataxia, spasticity and learning disabilities (56)."
path(MESHD:"spasticity") positiveCorrelation path(DO:"brain atrophy")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Gyrate atrophy patients have degenerative changes in the white matter and brain atrophy (57), whereas for ornithine translocase deficiency patients usually show developmental delay, ataxia, spasticity and learning disabilities (56)."
a(CHEBI:"cholesterol") increases a(CHEBI:"citrulline")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "We identified metabolic pathways known to occur within these cells, including sIEC-specific pathways, such as citrulline and proline metabolism, the conversion of fructose to glucose and the re-synthesis of triglyceride and cholesterol-ester."
a(CHEBI:"cholesterol") increases a(CHEBI:"glucose")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The liver synthesizes bile acids from cholesterol, which are then delivered to the intestinal lumen to aid in the digestion and absorption of fat with their emulsifying properties."
a(CHEBI:"cholesterol") increases a(CHEBI:"bile acids")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The liver synthesizes bile acids from cholesterol, which are then delivered to the intestinal lumen to aid in the digestion and absorption of fat with their emulsifying properties."
bp(GOBP:"digestion") increases a(CHEBI:"cholesterol")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The liver synthesizes bile acids from cholesterol, which are then delivered to the intestinal lumen to aid in the digestion and absorption of fat with their emulsifying properties."
bp(GOBP:"digestion") increases a(CHEBI:"bile acids")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Interestingly, these two IEMs showed the highest reduction in flux through the synthesis of GABA, an inhibitory neurotransmitter (59)."
a(CHEBI:"GABA") decreases bp(GOBP:"synthesis")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€œ | | Putrescine to GABA conversion | Exerts protective effect in small intestine."
a(CHEBI:"GABA") decreases a(CHEBI:"Putrescine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | | Putrescine to methionine conversion | Regeneration of methionine."
a(CHEBI:"Putrescine") increases a(CHEBI:"methionine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Additionally, MMA and propionic acidemia share common clinical features with respect to movement disorders, gastroenteritis and neurologic abnormalities (particularly vulnerable basal ganglia) (65)."
path(MESHD:"movement disorders") association path(MESHD:"propionic acidemia")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | Methylmalonic aciduria III | Methylmalonyl-CoA epimerase (MCEE, Gene ID: 84693 , E.C. 5.1.99.1) | Nervous system (OMIM: 251 120) | Co-occurrence of methylmalonic and propionic acidemia has been reported in patients, who also had gastroenteritis (65)."
path(MESHD:"propionic acidemia") positiveCorrelation path(DO:"Methylmalonic aciduria")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | Methylmalonic aciduria III | Methylmalonyl-CoA epimerase (MCEE, Gene ID: 84693 , E.C. 5.1.99.1) | Nervous system (OMIM: 251 120) | Co-occurrence of methylmalonic and propionic acidemia has been reported in patients, who also had gastroenteritis (65)."
path(DO:"Methylmalonic aciduria") positiveCorrelation p(HGNC:"MCEE")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Additionally, MMA and propionic acidemia share common clinical features with respect to movement disorders, gastroenteritis and neurologic abnormalities (particularly vulnerable basal ganglia) (65)."
path(MESHD:"gastroenteritis") association path(MESHD:"movement disorders")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Additionally, MMA and propionic acidemia share common clinical features with respect to movement disorders, gastroenteritis and neurologic abnormalities (particularly vulnerable basal ganglia) (65)."
path(MESHD:"gastroenteritis") association path(MESHD:"propionic acidemia")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | Glycerol kinase deficiency | Glycerol kinase (GK, GeneID: 2710, E.C. 2.7.1.30) | Digestive system, nervous system | GI symptoms (including gastroenteritis and decreased oral intake) are the initial features of this disease (OMIM: 307 030), (119)."
path(MESHD:"gastroenteritis") positiveCorrelation p(HGNC:"GK")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | Glycerol kinase deficiency | Glycerol kinase (GK, GeneID: 2710, E.C. 2.7.1.30) | Digestive system, nervous system | GI symptoms (including gastroenteritis and decreased oral intake) are the initial features of this disease (OMIM: 307 030), (119)."
p(HGNC:"GK") increases path(DO:"Glycerol kinase deficiency")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Our in silico analysis also predicted a failure to synthesize phosphatidylcholine from phosphatidylethanolamine in the latter two IEMs."
a(CHEBI:"phosphatidylethanolamine") increases a(CHEBI:"phosphatidylcholine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "This inability may also contribute to their similar clinical features, since phosphatidylcholine is an important membrane constituent and has been shown to exert anti-inflammatory roles, most highly beneficial in ulcerative colitis (66)."
a(CHEBI:"phosphatidylcholine") decreases path(MESHD:"ulcerative colitis")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "This inability may also contribute to their similar clinical features, since phosphatidylcholine is an important membrane constituent and has been shown to exert anti-inflammatory roles, most highly beneficial in ulcerative colitis (66)."
a(CHEBI:"anti-inflammatory") decreases a(CHEBI:"phosphatidylcholine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The high consumption of fructose from added sugars has been linked to hypertension (42) and its increased levels in serum and urine have also been found in patients with diabetes type 2 (43)."
a(CHEBI:"fructose") positiveCorrelation path(MESHD:"diabetes type 2")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "We identified metabolic pathways known to occur within these cells, including sIEC-specific pathways, such as citrulline and proline metabolism, the conversion of fructose to glucose and the re-synthesis of triglyceride and cholesterol-ester."
a(CHEBI:"fructose") increases a(CHEBI:"citrulline")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "We identified metabolic pathways known to occur within these cells, including sIEC-specific pathways, such as citrulline and proline metabolism, the conversion of fructose to glucose and the re-synthesis of triglyceride and cholesterol-ester."
a(CHEBI:"fructose") increases a(CHEBI:"glucose")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The conversion of fructose to glucose was not possible in the balanced diet due to the absence of fructose in this diet (1)."
a(CHEBI:"fructose") increases a(CHEBI:"glucose")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "We identified metabolic pathways known to occur within these cells, including sIEC-specific pathways, such as citrulline and proline metabolism, the conversion of fructose to glucose and the re-synthesis of triglyceride and cholesterol-ester."
a(CHEBI:"fructose") increases a(CHEBI:"cholesterol")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "We identified metabolic pathways known to occur within these cells, including sIEC-specific pathways, such as citrulline and proline metabolism, the conversion of fructose to glucose and the re-synthesis of triglyceride and cholesterol-ester."
a(CHEBI:"triglyceride") increases a(CHEBI:"citrulline")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | Mevalonic aciduria | Mevalonate kinase (MVK, Gene ID: 4598, E.C. 2.7.1.36) | Nervous system, liver, spleen, muscles (OMIM: 251 170) | One case reported complete jejunal and ileal obstruction and failure to thrive in mevalonic aciduria (114)."
path(MESHD:"Mevalonic aciduria") association p(HGNC:"MVK")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | Mevalonic aciduria | Mevalonate kinase (MVK, Gene ID: 4598, E.C. 2.7.1.36) | Nervous system, liver, spleen, muscles (OMIM: 251 170) | One case reported complete jejunal and ileal obstruction and failure to thrive in mevalonic aciduria (114)."
path(MESHD:"Mevalonic aciduria") increases path(MESHD:"obstruction")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | Mevalonic aciduria | Mevalonate kinase (MVK, Gene ID: 4598, E.C. 2.7.1.36) | Nervous system, liver, spleen, muscles (OMIM: 251 170) | One case reported complete jejunal and ileal obstruction and failure to thrive in mevalonic aciduria (114)."
path(MESHD:"Mevalonic aciduria") increases path(MESHD:"failure to thrive")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | SLOS | 7-Dehydrocholesterol reductase (DHCR7, Gene ID: 1717, E.C. 1.3.1.21) | Nervous system, muscles (OMIM: 270400) | Infants with SLOS usually present GI problems that include dysmotility, hypomotility, GI reflux, constipation, formula intolerance and developmental delay (38)."
p(HGNC:"DHCR7") positiveCorrelation path(MESHD:"SLOS")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
a(CHEBI:"methyl") increases a(CHEBI:"5-methyltetrahydrofolate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
a(CHEBI:"5-methyltetrahydrofolate") increases a(CHEBI:"folate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
a(CHEBI:"5-methyltetrahydrofolate") increases a(CHEBI:"amino acid")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Main Hcy determinants (MTHFR C677T status, vitamin B6, B12 and folate status) were also assessed."
a(CHEBI:"folate") association p(HGNC:"MTHFR")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
a(CHEBI:"folate") increases a(CHEBI:"methyl")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
a(CHEBI:"THF") increases a(CHEBI:"methyl")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
a(CHEBI:"THF") increases a(CHEBI:"5-methyltetrahydrofolate")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Table 2 summarizes homocysteine-related vitamin status and C677T polymorphism status for MTHFR gene in the studied groups."
p(HGNC:"MTHFR") association a(CHEBI:"Vitamin")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The synthesis flux of 5-methyltetrahydrofolate (5-methyl-THF) was higher in the balanced diet compared with the average American diet due to the influx of its precursor folate in the simulation of the balanced diet. 5-Methyl-THF is an important one carbon substituted folate and participates in amino acid and purine metabolism."
bp(GOBP:"purine metabolism") increases a(CHEBI:"5-methyltetrahydrofolate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Fatigue, dizziness, a rapid heartbeat, pale skin, and an enlarged liver and spleen (OMIM: 300751 )."
path(MESHD:"pale skin") positiveCorrelation path(MESHD:"Fatigue")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "This compound has potential antioxidant activity, comparable with that of beta-carotene and tocopherol, under low oxygen conditions (51) and, at very low concentrations, bilirubin tends to exert protective effects on the small intestine (52)."
a(CHEBI:"tocopherol") decreases a(CHEBI:"bilirubin")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The porphyria models were not able to secrete carbon monoxide (Fig. 4), which has various roles in the GI tract, including regulation of GI motility, activation of guanylate cyclase (suggested role in inflammation), function as a neurotransmitter, contribution to the membrane potential gradient and exerting protective role during GI injury (53,54)."
a(CHEBI:"carbon monoxide") association path(MESHD:"inflammation")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "The porphyria models were not able to secrete carbon monoxide (Fig. 4), which has various roles in the GI tract, including regulation of GI motility, activation of guanylate cyclase (suggested role in inflammation), function as a neurotransmitter, contribution to the membrane potential gradient and exerting protective role during GI injury (53,54)."
a(CHEBI:"carbon monoxide") increases p(HGNC:"GUCY2C")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Particularly, the latter role suggests that this compound may contribute to the GI inflammation observed in chronic inflammatory bowel disease (IBD)."
path(MESHD:"inflammatory bowel disease") increases path(MESHD:"inflammation")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Interestingly, IBD patients are prone to develop acute intermittent porphyria, i.e. AIP (55)."
path(MESHD:"IBD") increases path(MESHD:"AIP")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Atrophy patients, acting through the gutÃ¢â‚¬â€œbrain axis and (v) identification of known and novel co-morbidities."
bp(MESHPP:"gut brain axis") association path(MESHD:"atrophy")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Additionally, the reactions of the HMP were utilized to generate NADP, which was channeled into proline synthesis, and 5-phospho-alpha-D-ribose-1-diphosphate, which was used for the purine salvage pathway."
a(CHEBI:"NADP") increases a(CHEBI:"proline")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Additionally, the reactions of the HMP were utilized to generate NADP, which was channeled into proline synthesis, and 5-phospho-alpha-D-ribose-1-diphosphate, which was used for the purine salvage pathway."
a(CHEBI:"NADP") increases a(CHEBI:"D-ribose")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | Ornithine transcarbamylase deficiency | Ornithine carbamoyltransferase, mitochondrial (OTC, Gene ID: 5009, E.C. 2.1.3.3) | Nervous system, liver, skin, hair (OMIM: 311250) | Intestinal ornithine transcarbamylase /lactase ratio indicates degree of mucosal damage and atrophy (110)."
p(HGNC:"OTC") increases path(MESHD:"Ornithine transcarbamylase deficiency")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Pyrimidine synthesis | Maintenance of the purine level and important byproduct release."
a(CHEBI:"purine") regulates bp(GOBP:"Pyrimidine synthesis")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ || Fructose to glucose conversion | Fructose utilization"
a(CHEBI:"fructose") increases a(CHEBI:"glucose")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "However, the synthesis of phosphatidylethanolamine from phosphatidylserine in rat small intestine has been suggested (78).Deoxy-nucleotides have been also removed from the Recon 1 biomass reactions as sIECs cannot replicate (79)."
a(CHEBI:"phosphatidylserine") increases a(CHEBI:"phosphatidylethanolamine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Numerous metabolites, including bilirubin, nitric oxide and cholesterol, are also secreted into the lumen."
a(CHEBI:"nitric oxide") increases a(CHEBI:"bilirubin")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "An exception is the GLUT-2 transporter, which is usually present at the basolateral side, but which can also migrate onto the luminal side to aid in glucose absorption under fully fed state (29)."
p(HGNC:"SLC2A2") increases a(CHEBI:"glucose")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Additionally, we analyzed the in silico effect of cystinuria (OMIM: 220 100), which is caused by mutation in either solute carrier family 3 (SLC3A1, GeneID: 6519) or solute carrier family 7 (SLC7A9, GeneID: 11 136).Cystinuria was included in the analysis as the intestinal dibasic amino acid transport system is defective in these patients (35), and thus evidence of the expression of both the genes in human sIECs exists."
p(HGNC:"SLC3A1") increases path(MESHD:"cystinuria")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Additionally, blocked flux through HMP, reduced fluxes through reactions involved in pyrimidine synthesis, in the conversion of glutamine to carbon dioxide, and in the purine catabolism pathway contributed to a block in the biomass reaction for cystinuria."
path(MESHD:"cystinuria") decreases a(CHEBI:"glutamine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Additionally, blocked flux through HMP, reduced fluxes through reactions involved in pyrimidine synthesis, in the conversion of glutamine to carbon dioxide, and in the purine catabolism pathway contributed to a block in the biomass reaction for cystinuria."
path(MESHD:"cystinuria") decreases a(CHEBI:"carbon dioxide")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Additionally, blocked flux through HMP, reduced fluxes through reactions involved in pyrimidine synthesis, in the conversion of glutamine to carbon dioxide, and in the purine catabolism pathway contributed to a block in the biomass reaction for cystinuria."
path(MESHD:"cystinuria") decreases bp(GOBP:"purine catabolism")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Additionally, we analyzed the in silico effect of cystinuria (OMIM: 220 100), which is caused by mutation in either solute carrier family 3 (SLC3A1, GeneID: 6519) or solute carrier family 7 (SLC7A9, GeneID: 11 136).Cystinuria was included in the analysis as the intestinal dibasic amino acid transport system is defective in these patients (35), and thus evidence of the expression of both the genes in human sIECs exists."
p(HGNC:"SLC7A9") increases path(MESHD:"cystinuria")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "There is disordered intestinal function in both (102), while untreated type 1 b can lead to intestinal mucosal ulcers (103)."
path(MESHD:"type 1") increases path(MESHD:"ulcers")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Microvillus inclusion disease (MVID) is a rare congenital enteropathy associated with brush border atrophy and reduced expression of enzymes at the enterocyte's apical surface."
path(MESHD:"Microvillus inclusion disease") association path(MESHD:"atrophy")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Microvillus inclusion disease (MVID) is a rare congenital enteropathy associated with brush border atrophy and reduced expression of enzymes at the enterocyte's apical surface."
path(MESHD:"Microvillus inclusion disease") isA path(MESHD:"enteropathy")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | Congenital sucrase-isomaltase deficiency (CSI) | Sucrase-isomaltase (SI, Gene ID:6476, E.C. 3.2.1.48 and 3.2.1.10) | Digestive system | CSI is caused by a deficiency in sucraseisomaltase, an integral brush border membrane protein of the small intestine (OMIM:222 900).It is charaterized by fermentative diarrhea, abdominal pain and cramps (106)."
p(HGNC:"SI") positiveCorrelation path(MESHD:"Congenital sucrase-isomaltase deficiency")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | Propionic acidemia | Propionyl-CoA carboxylase (PCCA or PCCB, Gene ID: 5095, Gene ID: 5096, E.C. 6.4.1.3) | Nervous system, muscle, heart (OMIM: 606054) | Co-occurrence of methylmalonic and propionic acidemia has been reported in patients, who also had gastroenteritis (65)."
p(HGNC:"PCCA") positiveCorrelation path(MESHD:"Propionic acidemia")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Uptake and secretion of cholic acid | Enterohepatic circulation."
bp(MESHPP:"Enterohepatic circulation") increases a(CHEBI:"cholic acid")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Uptake and secretion of glyco-cholic acid | Enterohepatic circulation."
bp(MESHPP:"Enterohepatic circulation") increases a(CHEBI:"cholic acid")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Uptake and secretion of tauro-cholic acid | Enterohepatic circulation."
bp(MESHPP:"Enterohepatic circulation") increases a(CHEBI:"cholic acid")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Cysteine to pyruvate conversion | Maintenance of cytosolic pyruvate pool."
a(CHEBI:"cysteine") increases a(CHEBI:"pyruvate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Methionine to cysteine conversion | Synthesis of cysteine."
a(CHEBI:"cysteine") increases a(CHEBI:"Methionine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | | Synthesis of FMN | Conversion of riboflavin to active form."
a(CHEBI:"FMN") increases a(CHEBI:"riboflavin")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Synthesisof 5-methyl-tetrahydrofolate | Generated from folic acid, an important co-factor in one carbon metabolism."
a(CHEBI:"tetrahydrofolate") increases a(CHEBI:"methyl")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Causes of HHcy include the defects in its catabolism, which may be inherited (congenital enzymatic defects) or acquired (as in deficiencies of B6, folic acid, or vitamin B12 which are important enzymatic cofactors) and/or associated to conditions responsible for renal or liver failure [9,10,18-22]."
a(CHEBI:"folic acid") decreases a(CHEBI:"Vitamin B6")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Causes of HHcy include the defects in its catabolism, which may be inherited (congenital enzymatic defects) or acquired (as in deficiencies of B6, folic acid, or vitamin B12 which are important enzymatic cofactors) and/or associated to conditions responsible for renal or liver failure [9,10,18-22]."
a(CHEBI:"folic acid") increases path(MESHD:"liver failure")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Causes of HHcy include defects of its catabolism, due to inherited enzymatic and/ or vitamin deficiencies (B6, folic acid, or vitamin B12 are important enzymatic cofactors), and conditions responsible for renal or liver failure [9,10,18-22]."
a(CHEBI:"folic acid") increases path(MESHD:"liver failure")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Synthesisof 5-methyl-tetrahydrofolate | Generated from folic acid, an important co-factor in one carbon metabolism."
a(CHEBI:"folic acid") increases a(CHEBI:"methyl")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Synthesisof 5-methyl-tetrahydrofolate | Generated from folic acid, an important co-factor in one carbon metabolism."
a(CHEBI:"folic acid") increases a(CHEBI:"tetrahydrofolate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Synthesisof 5-methyl-tetrahydrofolate | Generated from folic acid, an important co-factor in one carbon metabolism."
bp(GOBP:"carbon metabolism") association a(CHEBI:"folic acid")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Synthesisof 5-methyl-tetrahydrofolate | Generated from folic acid, an important co-factor in one carbon metabolism."
bp(GOBP:"carbon metabolism") increases a(CHEBI:"tetrahydrofolate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Analysis of the model's metabolic capability revealed that this reduced cysteine secretion flux is due to the model's inability to convert methionine to cysteine."
a(CHEBI:"methionine") increases a(CHEBI:"cysteine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | TCA cycle flux | Energy generation, anaplerosis, and amphibolic role."
bp(PKG:"anaplerosis") association bp(GOBP:"TCA cycle")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Also, the cofactor requirement and sub-cellular localization of reactions included in the cholesterol synthesis pathway, which are catalyzed by the desmosterol reductase (E.C. 1.3.1.72) and HMG-CoA reductase (E.C. 2.3.3.10) reactions, were updated in accordance with the current literature evidence (76)."
a(CHEBI:"desmosterol") increases bp(GOBP:"cholesterol synthesis")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to citrulline conversion | For arginine synthesis."
a(CHEBI:"arginine") increases a(CHEBI:"citrulline")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to ornithine conversion | For spermine synthesis."
a(CHEBI:"spermine") increases a(CHEBI:"glutamine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to ornithine conversion | For spermine synthesis."
a(CHEBI:"spermine") increases a(CHEBI:"ornithine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| | | Glutamine to aspartate conversion | For nucleotide synthesis."
a(CHEBI:"aspartate") increases a(CHEBI:"glutamine")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to ammonia conversion | Glutaminase activity to generate glutamate."
p(HGNC:"GLS") increases a(CHEBI:"glutamate")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "| Ã¢â€ â€˜ | | Glutamine to ammonia conversion | Glutaminase activity to generate glutamate."
p(HGNC:"GLS") increases a(CHEBI:"ammonia")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Megaloblastic anemia leads to GI disturbances like malabsorption and diarrhea (118)."
path(MESHD:"malabsorption") association path(MESHD:"Megaloblastic anemia")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Consequently, one of the intestinal amino acid transporters (ATB0, SLC6A14, GeneID: 11254), which has a broad substrate specificity for both neutral and cationic amino acids (39) and requires the presence of sodium and chloride for its activity, could not be used in this diet."
p(HGNC:"SLC6A14") increases a(CHEBI:"sodium")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Consequently, one of the intestinal amino acid transporters (ATB0, SLC6A14, GeneID: 11254), which has a broad substrate specificity for both neutral and cationic amino acids (39) and requires the presence of sodium and chloride for its activity, could not be used in this diet."
a(CHEBI:"chloride") increases p(HGNC:"SLC6A14")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Other clinical signs include vomiting, failure to thrive, dehydration, disacchariduria including lactosuria, renal tubular acidosis and amino aciduria."
path(MESHD:"renal tubular acidosis") positiveCorrelation path(MESHD:"vomiting")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "Other clinical signs include vomiting, failure to thrive, dehydration, disacchariduria including lactosuria, renal tubular acidosis and amino aciduria."
path(MESHD:"renal tubular acidosis") positiveCorrelation path(MESHD:"dehydration")

SET Citation = {"PubMed", "23492669.0"}
SET DataSource = "manual-curation"
SET Support = "GSD type 1 a is casued due to mutations in G6PC and type 1 b due to defect in SLC37A. | Liver, kidney, digestive system, respiratory system, skeletal system (OMIM:232 200) | In both of these disorders, there is frequently occurring chronic diarrhea."
p(HGNC:"G6PC1") increases path(MESHD:"type 1")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Moreover, PLP is in important co-factor for Glutamate decarboxylase (GAD) activity, the sole enzyme able to synthesize ÃŽÂ³-aminobutyric acid (GABA), a major inhibitory neurotransmitter, whose reduced effect or availability has also been observed during AP exacerbations [60-61]."
path(MESHD:"GAD") increases a(CHEBI:"4-aminobutyric acid")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "In fact, in our survey all patients undergoing chronic Heme-arginate who developed venous thrombosis showed moderate to severe HHcy."
path(MESHD:"venous thrombosis") association a(CHEBI:"Heme")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "In fact, in our survey all patients undergoing chronic Heme-arginate who developed venous thrombosis showed moderate to severe HHcy."
a(CHEBI:"arginate") increases path(MESHD:"venous thrombosis")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Interestingly, both heme biosynthesis and sulphur amino acid metabolism require vitamin B6, (Pyridoxal-phosphate, PLP) an important cofactor of ALAS1 and of cystathionine ÃŽÂ² synthase (CBS) and cystathionine ÃŽÂ³-lyase (CGL) enzymes that catabolize homocysteine (Hcy)."
a(CHEBI:"Vitamin B6") positiveCorrelation a(CHEBI:"heme biosynthesis")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Interestingly, both heme biosynthesis and sulphur amino acid metabolism require vitamin B6, (Pyridoxal-phosphate, PLP) an important cofactor of ALAS1 and of cystathionine ÃŽÂ² synthase (CBS) and cystathionine ÃŽÂ³-lyase (CGL) enzymes that catabolize homocysteine (Hcy)."
a(CHEBI:"Vitamin B6") positiveCorrelation a(CHEBI:"cystathionine")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Interestingly, both heme biosynthesis and sulphur amino acid metabolism require vitamin B6, (Pyridoxal-phosphate, PLP) an important cofactor of ALAS1 and of cystathionine ÃŽÂ² synthase (CBS) and cystathionine ÃŽÂ³-lyase (CGL) enzymes that catabolize homocysteine (Hcy)."
a(CHEBI:"Vitamin B6") positiveCorrelation a(CHEBI:"sulphur")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Causes of HHcy include the defects in its catabolism, which may be inherited (congenital enzymatic defects) or acquired (as in deficiencies of B6, folic acid, or vitamin B12 which are important enzymatic cofactors) and/or associated to conditions responsible for renal or liver failure [9,10,18-22]."
a(CHEBI:"Vitamin B6") increases path(MESHD:"liver failure")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Causes of HHcy include defects of its catabolism, due to inherited enzymatic and/ or vitamin deficiencies (B6, folic acid, or vitamin B12 are important enzymatic cofactors), and conditions responsible for renal or liver failure [9,10,18-22]."
a(CHEBI:"Vitamin B6") increases path(MESHD:"liver failure")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Overall, the Hcy/Cys ratio showed a significant inverse correlation with plasma B6 levels (r = -.567, p = .000)."
a(CHEBI:"Vitamin B6") negativeCorrelation a(CHEBI:"cysteine")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Discussion Hyperhomocysteinemia, a condition defined by serum levels of homocysteine above 15 Ã‚Âµmol/L, has been claimed as an independent risk factor for the development of a wide range of diseases, including thrombosis, atherosclerosis, endothelial damage, osteoporosis and neuropsychiatric illness."
path(MESHD:"thrombosis") association path(MESHD:"Hyperhomocysteinemia")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Discussion Hyperhomocysteinemia, a condition defined by serum levels of homocysteine above 15 Ã‚Âµmol/L, has been claimed as an independent risk factor for the development of a wide range of diseases, including thrombosis, atherosclerosis, endothelial damage, osteoporosis and neuropsychiatric illness."
path(MESHD:"atherosclerosis") positiveCorrelation path(MESHD:"Hyperhomocysteinemia")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Blood samples were collected in EDTA tubes and immediately centrifuged in order to prevent Hcy and Cys efflux from erythrocytes to plasma."
a(CHEBI:"EDTA") decreases a(CHEBI:"cysteine")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Interestingly, both heme biosynthesis and sulphur amino acid metabolism require vitamin B6, (Pyridoxal-phosphate, PLP) an important cofactor of ALAS1 and of cystathionine ÃŽÂ² synthase (CBS) and cystathionine ÃŽÂ³-lyase (CGL) enzymes that catabolize homocysteine (Hcy)."
a(CHEBI:"cystathionine") positiveCorrelation a(CHEBI:"heme biosynthesis")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Interestingly, both heme biosynthesis and sulphur amino acid metabolism require vitamin B6, (Pyridoxal-phosphate, PLP) an important cofactor of ALAS1 and of cystathionine ÃŽÂ² synthase (CBS) and cystathionine ÃŽÂ³-lyase (CGL) enzymes that catabolize homocysteine (Hcy)."
a(CHEBI:"cystathionine") positiveCorrelation a(CHEBI:"sulphur")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Homocysteine (Hcy) is a metabolic intermediate of sulphur amino acid metabolism (Fig. 2) [8-10]: its elevation in plasma, a condition referred as hyperhomocysteinemia (HHcy), has been related to neurological and endothelial damage and increased risk for vascular diseases (atherosclerosis and arterial and venous thrombosis) [11-17]."
a(CHEBI:"sulphur") increases a(CHEBI:"Homocysteine")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Homocysteine-related vitamin status in AP studied groups."
a(CHEBI:"Homocysteine") association a(CHEBI:"Vitamin")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Homocysteine (Hcy) is a metabolic intermediate of sulphur amino acid metabolism (Fig. 2) [8-10]: its elevation in plasma, a condition referred as hyperhomocysteinemia (HHcy), has been related to neurological and endothelial damage and increased risk for vascular diseases (atherosclerosis and arterial and venous thrombosis) [11-17]."
a(CHEBI:"Homocysteine") increases path(MESHD:"venous thrombosis")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Homocysteine (Hcy) is a metabolic intermediate of sulphur amino acid metabolism (Fig. 2) [8-10]: its elevation in plasma, a condition referred as hyperhomocysteinemia (HHcy), has been related to neurological and endothelial damage and increased risk for vascular diseases (atherosclerosis and arterial and venous thrombosis) [11-17]."
a(CHEBI:"Homocysteine") increases path(MESHD:"hyperhomocysteinemia")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Table 2 summarizes homocysteine-related vitamin status and C677T polymorphism status for MTHFR gene in the studied groups."
a(CHEBI:"Vitamin") association a(CHEBI:"homocysteine")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "In order to evaluate the possible mechanisms underlying the observed HHcy in AP patients, we considered different well-known Hcy determinants, such as the vitamin status."
a(CHEBI:"Vitamin") association path(MESHD:"HHcy")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "The link between AP, HHcy and vitamin deficiency is also intriguing if considering that the clinic of peripheral neuropathy resulting from a deficiency in PLP shows striking resemblances to that observed in acute porphyrias [45-47].When considering the high prevalence of vitamin deficiencies in the general population [18,48,49], and in porphyria patients [50], it is likely that depletion of vitamin cofactors in multiple tissues promoted by a deficiency in heme biosynthesis may contribute to worsen other underlying deficiencies."
path(MESHD:"Vitamin deficiency") association path(MESHD:"HHcy")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "We measured plasma homocysteine in a group of patients with Acute porphyrias (AIP and VP), in order to determine whether these diseases are associated with a derangement of Hcy catabolism responsible for HHcy."
a(CHEBI:"Vitamins") association a(CHEBI:"homocysteine")

SET Citation = {"PubMed", "32554360.0"}
SET DataSource = "manual-curation"
SET Support = "Eventually, her seizure condition became much better controlled with one to two convulsive seizures per year using a combination of CBZ, clobazam and levetiracetam (age 29 to 32 years)."
a(CHEBI:"clobazam") decreases path(MESHD:"seizure")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Cyclosporine-A mainly inhibits T cell proliferation and is nephrotoxic (7,8)."
a(CHEBI:"Cyclosporine") decreases bp(GOBP:"cell proliferation")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Azathioprine can not be used together with febuxostat (9), and has potent myelosuppressive action (10)."
a(CHEBI:"febuxostat") causesNoChange a(CHEBI:"Azathioprine")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "The patient and her cousin underwent exon gene sequencing, and genes related to AIP and immunodeficiency disorders were analyzed."
path(MESHD:"immunodeficiency disorders") association path(MESHD:"AIP")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Since the patient was given artificial tears to relieve dry eyes, she was given mycophenolate mofetil to delay the progression of the primary disease."
a(MAXO:"artificial tears therapy") decreases path(MESHD:"dry eyes")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Since the patient was given artificial tears to relieve dry eyes, she was given mycophenolate mofetil to delay the progression of the primary disease."
a(CHEBI:"mycophenolate mofetil") decreases path(MESHD:"dry eyes")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "The woman had severe abdominal pain after a cold, flaccid paralysis of the limbs, and muscle atrophy in the left hand."
bp(GOBP:"muscle atrophy") positiveCorrelation path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Each attack was treated with high concentration of glucose, heme arginate, an analgesic, and a beta blocker to lower blood pressure; the condition was relieved for one-three weeks."
a(CHEBI:"analgesic") decreases a(CHEBI:"glucose")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Test results (Table 1) indicated that serum immunoglobulins (IgG and IgA) were elevated, and serum anti-SS-A antibody, serum anti-SS-B antibody, Schirmer's test were positive."
p(HGNC:"IGHD") positiveCorrelation a(GO:"IgG")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "On the other hand, there were typical clinical manifestations of PSS such as dry eyes and a dry mouth, the elevation of immunoglobulins (IgG and IgA) and the results of Schirmer's test, an anti-SS-A antibody test, an anti-SS-B antibody test, and a labial gland biopsy were all positive."
p(HGNC:"IGHD") positiveCorrelation a(GO:"IgG")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Serum immunoglobulin continued to rise (IgG: 16.70 Ã¢â€ â€™ 28.00 g / L, IgA: 5.23 Ã¢â€ â€™ 6.24 g / L )."
p(HGNC:"IGHD") positiveCorrelation a(GO:"IgG")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Test results (Table 1) indicated that serum immunoglobulins (IgG and IgA) were elevated, and serum anti-SS-A antibody, serum anti-SS-B antibody, Schirmer's test were positive."
p(HGNC:"SSB") positiveCorrelation a(GO:"IgG")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Test results (Table 1) indicated that serum immunoglobulins (IgG and IgA) were elevated, and serum anti-SS-A antibody, serum anti-SS-B antibody, Schirmer's test were positive."
p(HGNC:"SSB") positiveCorrelation p(HGNC:"IGHD")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "# The challenge of managing comorbidities: a case report of primary Sjogren's syndrome in a patient with acute intermittent porphyria Qing Teng ^1, Liyan Ma^2, Yuelin Ma^1, Yiran Zhang ^3, Ninglin Kang ^4, Yuanxiang Hu^5, Songyun Zhang ^1, * ^1 Department of Endocrinology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China; ^2 Department of Rheumatology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China; ^3 School of First Clinical Medical College, Southern Medical University, Guangzhou, Guangdong, China; ^4 Hebei Provincial Hospital of Traditional Chinese Medicine, Shijiazhuang, Hebei, China; ^5 Geriatrics, First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei, China."
path(MESHD:"Sjogren's syndrome") positiveCorrelation path(MESHD:"AIP")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Primary Sjogren's syndrome (PSS) is a common autoimmune disease."
path(MESHD:"Sjogren's syndrome") isA path(MESHD:"autoimmune disease")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "The woman developed mumps 3 times, and rampant dental caries and tooth loss gradually appeared."
path(MESHD:"dental caries") positiveCorrelation path(MESHD:"mumps")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "The woman developed mumps 3 times, and rampant dental caries and tooth loss gradually appeared."
path(MESHD:"mumps") increases path(MESHD:"tooth loss")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "The woman developed mumps 3 times, and rampant dental caries and tooth loss gradually appeared."
path(MESHD:"tooth loss") positiveCorrelation path(MESHD:"dental caries")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Five years ago, the woman was diagnosed with Hashimoto's thyroiditis (subclinical hypothyroidism), and she was given Euthyrox 50 ug / d. Three years ago, intermittent purpura developed on the skin of the lower limbs after physical activity, though this was not treated."
path(MESHD:"Hashimoto's thyroiditis") positiveCorrelation path(MESHD:"purpura")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Some studies have reported increased risks of schizophrenia and bipolar disease in AHP cohorts, and an increased prevalence of AHP in psychiatric patient cohorts."
path(MESHD:"bipolar disease") positiveCorrelation path(MESHD:"schizophrenia")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The difference in cardiovascular disease between porphyria patients and the general population was not significant ( 41.73 % vs. 36.79 % p=.150 ).All diseases except renal diseases were more frequent in the reference group with fibromyalgia compared to the porphyria patients."
path(MESHD:"kidney disease") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Except for deaths due to PLC and porphyria per se, a higher risk of death due to renal diseases was also detected, confirming previous results from a regional single center cohort."
path(MESHD:"kidney disease") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with AHP had a nonsignificant trend towards lower rates of two cancer forms that are related to smoking, lung cancer, and bladder cancer (Table 3), compared to the matched comparators."
path(DO:"bladder cancer") association path(DO:"lung cancer")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The rate of cerebrovascular disease was increased in U-PBG positive AIP ( aHR=1.40[95 %CI=1.06-1.85] ), mainly related to an increased rate of hemorrhagic stroke ( aHR=1.91 [95 %CI=1.11-3.31] ), but not in AHP in general."
path(MESHD:"cerebrovascular disease") increases path(MESHD:"hemorrhagic stroke")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The risk of cerebrovascular disease in U-PBG positive patients with AIP was mainly associated to an increased risk of hemorrhagic stroke ( aHR=1.91 [ 95 % CI=1.11-3.31] ), which might be related to the high frequency of HT in these patients."
path(MESHD:"hemorrhagic stroke") positiveCorrelation path(MESHD:"cerebrovascular disease")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The risk of other cardiovascular conditions commonly associated with HT such as heart failure, atrial fibrillation, ischemic heart disease, and peripheral artery disease did not differ between the AHP groups and comparators."
path(MESHD:"ischemic heart disease") association path(MESHD:"atrial fibrillation")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "The risk of other cardiovascular conditions commonly associated with HT such as heart failure, atrial fibrillation, ischemic heart disease, and peripheral artery disease did not differ between the AHP groups and comparators."
path(MESHD:"ischemic heart disease") association path(MESHD:"heart failure")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Similarly, risks of specified forms of psychiatric disorders such as mood disorders, psychosis, and addiction were not different from the matched reference population."
path(MESHD:"mood disorders") association path(MESHD:"psychiatric disorders")

SET Citation = {"PubMed", "36546345.0"}
SET DataSource = "manual-curation"
SET Support = "Furthermore, studies have proposed that the disease-associated gene in AIP, H M B S (hydroxymethylbilane synthase), has a tumor suppressor function."
bp(MESHPP:"tumor suppressor") association p(HGNC:"HMBS")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "erythropoietic protoporphyrias (EPP and XLEPP) can develop a severe cholestatic liver disease that is often fatal without a liver transplantation. In AP, some patients have severe recurrent attacks that do not respond to treatment and LT is a curative treatment option. Hence, the treatment aims for LT in porphyrias can be quite different."
a(NCIT:"curative treatment") increases path(MESHD:"cholestatic liver disease")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "Four frequent problems have been identified in LT for EPPassociated liver disease: disease recurrence in the graft, phototoxic tissue injuries from surgical lights, high frequencies of postoperative neuropathies and biliary tract complications."
path(MESHD:"neuropathies") association path(MESHD:"liver disease")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy."
path(MESHD:"hyperplasia") association path(MESHD:"atrophy")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Histological findings suggest that renal arterioles may be permanently injured, leading to chronic vasculopathy with narrowed lumen and tissue ischaemia contributing to CKD. Human peptide transporter 2 (PEPT2) has been suggested to have an impact on PAKD"
path(MESHD:"ischaemia") increases path(MESHD:"vasculopathy")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Histological findings suggest that renal arterioles may be permanently injured, leading to chronic vasculopathy with narrowed lumen and tissue ischaemia contributing to CKD. Human peptide transporter 2 (PEPT2) has been suggested to have an impact on PAKD in French patients with AP. ALA, which is highly hydrophilic, is freely filtered in the urine and reabsorbed by PEPT2 in the proximal tubule."
path(MESHD:"vasculopathy") increases path(MESHD:"ischaemia")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "If the levels of porphyrin precursors are close to normal (<2Ã¢â‚¬Âfold increase), the association between chronic pain and AP is unlikely."
path(MESHD:"chronic pain") association a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Most studies are descriptive and lack biochemical porphyria markers and criteria for chronic pain and specific categorisation of chronic pain types."
path(MESHD:"chronic pain") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Chronic pain mainly represents the neuropathic type based on burning and tingling sensations, poor response to painkillers and numbness. In some cases, it is diffuse, affecting the whole abdomen or Ã¢â‚¬Ëœwhole body'. Overlap with signs of sensory (19%) Overlap with signs of sensory (19%) and motor (22%) neuropathy and chronic pain (25%-40%) was common. The frequency and proportion of pain types have varied in different series (Table 1) due to variability in the severity of AP and the methodological issues mentioned above."
path(MESHD:"chronic pain") association path(MESHD:"neuropathic")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Chronic pain occurs in patients with recurrent attacks, combined with chronic fatigue and nausea, leading to poor quality of life."
path(MESHD:"chronic pain") positiveCorrelation path(MESHD:"nausea")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Chronic pain itself can cause nausea."
path(MESHD:"chronic pain") increases path(MESHD:"nausea")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "On neurophysiological assessment, classic nerve conduction studies are usually normal or show sequelae of previous acute PNP. Quantitative thermal sensation testing and skin punch biopsy may help to confirm the diagnosis of small fibre neuropathy in chronic neuropathic pain, but these studies are lacking in AP."
path(MESHD:"chronic neuropathic pain") increases path(MESHD:"neuropathy")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "This could include mirtazapine for patients with a low BMI, or escitalopram or trazodone for severe insomnia."
a(CHEBI:"escitalopram") decreases path(MESHD:"severe insomnia")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Considering the clinical severity of AIP in these patients, surprisingly few histopathological findings could be detected. Based on the 25 explanted livers, none of the AP patients had cirrhosis and only one subject had stage III fibrosis due to advanced hemosiderosis. Histological studies of peritumoral liver samples resected from patients with APÃ¢â‚¬Âassociated PLC showed cirrhosis or advanced fibrosis in several patients."
path(MESHD:"hemosiderosis") increases path(MESHD:"cirrhosis")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Considering the clinical severity of AIP in these patients, surprisingly few histopatho- logical findings could be detected. Based on the 25 explanted livers, none of the AP patients had cirrhosis and only one subject had stage III fibrosis due to advanced hemosiderosis."
path(MESHD:"hemosiderosis") increases path(MESHD:"fibrosis")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Of note, CYP450Ã¢â‚¬Ârelated drug interactions should be checked if givosiran is used.45 The use of antidepressants is justified as 67 also reported in AP9, 10, 11 (Table 1)."
bp(MESHPP:"drug interactions") association a(CHEBI:"CYP450")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Of the 251 AP patients in the Norwegian porphyria Register, three cases (1.2%) were identi fied compared to 6868 cases out of 4 398 546 individuals (.1%) in the reference population, resulting in the HR of 7.6.75 The Swedish registry- based cohort study with 1244 AP and 12 362 individuals in the reference population identified 10 (.8%) cases versus 27 (.2%) in the comparators, giving the HR = 3.92.48 Four of the tumours were clear cell renal cell carcinoma and two were chromophobe renal cell carcinoma."
path(DO:"clear cell renal cell carcinoma") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "The role of haem depletion or mitochondrial dysfunction is also possible in chronic fatigue syndrome associated with AP."
path(MESHD:"chronic fatigue syndrome") association path(MESHD:"mitochondrial dysfunction")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "As chronic fatigue and depression often overlap, the use of cognitive behavioural therapy and/or antidepressants may have some effect. As with myalgic encephalomyelitis or chronic fatigue syndrome, an energy coping strategy of finding individual limits to mental and physical activity and following this balance may be recommended."
a(CHEBI:"antidepressants") decreases path(MESHD:"chronic fatigue")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Proton pump inhibitors are worth trying to rule out gastroÃ¢â‚¬Âoesophageal reflux disease."
path(MESHD:"gastro oesophageal reflux disease") association a(CHEBI:"Proton pump inhibitors")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Central antiemetics such as ondansetron or metoclopramide may be used for severe attacks of nausea in AP."
a(CHEBI:"metoclopramide") decreases path(MESHD:"nausea")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Chronic pain mainly represents the neuropathic type based on burning and tingling sensations, poor response to painkillers and numbness. In some cases, it is diffuse, affecting the whole abdomen or Ã¢â‚¬Ëœwhole body'. Overlap with signs of sensory (19%) Overlap with signs of sensory (19%) and motor (22%) neuropathy and chronic pain (25%-40%) was common. The frequency and proportion of pain types have varied in different series (Table 1) due to variability in the severity of AP and the methodological issues mentioned above."
path(MESHD:"tingling sensations") association path(MESHD:"chronic pain")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Chronic pain mainly represents the neuropathic type based on burning and tingling sensations, poor response to painkillers and numbness. In some cases, it is diffuse, affecting the whole abdomen or Ã¢â‚¬Ëœwhole body'. Overlap with signs of sensory (19%) Overlap with signs of sensory (19%) and motor (22%) neuropathy and chronic pain (25%-40%) was common. The frequency and proportion of pain types have varied in different series (Table 1) due to variability in the severity of AP and the methodological issues mentioned above."
path(MESHD:"numbness") association path(MESHD:"chronic pain")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Chronic pain mainly represents the neuropathic type based on burning and tingling sensations, poor response to painkillers and numbness. In some cases, it is diffuse, affecting the whole abdomen or Ã¢â‚¬Ëœwhole body'. Overlap with signs of sensory (19%) Overlap with signs of sensory (19%) and motor (22%) neuropathy and chronic pain (25%-40%) was common. The frequency and proportion of pain types have varied in different series (Table 1) due to variability in the severity of AP and the methodological issues mentioned above."
bp(MESHPP:"diffuse") association path(MESHD:"chronic pain")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
path(MESHD:"tubulointerstitial") increases path(MESHD:"kidney disease")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Fourteen kidney biopsies from PAKD patients revealed chronic tubulointerstitial disease, characterised by interstitial fibrosis and tubular atrophy"
path(MESHD:"tubulointerstitial") increases path(MESHD:"atrophy")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "Severe vascular lesions were present in half of the biopsies, with fibrous intimal hyperplasia associated with focal cortical atrophy. ALA and hypertension could promote acute renal vasospasm via autonomic dysfunction during an attack and, together with hypovolemia, induce acute renal failure."
path(MESHD:"hypovolemia") association path(MESHD:"hypertension")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Stacked bar chart showing the proportion of total physician visits among acute porphyria patients, stratified by specialist group and compared to the general population and fibromyalgia patients."
path(MESHD:"fibromyalgia") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "In particular, the difference between porphyria patients and those diagnosed with fibromyalgia was statistically significant (p = .013)."
path(MESHD:"fibromyalgia") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "A closer look at the subgroups of porphyria patients compared to fibromyalgia patients showed that the mean number of sick days of active porphyria patients with <2 attacks was 25.0 (IQR: 14.1Ã¢â‚¬â€œ28.5), which is comparable to that of fibromyalgia patients."
path(MESHD:"fibromyalgia") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "The dynamics of hospitalization in porphyria patients show an evolution, with an increase from 27.4 % to 33.8 % between the 4th and the 1st year before the index (Figure 3).Among fibromyalgia patients, 35.8 % experienced at least one hospitalization in the first-year pre-index, compared with 19.3 % of the general population, the latter difference being significant when compared with the porphyria study population ( p<.001 )."
path(MESHD:"fibromyalgia") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "However, similar to the porphyria patients, the fibromyalgia patients also had a high visit rate of 99.8 %."
path(MESHD:"fibromyalgia") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "In patients with active porphyria, patients had similar median sickness days than patients with fibromyalgia (20 vs. 23.5 days, p = .736)."
path(MESHD:"sickness") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Cardiovascular diseases were diagnosed in 41.7 % of the porphyria patients 1 year before the index, with a higher incidence in active patients with at least 2 attacks ( 56.7 % ), and in active porphyria patients with fewer than 2 attacks compared to the porphyria patients."
path(MESHD:"cardiovascular diseasess") positiveCorrelation path(MESHD:"porphyria")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Looking more closely at the health challenges faced by acute porphyria patients, it was found that these patients were more likely to suffer from nervous system disorders, pain, and mental disorders in the first year before the index compared to the general population."
path(MESHD:"mental disorders") association path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "In patients with fibromyalgia, 31.6 % received opioids."
a(CHEBI:"opioids") decreases path(MESHD:"fibromyalgia")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Gastrointestinal diseases include abdominal pain, appendicitis, nausea and vomiting, constipation, diarrhoea and ileus."
path(MESHD:"appendicitis") association path(MESHD:"gastrointestinal disorders")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Nervous system disorders cover e.g. epilepsy, polyneuropathy, convulsions, paranesthesia, and motor weakness."
path(MESHD:"polyneuropathy") association path(DO:"Nervous system disorders")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Nervous system disorders cover e.g. epilepsy, polyneuropathy, convulsions, paranesthesia, and motor weakness."
path(MESHD:"motor weakness") association path(MESHD:"epilepsy")

SET Citation = {"PubMed", "39016183.0"}
SET DataSource = "manual-curation"
SET Support = "Nervous system disorders cover e.g. epilepsy, polyneuropathy, convulsions, paranesthesia, and motor weakness."
path(MESHD:"motor weakness") association path(DO:"Nervous system disorders")

SET Citation = {"PubMed", "39463915.0"}
SET DataSource = "manual-curation"
SET Support = "Notably, the use of trimethoprim, an antibiotic contraindicated in AIP due to its potential to disrupt heme biosynthesis, was identified as a trigger for her acute crisis."
a(CHEBI:"trimethoprim") decreases a(CHEBI:"heme biosynthesis")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Heme synthesis requires condensation of glycine and succinyl-CoA into 5-aminolevulinic acid (5-ALA) and the subsequent enzymatic conversion of 5-ALA into heme."
a(CHEBI:"glycine") increases a(CHEBI:"heme")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Heme synthesis requires condensation of glycine and succinyl-CoA into 5-aminolevulinic acid (5-ALA) and the subsequent enzymatic conversion of 5-ALA into heme."
a(CHEBI:"succinyl-CoA") increases a(CHEBI:"Heme")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "A defect in this pathway can lead to the accumulation of porphyrins, which absorb electromagnetic radiation from sunlight similarly to the chlorophyll in plants and algae that utilize solar energy for photosynthesis."
bp(MESHPP:"electromagnetic radiation") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "A defect in this pathway can lead to the accumulation of porphyrins, which absorb electromagnetic radiation from sunlight similarly to the chlorophyll in plants and algae that utilize solar energy for photosynthesis."
bp(MESHPP:"sunlight") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "A defect in this pathway can lead to the accumulation of porphyrins, which absorb electromagnetic radiation from sunlight similarly to the chlorophyll in plants and algae that utilize solar energy for photosynthesis."
bp(GOBP:"photosynthesis") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Phlebotomy is first-line treatment and mitigates the presence of iron overload, and hydroxychloroquine serves to inhibit porphyrin formation and promote urinary excretion of the porphyrins."
a(CHEBI:"hydroxychloroquine") decreases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Treatment includes therapeutic phlebotomy to decrease total body iron levels and low-dose hydroxychloroquine, which reduces hepatic porphyrin content."
a(CHEBI:"hydroxychloroquine") decreases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Patients with porphyria cutanea tarda benefit from iron depletion, hydroxychloroquine therapy, and, if applicable, elimination of the hepatitis C virus."
a(CHEBI:"hydroxychloroquine") decreases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Identify effective treatments for PCT, including phlebotomy and hydroxychloroquine"
a(CHEBI:"hydroxychloroquine") decreases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Low-dose hydroxychloroquine (100 mg orally twice weekly) is an alternative option for patients with PCT who do not have access to or cannot tolerate therapeutic phlebotomy, and who do not have marked iron overload. Chloroquine can be used as well, but hydroxychloroquine is preferred because of its superior safety pro file. These 4-aminoquinolines are taken up in hepatocyte lysosomes, which then release large amounts of accumu lated porphyrins."
a(CHEBI:"hydroxychloroquine") decreases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
a(CHEBI:"hydroxychloroquine") decreases path(MESHD:"PCT")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "However, studies have shown that the use of dialysis machines with higher specifications, and with more modern, high-flux dialysis membranes combined with higher blood flow rates during dialysis may lead to increased porphyrin clearance within the dialysate."
bp(MESHPP:"blood flow") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
path(MESHD:"vascular diseases") increases path(MESHD:"kidney disease")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
path(DO:"urinary tract obstruction") increases path(MESHD:"kidney disease")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "The main causes of kidney disease include diabetes mellitus, hypertension, vascular diseases, glomerular disease (primary and secondary), tubulointerstitial diseases, and urinary tract obstruction or dysfunction."
path(MESHD:"dysfunction") increases path(MESHD:"kidney disease")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "As with most compounds transported by MRP2, CP1, and CP3 are also transported by the basolateral efflux transporter MRP3 ( A B C C 3 )."
p(HGNC:"ABCC2") increases p(HGNC:"PCBP1")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Normally, Urine CP1/ Urine CP1+CP 3 is less than 33 %, but in the absence of MRP2, this ratio is increased, often to greater than 80 %.Urinary CP1 fraction greater than 80 % has close to 100 % specificity and sensitivity for Dubin-Johnson syndrome."
p(HGNC:"ABCC2") increases p(HGNC:"PCBP1")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "However when MRP2 function is impaired (eg, in Dubin-Johnson syndrome), MRP3 levels increase to provide a compensatory pathway for hepatic efflux."
path(MESHD:"Dubin-Johnson syndrome") decreases p(HGNC:"ABCC2")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "As in Dubin-Johnson syndrome, the proportion of urinary CP1 exceeds that of CP3 in a ratio of about 2-3/1."
path(MESHD:"Dubin-Johnson syndrome") positiveCorrelation p(HGNC:"PCBP1")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Thus, there likely can be competition for succinylCoA between heme synthesis and the formation of succinate, fumarate, malate, and other tricarboxylic acid cycle intermediates."
a(CHEBI:"succinate") association a(CHEBI:"heme")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Thus, there likely can be competition for succinylCoA between heme synthesis and the formation of succinate, fumarate, malate, and other tricarboxylic acid cycle intermediates."
a(CHEBI:"malate") association a(CHEBI:"heme")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "In Rotor syndrome total urinary CP excretion is markedly increased."
path(SNOMED:"Rotor syndrome") increases bp(GOBP:"excretion")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "In contrast, the need for erythroid heme synthesis is rather constant throughout life, although it, too, maybe stimulated under conditions of blood loss or hemolysis."
path(MESHD:"blood loss") positiveCorrelation a(CHEBI:"heme")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Xenobiotics inhibit the activities of multidrug resistance-associated proteins and/or OATPs and affect the metabolism and disposition of CPs."
bp(MESHPP:"multidrug resistance-associated proteins") association a(CHEBI:"Xenobiotics")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Ethanol decreases activities of ALAD, UROD, CPOX, and FECH."
a(CHEBI:"Ethanol") decreases p(HGNC:"ALAD")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Ethanol decreases activities of ALAD, UROD, CPOX, and FECH."
a(CHEBI:"Ethanol") decreases p(HGNC:"UROD")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Ethanol decreases activities of ALAD, UROD, CPOX, and FECH."
a(CHEBI:"Ethanol") decreases p(HGNC:"FECH")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Ethanol decreases activities of ALAD, UROD, CPOX, and FECH."
a(CHEBI:"Ethanol") decreases p(HGNC:"CPOX")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Ethanol leads to modest increases in ALA synthase- 1^66,67 and to CYPs, especially CYP2E1."
a(CHEBI:"Ethanol") increases a(CHEBI:"CYPs")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Ethanol leads to modest increases in ALA synthase- 1^66,67 and to CYPs, especially CYP2E1."
a(CHEBI:"Ethanol") increases p(HGNC:"CYP2E1")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "## MRP2 and Dubin-Johnson Syndrome (Mendelian Inheritance in Man 237500) The Dubin-Johnson syndrome is characterized by chronic conjugated hyperbilirubinemia."
path(MESHD:"Dubin-Johnson Syndrome") association p(HGNC:"ABCC2")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "## MRP2 and Dubin-Johnson Syndrome (Mendelian Inheritance in Man 237500) The Dubin-Johnson syndrome is characterized by chronic conjugated hyperbilirubinemia."
a(CHEBI:"hyperbilirubinemia") association p(HGNC:"ABCC2")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Coproporphyrins (CPs) are tetrapyrroles, formed by nearly all organisms."
a(CHEBI:"tetrapyrroles") isA a(CHEBI:"Coproporphyrins")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "or in hereditary tyrosinemia type 1 , in which 4,6-dioxoheptanoic acid (also known as succinyl acetone), a potent inhibitor of ALAD, accumulates."
a(CHEBI:"succinyl acetone") decreases p(HGNC:"ALAD")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Type 1 tyrosinemia is not a primary disorder of porphyrin metabolism but indirectly leads to similar biochemical changes and porphyria-like symptoms as in ALADP, caused by the accumulation of succinyl acetone, a potent inhibitor of ALAD."
a(CHEBI:"succinyl acetone") decreases path(MESHD:"tyrosinemia")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "TPO, a hormone constitutively produced by the liver, is responsible for the growth and maturation of megakaryocytes in the bone marrow."
a(CHEBI:"hormone") increases p(HGNC:"TPO")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "All TPO values in our cohort were within the normal range, suggesting that there is no global alteration in platelet production in patients with EPP."
p(HGNC:"TPO") causesNoChange bp(GOBP:"platelet production")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Mild microcytic anaemia and iron deficiency have long been recognized as features of EPP"
path(MESHD:"anemias") positiveCorrelation path(MESHD:"EPP")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Mild microcytic anaemia and iron deficiency have long been recognized as features of EPP"
path(MESHD:"iron deficiency") positiveCorrelation path(MESHD:"EPP")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Finally, spleen size, a potential marker for extra medullary haematopoiesis, has not been rigorously exam ined in EPP, nor has its relationship with protoporphyrin levels and thrombocytopenia."
a(MESH:"Spleen") association path(MESHD:"EPP")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "For the first time, to our knowledge, we documented mild splenic enlargement in patients with EPP and found a direct relationship between protoporphyrin levels and spleen length."
a(MESH:"Spleen") association path(MESHD:"EPP")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "Finally, spleen size, a potential marker for extra medullary haematopoiesis, has not been rigorously exam ined in EPP, nor has its relationship with protoporphyrin levels and thrombocytopenia."
a(MESH:"Spleen") association bp(MESHPP:"extramedullary hematopoiesis")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "This study, comprising 108 patients with PCT, was intended to define the role of hemochro matosis gene (HFE) mutations in the expression of PCT and to determine the contribution of acquired factors includ ing alcohol, hepatitis C virus (HCV), and estrogen. The 2 known HFE mutations, cysteine 282 tyrosine (Cys282Tyr) and histidine 63 asparagine (His63Asp), were detected by polymerase chain reaction, and anti-HCV immunoglobulin G was detected serologically."
p(HGNC:"HFE",var("p.Cys282Tyr")) association path(MESHD:"PCT")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Other recent evidence indicates that the prevalence of HFE gene mutations is increased in chronic viral hepatitis and that patients with chronic hepatitis C harboring especially the C282Y mutation are more likely to suffer from advanced hepatic fibrosis or cirrhosis and to do so at younger ages."
p(HGNC:"HFE",var("p.Cys282Tyr")) association path(MESHD:"hepatic fibrosis")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Other recent evidence indicates that the prevalence of HFE gene mutations is increased in chronic viral hepatitis and that patients with chronic hepatitis C harboring especially the C282Y mutation are more likely to suffer from advanced hepatic fibrosis or cirrhosis and to do so at younger ages."
p(HGNC:"HFE",var("p.Cys282Tyr")) association path(MESHD:"liver cirrhosis")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "For instance, in 1 study of 108 patients with PCT, 19% were homozygous for the HFE C282Y pathogenic variant."
p(HGNC:"HFE",var("p.Cys282Tyr")) positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "For instance, in 1 study of 108 patients with PCT, 19% were homozygous for the HFE C282Y pathogenic variant."
p(HGNC:"HFE",var("p.Cys282Tyr")) increases p(HGNC:"HFE")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Other recent evidence indicates that the prevalence of HFE gene mutations is increased in chronic viral hepatitis and that patients with chronic hepatitis C harboring especially the C282Y mutation are more likely to suffer from advanced hepatic fibrosis or cirrhosis and to do so at younger ages."
path(MESHD:"Chronic hepatitis C") positiveCorrelation p(HGNC:"HFE",var("p.Cys282Tyr"))

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Alcohol further contributes by down-regulating hepcidin and enhancing oxidative stress."
bp(MESHPP:"Alcohol") decreases p(HGNC:"HAMP")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "The results were interpreted to indicate that the effect of ethanol to produce a PCT phenotype is mediated by effects of alcohol on iron metabolism, specifically an effect to increase iron within hepatocytes."
bp(MESHPP:"Alcohol") increases a(CHEBI:"iron")

SET Citation = {"PubMed", "16315139.0"}
SET DataSource = "manual-curation"
SET Support = "Results from early work showed that relatively large doses of alcohol given to rodents were capable of increasing activity of 5-aminolevulinate synthase, the first and rate-controlling enzyme of heme synthesis. However, levels of activity of 5-aminolevulinate synthase in human beings with PCT have not been shown to be increased. Thus, the relevance of this finding to clinical PCT has remained uncertain."
bp(MESHPP:"Alcohol") increases p(HGNC:"ALAS")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Treatment for one year with clodronate and a high transfusion regime was associated with small reductions in serum alkaline phosphatase and urine hydroxy- proline excretion, but there was no improvement in bone mineral density."
a(CHEMBL:"clodronate") decreases p(HGNC:"ALPL")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Treatment for one year with clodronate and a high transfusion regime was associated with small reductions in serum alkaline phosphatase and urine hydroxy- proline excretion, but there was no improvement in bone mineral density."
a(CHEMBL:"clodronate") decreases a(CHEMBL:"hydroxyproline")

SET Citation = {"PubMed", "22273750.0"}
SET DataSource = "manual-curation"
SET Support = "Tracking infections and providing prompt therapy is important because they are often the cause of AIP exacerbations."
path(MESHD:"Infections") increases path(MESHD:"AIP")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Tachycardia coupled with hypertension and a reddish dark urine are further diagnostic signs (Figure 2A)."
path(MESHD:"reddish") positiveCorrelation path(MESHD:"Tachycardia")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Intravenous heme (Normosang; Orphan Europe, Puteaux, France, in Europe and some other regions, and Panhematin; Recordati Rare Diseases, Lebanon, NJ, in the United States, Mexico, and elsewhere) acts as a transcription factor that reduces expression of the ratelimiting hepatic enzyme ALAS1."
path(MESHD:"Rare Diseases") decreases a(CHEBI:"heme")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Increased plasma levels of porphyrins, especially zinc protoporphyrin and coproporphyrin, are found in patients with diseases other than porphyrias, such as in colorectal adenocarcinoma."
path(DO:"colorectal adenocarcinoma") association path(MESHD:"porphyria")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Most of the porphyrins emit red fluorescence when exposed to long-wave ( 366 nm ) ultraviolet light, as exemplified by brown, high protoporphyrin-containing chicken eggshells (Supplementary Figure 1)."
bp(MESHPP:"ultraviolet light") increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "If liver biopsies are exposed to long-wave ultraviolet light, those from PCT produce red fluorescence."
bp(MESHPP:"ultraviolet light") increases bp(MESHPP:"fluorescence")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^110 As many as 23 % of patients with EPP develop protoporphyrin-containing gallstones that emit red fluorescence under long-wave ultraviolet light."
bp(MESHPP:"ultraviolet light") increases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Uncontrolled observations suggest successful treatment with ursodeoxycholic acid that may increase hepatic clearance, and with cholestyramine that may bind protoporphyrin and interrupt its enterohepatic circulation."
a(CHEBI:"ursodeoxycholic acid") decreases a(CHEBI:"protoporphyrin")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "An inappropriately high secretion of antidiuretic hormone (Schwartz-Bartter syndrome) leads to a potentially lifethreatening severe hyponatremia, another diagnostic feature of acute porphyrias."
path(MESHD:"Bartter syndrome") increases path(MESHD:"hyponatremia")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^38 PEPT2*1 is also found in the choroid plexus and may be important in pumping variable amounts of toxic ALA into the brain, which could explain the variable susceptibility to neuropsychiatric symptoms in patients."
p(HGNC:"SLC15A2") increases path(MESHD:"neuropsychiatric symptoms")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "A variant of kidney peptide transporter 2 (PEPT2*1*) has high affinity for ALA and promotes its reabsorption, likely contributing to renal damage."
p(HGNC:"SLC15A2") increases path(MESHD:"renal damage")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Laboratory analysis again showed severe hyponatremia (112 mEq/L) with a urine sodium level of 114 mEq / L. Careful substitution with 3 % sodium chloride was started, with intensive monitoring and hourly controls of serum sodium to prevent pontine myelinolysis."
a(CHEBI:"sodium chloride") increases path(MESHD:"hyponatremia")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Laboratory analysis again showed severe hyponatremia (112 mEq/L) with a urine sodium level of 114 mEq / L. Careful substitution with 3 % sodium chloride was started, with intensive monitoring and hourly controls of serum sodium to prevent pontine myelinolysis."
a(CHEBI:"sodium chloride") decreases path(MESHD:"pontine myelinolysis")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "In retrospect, it was apparent that a vicious cycle of fasting, worsening vomiting, and abdominal pain, likely induced by a mild eating disorder, caused excessive induction of hepatic ALAS1.With adherence to expert advice to avoid trigger factors for AIP, especially fasting, she remained stable and free of further acute attacks during a 3-year follow-up period."
path(MESHD:"eating disorder") increases path(MESHD:"abdominal pain")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "In retrospect, it was apparent that a vicious cycle of fasting, worsening vomiting, and abdominal pain, likely induced by a mild eating disorder, caused excessive induction of hepatic ALAS1.With adherence to expert advice to avoid trigger factors for AIP, especially fasting, she remained stable and free of further acute attacks during a 3-year follow-up period."
path(MESHD:"eating disorder") increases path(MESHD:"vomiting")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "In retrospect, it was apparent that a vicious cycle of fasting, worsening vomiting, and abdominal pain, likely induced by a mild eating disorder, caused excessive induction of hepatic ALAS1.With adherence to expert advice to avoid trigger factors for AIP, especially fasting, she remained stable and free of further acute attacks during a 3-year follow-up period."
path(MESHD:"eating disorder") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "In retrospect, it was apparent that a vicious cycle of fasting, worsening vomiting, and abdominal pain, likely induced by a mild eating disorder, caused excessive induction of hepatic ALAS1.With adherence to expert advice to avoid trigger factors for AIP, especially fasting, she remained stable and free of further acute attacks during a 3-year follow-up period."
path(MESHD:"eating disorder") increases path(MESHD:"worsening")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^6,95,96 During the first 3 months after patients begin receiving 4-aminoquinolines, urinary porphyrin excretion usually increases more than 2-fold and skin photosensitivity can worsen, but thereafter decreases, resulting in clinical remission and improved liver enzyme activities in 95 % of patients."
a(MESHD:"Remission") decreases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "After subcutaneous injection, Givosiran is directed to and endocytosed by hepatocytes that carry the N -acetylgalactosamine binding asialoglycoprotein receptor."
a(CHEBI:"acetylgalactosamine") increases a(DB:"Givosiran")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "After subcutaneous injection, Givosiran is directed to and endocytosed by hepatocytes that carry the N -acetylgalactosamine binding asialoglycoprotein receptor."
p(HGNC:"ASGR1") increases a(DB:"Givosiran")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^131,132 GATA1, encoded by a gene on the X chromosome, is a transcription factor that regulates heme biosynthesis."
p(HGNC:"GATA1") regulates a(CHEBI:"heme biosynthesis")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "ALAS1 is induced via induction of cytochrome P450 (CyP450), such as by xenobiotics, smoking, excess alcohol consumption, fasting, and female sex hormones."
a(CHEBI:"xenobiotics") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^23,25 Moreover, a drug-responsive sequence in the ALAS1 gene mediates a direct transcriptional activation via drugs such as barbiturates, hydantoins, and metyrapone."
a(CHEBI:"hydantoins") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^23,25 Moreover, a drug-responsive sequence in the ALAS1 gene mediates a direct transcriptional activation via drugs such as barbiturates, hydantoins, and metyrapone."
a(CHEBI:"metyrapone") increases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^23,25 Moreover, a drug-responsive sequence in the ALAS1 gene mediates a direct transcriptional activation via drugs such as barbiturates, hydantoins, and metyrapone."
a(CHEBI:"metyrapone") increases a(CHEBI:"hydantoins")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^26-29 Glucose activation of peroxisome proliferator-activated receptor ÃŽÂ³-coactivator 1 ÃŽÂ± prevents transcription of ALAS1."
a(CHEBI:"Glucose") decreases p(HGNC:"ALAS1")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "^12 The lipophilic PPIX, which is eliminated via bile, is hepatotoxic at high concentrations, causing varying degrees of liver damage."
a(CHEBI:"PPIX") increases path(MESHD:"liver damage")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Patients have symptoms of burning, itching, pain, erythema, and edema on sun-exposed skin areas, sometimes but not always resembling sunburn."
path(MESHD:"sunburn") positiveCorrelation path(MESHD:"erythema")

SET Citation = {"PubMed", "31085196.0"}
SET DataSource = "manual-curation"
SET Support = "Patients have symptoms of burning, itching, pain, erythema, and edema on sun-exposed skin areas, sometimes but not always resembling sunburn."
path(MESHD:"sunburn") positiveCorrelation path(MESHD:"edema")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "In order to better define the association between HHcy and AP, patients were assessed in respect to heme arginate prophylactic therapy. Surprisingly, patients under heme arginate prophylactic therapy showed significantly higher serum Hcy mean levels."
a(DB:"Heme arginate") increases a(CHEBI:"homocysteine")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "Total plasma (TPP), erythrocyte (TEP), and urine por phyrin levels (TUP) measured at follow-up were significantly reduced from pretransplant levels"
a(MESH:"Hematopoietic Stem Cell Transplantation") decreases a(PKG:"plasma porphyrins")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "Total plasma (TPP), erythrocyte (TEP), and urine por phyrin levels (TUP) measured at follow-up were significantly reduced from pretransplant levels"
a(MESH:"Hematopoietic Stem Cell Transplantation") decreases a(PKG:"erythrocyte porphyrins")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "Total plasma (TPP), erythrocyte (TEP), and urine por phyrin levels (TUP) measured at follow-up were significantly reduced from pretransplant levels"
a(MESH:"Hematopoietic Stem Cell Transplantation") decreases a(CHEBI:"uroporphyrins")

SET Citation = {"PubMed", "34245225.0"}
SET DataSource = "manual-curation"
SET Support = "Patient 1, who had pretransplant liver biopsy with iron of 6466 Ã‚Âµg/g tissue dry weight and an iron index of 5.8 Ã‚Âµmol/g/year, developed veno-occlusive disease (VOD),"
a(MESH:"Hematopoietic Stem Cell Transplantation") increases path(MESH:"Hepatic Veno-Occlusive Disease")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda (PCT) arises due to the inhibition of uroporphyrinogen decarboxylase (UROD) in the presence of hepatic iron and oxidative stress."
p(HGNC:"UROD",var("p.?")) increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Factors contributing to the development of PCT include alcohol use, hepatitis C virus infection, human immunodeficiency virus, estrogen use, UROD pathogenic variants, and hereditary hemochromatosis."
p(HGNC:"UROD",var("p.?")) increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Understand that PCT arises from decreased UROD activ ity in the liver"
p(HGNC:"UROD",var("p.?")) increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda (PCT) occurs due to inhibition of the fifth enzyme of heme biosynthesis, uroporphyrinogen decarboxylase (UROD)."
p(HGNC:"UROD",var("p.?")) increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT usually occurs in the absence of a UROD pathogenic variant, and a heterozygous UROD pathogenic variant alone is not sufficient to cause the disease."
p(HGNC:"UROD",var("p.?")) increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The decreased activity of UROD, the fifth step in the pathway, leads to porphyria cutanea tarda."
p(HGNC:"UROD",var("p.?")) increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Inherited factors may include UROD and HFE pathogenic variants."
p(HGNC:"UROD",var("p.?")) increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
p(HGNC:"UROD",var("p.?")) increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT is a hepatic porphyria that arises due to the acquired inhibition of hepatic UROD."
p(HGNC:"UROD",var("p.?")) increases path(MESHD:"PCT")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda is the result of absent or defective uropor phyrinogen III decarboxylase (UROD), the enzyme responsible for the conversion of uroporphyrinogen III into coproporphyrinogen III."
p(HGNC:"UROD",var("p.?")) increases path(MESHD:"PCT")

SET Citation = {"PubMed", "35193623.0"}
SET DataSource = "manual-curation"
SET Support = "porphyria cutanea tarda (PCT) is a skin disorder caused by a defect in the liver enzyme uroporphyrino gen decarboxylase and is associated with hepatitis C virus infection, high alcohol intake, smoking and iron overload."
p(HGNC:"UROD",var("p.?")) increases path(MESHD:"PCT")

SET Citation = {"PubMed", "35193623.0"}
SET DataSource = "manual-curation"
SET Support = "In susceptible individuals, impaired UROD activity causes accumulation of porphyrins in the liver"
p(HGNC:"UROD",var("p.?")) increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Treatment includes therapeutic phlebotomy to decrease total body iron levels and low-dose hydroxychloroquine, which reduces hepatic porphyrin content."
bp(MESHD:"Phlebotomy") decreases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Identify effective treatments for PCT, including phlebotomy and hydroxychloroquine"
bp(MESHD:"Phlebotomy") decreases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
bp(MESHD:"Phlebotomy") decreases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "A reduction in hepatic iron stores via therapeutic phlebotomy is an effective and well-tolerated therapy in the majority of patients."
bp(MESHD:"Phlebotomy") decreases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Treatment includes therapeutic phlebotomy to decrease total body iron levels and low-dose hydroxychloroquine, which reduces hepatic porphyrin content."
bp(MESHD:"Phlebotomy") decreases a(CHEBI:"iron")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "A reduction in hepatic iron stores via therapeutic phlebotomy is an effective and well-tolerated therapy in the majority of patients."
bp(MESHD:"Phlebotomy") decreases a(CHEBI:"iron")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Pseudoporphyria is a dermatologic condition with blistering skin lesions identical to those observed in PCT, but without alterations in heme biosynthesis or evi dence of porphyrin accumulation."
path(SNOMED:"Pseudoporphyria (disorder)") positiveCorrelation path(MESHD:"blisters")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Pseudoporphyria is a dermatologic condition with blistering skin lesions identical to those observed in PCT, but without alterations in heme biosynthesis or evi dence of porphyrin accumulation."
path(SNOMED:"Pseudoporphyria (disorder)") positiveCorrelation path(MESHD:"Skin Diseases")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Pseudoporphyria is a dermatologic condition with blistering skin lesions identical to those observed in PCT, but without alterations in heme biosynthesis or evi dence of porphyrin accumulation."
path(SNOMED:"Pseudoporphyria (disorder)") negativeCorrelation a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "UROD deficiency re sults in the accumulation of uroporphyrinogen III in skin tissues, and upon sun exposure, uroporphyrinogen III generates reactive oxygen species, resulting in a high susceptibility to sun-damaged skin amongst this patient population."
a(CHEBI:"uroporphyrinogen III") increases path(MESHD:"Skin Diseases")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "The predominant clinical manifestations of PCT are skin fragility and blistering skin lesions."
a(CHEBI:"uroporphyrinogen III") increases path(MESHD:"Skin Diseases")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "UROD deficiency re sults in the accumulation of uroporphyrinogen III in skin tissues, and upon sun exposure, uroporphyrinogen III generates reactive oxygen species, resulting in a high susceptibility to sun-damaged skin amongst this patient population."
a(CHEBI:"uroporphyrinogen III") increases path(MESH:"Photosensitivity Disorders")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "UROD deficiency re sults in the accumulation of uroporphyrinogen III in skin tissues, and upon sun exposure, uroporphyrinogen III generates reactive oxygen species, resulting in a high susceptibility to sun-damaged skin amongst this patient population."
a(CHEBI:"uroporphyrinogen III") increases a(CHEBI:"reactive oxygen species")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "The predominant clinical manifestations of PCT are skin fragility and blistering skin lesions."
a(CHEBI:"uroporphyrinogen III") increases path(MESHD:"blisters")

SET Citation = {"PubMed", "10688809.0"}
SET DataSource = "manual-curation"
SET Support = "This study, comprising 108 patients with PCT, was intended to define the role of hemochro matosis gene (HFE) mutations in the expression of PCT and to determine the contribution of acquired factors includ ing alcohol, hepatitis C virus (HCV), and estrogen. The 2 known HFE mutations, cysteine 282 tyrosine (Cys282Tyr) and histidine 63 asparagine (His63Asp), were detected by polymerase chain reaction, and anti-HCV immunoglobulin G was detected serologically."
p(HGNC:"HFE",var("p.His63Asp")) association path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Other HFE genotypes are reported to occur at higher frequencies in patients with PCT as compared with controls, including compound heterozygous C282Y/H63D."
p(HGNC:"HFE",var("p.His63Asp")) positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Other HFE genotypes are reported to occur at higher frequencies in patients with PCT as compared with controls, including compound heterozygous C282Y/H63D."
p(HGNC:"HFE",var("p.His63Asp")) increases p(HGNC:"HFE")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Hepcidin, a peptide hormone produced by the liver that serves as a master regulator of iron homeostasis, is thought to be involved in PCT pathogenesis."
p(HGNC:"HAMP",var("p.?")) association path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Ajioka et al found that hepatic expression of HAMP, the gene that encodes hepcidin, is significantly reduced in patients with PCT with out ESKD and that hepcidin would also be expected to be reduced."
p(HGNC:"HAMP",var("p.?")) negativeCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "The most common environmental or acquired factors are alcohol use, HCV, estrogen use, human immunodeficiency virus (HIV), and smoking."
path(MESHD:"Smoking") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Low-dose hydroxychloroquine (100 mg orally twice weekly) is an alternative option for patients with PCT who do not have access to or cannot tolerate therapeutic phlebotomy, and who do not have marked iron overload. Chloroquine can be used as well, but hydroxychloroquine is preferred because of its superior safety pro file. These 4-aminoquinolines are taken up in hepatocyte lysosomes, which then release large amounts of accumu lated porphyrins."
a(DB:"4-aminoquinoline") decreases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "figure 4"
a(MESHD:"Tobacco Products") increases path(MESHD:"PCT")

SET Citation = {"PubMed", "40097071.0"}
SET DataSource = "manual-curation"
SET Support = "Tobacco use, alcohol dependence, hepatitis C, and HIV were associated with an increased risk of PCT."
p(MESH:"Tobacco Use") association path(MESHD:"PCT")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and ÃŽÂ´-aminolevulinic acid [ÃŽÂ´-ALA]) in the body [1]."
path(HP:"abnormal enzyme activity") positiveCorrelation path(MESHD:"AIP")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and ÃŽÂ´-aminolevulinic acid [ÃŽÂ´-ALA]) in the body [1]."
p(HGNC:"HMBS",var("p.?")) increases path(MESHD:"AIP")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The mutations associated with AIP have been observed only in the HMBS gene, which encodes HMBS (PBGD)."
p(HGNC:"HMBS",var("p.?")) increases path(MESHD:"AIP")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "This mutation is a splicing mutation, which leads to a functional defect in HMBS (PBGD) and thereby induces AIP."
p(HGNC:"HMBS",var("p.?")) increases path(MESHD:"AIP")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "AIP is caused by a mutation in the HMBS gene (also known as PBGD) and is involved in the synthesis of porphyrinogen in the porphyrin bio synthesis pathway, with a prevalence rate of 50 cases per 1 million people [2Ã¢â‚¬â€œ4]"
p(HGNC:"HMBS",var("p.?")) increases path(MESHD:"AIP")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and ÃŽÂ´-aminolevulinic acid [ÃŽÂ´-ALA]) in the body [1]."
p(HGNC:"HMBS",var("p.?")) increases a(CHEBI:"porphobilinogen")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and ÃŽÂ´-aminolevulinic acid [ÃŽÂ´-ALA]) in the body [1]."
p(HGNC:"HMBS",var("p.?")) increases a(CHEBI:"5-aminolevulinic acid")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "It is caused by defects in enzymes associated with porphyrin synthesis, in particular reduced activity of hydroxymethylbilane synthase (HMBS) (also referred to as porphobilinogen [PBG] deaminase [PBGD]; OMIM 609806), leading to the accumulation of porphyrin precursors (e.g., PBG and ÃŽÂ´-aminolevulinic acid [ÃŽÂ´-ALA]) in the body [1]."
p(HGNC:"HMBS",var("p.?")) increases a(CHEBI:"porphyrins")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "Intravenous hemin administration (4mg/kg once daily for 7 consecutive days) to inhibit ÃŽÂ´-ALA synthase (ALAS) activity and reduce porphyrin precursor accumulation; discontinuation of sodium valproate (which may exacerbate AIP) and replacement with levetiracetam (500mgtwicedaily) for seizure control; and maintenance of acid-base balance, correction of electrolyte disturbances, and a high-carbohydrate diet (daily intake Ã¢â€°Â¥ 300g) to stabilize metabolism."
a(CHEBI:"sodium valproate") increases path(MESHD:"AIP")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The treatment strategy for our patient, including intravenous hemin administration, discontinuation of so dium valproate (a known AIP exacerbant), and initiation of a high-carbohydrate diet, is consistent with the recom mendations in the Chinese Expert Consensus on Diagnosis and Treatment of AIP."
a(CHEBI:"sodium valproate") increases path(MESHD:"AIP")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The pathogenesis of PRES is still unclear, and there are several proposed hypotheses for its pathogenesis, including high perfusion pressure breakthrough and vascular endo thelial injury. It is generally considered a result of a com bination of factors, such as increased activity of the reninÃ¢â‚¬â€œangiotensin system, increased blood pressure, waterÃ¢â‚¬â€œsodium retention, metabolite accumulation, and damage to the bloodÃ¢â‚¬â€œbrain barrier."
path(MESHD:"Renin-Angiotensin System") positiveCorrelation path(MESHD:"PRES")

SET Citation = {"PubMed", "41180247.0"}
SET DataSource = "manual-curation"
SET Support = "The pathogenesis of PRES is still unclear, and there are several proposed hypotheses for its pathogenesis, including high perfusion pressure breakthrough and vascular endo thelial injury. It is generally considered a result of a com bination of factors, such as increased activity of the reninÃ¢â‚¬â€œangiotensin system, increased blood pressure, waterÃ¢â‚¬â€œsodium retention, metabolite accumulation, and damage to the bloodÃ¢â‚¬â€œbrain barrier."
path(MESHD:"Water-Electrolyte Balance") increases path(MESHD:"PRES")

SET Citation = {"PubMed", "38456621.0"}
SET DataSource = "manual-curation"
SET Support = "It has been speculated that the high incidence of AP- associated PLC found in Swedish studies might be related to the presence of the dominating HMBS founder gene variant (c.593G>A), found in approximately 2/3 of Swedish patients with AIP"
p(HGNC:"HMBS",var("p.R26H")) positiveCorrelation path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "40495387.0"}
SET DataSource = "manual-curation"
SET Support = "EPP arises due to pathogenic variants in ferrochelatase (FECH), the last step in haem biosynthesis, which incorpo rates iron into protoporphyrin to form haem."
p(HGNC:"FECH",var("p.?")) increases path(MESHD:"EPP")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "PCT can be classified based on the presence or absence of UROD pathogenic variants and family his tory. Most cases (~80%) are sporadic (type 1), with no UROD pathogenic variants. A heterozygous UROD pathogenic variant is found in familial (type 2), which is an autosomal dominant condition with low penetrance, such that there is usually no family history of PCT."
p(HGNC:"UROD",var("p.G281E")) positiveCorrelation path(MESHD:"PCT")

SET Citation = {"PubMed", "39644053.0"}
SET DataSource = "manual-curation"
SET Support = "Hepatoerythropoietic por phyria (HEP) is an ultra rare form of por phyria caused by homo zy gous path o genic UROD var i ants that usu ally pres ents in early child hood with blis ter ing skin lesions, ane mia, and hepato splenomegaly and resem bles con gen i tal eryth ro poi etic por"
p(HGNC:"UROD",var("c.[404T>G];[404T>G]")) positiveCorrelation path(MESHD:"hepatoerythropoietic porphyria")

SET Citation = {"PubMed", "33953217.0"}
SET DataSource = "manual-curation"
SET Support = "One such example is congenital erythropoietic porphyria (CEP), most commonly caused by loss of function mutation in uroporphyrinogen III synthase (UROS; Fig.S1), the enzyme that catalyzes the third step of the heme biosyn thetic pathway"
p(HGNC:"UROS",var("c.217T>C")) increases path(MESHD:"CEP")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "Congenital erythropoietic heme biosynthesis, porphyria (CEP) is a rare disorder of resulting from reduced activity enzyme uroporphyrinogen (III) cosynthetase."
p(HGNC:"UROS",var("c.217T>C")) increases path(MESHD:"CEP")

SET Citation = {"PubMed", "2064845.0"}
SET DataSource = "manual-curation"
SET Support = "It is autosomal recessive, and associated with reduced UROS activity (5% of normal) and consequent accumulation of uro/coproporphyrin-I (uro/copro-I) in bone marrow, erythrocytes, plasma, and increased uro/copro-I excretion in urine and stool"
p(HGNC:"UROS",var("c.217T>C")) increases path(MESHD:"CEP")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Acute porphyrias (AP) are characterized by heme deficiency and induction of hepatic 5-aminole vulinate synthase (ALAS1)."
p(HGNC:"ALAS1",var("c.604C>T")) increases path(MESHD:"AIP")

SET Citation = {"PubMed", "32487371.0"}
SET DataSource = "manual-curation"
SET Support = "Carriers of these enzymatic defects are at a risk of presenting acute and severe neuro-visceral attacks (acute porphyric attacks, APAs) that are associated with induction of liver 5-aminole vulinate synthase (ALAS1), responsible for overproduction and tissue accumulation of neurotoxic non-porphyrin intermediates [porphobili nogen (PBG) and ÃŽÂ´-aminolevulinic acid (ALA)]"
p(HGNC:"ALAS1",var("c.604C>T")) increases path(MESHD:"AIP")

SET Citation = {"PubMed", "40228600.0"}
SET DataSource = "manual-curation"
SET Support = "Thus, relative deficiency of heme, such as may occur in the hepatic porphy rias, in which there are defects in enzymes distal to ALA synthase-1, leads to marked up-regulation of ALA syn thase-1, whereas sufficiency of heme, which may be sup plied to hepatocytes from other cells or from the blood, such as when patients are treated with intravenous heme for acute porphyric attacks, leads to rapid down-regulation of ALA synthase-1"
p(HGNC:"ALAS1",var("c.604C>T")) increases path(MESHD:"AIP")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Detection of a mutation in the HMBS gene causing porphyria: c. 806C>G: p.T269R."
p(HGNC:"HMBS",var("p.Thr269Arg")) increases path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "Whole exon sequencing revealed a heterozygous missense mutation HMBS:NM_000190:exon12:c.806C>G (p.Thr269Arg) in the woman and her cousin."
p(HGNC:"HMBS",var("p.Thr269Arg")) increases path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "32844069.0"}
SET DataSource = "manual-curation"
SET Support = "NM_000190.4(HMBS):c.806C>T (p.Thr269Ile)"
p(HGNC:"HMBS",var("p.Thr269Ile")) increases path(MESHD:"Acute porphyria")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "A variant of the gene encoding PEPT2, PEPT2*2, reduces the transporter's affinity for ALA and has been associated with reduced severity and slower progression of PAKD, supporting the hypothesis of ALA in tubular injury."
p(HGNC:"SLC15A2",var("hPEPT2*1|*2")) increases p(MESH:"kidney diseases")

SET Citation = {"PubMed", "38819621.0"}
SET DataSource = "manual-curation"
SET Support = "nan"
p(HGNC:"SLC15A3",var("rs12345")) increases p(MESH:"kidney diseases")

